FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Oliveira, LB
   Celes, FS
   Paiva, CN
   de Oliveira, CI
AF Oliveira, Laise B.
   Celes, Fabiana S.
   Paiva, Claudia N.
   de Oliveira, Camila I.
TI The Paradoxical Leishmanicidal Effects of Superoxide Dismutase
   (SOD)-Mimetic Tempol in Leishmania braziliensis Infection in vitro
SO FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
LA English
DT Article
DE L. braziliensis; oxidants; anti-oxidants; leishmaniasis; chemotherapy
ID HYDROGEN-PEROXIDE; N-ACETYLCYSTEINE; MACROPHAGES; INFLAMMATION;
   NEUTROPHIL; MECHANISMS; GENERATION; APOPTOSIS; CELLS; ROS
AB Leishmaniasis is an infectious disease caused by protozoans of the genus Leishmania. The macrophage is the resident cell in which the parasite replicates and it is important to identify new compounds that can aid in parasite elimination since the drugs used to treat leishmaniasis are toxic and present side effects. We have previously shown that treatment of Leishmania braziliensis-infected macrophages with DETC (Diethyldithiocarbamate) induces parasite killing, in vivo. Thus, the objective of this study was to further evaluate the effect of oxidants and antioxidants in L. braziliensis-infected macrophages, following treatment with either oxidizing Hydrogen Peroxide, Menadione, DETC, or antioxidant [NAC (N-Acetyl-Cyteine), Apocynin, and Tempol] compounds. We determined the percentage of infected macrophages and number of amastigotes. Promastigote survival was also evaluated. Both DETC (SOD-inhibitor) and Tempol (SOD-mimetic) decreased the percentage of infected cells and parasite load. Hydrogen peroxide did not interfere with parasite burden, while superoxide-generator Menadione had a reducing effect. On the other hand, NAC (GSH-replenisher) and Apocynin (NADPH-oxidase inhibitor) increased parasite burden. Tempol surfaces as an interesting candidate for the chemotherapy of CL with an IC50 of 0.66 +/- 0.08 mM and selectivity index of 151. While it remains obscure how a SOD-mimetic may induce leishmanicidal effects, we suggest the possibility of developing Tempol-based topical applications for the treatment of cutaneous leishmaniasis caused by L. braziliensis.
C1 [Oliveira, Laise B.; Celes, Fabiana S.; de Oliveira, Camila I.] Fiocruz MS, IGM, Salvador, BA, Brazil.
   [Paiva, Claudia N.] Univ Fed Rio de Janeiro, Inst Microbiol, Rio De Janeiro, Brazil.
   [de Oliveira, Camila I.] Inst Invest Imunol, Sao Paulo, Brazil.
RP de Oliveira, CI (corresponding author), Fiocruz MS, IGM, Salvador, BA, Brazil.; de Oliveira, CI (corresponding author), Inst Invest Imunol, Sao Paulo, Brazil.
EM camila@bahia.fiocruz.br
RI de Oliveira, Camila I/B-4358-2009
OI de Oliveira, Camila I/0000-0002-7868-5164
FU CNPq fellowship (Iniciacao Cientifica); Coordenacao de Aperfeicoamento
   de pessoal de Nivel Superior-Brasil (CAPES) [001]; Instituto Goncalo
   Moniz (IGM)-Fiocruz
FX LO was the recipient of a CNPq fellowship (Iniciacao Cientifica). FC was
   financed by the Coordenacao de Aperfeicoamento de pessoal de Nivel
   Superior-Brasil (CAPES)-Finance Code 001. CO is a senior investigator
   from CNPq. This work was funded in part by Instituto Goncalo Moniz
   (IGM)-Fiocruz.
CR Aldini G, 2018, FREE RADICAL RES, V52, P751, DOI 10.1080/10715762.2018.1468564
   Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
   Annaloro C, 2009, J ANTIMICROB CHEMOTH, V63, P625, DOI 10.1093/jac/dkn549
   Batinic-Haberle I, 2010, ANTIOXID REDOX SIGN, V13, P877, DOI 10.1089/ars.2009.2876
   Bittencourt Achiléa, 2003, Braz J Infect Dis, V7, P229, DOI 10.1590/S1413-86702003000300009
   Carneiro MBH, 2018, J IMMUNOL, V200, P196, DOI 10.4049/jimmunol.1700899
   Carneiro PP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148084
   Celes FS, 2016, SCI REP-UK, V6, DOI 10.1038/srep38330
   CHANNON JY, 1985, PARASITOLOGY, V91, P207, DOI 10.1017/S0031182000057310
   Criddle DN, 2006, J BIOL CHEM, V281, P40485, DOI 10.1074/jbc.M607704200
   Croft SL, 2003, TRENDS PARASITOL, V19, P502, DOI 10.1016/j.pt.2003.09.008
   Fischer Andrew H, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot4986
   Gantt KR, 2001, J IMMUNOL, V167, P893, DOI 10.4049/jimmunol.167.2.893
   Gariboldi MB, 1998, FREE RADICAL BIO MED, V24, P913, DOI 10.1016/S0891-5849(97)00372-9
   Grinberg L, 2005, FREE RADICAL BIO MED, V38, P136, DOI 10.1016/j.freeradbiomed.2004.09.025
   Hahn SM, 1997, FREE RADICAL BIO MED, V23, P879, DOI 10.1016/S0891-5849(97)00079-8
   Hassan GS, 2013, PROF DRUG SUB EXCIP, V38, P227, DOI 10.1016/B978-0-12-407691-4.00006-X
   Inacio JDF, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003093
   Khouri R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014394
   Khouri R, 2009, J IMMUNOL, V182, P2525, DOI 10.4049/jimmunol.0802860
   Kim JY, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01720
   Linares E, 2008, FREE RADICAL BIO MED, V44, P1668, DOI 10.1016/j.freeradbiomed.2008.01.027
   Llanos-Cuentas A, 2008, CLIN INFECT DIS, V46, P223, DOI 10.1086/524042
   Machado PR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000912
   Metz JM, 2004, CLIN CANCER RES, V10, P6411, DOI 10.1158/1078-0432.CCR-04-0658
   Mittra B, 2013, J EXP MED, V210, P401, DOI 10.1084/jem.20121368
   Novais FO, 2014, J INFECT DIS, V209, P1288, DOI 10.1093/infdis/jiu013
   Novais FO, 2009, J IMMUNOL, V183, P8088, DOI 10.4049/jimmunol.0803720
   Paiva CN, 2012, J CLIN INVEST, V122, P2531, DOI 10.1172/JCI58525
   Roma EH, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1472-y
   Shilo S, 2003, ANTIOXID REDOX SIGN, V5, P273, DOI 10.1089/152308603322110850
   SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x
   Srivastav S, 2014, J BIOL CHEM, V289, P1092, DOI 10.1074/jbc.M113.496323
   Suh KS, 2010, CELL BIOL TOXICOL, V26, P189, DOI 10.1007/s10565-009-9137-7
   Sun SY, 2010, CANCER BIOL THER, V9, P109, DOI 10.4161/cbt.9.2.10583
   Weischenfeldt Joachim, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot5080
   Wilcox CS, 2010, PHARMACOL THERAPEUT, V126, P119, DOI 10.1016/j.pharmthera.2010.01.003
NR 37
TC 4
Z9 4
U1 0
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2235-2988
J9 FRONT CELL INFECT MI
JI Front. Cell. Infect. Microbiol.
PD JUN 26
PY 2019
VL 9
AR 237
DI 10.3389/fcimb.2019.00237
PG 7
WC Immunology; Microbiology
SC Immunology; Microbiology
GA IF7ED
UT WOS:000473243400001
PM 31297344
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Mazur, KL
   Feuser, PE
   Valerio, A
   Cordeiro, AP
   de Oliveira, CI
   Assolini, JP
   Pavanelli, WR
   Sayer, C
   Araujo, PHH
AF Mazur, Karin Luize
   Feuser, Paulo Emilio
   Valerio, Alexsandra
   Cordeiro, Arthur Poester
   de Oliveira, Camila Indiani
   Assolini, Joao Paulo
   Pavanelli, Wander Rogerio
   Sayer, Claudia
   Araujo, Pedro H. H.
TI Diethyldithiocarbamate loaded in beeswax-copaiba oil nanoparticles
   obtained by solventless double emulsion technique promote promastigote
   death in vitro
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Solid lipid nanoparticles; Diethyldithiocarbamate; Hydrophilic drugs;
   Beeswax; L. amazonensis
ID SOLID LIPID NANOPARTICLES; CONTROLLED DRUG-DELIVERY; OPTIMIZATION;
   CARRIERS; RELEASE; BIOCOMPATIBILITY; LEISHMANIASIS; FORMULATION;
   MACROPHAGE; SYSTEM
AB Leishmaniasis is considered a neglected tropical disease that represents a Public Health problem due to its high incidence. In the search of new alternatives for Leishmaniasis treatment diethyldithiocarbamate (DETC) has shown an excellent leishmanicidal activity and the incorporation into drug carrier systems, such as solid lipid nanoparticles (SLNs), is very promising. In the present work DETC loaded in beeswax nanoparticles containing copaiba oil were obtained by the double emulsion/melt technique. The nanoparticles were characterized and leishmanicidal activity against L. amazonensis promastigotes forms and cytotoxicity in murine macrophages were evaluated. SLNs presented size below 200 nm, spherical morphology, negative charge surface, high encapsulation efficiency, above 80%, and excellent stability. Moreover, Fourier transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) analyses were performed to evaluate the chemical structure and possible interactions between DETC and SLNs. SLNs provided a protection for DETC, decreasing its cytotoxic effects in macrophages, which led to an improvement in the selectivity against the parasites, which almost doubled from free DETC (11.4) to DETC incorporated in SLNs (18.2). These results demonstrated that SLNs had a direct effect on L. amazonensis promastigotes without affect the viability of macrophage cell, can be a promising alternative therapy for the cutaneous treatment of L. amazonensis
C1 [Mazur, Karin Luize; Feuser, Paulo Emilio; Valerio, Alexsandra; Cordeiro, Arthur Poester; Sayer, Claudia; Araujo, Pedro H. H.] Univ Fed Santa Catarina, Dept Chem Engn & Food Engn, BR-88010970 Florianopolis, SC, Brazil.
   [de Oliveira, Camila Indiani] Fundacao Oswaldo Cruz FIOCRUZ, Inst Goncalo Moniz, Salvador, BA, Brazil.
   [Assolini, Joao Paulo; Pavanelli, Wander Rogerio] Univ Estadual Londrina, Ctr Biol Sci, Dept Pathol Sci, Lab Expt Protozool, Londrina, PR, Brazil.
RP Araujo, PHH (corresponding author), Univ Fed Santa Catarina, Dept Chem Engn & Food Engn, BR-88010970 Florianopolis, SC, Brazil.
EM pedro.h.araujo@ufsc.br
RI de Oliveira, Camila I/B-4358-2009; Valerio, Alexsandra/A-6699-2013;
   Sayer, Claudia/AAT-7059-2020; Assolini, Joao Paulo/U-3748-2017; Feuser,
   Paulo Emilio/D-3202-2018; Araujo, Pedro H. H./Q-9549-2019
OI de Oliveira, Camila I/0000-0002-7868-5164; Sayer,
   Claudia/0000-0003-1044-2905; Assolini, Joao Paulo/0000-0003-4190-8835;
   Feuser, Paulo Emilio/0000-0003-2372-8945; Araujo, Pedro H.
   H./0000-0001-5905-0158; Valerio, Alexsandra/0000-0001-5046-7088; Poester
   Cordeiro, Arthur/0000-0001-6660-004X
FU CAPES - Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   TecnologicoCAPES; CNPq - Conselho Nacional de Desenvolvimento Cientifico
   e TecnologicoNational Council for Scientific and Technological
   Development (CNPq)
FX The authors thank financial support from CAPES - Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior Tecnologico and CNPq -
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico and
   Laboratorio Central de Microscopia Eletronica (LCME) of Federal
   University of Santa Catarina for the TEM analyses.
CR Almeida AJ, 2007, ADV DRUG DELIVER REV, V59, P478, DOI 10.1016/j.addr.2007.04.007
   Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
   Amato VS, 2008, ACTA TROP, V105, P1, DOI 10.1016/j.actatropica.2007.08.003
   Attama AA, 2008, COLLOID SURFACE A, V315, P189, DOI 10.1016/j.colsurfa.2007.07.035
   Barros NB, 2013, EXP PARASITOL, V135, P337, DOI 10.1016/j.exppara.2013.07.022
   Carpenter J, 2017, ULTRASON SONOCHEM, V35, P422, DOI 10.1016/j.ultsonch.2016.10.021
   Celes FS, 2016, SCI REP-UK, V6, DOI 10.1038/srep38330
   da Rocha Filho P. A, 2014, JSM NANOTECHNOL NANO, V2, P2
   Dal Pizzol C, 2014, INT J ENV RES PUB HE, V11, P8581, DOI 10.3390/ijerph110808581
   Borges VRD, 2016, MAT SCI ENG C-MATER, V64, P310, DOI 10.1016/j.msec.2016.03.094
   Desjeux P, 2004, NAT REV MICROBIOL, V2, P692, DOI 10.1038/nrmicro981
   Ganesan P, 2017, SUSTAIN CHEM PHARM, V6, P37, DOI 10.1016/j.scp.2017.07.002
   Gao TT, 2017, J TAIWAN INST CHEM E, V71, P426, DOI 10.1016/j.jtice.2016.11.033
   Ghadiri M, 2012, INT J PHARMACEUT, V424, P128, DOI 10.1016/j.ijpharm.2011.12.037
   Goncalves MD, 2018, FITOTERAPIA, V128, P224, DOI 10.1016/j.fitote.2018.05.027
   Goncalves VSS, 2015, INT J PHARMACEUT, V495, P302, DOI 10.1016/j.ijpharm.2015.08.026
   Gontijo Bernardo, 2003, Rev. Soc. Bras. Med. Trop., V36, P71, DOI 10.1590/S0037-86822003000100011
   Gumiero VC, 2012, J DISPER SCI TECHNOL, V33, P1569, DOI 10.1080/01932691.2011.625219
   Haldar Arun Kumar, 2011, Mol Biol Int, V2011, P571242, DOI 10.4061/2011/571242
   He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065
   Heidari-Kharaji M, 2016, PARASITE IMMUNOL, V38, P599, DOI 10.1111/pim.12340
   Nguyen HM, 2012, PEST MANAG SCI, V68, P1062, DOI 10.1002/ps.3268
   Iqbal M, 2015, INT J PHARMACEUT, V496, P173, DOI 10.1016/j.ijpharm.2015.10.057
   Kheradmandnia S, 2010, NANOMED-NANOTECHNOL, V6, P753, DOI 10.1016/j.nano.2010.06.003
   Khouri R., 2010, PLOS ONE, V5, P8, DOI [10.1371/joumal.pone.0014394, DOI 10.1371/JOUMAL.PONE.0014394]
   Kumar R, 2018, ULTRASON SONOCHEM, V40, P686, DOI 10.1016/j.ultsonch.2017.08.018
   Li L, 2012, CORROS SCI, V59, P249, DOI 10.1016/j.corsci.2012.03.008
   Lopes R, 2012, EUR J PHARM SCI, V45, P442, DOI 10.1016/j.ejps.2011.09.017
   Luo WG, 2012, J ARCHAEOL SCI, V39, P1227, DOI 10.1016/j.jas.2011.12.035
   Makled S, 2017, INT J PHARMACEUT, V517, P312, DOI 10.1016/j.ijpharm.2016.12.026
   Matias AC, 2013, TOXICOL IN VITRO, V27, P349, DOI 10.1016/j.tiv.2012.08.017
   Monteiro WM, 2008, CAD SAUDE PUBLICA, V24, P1291, DOI 10.1590/S0102-311X2008000600010
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Omwoyo WN, 2014, INT J NANOMED, V9, P3865, DOI 10.2147/IJN.S62630
   Peres LB, 2016, COLLOID SURFACE B, V140, P317, DOI 10.1016/j.colsurfb.2015.12.033
   Pinto AC, 2000, J BRAZIL CHEM SOC, V11, P355, DOI 10.1590/S0103-50532000000400005
   Reithmeier H, 2001, J CONTROL RELEASE, V73, P339, DOI 10.1016/S0168-3659(01)00354-6
   Ribeiro TG, 2014, INT J NANOMED, V9, P877, DOI 10.2147/IJN.S55678
   Rompicharla SVK, 2017, CHEM PHYS LIPIDS, V208, P10, DOI 10.1016/j.chemphyslip.2017.08.009
   Severino P, 2014, EUR J MED CHEM, V81, P28, DOI 10.1016/j.ejmech.2014.04.084
   Shidhaye S. S., 2008, Current Drug Delivery, V5, P324, DOI 10.2174/156720108785915087
   Tahir N, 2017, INT J PHARMACEUT, V533, P156, DOI 10.1016/j.ijpharm.2017.09.061
   Tan SW, 2014, AAPS PHARMSCITECH, V15, P287, DOI 10.1208/s12249-013-0056-9
   Tomiotto-Pellissier F, 2018, BIOMED PHARMACOTHER, V98, P662, DOI 10.1016/j.biopha.2017.12.083
   Valerio A, 2017, J NANOSCI NANOTECHNO, V17, P4955, DOI 10.1166/jnn.2017.13434
   Verma A, 2010, SMALL, V6, P12, DOI 10.1002/smll.200901158
   Yan PF, 2016, J CLEAN PROD, V122, P308, DOI 10.1016/j.jclepro.2016.02.037
   Yasir M, 2014, ACTA PHARM SIN B, V4, P454, DOI 10.1016/j.apsb.2014.10.005
   Zhang Y, 2008, BIOMED MICRODEVICES, V10, P321, DOI 10.1007/s10544-007-9139-2
NR 49
TC 3
Z9 3
U1 0
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0927-7765
EI 1873-4367
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD APR 1
PY 2019
VL 176
BP 507
EP 512
DI 10.1016/j.colsurfb.2018.12.048
PG 6
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA HU1SJ
UT WOS:000465051800058
PM 30711703
DA 2020-12-08
ER

PT J
AU Luz, NF
   DeSouza-Vieira, T
   De Castro, W
   Vivarini, AC
   Pereira, L
   Franca, RR
   Silveira-Mattos, PS
   Costa, DL
   Teixeira, C
   Meneses, C
   Boaventura, VS
   de Oliveira, CI
   Lopes, UG
   Aronson, N
   Andrade, BB
   Brodskyn, CI
   Valenzuela, JG
   Kamhawi, S
   Borges, VM
AF Luz, Nivea F.
   DeSouza-Vieira, Thiago
   De Castro, Waldione
   Vivarini, Aislan Carvalho
   Pereira, Lais
   Franca, Riam Rocha
   Silveira-Mattos, Paulo S.
   Costa, Diego L.
   Teixeira, Clarissa
   Meneses, Claudio
   Boaventura, Viviane S.
   de Oliveira, Camila I.
   Lopes, Ulisses Gazos
   Aronson, Naomi
   Andrade, Bruno B.
   Brodskyn, Claudia I.
   Valenzuela, Jesus G.
   Kamhawi, Shaden
   Borges, Valeria M.
TI Lutzomyia Iongipalpis Saliva Induces Heme Oxygenase-1 Expression at Bite
   Sites
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE Lutzomyia longipalpis; sand fly bite; saliva; skin; macrophages; heme
   oxygenase-1; Nrf2
ID LEISHMANIA-MAJOR; LONGIPALPIS; INFECTION; SEVERITY; PROTECTS; SYSTEM
AB Sand flies bite mammalian hosts to obtain a blood meal, driving changes in the host inflammatory response that support the establishment of Leishmania infection. This effect is partially attributed to components of sand fly saliva, which are able to recruit and activate leukocytes. Our group has shown that heme oxygenase-1 (HO-1) favors Leishmania survival in infected cells by reducing inflammatory responses. Here, we show that exposure to sand fly bites is associated with induction of HO-1 in vivo. Histopathological analyses of skin specimens from human volunteers experimentally exposed to sand fly bites revealed that HO-1 and Nrf2 are produced at bite sites in the skin. These results were recapitulated in mice ears injected with a salivary gland sonicate (SGS) or exposed to sand fly bites, indicating that vector saliva may be a key factor in triggering HO-1 expression. Resident skin macrophages were the main source HO-1 at 24-48 h after bites. Additionally, assays in vivo after bites and in vitro after stimulation with saliva both demonstrated that HO-1 production by macrophages was Nrf2-dependent. Collectively, our data demonstrates that vector saliva induces early HO-1 production at the bite sites, representing a major event associated with establishment of naturally-transmitted Leishmania infections.
C1 [Luz, Nivea F.; Franca, Riam Rocha; Silveira-Mattos, Paulo S.; Boaventura, Viviane S.; de Oliveira, Camila I.; Andrade, Bruno B.; Brodskyn, Claudia I.; Borges, Valeria M.] Fundacao Oswaldo Cruz, Goncalo Moniz Inst, Salvador, BA, Brazil.
   [DeSouza-Vieira, Thiago; De Castro, Waldione; Pereira, Lais; Meneses, Claudio; Valenzuela, Jesus G.; Kamhawi, Shaden] NIAID, Vector Mol Biol Sect, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA.
   [Vivarini, Aislan Carvalho; Lopes, Ulisses Gazos] Univ Fed Rio de Janeiro, Carlos Chagas Filho Biophys Inst, Ctr Hlth Sci, Lab Mol Parasitol, Rio De Janeiro, Brazil.
   [Franca, Riam Rocha; Silveira-Mattos, Paulo S.; Boaventura, Viviane S.; de Oliveira, Camila I.; Andrade, Bruno B.; Brodskyn, Claudia I.; Borges, Valeria M.] Univ Fed Bahia, Fac Med Bahia, Salvador, BA, Brazil.
   [Costa, Diego L.] NIAID, Immunobiol Sect, Lab Parasit Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Teixeira, Clarissa] Oswaldo Cruz Fdn Fiocruz PI, Teresina, Brazil.
   [Aronson, Naomi] Uniformed Serv Univ Hlth Sci, Infect Dis Div, Bethesda, MD 20814 USA.
   [Andrade, Bruno B.] Fundacao Jose Silveira, Multinatl Org Network Sponsoring Translat & Epide, Salvador, BA, Brazil.
RP Borges, VM (corresponding author), Fundacao Oswaldo Cruz, Goncalo Moniz Inst, Salvador, BA, Brazil.; Kamhawi, S (corresponding author), NIAID, Vector Mol Biol Sect, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA.; Borges, VM (corresponding author), Univ Fed Bahia, Fac Med Bahia, Salvador, BA, Brazil.
EM skamhawi@niaid.nih.gov; vborges@bahia.fiocruz.br
RI Lopes, Ulisses Gazos/T-6634-2019; Borges, Val/N-6647-2019; de Oliveira,
   Camila I/B-4358-2009; Andrade, Bruno/AAI-2248-2020; Costa, Diego
   Luis/F-7168-2019; Borges, Valeria/G-2009-2014; Boaventura, Viviane
   S/H-9165-2015
OI Borges, Val/0000-0002-2775-5409; de Oliveira, Camila
   I/0000-0002-7868-5164; Costa, Diego Luis/0000-0002-9440-2814; Andrade,
   Bruno/0000-0001-6833-3811
FU Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB) e Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); NIH,
   National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID);
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil
   (CAPES)CAPES [001]; CAPES BrazilCAPES; FAPESB; Programa Nacional de
   Pos-Doutorado/CAPES; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [ZIAAI000932, ZIAAI000932, ZIAAI000932]
   Funding Source: NIH RePORTER
FX This study was supported by grants from Fundacao de Amparo a Pesquisa do
   Estado da Bahia (FAPESB) e Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), and by the Intramural Research Program
   of the NIH, National Institute of Allergy and Infectious Diseases. This
   study was financed in part by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior - Brasil (CAPES) - Finance Code 001. NL is a
   fellowship recipient from CAPES Brazil; PM is a fellowship recipient
   from FAPESB; AV is a fellowship recipient from Programa Nacional de
   Pos-Doutorado/CAPES; CdO, UL, CB and VMB are senior investigators of
   CNPq.
CR Abdeladhim M, 2014, INFECT GENET EVOL, V28, P691, DOI 10.1016/j.meegid.2014.07.028
   Almeida BFM, 2017, PARASITE IMMUNOL, V39, DOI 10.1111/pim.12494
   Anderson JM, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001139
   Andrade BB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062618
   Atayde VD, 2015, CELL REP, V13, P957, DOI 10.1016/j.celrep.2015.09.058
   Costa DJ, 2004, INFECT IMMUN, V72, P1298, DOI 10.1128/IAI.72.3.1298-1305.2004
   Das S, 2013, J ANTIMICROB CHEMOTH, V68, P2059, DOI 10.1093/jac/dkt162
   Dey R, 2018, CELL HOST MICROBE, V23, P134, DOI 10.1016/j.chom.2017.12.002
   Dutra FF, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00115
   Georgiadou SP, 2015, J TRANSL INTERN MED, V3, P43, DOI 10.1515/jtim-2015-0002
   Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600
   Igarashi K, 2006, ANTIOXID REDOX SIGN, V8, P107, DOI 10.1089/ars.2006.8.107
   Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943
   Kato H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-226
   Kim HP, 2011, BIOCHEM BIOPH RES CO, V404, P1, DOI 10.1016/j.bbrc.2010.11.067
   Lestinova T, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005600
   Luz NF, 2012, J IMMUNOL, V188, P4460, DOI 10.4049/jimmunol.1103072
   Luz NF, 2016, J IMMUNOL, V196, P5056, DOI 10.4049/jimmunol.1502492
   Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517
   Malta-Santos H, 2017, SCI REP-UK, V7, DOI 10.1038/srep46363
   Mendonca VRR, 2012, INFECT IMMUN, V80, P1445, DOI 10.1128/IAI.05933-11
   Monteiro MC, 2007, AM J TROP MED HYG, V76, P88, DOI 10.4269/ajtmh.2007.76.88
   Morris RV, 2001, J IMMUNOL, V167, P5226, DOI 10.4049/jimmunol.167.9.5226
   Murray HW, 2005, LANCET, V366, P1561, DOI 10.1016/S0140-6736(05)67629-5
   Pereira MLM, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00161
   Prates Deboraci Brito, 2012, Journal of Parasitology Research, P643029, DOI 10.1155/2012/643029
   Prates DB, 2011, J LEUKOCYTE BIOL, V90, P575, DOI 10.1189/jlb.0211105
   Quintela-Carvalho G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01620
   Ribeiro JMC, 2003, ANNU REV ENTOMOL, V48, P73, DOI 10.1146/annurev.ento.48.060402.102812
   Ricchetti GA, 2004, J LEUKOCYTE BIOL, V76, P719, DOI 10.1189/jlb.0104046
   Rogers ME, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00223
   Soares MP, 2016, CURR OPIN IMMUNOL, V38, P94, DOI 10.1016/j.coi.2015.11.006
   Teixeira CR, 2005, J IMMUNOL, V175, P8346, DOI 10.4049/jimmunol.175.12.8346
   TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748
   TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436
   Vijayan V, 2018, BIOCHEM PHARMACOL, V153, P159, DOI 10.1016/j.bcp.2018.02.010
   Vivarini AD, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01127
   Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5
   Waza AA, 2018, INFLAMM RES, V67, P579, DOI 10.1007/s00011-018-1151-x
   Wheat WH, 2017, VACCINE, V35, P6611, DOI 10.1016/j.vaccine.2017.10.039
NR 40
TC 6
Z9 6
U1 0
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD NOV 28
PY 2018
VL 9
AR 2779
DI 10.3389/fimmu.2018.02779
PG 10
WC Immunology
SC Immunology
GA HC2WU
UT WOS:000451663400001
PM 30546363
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Fukutani, KF
   Nascimento-Carvalho, CM
   Bouzas, ML
   Oliveira, JR
   Barral, A
   Dierckx, T
   Khouri, R
   Nakaya, HI
   Andrade, BB
   Van Weyenbergh, J
   de Oliveira, CI
AF Fukutani, Kiyoshi F.
   Nascimento-Carvalho, Cristiana M.
   Bouzas, Maiara L.
   Oliveira, Juliana R.
   Barral, Aldina
   Dierckx, Tim
   Khouri, Ricardo
   Nakaya, Helder I.
   Andrade, Bruno B.
   Van Weyenbergh, Johan
   de Oliveira, Camila I.
TI In situ Immune Signatures and Microbial Load at the Nasopharyngeal
   Interface in Children With Acute Respiratory Infection
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE network analysis; ARI; immune response; nCounter; interferon; viral
   load; innate immunity; adaptive immunity
ID HAEMOPHILUS-INFLUENZAE; STREPTOCOCCUS-PNEUMONIAE; MORAXELLA-CATARRHALIS;
   EPITHELIAL-CELLS; SYNCYTIAL VIRUS; INDUCTION; BACTERIAL; PROTEIN;
   INTERFERONS; SYMPTOMS
AB Acute respiratory infection (ARI) is the most frequent cause for hospitalization in infants and young children. Using multiplexed nCounter technology to digitally quantify 600 human mRNAs in parallel with 14 virus- and 5 bacterium-specific RNAs, we characterized viral and bacterial presence in nasopharyngeal aspirates (NPA) of 58 children with ARI and determined the corresponding in situ immune profiles. NPA contained different groups of organisms and these were classified into bacterial (n = 27), viral (n = 5), codetection [containing both viral and bacterial transcripts (n = 21), or indeterminate intermediate where microbial load is below threshold (n = 5)]. We then identified differentially expressed immune transcripts (DEITs) comparing NPAs from symptomatic children vs. healthy controls, and comparing children presenting NPAs with detectable microbial load vs. indeterminate. We observed a strong innate immune response in NPAs, due to the presence of evolutionarily conserved type I Interferon (IFN)-stimulated genes (ISG), which was correlated with total bacterial and/or viral load. In comparison with indeterminate NPAs, adaptive immunity transcripts discriminated among viral, bacterial, and codetected microbial profiles. In viral NPAs, B cell transcripts were significantly enriched among DEITs, while only type III IFN was correlated with viral load. In bacterial NPAs, myeloid cells and coinhibitory transcripts were enriched and significantly correlated with bacterial load. In conclusion, digital nCounter transcriptomics provide a microbial and immunological in situ "snapshot" of the nasopharyngeal interface in children with ARI. This enabled discrimination among viral, bacterial, codetection, and indeterminate transcripts in the samples using non-invasive sampling.
C1 [Fukutani, Kiyoshi F.; Barral, Aldina; Khouri, Ricardo; Andrade, Bruno B.; de Oliveira, Camila I.] Fiocruz MS, Inst Goncalo Moniz, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.; Bouzas, Maiara L.; Oliveira, Juliana R.; Barral, Aldina; Khouri, Ricardo; de Oliveira, Camila I.] Univ Fed Bahia, Sch Med, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
   [Dierckx, Tim; Van Weyenbergh, Johan] Katholieke Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, Leuven, Belgium.
   [Nakaya, Helder I.] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, Sao Paulo, Brazil.
   [Andrade, Bruno B.] Fdn Jose Silveira, Multinatl Org Network Sponsoring Translat & Epide, Salvador, BA, Brazil.
RP de Oliveira, CI (corresponding author), Fiocruz MS, Inst Goncalo Moniz, Salvador, BA, Brazil.; de Oliveira, CI (corresponding author), Univ Fed Bahia, Sch Med, Salvador, BA, Brazil.; Van Weyenbergh, J (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, Leuven, Belgium.
EM j.vw@live.be; camila@bahia.fiocruz.br
RI Khouri, Ricardo/M-3184-2018; de Oliveira, Camila I/B-4358-2009; Andrade,
   Bruno/AAI-2248-2020; Fukutani, Kiyoshi/T-1630-2019; Nakaya,
   Helder/AAF-1738-2020; Nakaya, Helder I/A-1397-2010; Fukutani,
   Kiyoshi/N-7905-2016; Van Weyenbergh, Johan/Q-3829-2019; Van Weyenbergh,
   Johan/B-4187-2009
OI Khouri, Ricardo/0000-0001-5664-4436; de Oliveira, Camila
   I/0000-0002-7868-5164; Nakaya, Helder/0000-0001-5297-9108; Nakaya,
   Helder I/0000-0001-5297-9108; Fukutani, Kiyoshi/0000-0003-2223-0918; Van
   Weyenbergh, Johan/0000-0003-3234-8426; Van Weyenbergh,
   Johan/0000-0003-3234-8426; Dierckx, Tim/0000-0002-1969-7974; Andrade,
   Bruno/0000-0001-6833-3811
FU Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB)
   [PNX0019/2009]; Belgian FWOFWO [G0D6817N]; Science without Borders (PVE
   Anne-Mieke Vandamme); Institute for the Promotion of Innovation through
   Science and Technology Flanders (IWT-Vlaanderen)Institute for the
   Promotion of Innovation by Science and Technology in Flanders (IWT)
   [141614]; FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2012/19278-6, 2017/50137-3]; National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [U01AI115940]; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [U01AI115940,
   U01AI115940, U01AI115940, U01AI115940, U01AI115940, U01AI115940] Funding
   Source: NIH RePORTER
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado da
   Bahia (FAPESB; Grant PNX0019/2009 to AB) and Belgian FWO (Grant
   G0D6817N). KF was supported by a fellowship from Science without Borders
   (PVE Anne-Mieke Vandamme). TD was supported by the Institute for the
   Promotion of Innovation through Science and Technology Flanders
   (IWT-Vlaanderen), project 141614. CN-C, AB, and CO were senior
   investigators from Conselho Nacional de Pesquisa Cientifica (CNPq). HN
   was supported by FAPESP (Grant Nos. 2012/19278-6 and 2017/50137-3). BA
   was supported by the National Institutes of Health (U01AI115940).
CR Andrade DC, 2016, PEDIATR INFECT DIS J, V35, P683, DOI 10.1097/INF.0000000000001126
   Andreakos E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01232
   Andris F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00480
   Avadhanula V, 2006, J VIROL, V80, P1629, DOI 10.1128/JVI.80.4.1629-1636.2006
   Blondel VD, 2008, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2008/10/P10008
   Bogaert D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017035
   Bouzas ML, 2018, J CLIN VIROL, V106, P34, DOI 10.1016/j.jcv.2018.07.003
   Bouzas ML, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005142
   Chaussabel D, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-84
   Durbin RK, 2013, IMMUNOL REV, V255, P25, DOI 10.1111/imr.12101
   Fabregat A, 2016, NUCLEIC ACIDS RES, V44, pD481, DOI 10.1093/nar/gkv1351
   Fukutani KF, 2015, J CLIN VIROL, V69, P190, DOI 10.1016/j.jcv.2015.06.005
   Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385
   Hallstrom T, 2007, J IMMUNOL, V178, P6359, DOI 10.4049/jimmunol.178.10.6359
   Heinonen S, 2016, AM J RESP CRIT CARE, V193, P772, DOI 10.1164/rccm.201504-0749OC
   HOWARD AJ, 1988, EPIDEMIOL INFECT, V100, P193, DOI 10.1017/S0950268800067327
   Ishizuka S, 2003, J INFECT DIS, V188, P1928, DOI 10.1086/379833
   Jogdand GM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00520
   Khaitov MR, 2009, ALLERGY, V64, P375, DOI 10.1111/j.1398-9995.2008.01826.x
   Liquet B, 2016, BIOINFORMATICS, V32, P35, DOI 10.1093/bioinformatics/btv535
   Maler MD, 2017, MBIO, V8, DOI 10.1128/mBio.00670-17
   Mejias A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001549
   Metzemaekers M, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01970
   Moens B, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-171
   Nakaya HI, 2016, P NATL ACAD SCI USA, V113, P1853, DOI 10.1073/pnas.1519690113
   Nakaya HI, 2012, ARTHRITIS RHEUM-US, V64, P3553, DOI 10.1002/art.34631
   Nascimento-Carvalho CM, 2016, PEDIATR INFECT DIS J, V35, P338, DOI 10.1097/INF.0000000000001032
   Nascimento-Carvalho CM, 2013, SCAND J INFECT DIS, V45, P478, DOI 10.3109/00365548.2012.754106
   Nascimento-Carvalho CM, 2010, SCAND J INFECT DIS, V42, P839, DOI 10.3109/00365548.2010.498020
   Nolan VG, 2018, J INFECT DIS, V218, P179, DOI 10.1093/infdis/jix641
   Nordstrom T, 2004, J IMMUNOL, V173, P4598, DOI 10.4049/jimmunol.173.7.4598
   Parnell GP, 2012, CRIT CARE, V16, DOI 10.1186/cc11477
   R Core Team, 2013, R LANG ENV STAT COMP
   Ruohola A, 2013, J INFECTION, V66, P247, DOI 10.1016/j.jinf.2012.12.002
   Sadler AJ, 2008, NAT REV IMMUNOL, V8, P559, DOI 10.1038/nri2314
   Shaw AE, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2004086
   Shoemaker JE, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-460
   Skevaki CL, 2015, PEDIATR INFECT DIS J, V34, P1296, DOI 10.1097/INF.0000000000000872
   Spann KM, 2004, J VIROL, V78, P4363, DOI 10.1128/JVI.78.8.4363-4369.2004
   Suarez NM, 2015, J INFECT DIS, V212, P213, DOI 10.1093/infdis/jiv047
   Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369
   Sweeney TE, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf7165
   Tregoning JS, 2010, CLIN MICROBIOL REV, V23, P74, DOI 10.1128/CMR.00032-09
   Uitti JM, 2015, PEDIATR INFECT DIS J, V34, P1056, DOI 10.1097/INF.0000000000000800
   Waggott D, 2012, BIOINFORMATICS, V28, P1546, DOI 10.1093/bioinformatics/bts188
   Wiertsema SP, 2011, J MED VIROL, V83, P2008, DOI 10.1002/jmv.22221
   Zhai YJ, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004869
NR 47
TC 1
Z9 1
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD NOV 9
PY 2018
VL 9
AR 2475
DI 10.3389/fmicb.2018.02475
PG 13
WC Microbiology
SC Microbiology
GA GZ7DP
UT WOS:000449637600001
PM 30473680
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Bouzas, ML
   Oliveira, JR
   Queiroz, A
   Fukutani, KF
   Barral, A
   Rector, A
   Wollants, E
   Keyaertse, E
   Van der Gucht, W
   Van Ranst, M
   Beuselinck, K
   de Oliveira, CI
   Van Weyenbergh, J
   Nascimento-Carvalho, CM
AF Bouzas, Maiara L.
   Oliveira, Juliana R.
   Queiroz, Artur
   Fukutani, Kiyoshi F.
   Barral, Aldina
   Rector, Annabel
   Wollants, Elke
   Keyaertse, Els
   Van der Gucht, Winke
   Van Ranst, Marc
   Beuselinck, Kurt
   de Oliveira, Camila, I
   Van Weyenbergh, Johan
   Nascimento-Carvalho, Cristiana M.
CA Acute Resp Infect Wheeze Study Grp
TI Diagnostic accuracy of digital RNA quantification versus real-time PCR
   for the detection of respiratory syncytial virus in nasopharyngeal
   aspirates from children with acute respiratory infection
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE RSV; Diagnostics; Respiratory viruses; Virus detection; Viral
   respiratory infection; Transcriptomics
ID ALIGNMENT
AB Background: Virus-specific molecular assays such as real-time polymerase chain reaction (RT-PCR) are regularly used as the gold standard to diagnose viral respiratory tract infections, but simultaneous detection of multiple different pathogens is often challenging. A multiplex digital method of RNA quantification, nCounter (NanoString Technologies), can overcome this disadvantage and identify, in a single reaction, the presence of different respiratory viruses.
   Objectives: To evaluate the accuracy of nCounter to identify and quantify RSV-A and RSV-B in nasopharyngeal aspirates (NPA) of children (6-23-months-old) with acute respiratory infection.
   Study design: NPA was collected at enrolment in a prospective cross-sectional study conducted in Salvador, Brazil. A quantitative RT-PCR with a subgroup-specific primer and probeset for RSV-A and RSV-B was performed in parallel with a customized nCounter probeset containing viral targets in NPA.
   Results: Of 559 NPA tested, RSV was detected by RT-PCR in 139 (24.9%), by nCounter in 122 (21.8%) and by any method in 158 (28.3%) cases. Compared to the gold standard of qRT-PCR, sensitivity of nCounter was 74.3% (95%CI:63.3%-82.9% RSV-A) and 77.6% (95%CI:66.3%-85.9% RSV-B); specificity was 98.4% (95%CI:96.8%-99.2% RSV-A) and 97.8% (95%CI:96.0%-98.8% RSV-B); positive predictive value was 87.3% (95%CI:76.9%-93.4% RSV-A) and 82.5% (95%CI:71.4%-90.0% RSV-B) and negative predictive value was 96.1% (95%CI:94.1%-97.5% RSV-A), and 96.9% (95%CI:95.1%-98.2% RSV-B). Accuracy was 95.2% (95%CI:93.1%-96.7%) for RSV-A and 95.3% (95%CI:93.3%-96.9%) for RSV-B, while both methods significantly correlated for RSV-A (r = 0.44, p = 8 x 10(-5)) and RSV-B (r = 0.73, p = 3 x 10(-12)) quantification.
   Conclusions: nCounter is highly accurate in detecting RSV-A/B in NPA. Robustness and high-throughput multiplexing indicate its use in large-scale epidemiological studies.
C1 [Bouzas, Maiara L.; Oliveira, Juliana R.; Fukutani, Kiyoshi F.; Barral, Aldina; de Oliveira, Camila, I; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
   [Queiroz, Artur; Barral, Aldina; de Oliveira, Camila, I] Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisas Goncalo Moniz CPqGM, Salvador, BA, Brazil.
   [Fukutani, Kiyoshi F.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Biochem Immunol & Cell Biol, Ribeirao Preto, Brazil.
   [Barral, Aldina] Univ Fed Bahia, Sch Med, Dept Pathol, Salvador, BA, Brazil.
   [Rector, Annabel; Wollants, Elke; Keyaertse, Els; Van der Gucht, Winke; Van Ranst, Marc; Van Weyenbergh, Johan] Katholieke Univ Leuven, Rega Inst Med Res, Lab Clin & Epidemiol Virol, Dept Microbiol & Immunol, Leuven, Belgium.
   [Keyaertse, Els; Van Ranst, Marc; Beuselinck, Kurt] Univ Hosp Leuven, Dept Lab Med, Leuven, Belgium.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
RP Bouzas, ML (corresponding author), Univ Fed Bahia, Sch Med, Program Hlth Sci, Ctr Hist, Largo Terreiro de Jesus S-N, BR-40025010 Salvador, BA, Brazil.
EM maiara.lanna@gmail.com
RI Fukutani, Kiyoshi/T-1630-2019; Van Ranst, Marc/P-7522-2017; Van
   Weyenbergh, Johan/B-4187-2009; Van Weyenbergh, Johan/Q-3829-2019; de
   Oliveira, Camila I/B-4358-2009; Keyaerts, Els/F-2305-2018; Rector,
   Annabel/E-7619-2018
OI Van Ranst, Marc/0000-0002-1674-4157; Van Weyenbergh,
   Johan/0000-0003-3234-8426; Van Weyenbergh, Johan/0000-0003-3234-8426; de
   Oliveira, Camila I/0000-0002-7868-5164; Keyaerts,
   Els/0000-0002-1849-3240; Wollants, Elke/0000-0002-4057-2236; de Queiroz,
   Artur Trancoso Lopo/0000-0003-4908-9993; Fukutani,
   Kiyoshi/0000-0003-2223-0918; Rector, Annabel/0000-0003-3714-449X
FU Fundacao de Amparo a pesquisa do Estado da Bahia (FAPESB)
   [PNX0019/2009]; FAPESB; Conselho Nacional de Desenvolvimento Cientifico
   e Tecnologico (CNPQ)National Council for Scientific and Technological
   Development (CNPq); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2017/03491-6]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES)CAPES; Research Foundation - Flanders FWOFWO [G0D6817N]
FX This work was supported by Fundacao de Amparo a pesquisa do Estado da
   Bahia (FAPESB; grant PNX0019/2009). MLB was supported by fellowships
   from FAPESB. KFF was supported by fellowships from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPQ), FAPESB and Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP no. 2017/03491-6). JRO
   was supported by fellowships from FAPESB and Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES). AB, CIO, CMN-C are
   senior investigators from CNPQ. JVW was supported by (Research
   Foundation - Flanders FWO; grant G0D6817N).
CR ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   Andrade DC, 2017, VACCINE, V35, P4105, DOI 10.1016/j.vaccine.2017.06.048
   Bouzas ML, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005142
   Durigon GS, 2015, INT J INFECT DIS, V34, P3, DOI 10.1016/j.ijid.2015.03.003
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Fukutani KF, 2015, J CLIN VIROL, V69, P190, DOI 10.1016/j.jcv.2015.06.005
   Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385
   Houspie L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060416
   Khouri R, 2014, J INFECT DIS, V210, P306, DOI 10.1093/infdis/jiu087
   Kuypers J, 2004, J CLIN VIROL, V31, P123, DOI 10.1016/j.jcv.2004.03.018
   Moens B, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-171
   Nascimento-Carvalho CM, 2010, SCAND J INFECT DIS, V42, P839, DOI 10.3109/00365548.2010.498020
   Salez N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130378
   Speranza E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15145-7
   Thorburn F, 2015, J CLIN VIROL, V69, P96, DOI 10.1016/j.jcv.2015.06.082
   Ye J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-134
   Zlateva KT, 2007, J CLIN MICROBIOL, V45, P3022, DOI 10.1128/JCM.00339-07
   Zlateva KT, 2005, J VIROL, V79, P9157, DOI 10.1128/JVI.79.14.9157-9167.2005
NR 18
TC 4
Z9 4
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD SEP
PY 2018
VL 106
BP 34
EP 40
DI 10.1016/j.jcv.2018.07.003
PG 7
WC Virology
SC Virology
GA GR2AR
UT WOS:000442361000009
PM 30031351
DA 2020-12-08
ER

PT J
AU Sharma, R
   Santos, LC
   da Silva, RA
   Goncalves, CV
   Calado, SD
   Santos, DP
   de Melo, JPD
   Rampazzo, RDP
   Requiao, L
   Krieger, MA
   Barral-Netto, M
   de Oliveira, CI
AF Sharma, Rohit
   Santos, Larissa Costa
   da Silva, Robson A.
   Goncalves, Caroline V.
   Calado, Stefano de Melo
   Santos, Denisar P.
   de Andrade de Melo, Josana P.
   Pontello Rampazzo, Rita de Cassia
   Requiao, Luciana
   Krieger, Marco A.
   Barral-Netto, Manoel
   de Oliveira, Camila I.
TI Surveillance of donated blood during the 2016 arbovirus outbreak in
   Brazil
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE NAT; transfusion; ZIKV
ID ZIKA VIRUS; PUERTO-RICO; TRANSFUSION; TRANSMISSION; DONORS; STATES; RNA
AB Reports of arboviral transmission via blood transfusion may be a cause of concern among asymptomatic infected donors. This study evaluated the presence of arboviruses in donated blood products during the 2016 outbreak in Vitoria da Conquista (Bahia-Brazil). Serum samples (n=676) were screened for ZIKV, CHIKV, and the four DENV serotypes using a one-step reverse transcriptase-based Real-Time Polymerase Chain Reaction (RT-PCR). No samples tested positive for any of the targets, whereas positive controls performed as expected. The results suggest a low risk of arboviral transmission via transfusion of blood products in the endemic area studied during the 2016 outbreak.
C1 [Sharma, Rohit; Santos, Larissa Costa; Barral-Netto, Manoel; de Oliveira, Camila I.] Fiocruz MS, IGM, Salvador, BA, Brazil.
   [da Silva, Robson A.; Goncalves, Caroline V.; Calado, Stefano de Melo; Santos, Denisar P.] UFBA, IMS, Vitoria Da Conquista, BA, Brazil.
   [de Andrade de Melo, Josana P.] Serv Hemoterapia Sudoeste, Vitoria Da Conquista, PR, Brazil.
   [Pontello Rampazzo, Rita de Cassia; Requiao, Luciana; Krieger, Marco A.] IBMP, Curitiba, PR, Brazil.
   [Krieger, Marco A.] Fiocruz MS, ICC, Curitiba, PR, Brazil.
   [Barral-Netto, Manoel; de Oliveira, Camila I.] Inst Nacl Ciencia & Tecnol Invest Imunol, Sao Paulo, SP, Brazil.
RP de Oliveira, CI (corresponding author), Fiocruz MS, IGM, Rua Waldemar Falcao 121, BR-40196710 Candeal Salvador, BA, Brazil.
EM camila@bahia.fiocruz.br
RI de Oliveira, Camila I/B-4358-2009; Rampazzo, Rita/AAA-4590-2020; Silva,
   Robson A A/N-8801-2018; Krieger, Marco/AAE-8611-2020; Barral Netto,
   Manoel/B-3904-2009
OI de Oliveira, Camila I/0000-0002-7868-5164; Rampazzo,
   Rita/0000-0002-8367-999X; Barral Netto, Manoel/0000-0002-5823-7903;
   Goncalves, Caroline/0000-0003-0895-1583
FU CAPES FellowshipCAPES
FX CAPES Fellowship
CR Aubry M, 2016, TRANSFUSION, V56, P33, DOI 10.1111/trf.13271
   Barreto ML, 2016, LANCET, V387, P919, DOI 10.1016/S0140-6736(16)00545-6
   Bierlaire D, 2017, TRANSFUSION, V57, P729, DOI 10.1111/trf.14028
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Azevedo RDD, 2015, REV SAUDE PUBL, V49, DOI 10.1590/S0034-8910.2015049006219
   Donalisio MR, 2017, REV SAUDE PUBL, V51, DOI [10.1590/S1518-8787.2017051006889, 10.1590/s1518-8787.2017051006889]
   Galel SA, 2017, TRANSFUSION, V57, P762, DOI 10.1111/trf.14029
   Gallian P, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005254
   Johansson MA, 2016, NEW ENGL J MED, V375, P1, DOI 10.1056/NEJMp1605367
   Laughhunn A, 2017, TRANSFUSION, V57, P779, DOI 10.1111/trf.13993
   Motta IJF, 2016, NEW ENGL J MED, V375, P1101, DOI 10.1056/NEJMc1607262
   Musso D, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.14.20761
   Pealer LN, 2003, NEW ENGL J MED, V349, P1236, DOI 10.1056/NEJMoa030969
   Sabino EC, 2016, J INFECT DIS, V213, P694, DOI 10.1093/infdis/jiv326
   Santa Maria F, 2017, TRANSFUSION, V57, P2016, DOI 10.1111/trf.14161
   Slavov SN, 2017, TRANSFUSION, V57, P2897, DOI 10.1111/trf.14322
   Stramer SL, 2012, TRANSFUSION, V52, P1657, DOI 10.1111/j.1537-2995.2012.03566.x
   Vasquez AM, 2016, MMWR-MORBID MORTAL W, V65, P375, DOI 10.15585/mmwr.mm6514e1
   Williamson PC, 2017, TRANSFUSION, V57, P770, DOI 10.1111/trf.14041
NR 19
TC 1
Z9 1
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD AUG
PY 2018
VL 90
IS 8
BP 1406
EP 1410
DI 10.1002/jmv.25193
PG 5
WC Virology
SC Virology
GA GK0JY
UT WOS:000435797200020
PM 29667206
DA 2020-12-08
ER

PT J
AU Viana, SM
   Celes, FS
   Ramirez, L
   Kolli, B
   Ng, DKP
   Chang, KP
   de Oliveira, CI
AF Viana, Sayonara M.
   Celes, Fabiana S.
   Ramirez, Laura
   Kolli, Bala
   Ng, Dennis K. P.
   Chang, Kwang P.
   de Oliveira, Camila I.
TI Photodynamic Vaccination of BALB/c Mice for Prophylaxis of Cutaneous
   Leishmaniasis Caused by Leishmania amazonensis
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE Leishmania; leishmaniasis; potosensitizer; phthalocyanine; uroporphyrin;
   photodynamic vaccination; suicidal vaccination; cutaneous leishmaniasis
ID 5-AMINOLEVULINIC ACID; PROTECTIVE IMMUNITY; CELL CARCINOMA; THERAPY;
   INACTIVATION; INFECTION; PARASITES; MEXICANA; MUTANTS; PHOTOTOXICITY
AB Background: Photosensitizers (PS), like porphyrins and phthalocyanines (PC) are excitable by light to generate cytotoxic singlet oxygen and other reactive oxygen species in the presence of atmospheric O-2. Photodynamic inactivation of Leishmania by this means renders them non-viable, but preserves their effective use as vaccines. Leishmania can be photo-inactivated after PS-sensitization by loading via their endocytic uptake of PC or endogenous induction of transgenic mutants with delta-aminolevulinate (ALA) to accumulate cytosolic uroporphyrin I (URO). Here, PS-sensitization and photo-inactivation of Leishmania amazonensis was further examined in vitro and in vivo for vaccination against cutaneous leishmaniasis (CL).
   Methods and Results: Leishmania amazonensis promastigotes were photodynamically inactivated in vitro by PC-loading followed by exposure to red light (1-2 J/cm(2)) or ALA-induction of uroporphyrinogenic transfectants to accumulate cytosolic URO followed by longwave UV exposure. When applied individually, both strategies of photodynamic inactivation were found to significantly, albeit incompletely abolish the MTT reduction activities of the promastigotes, their uptake by mouse bone marrow-derived macrophages in vitro and their infectivity to mouse ear dermis in vivo. Inactivation of Leishmania to completion by using a combination of both strategies was thus used for the sake of safety as whole-cell vaccines for immunization of BALB/c mice. Different cutaneous sites were assessed for the efficacy of such photodynamic vaccination in vivo. Each site was inoculated first with in vitro doubly PS-sensitized promastigotes and then spot-illuminated with white light (50 J/cm(2)) for their photo-inactivation in situ. Only in ear dermis parasites were photo-inactivated beyond detection. Mice were thus immunized once in the ear and challenged 3 weeks later at the tail base with virulent L. amazonensis. Prophylaxis was noted in mice photodynamically vaccinated with doubly photo-inactivated parasites, as indicated by a significant delay in the onset of lesion development and a substantial decrease in the parasite loads.
   Conclusion: Leishmania doubly PS-sensitized and in situ photo-inactivated as described proved to be safe and effective when used for one-time immunization of ear dermis, as indicated by its significant protection of the inherently very susceptible BALB/c mice against CL.
C1 [Viana, Sayonara M.; Celes, Fabiana S.; Ramirez, Laura; de Oliveira, Camila I.] Fiocruz MS, IGM, Salvador, BA, Brazil.
   [Kolli, Bala; Chang, Kwang P.] Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Microbiol Immunol, N Chicago, IL USA.
   [Ng, Dennis K. P.] Chinese Univ Hong Kong, Dept Chem, Hong Kong, Hong Kong, Peoples R China.
   [de Oliveira, Camila I.] INCT, Iii, Sao Paulo, Brazil.
RP de Oliveira, CI (corresponding author), Fiocruz MS, IGM, Salvador, BA, Brazil.; Chang, KP (corresponding author), Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Microbiol Immunol, N Chicago, IL USA.; de Oliveira, CI (corresponding author), INCT, Iii, Sao Paulo, Brazil.
EM kwangpoo.chang@rosalindfranklin.edu; camila@bahia.fiocruz.br
RI de Oliveira, Camila I/B-4358-2009; Ramirez, Laura/Q-5502-2018
OI de Oliveira, Camila I/0000-0002-7868-5164; Ramirez,
   Laura/0000-0003-0597-400X; Ng, Dennis/0000-0001-9087-960X
FU NIH-NIAID grant [AI-68835, AI-7712375, AI-097830]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq) [402312/2012-0]; CNPq
   fellowshipsNational Council for Scientific and Technological Development
   (CNPq)
FX We thank to the support of NIH-NIAID grant # AI-68835, AI-7712375, and
   AI-097830 to KC. Technical assistance of Sujoy Dutta to portion of this
   work is gratefully acknowledged. We also acknowledge the support of
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) -
   (Programa Visitante Especial) Processo 402312/2012-0 to CdO. SV, FC, and
   LR were supported by CNPq fellowships and CdO is a senior investigator
   for CNPq.
CR Acedo P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.77
   AFONSO LCC, 1993, INFECT IMMUN, V61, P2952, DOI 10.1128/IAI.61.7.2952-2959.1993
   Al-Qahtani A, 2016, ANTIMICROB AGENTS CH, V60, P2003, DOI 10.1128/AAC.01879-15
   Alexander J, 1998, J IMMUNOL, V161, P6794
   ALEXANDER J, 1982, T ROY SOC TROP MED H, V76, P646, DOI 10.1016/0035-9203(82)90232-2
   Bhattacharya P, 2015, INFECT IMMUN, V83, P3800, DOI 10.1128/IAI.00184-15
   BITTENCOURT AL, 1993, INT J DERMATOL, V32, P802, DOI 10.1111/j.1365-4362.1993.tb02767.x
   Canavan TN, 2017, PHOTODIAGN PHOTODYN, V18, P257, DOI 10.1016/j.pdpdt.2017.03.019
   Chang Kwang Poo, 2014, J Immunol Immunotech, V1, DOI 10.17653/2374-9105.SSe0001
   Chang KP, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1674-3
   Chen T, 2017, CLIN EXP DERMATOL, V42, P849, DOI 10.1111/ced.13148
   COOK MJ, 1995, PHOTOCHEM PHOTOBIOL, V62, P542, DOI 10.1111/j.1751-1097.1995.tb02381.x
   Cortes DF, 2010, MEM I OSWALDO CRUZ, V105, P736, DOI 10.1590/S0074-02762010000600002
   Daneshvar H, 2003, J INFECT DIS, V187, P1662, DOI 10.1086/374783
   Dey R, 2013, J IMMUNOL, V190, P2138, DOI 10.4049/jimmunol.1202801
   Dutta S, 2005, ANTIMICROB AGENTS CH, V49, P4474, DOI 10.1128/AAC.49.11.4474-4484.2005
   Dutta S, 2008, EUKARYOT CELL, V7, P1146, DOI 10.1128/EC.00365-07
   Dutta S, 2012, PHOTOCHEM PHOTOBIOL, V88, P620, DOI 10.1111/j.1751-1097.2012.01076.x
   Dutta S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020786
   Enk CD, 2015, BRIT J DERMATOL, V172, P1364, DOI 10.1111/bjd.13490
   Gyenge EB, 2013, PHOTOCHEM PHOTOBIOL, V89, P150, DOI 10.1111/j.1751-1097.2012.01217.x
   Kumari S, 2009, EUR J IMMUNOL, V39, P178, DOI 10.1002/eji.200838389
   McMahon-Pratt D, 2004, IMMUNOL REV, V201, P206, DOI 10.1111/j.0105-2896.2004.00190.x
   NADIM A, 1983, B SOC PATHOL EXOT, V76, P377
   Palatnik-De-Sousa CB, 2008, VACCINE, V26, P1709, DOI 10.1016/j.vaccine.2008.01.023
   Reithinger R, 2007, LANCET INFECT DIS, V7, P581, DOI 10.1016/S1473-3099(07)70209-8
   Sah JF, 2002, J BIOL CHEM, V277, P14902, DOI 10.1074/jbc.M200107200
   Pereira BAS, 2008, VET PARASITOL, V158, P239, DOI 10.1016/j.vetpar.2008.09.015
   Schneider-Yin XY, 2009, PHOTODIAGN PHOTODYN, V6, P12, DOI 10.1016/j.pdpdt.2009.02.001
   Selvapandiyan A, 2009, J IMMUNOL, V183, P1813, DOI 10.4049/jimmunol.0900276
   Soong L, 1997, J IMMUNOL, V158, P5374
   Spath GF, 2000, P NATL ACAD SCI USA, V97, P9258, DOI 10.1073/pnas.160257897
   Sundar S, 2014, EXPERT REV VACCINES, V13, P489, DOI 10.1586/14760584.2014.894467
   Uzonna JE, 2004, J IMMUNOL, V172, P3793, DOI 10.4049/jimmunol.172.6.3793
   Villanueva A, 2010, PHOTOCH PHOTOBIO SCI, V9, P295, DOI 10.1039/b9pp00153k
   Wang Y, 2016, J CANCER RES CLIN, V142, P813, DOI 10.1007/s00432-015-2066-3
   Weischenfeldt Joachim, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot5080
   WHO, 2010, WHO TECH REP SER, V949, P1
   Yasinzai M, 2013, FUTURE MED CHEM, V5, P1877, DOI [10.4155/FMC.13.143, 10.4155/fmc.13.143]
NR 39
TC 3
Z9 3
U1 0
U2 13
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD FEB 6
PY 2018
VL 9
AR 165
DI 10.3389/fmicb.2018.00165
PG 10
WC Microbiology
SC Microbiology
GA FU9YD
UT WOS:000424212200001
PM 29467751
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Fukutani, KF
   Kasprzykowski, JI
   Paschoal, AR
   Gomes, MD
   Barral, A
   de Oliveira, CI
   Ramos, PIP
   de Queiroz, ATL
AF Fukutani, Kiyoshi Ferreira
   Kasprzykowski, Jose Irahe
   Paschoal, Alexandre Rossi
   Gomes, Matheus de Souza
   Barral, Aldina
   de Oliveira, Camila, I
   Pereira Ramos, Pablo Ivan
   Lopo de Queiroz, Artur Trancoso
TI Meta-Analysis of Aedes Aegypti Expression Datasets: Comparing Virus
   Infection and Blood-Fed Transcriptomes to Identify Markers of Virus
   Presence
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE Aedes aegypti; alimentation; blood-feeding; meta-analysis;
   transcriptomics; vector-borne diseases; virus infection
AB The mosquito Aedes aegypti (L.) is vector of several arboviruses including dengue, yellow fever, chikungunya, and more recently zika. Previous transcriptomic studies have been performed to elucidate altered pathways in response to viral infection. However, the intrinsic coupling between alimentation and infection were unappreciated in these studies. Feeding is required for the initial mosquito contact with the virus and these events are highly dependent. Addressing this relationship, we reinterrogated datasets of virus-infected mosquitoes with two different diet schemes (fed and unfed mosquitoes), evaluating the metabolic cross-talk during both processes. We constructed coexpression networks with the differentially expressed genes of these comparison: virus-infected versus blood-fed mosquitoes and virus-infected versus unfed mosquitoes. Our analysis identified one module with 110 genes that correlated with infection status (representing similar to 0.7% of the A. aegypti genome). Furthermore, we performed a machine-learning approach and summarized the infection status using only four genes (AAEL012128, AAEL014210, AAEL002477, and AAEL005350). While three of the four genes were annotated as hypothetical proteins, AAEL012128 gene is a membrane amino acid transporter correlated with viral envelope binding. This gene alone is able to discriminate all infected samples and thus should have a key role to discriminate viral infection in the A. aegypti mosquito. Moreover, validation using external datasets found this gene as differentially expressed in four transcriptomic experiments. Therefore, these genes may serve as a proxy of viral infection in the mosquito and the others 106 identified genes provides a framework to future studies.
C1 [Fukutani, Kiyoshi Ferreira; Kasprzykowski, Jose Irahe; Barral, Aldina; de Oliveira, Camila, I; Pereira Ramos, Pablo Ivan; Lopo de Queiroz, Artur Trancoso] Fundacao Oswaldo Cruz FIOCRUZ, Inst Goncalo Moniz, Salvador, BA, Brazil.
   [Kasprzykowski, Jose Irahe; Lopo de Queiroz, Artur Trancoso] Fundacao Oswaldo Cruz FIOCRUZ, Postgrad Program Biotechnol Hlth & Invest, Salvador, BA, Brazil.
   [Paschoal, Alexandre Rossi] Univ Tecnol Fed Parana, UTFPR, Campus Cornell Procopio, Cornell Procopio, Brazil.
   [Gomes, Matheus de Souza] Univ Fed Uberlandia, Patos De Minas, Brazil.
   [Barral, Aldina; de Oliveira, Camila, I] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
   [Lopo de Queiroz, Artur Trancoso] Univ Estadual Feira de Santana, Postgrad Program Appl Computat, Feira De Santana, Brazil.
   [Fukutani, Kiyoshi Ferreira] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Biochem & Immunol, Ribeirao Preto, SP, Brazil.
RP Fukutani, KF; de Queiroz, ATL (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Inst Goncalo Moniz, Salvador, BA, Brazil.; de Queiroz, ATL (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Postgrad Program Biotechnol Hlth & Invest, Salvador, BA, Brazil.; de Queiroz, ATL (corresponding author), Univ Estadual Feira de Santana, Postgrad Program Appl Computat, Feira De Santana, Brazil.; Fukutani, KF (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Biochem & Immunol, Ribeirao Preto, SP, Brazil.
EM ferreirafk@gmail.com; arturqueiroz@bahia.fiocruz.br
RI Ramos, Pablo I. Pereira/H-6276-2019; Fukutani, Kiyoshi/T-1630-2019;
   Paschoal, Alexandre Rossi Rossi/I-4074-2013; de Oliveira, Camila
   I/B-4358-2009
OI Ramos, Pablo I. Pereira/0000-0002-9075-7861; Paschoal, Alexandre Rossi
   Rossi/0000-0002-8887-0582; de Oliveira, Camila I/0000-0002-7868-5164; de
   Queiroz, Artur Trancoso Lopo/0000-0003-4908-9993; Fukutani,
   Kiyoshi/0000-0003-2223-0918
FU Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB)
   [JCB0004/2013]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2017/03491-6]; CNPq-Grant Edital Universal MCTI/CNPQ/Universal14/2014
   [454505/2014-0]
FX AQ acknowledges financial support from Fundacao de Amparo a Pesquisa do
   Estado da Bahia (FAPESB process no. JCB0004/2013). KF was supported by
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP no.
   2017/03491-6). AP acknowledges financial support from CNPq-Grant Edital
   Universal MCTI/CNPQ/Universal14/2014 (Process No.: 454505/2014-0).
CR Arrese EL, 2010, ANNU REV ENTOMOL, V55, P207, DOI 10.1146/annurev-ento-112408-085356
   Bae HG, 2005, J CLIN VIROL, V33, P274, DOI 10.1016/j.jcv.2004.12.001
   Bartholomay LC, 2010, SCIENCE, V330, P88, DOI 10.1126/science.1193162
   Behura SK, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001385
   Bonizzoni M, 2012, G3-GENES GENOM GENET, V2, P103, DOI 10.1534/g3.111.001107
   Bonizzoni M, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-82
   Bottino-Rojas V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135985
   Boudko DY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9546
   Cauchemez S, 2014, EUROSURVEILLANCE, V19, P15, DOI 10.2807/1560-7917.ES2014.19.28.20854
   Chen Y, 2012, DEV COMP IMMUNOL, V38, P88, DOI 10.1016/j.dci.2012.04.007
   Colpitts TM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002189
   Davis TJ, 2016, J MED ENTOMOL, V53, P273, DOI 10.1093/jme/tjv201
   Dissanayake Sumudu N, 2010, BMC Res Notes, V3, P248, DOI 10.1186/1756-0500-3-248
   Dong YM, 2009, J BIOL CHEM, V284, P9835, DOI 10.1074/jbc.M807084200
   Espindola MS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145261
   Evans AM, 2009, J EXP BIOL, V212, P3263, DOI 10.1242/jeb.029553
   Giraldo-Calderon GI, 2015, NUCLEIC ACIDS RES, V43, pD707, DOI 10.1093/nar/gku1117
   Gruber AR, 2008, NUCLEIC ACIDS RES, V36, pW70, DOI 10.1093/nar/gkn188
   Hansen IA, 2011, J BIOL CHEM, V286, P10803, DOI 10.1074/jbc.M110.179739
   Helt AM, 2005, J VIROL, V79, P13218, DOI 10.1128/JVI.79.21.13218-13230.2005
   Ito K, 2008, P NATL ACAD SCI USA, V105, P7523, DOI 10.1073/pnas.0711841105
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Jupatanakul N, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005187
   Kasai S, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002948
   Kerpedjiev P, 2015, BIOINFORMATICS, V31, P3374, DOI 10.1093/bioinformatics/btv372
   Kogelman LJA, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-57
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559
   Langfelder P, 2012, J STAT SOFTW, V46, P1
   Leming MT, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-1128
   Lorenzo MG, 2014, J BRAZIL CHEM SOC, V25, P1799, DOI 10.5935/0103-5053.20140202
   Luplertlop N, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001252
   Mackenzie JS, 2004, NAT MED, V10, pS98, DOI 10.1038/nm1144
   Medeiros MCI, 2016, AM J TROP MED HYG, V95, P1121, DOI 10.4269/ajtmh.16-0236
   Medlock JM, 2012, VECTOR-BORNE ZOONOT, V12, P435, DOI 10.1089/vbz.2011.0814
   Morens DM, 2014, NEW ENGL J MED, V371, P885, DOI 10.1056/NEJMp1408509
   Mosso C, 2008, VIROLOGY, V378, P193, DOI 10.1016/j.virol.2008.05.012
   Nene V, 2007, SCIENCE, V316, P1718, DOI 10.1126/science.1138878
   Pan Y, 2012, J ETHNOPHARMACOL, V143, P586, DOI 10.1016/j.jep.2012.07.024
   Petersen E, 2016, INT J INFECT DIS, V44, P11, DOI 10.1016/j.ijid.2016.02.001
   Porse Charsey Cole, 2015, Emerg Infect Dis, V21, P1827, DOI 10.3201/3210.150494
   Pradier S, 2012, REV SCI TECH OIE, V31, P829
   Ptitsyn AA, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-153
   Roth A, 2014, EUROSURVEILLANCE, V19, P2, DOI 10.2807/1560-7917.ES2014.19.41.20929
   Sathler-Avelar R, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004302
   Seixas G, 2013, MEM I OSWALDO CRUZ, V108, P3, DOI 10.1590/0074-0276130386
   Sim S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002631
   Sim S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010678
   Skalsky RL, 2010, ANNU REV MICROBIOL, V64, P123, DOI 10.1146/annurev.micro.112408.134243
   Slavov SN, 2016, BRAZ J MED BIOL RES, V49, DOI 10.1590/1414-431X20165420
   Souza-Neto JA, 2009, P NATL ACAD SCI USA, V106, P17841, DOI 10.1073/pnas.0905006106
   Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800
   Umesh A, 2003, J EXP BIOL, V206, P2241, DOI 10.1242/jeb.00430
   WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0
   Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484
   Wickham H., 2016, ELEGANT GRAPHICS DAT
   World Health Organization [WHO], 2015, GLOB STRAT DENG PREV
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 57
TC 7
Z9 7
U1 0
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD JAN 11
PY 2018
VL 5
AR 84
DI 10.3389/fbioe.2017.00084
PG 13
WC Biotechnology & Applied Microbiology; Multidisciplinary Sciences
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA GO7MB
UT WOS:000440249200001
PM 29376049
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Carvalho, AM
   Novais, F
   De Oliveira, CI
   Carvalho, LP
   Scott, P
   Carvalho, EM
AF Carvalho, Augusto
   Novais, Fernanda
   De Oliveira, Camila
   Carvalho, Lucas
   Scott, Phillip
   Carvalho, Edgar
TI GLYBURIDE, A NLRP3 INHIBITOR REDUCES INFLAMMATORY RESPONSE AND
   IMMUNOPATHOLOGY IN <it>LEISHMANIA BRAZILIENSIS</it> INFECTION
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 67th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTHM)
CY OCT 28-NOV 01, 2018
CL New Orleans, LA
SP Amer Soc Trop Med & Hyg, Bill & Melinda Gates Fdn, Takeda Pharmaceut Int AG, Novartis Social Business, Celgene Corp, Techlab Inc, Indiana Univ, Sch Med, B EI Resources, Sanofi Pasteur, Welcome, PLOS, Elsevier
C1 [Carvalho, Augusto; Carvalho, Lucas; Carvalho, Edgar] Univ Fed Bahia, Salvador, BA, Brazil.
   [Novais, Fernanda; Scott, Phillip] Univ Penn, Philadelphia, PA 19104 USA.
   [De Oliveira, Camila] Fiocruz MS, Inst Goncalo Moniz, Salvador, BA, Brazil.
RI Carvalho, Lucas/AAP-1844-2020; de Oliveira, Camila I/B-4358-2009
OI de Oliveira, Camila I/0000-0002-7868-5164
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PY 2018
VL 99
IS 4
SU S
MA 2054
BP 646
EP 646
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA HP0WF
UT WOS:000461386605105
DA 2020-12-08
ER

PT J
AU Quintela-Carvalho, G
   Luz, NF
   Celes, FS
   Zanette, DL
   Andrade, D
   Menezes, D
   Tavares, NM
   Brodskyn, CI
   Prates, DB
   Goncalves, MS
   de Oliveira, CI
   Almeida, RP
   Bozza, MT
   Andrade, BB
   Borges, VM
AF Quintela-Carvalho, Graziele
   Luz, Nivea F.
   Celes, Fabiana S.
   Zanette, Dalila L.
   Andrade, Daniela
   Menezes, Diego
   Tavares, Natalia M.
   Brodskyn, Claudia I.
   Prates, Deboraci B.
   Goncalves, Marilda S.
   de Oliveira, Camila I.
   Almeida, Roque P.
   Bozza, Marcelo T.
   Andrade, Bruno B.
   Borges, Valeria M.
TI Heme Drives Oxidative Stress-Associated Cell Death in Human Neutrophils
   Infected with Leishmania infantum
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE Leishmania infantum; heme; iron; neutrophils; cell death; heme oxygenase
   1
ID NF-KAPPA-B; VISCERAL LEISHMANIASIS; CUTANEOUS LEISHMANIASIS; PARASITE
   BURDEN; INNATE IMMUNITY; MACROPHAGES; SUPEROXIDE; AMAZONENSIS;
   MECHANISMS; APOPTOSIS
AB Free heme is an inflammatory molecule capable of inducing migration and activation of neutrophils. Here, we examine the heme-driven oxidative stress-associated cell death mechanisms in human neutrophils infected with Leishmania infantum, an etiologic agent of visceral leishmaniasis (VL). We first performed exploratory analyses in a population of well characterized treatment-naive VL patients as well as uninfected controls, who were part of previously reported studies. We noted a positive correlation between serum concentrations of heme with heme oxygenase-1 (HO-1) and lactate deydrogenase, as well as, a negative correlation between heme values and peripheral blood neutrophils counts. Moreover, in vitro infection with L. infantum in the presence of heme enhanced parasite burden in neutrophils, while increasing the production of reactive oxygen species and release of neutrophilic enzymes. Additional experiments demonstrated that treatment of infected neutrophils with ferrous iron (Fe+2), a key component of the heme molecule, resulted in increased parasite survival without affecting neutrophil activation status. Furthermore, stimulation of infected neutrophils with heme triggered substantial increases in HO-1 mRNA expression as well as in superoxide dismutase-1 enzymatic activity. Heme, but not Fe+2, induced oxidative stress-associated cell death. These findings indicate that heme promotes intracellular L. infantum survival via activation of neutrophil function and oxidative stress. This study opens new perspectives for the understanding of immunopathogenic mechanisms involving neutrophils in VL.
C1 [Quintela-Carvalho, Graziele; Luz, Nivea F.; Celes, Fabiana S.; Zanette, Dalila L.; Andrade, Daniela; Menezes, Diego; Tavares, Natalia M.; Brodskyn, Claudia I.; Goncalves, Marilda S.; de Oliveira, Camila I.; Andrade, Bruno B.; Borges, Valeria M.] IGM, Fundacao Oswaldo Cruz FIOCRUZ, Salvador, BA, Brazil.
   [Quintela-Carvalho, Graziele; Celes, Fabiana S.; Tavares, Natalia M.; Brodskyn, Claudia I.; Goncalves, Marilda S.; de Oliveira, Camila I.; Borges, Valeria M.] Univ Fed Bahia UFBA, Fac Med, Salvador, BA, Brazil.
   [Quintela-Carvalho, Graziele] Inst Fed Educ Ciencia & Tecnol Baiano IFBaiano, Santa Ines, Brazil.
   [Menezes, Diego] ITP, Aracaju, Brazil.
   [Prates, Deboraci B.] Univ Fed Bahia UFBA, Inst Cienc Saude, Dept Biomorfol, Salvador, BA, Brazil.
   [Almeida, Roque P.] UFS, Hosp Univ, Dept Med, Aracaju, Brazil.
   [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Dept Imunol, Rio de Janeiro, RJ, Brazil.
   [Andrade, Bruno B.] MONSTER Initiat, Salvador, BA, Brazil.
   [Andrade, Bruno B.] Laureate Univ, Univ Salvador UNIFACS, Salvador, BA, Brazil.
   [Andrade, Bruno B.] Escola Bahiana Med & Saude Publ, Salvador, BA, Brazil.
RP Andrade, BB; Borges, VM (corresponding author), IGM, Fundacao Oswaldo Cruz FIOCRUZ, Salvador, BA, Brazil.; Borges, VM (corresponding author), Univ Fed Bahia UFBA, Fac Med, Salvador, BA, Brazil.; Andrade, BB (corresponding author), MONSTER Initiat, Salvador, BA, Brazil.; Andrade, BB (corresponding author), Laureate Univ, Univ Salvador UNIFACS, Salvador, BA, Brazil.; Andrade, BB (corresponding author), Escola Bahiana Med & Saude Publ, Salvador, BA, Brazil.
EM bruno.andrade@bahia.fiocruz.br; vborges@bahia.fiocruz.br
RI Andrade, Bruno/AAI-2248-2020; Menezes, Diego/T-4794-2019; Borges,
   Valeria/G-2009-2014; de Oliveira, Camila I/B-4358-2009; Tavares,
   Natalia/AAQ-1527-2020; Borges, Val/N-6647-2019
OI de Oliveira, Camila I/0000-0002-7868-5164; Borges,
   Val/0000-0002-2775-5409; zanette, dalila l./0000-0001-9397-4127; Machado
   Tavares, Natalia/0000-0002-4026-679X; Andrade,
   Bruno/0000-0001-6833-3811; Farias Luz, Nivea/0000-0003-1958-7043
FU Fundacao de Amparo a Pesquisa do Estado da Bahia-FAPESB [RED0018/2013];
   Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico-CNPqNational Council for Scientific and Technological
   Development (CNPq) [478480/2013-0, 552721/2011-5, 019.203.02712/2009-8
   FAPITEC/CNPq]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   SuperiorCAPES [CAPES: 23038.005304/2011-01]; FAPESB; CAPESCAPES
FX This work was supported by grants from Fundacao de Amparo a Pesquisa do
   Estado da Bahia-FAPESB (RED0018/2013 to VB) and from Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico-CNPq (478480/2013-0 to VB,
   552721/2011-5 and 019.203.02712/2009-8 FAPITEC/CNPq to RA). RA also
   received a grant from Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES: 23038.005304/2011-01). GQ-C received a fellowship from
   FAPESB. NL received a fellowship from CAPES. VB, MB, RA, CO, CB, and MG
   are senior investigators from CNPq. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abdelmoula Mohamed Slim, 2003, Tunis Med, V81, P535
   Afonso L, 2008, J LEUKOCYTE BIOL, V84, P389, DOI 10.1189/jlb.0108018
   Almeida BFM, 2017, PARASITE IMMUNOL, V39, DOI 10.1111/pim.12494
   Amaral EP, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0872-7
   Andrade BB, 2010, J IMMUNOL, V185, P1196, DOI 10.4049/jimmunol.0904179
   Araujo-Santos T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04595-8
   Arruda MA, 2004, J IMMUNOL, V173, P2023, DOI 10.4049/jimmunol.173.3.2023
   Ballas SK, 2013, BLOOD, V121, P243, DOI 10.1182/blood-2012-10-462135
   Belic A, 2000, Med Pregl, V53, P89
   Borregaard N, 2007, TRENDS IMMUNOL, V28, P340, DOI 10.1016/j.it.2007.06.002
   Boukhris I, 2015, PAN AFR MED J, V22, DOI 10.11604/pamj.2015.22.96.5662
   Carvalho MOS, 2018, BRIT J HAEMATOL, V182, P933, DOI 10.1111/bjh.14896
   Carvalho S, 2009, ACTA TROP, V109, P131, DOI 10.1016/j.actatropica.2008.10.007
   Cassat JE, 2013, CELL HOST MICROBE, V13, P510, DOI 10.1016/j.chom.2013.04.010
   Celes FS, 2016, SCI REP-UK, V6, DOI 10.1038/srep38330
   Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748
   Huynh C, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002795
   Chen G, 2014, BLOOD, V123, P3818, DOI 10.1182/blood-2013-10-529982
   Dey S, 2012, J BIOL CHEM, V287, P26630, DOI 10.1074/jbc.M112.341255
   Dutra FF, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00115
   Falcao SAC, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003601
   Fenton H.J.H., 1894, J CHEM SOC, V65, P899, DOI [DOI 10.1039/CT8946500899, 10.1039/CT8946500899]
   Fortes GB, 2012, BLOOD, V119, P2368, DOI 10.1182/blood-2011-08-375303
   Fukai T, 2011, ANTIOXID REDOX SIGN, V15, P1583, DOI 10.1089/ars.2011.3999
   Gardinassi LG, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2222-5
   Gardinassi LG, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005123
   Goto Y, 2017, PARASITOL RES, V116, P457, DOI 10.1007/s00436-016-5313-x
   Gozzelino R, 2012, CELL HOST MICROBE, V12, P693, DOI 10.1016/j.chom.2012.10.011
   Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600
   Graca-Souza AV, 2002, BLOOD, V99, P4160, DOI 10.1182/blood.V99.11.4160
   Hurrell BP, 2016, TRENDS PARASITOL, V32, P392, DOI 10.1016/j.pt.2016.02.003
   Kapitulnik J, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00026
   Kedzierski L, 2011, HUM VACCINES, V7, P1204, DOI 10.4161/hv.7.11.17752
   Khouri R, 2009, J IMMUNOL, V182, P2525, DOI 10.4049/jimmunol.0802860
   Larsen R, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00077
   Luz NF, 2012, J IMMUNOL, V188, P4460, DOI 10.4049/jimmunol.1103072
   Luz NF, 2016, J IMMUNOL, V196, P5056, DOI 10.4049/jimmunol.1502492
   Miralda I, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00217
   Mittra B, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005340
   Monteiro APT, 2011, J IMMUNOL, V186, P6562, DOI 10.4049/jimmunol.1002400
   Nauseef WM, 2014, CELL MICROBIOL, V16, P1146, DOI 10.1111/cmi.12312
   Novais FO, 2009, J IMMUNOL, V183, P8088, DOI 10.4049/jimmunol.0803720
   Paiva CN, 2014, ANTIOXID REDOX SIGN, V20, P1000, DOI 10.1089/ars.2013.5447
   Paiva CN, 2012, J CLIN INVEST, V122, P2531, DOI 10.1172/JCI58525
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Pham NK, 2005, INFECT IMMUN, V73, P8322, DOI 10.1128/IAI.73.12.8322-8333.2005
   Porto BN, 2007, J BIOL CHEM, V282, P24430, DOI 10.1074/jbc.M703570200
   Prates DB, 2011, J LEUKOCYTE BIOL, V90, P575, DOI 10.1189/jlb.0211105
   Ribeiro-Gomes FL, 2004, J IMMUNOL, V172, P4454, DOI 10.4049/jimmunol.172.7.4454
   Ribeiro-Gomes FL, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00059
   SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970
   Soares MP, 2016, CURR OPIN IMMUNOL, V38, P94, DOI 10.1016/j.coi.2015.11.006
   Tavares N, 2016, J IMMUNOL, V196, P1865, DOI 10.4049/jimmunol.1502224
   Tavares NM, 2014, J INFECT DIS, V210, P656, DOI 10.1093/infdis/jiu158
   Thakur AK, 2013, EXP PARASITOL, V135, P595, DOI 10.1016/j.exppara.2013.09.008
   Whyte M, 1999, BIOCHEM SOC T, V27, P802, DOI 10.1042/bst0270802
NR 56
TC 9
Z9 9
U1 0
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD NOV 23
PY 2017
VL 8
AR 1620
DI 10.3389/fimmu.2017.01620
PG 12
WC Immunology
SC Immunology
GA FN4YS
UT WOS:000416013600002
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Andrade, DC
   Borges, IC
   Bouzas, ML
   Oliveira, JR
   Fukutani, KF
   Queiroz, AT
   de Oliveira, CI
   Barral, A
   Van Weyenbergh, J
   Nascimento-Carvalho, C
AF Andrade, Dafne C.
   Borges, Igor C.
   Bouzas, Maiara L.
   Oliveira, Juliana R.
   Fukutani, Kiyoshi F.
   Queiroz, Artur T.
   de Oliveira, Camila Indiani
   Barral, Aldina
   Van Weyenbergh, Johan
   Nascimento-Carvalho, Cristiana
TI 10-valent pneumococcal conjugate vaccine (PCV10) decreases metabolic
   activity but not nasopharyngeal carriage of Streptococcus pneumoniae and
   Haemophilus influenzae
SO VACCINE
LA English
DT Article
DE Capsular polysaccharides; Metabolism; Nasopharyngeal colonization;
   Protein D
ID RESPIRATORY-TRACT INFECTION; YOUNG-CHILDREN; MORAXELLA-CATARRHALIS;
   BRAZIL; IDENTIFICATION; PATHOGENS; RNA
AB Background: The effect of pneumococcal vaccination is widely variable when measured by nasopharyngeal carriage of vaccine and non-vaccine targets. The aim of this study was to compare the carriage rates and metabolic activity of Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae and Moraxella catarrhalis among children who were or were not vaccinated with PCV10.
   Methods: We included children with acute respiratory infection aged 6-23 months from a cross-sectional study (CHIADO-IVAS). Nasopharyngeal aspirates were collected and respiratory pathogens were quantified by nCounter digital transcriptomics (Nanostririg) and metagenomic sequencing of 16S ribosomal RNA (Illumina). The metabolic rate was calculated by the ratio between RNA transcripts and 16S DNA reads.
   Results: Out of the 80 patients in this study, 53 were vaccinated with PCV10 and 27 were unvaccinated. There was no difference in nasopharyngeal carriage rates of S. pneumoniae, S. aureus, H. influenzae or M. catarrhalis by either transcriptomic analysis or 16S metagenomics. However, unvaccinated children presented a higher metabolic rate for S. pneumoniae compared to PCV10-vaccinated children (Median [25-75th percentiles]: 126 [22.75-218.41] vs. 0[0-47.83], p = 0.004). Furthermore, unvaccinated children presented a positive correlation between mRNA counts and 16S DNA reads for S. pneumoniae (r = 0.707; p < 0.001) and H. influenzae (r = 0.525; p = 0.005), in contrast to vaccinated children. No such effect was observed for S. aureus and M catarrhalis.
   Conclusions: Vaccination by PCV10 exerts a pathogen-specific effect on pneumococcal metabolic rate. Pathogen RNA/DNA ratio might represent a more sensitive readout for vaccine follow-up, as compared to nasopharyngeal carriage. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Andrade, Dafne C.; Borges, Igor C.; Bouzas, Maiara L.; Oliveira, Juliana R.; de Oliveira, Camila Indiani; Barral, Aldina; Nascimento-Carvalho, Cristiana] Univ Fed Bahia, Sch Med, Postgrad Programme Hlth Sci, Salvador, BA, Brazil.
   [Fukutani, Kiyoshi F.; Queiroz, Artur T.; de Oliveira, Camila Indiani; Barral, Aldina] Fundacao Oswaldo Cruz, Ctr Pesquisa Goncalo Moniz, Salvador, BA, Brazil.
   [de Oliveira, Camila Indiani; Barral, Aldina] Iii INCT, Sao Paulo, Brazil.
   [Van Weyenbergh, Johan] Katholieke Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, Leuven, Belgium.
   [Nascimento-Carvalho, Cristiana] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
RP Andrade, DC (corresponding author), Praca XV Novembro,S-N Largo Terreiro Jesus, BR-40025010 Salvador, BA, Brazil.
EM andradedafne@yahoo.com.br
RI Van Weyenbergh, Johan/B-4187-2009; de Oliveira, Camila I/B-4358-2009;
   Van Weyenbergh, Johan/Q-3829-2019; Borges, Igor Carmo/AAG-8531-2019;
   Fukutani, Kiyoshi/T-1630-2019
OI Van Weyenbergh, Johan/0000-0003-3234-8426; de Oliveira, Camila
   I/0000-0002-7868-5164; Van Weyenbergh, Johan/0000-0003-3234-8426; Carmo
   Borges, Igor/0000-0003-2749-0313; Fukutani, Kiyoshi/0000-0003-2223-0918
FU Bahia State Agency for Research Funding (FAPESB), in Brazil
   [APP0045/2009, PNX 0019/2009, PET 007/2012]; FWO in Belgium [G0D6817N]
FX The research project was supported by the Bahia State Agency for
   Research Funding (FAPESB) (grants APP0045/2009, PNX 0019/2009, PET
   007/2012), in Brazil; and FWO (grant G0D6817N) in Belgium. Aldina
   Barral, Camila I. de Oliveira, and Cristiana Nascimento-Carvalho are
   senior investigators at the Brazilian Council for Scientific and
   Technological Development (CNPq), Brazil.
CR Barczak AK, 2012, P NATL ACAD SCI USA, V109, P6217, DOI 10.1073/pnas.1119540109
   Brandileone MCD, 2016, VACCINE, V34, P5604, DOI 10.1016/j.vaccine.2016.09.027
   Camilli R, 2015, VACCINE, V33, P4559, DOI 10.1016/j.vaccine.2015.07.009
   Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303
   Fukutani KF, 2015, J CLIN VIROL, V69, P190, DOI 10.1016/j.jcv.2015.06.005
   Ilboudo H, 2015, J INFECT DIS, V212, P1996, DOI 10.1093/infdis/jiv337
   Jartti T, 2011, EUR J CLIN MICROBIOL, V30, P233, DOI 10.1007/s10096-010-1075-z
   Laval CB, 2006, CLIN MICROBIOL INFEC, V12, P50, DOI 10.1111/j.1469-0691.2005.01304.x
   Lindstrand A, 2016, VACCINE, V34, P4565, DOI 10.1016/j.vaccine.2016.07.031
   Meier PS, 2002, VACCINE, V20, P1754, DOI 10.1016/S0264-410X(02)00030-0
   Navne JE, 2016, EPIDEMIOL INFECT, V144, P3226, DOI 10.1017/S0950268816001461
   Oliveira JR, 2016, VACCINE, V34, P2556, DOI 10.1016/j.vaccine.2016.04.015
   Prymula R, 2009, VACCINE, V28, P71, DOI 10.1016/j.vaccine.2009.09.113
   Rodrigues HG, 2017, EPIDEMIOL INFECT, V145, P1720, DOI 10.1017/S0950268817000449
   Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/erv.12.53, 10.1586/ERV.12.53]
   Simoes AS, 2016, DIAGN MICR INFEC DIS, V85, P141, DOI 10.1016/j.diagmicrobio.2016.03.018
   Tenenbaum T, 2012, EUR J CLIN MICROBIOL, V31, P3173, DOI 10.1007/s10096-012-1682-y
   van den Bergh MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047711
   van der Poll T, 2009, LANCET, V374, P1543, DOI 10.1016/S0140-6736(09)61114-4
   van Gils EJM, 2011, VACCINE, V29, P7595, DOI 10.1016/j.vaccine.2011.08.049
   Vesikari T, 2016, J PEDIAT INF DIS SOC, V5, P237, DOI 10.1093/jpids/piw010
   Watkins ER, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005034
   Xu QF, 2012, EMERG INFECT DIS, V18, P1738, DOI 10.3201/eid1811.111904
   Yu D, 2010, CLIN MICROBIOL INFEC, V16, P1399, DOI [10.1111/j.1469-0691.2010.03147.x, 10.1111/j.1469-0691.2009.03147.x]
   Zanella RC, 2015, MEM I OSWALDO CRUZ, V110, P755, DOI 10.1590/0074-02760150140
NR 25
TC 8
Z9 8
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 24
PY 2017
VL 35
IS 33
BP 4105
EP 4111
DI 10.1016/j.vaccine.2017.06.048
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA FC3JS
UT WOS:000406735500009
PM 28668567
DA 2020-12-08
ER

PT J
AU Lestinova, T
   Rohousova, I
   Sima, M
   de Oliveira, CI
   Volf, P
AF Lestinova, Tereza
   Rohousova, Iva
   Sima, Michal
   de Oliveira, Camila I.
   Volf, Petr
TI Insights into the sand fly saliva: Blood-feeding and immune interactions
   between sand flies, hosts, and Leishmania
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Review
ID LUTZOMYIA-LONGIPALPIS SALIVA; DELAYED-TYPE HYPERSENSITIVITY; PROTEIN
   PHOSPHATASE-ACTIVITY; NITRIC-OXIDE PRODUCTION; AMINE-BINDING PROTEIN;
   PHLEBOTOMUS-PAPATASI; VISCERAL LEISHMANIASIS; CUTANEOUS LEISHMANIASIS;
   ANTIBODY-RESPONSE; BRAZILIENSIS INFECTION
AB Background
   Leishmaniases are parasitic diseases present worldwide that are transmitted to the vertebrate host by the bite of an infected sand fly during a blood feeding. Phlebotomine sand flies inoculate into the mammalian host Leishmania parasites embedded in promastigote secretory gel (PSG) with saliva, which is composed of a diverse group of molecules with pharmacological and immunomodulatory properties.
   Methods and findings
   In this review, we focus on 3 main aspects of sand fly salivary molecules: (1) structure and composition of salivary glands, including the properties of salivary molecules related to hemostasis and blood feeding, (2) immunomodulatory properties of salivary molecules and the diverse impacts of these molecules on leishmaniasis, ranging from disease exacerbation to vaccine development, and (3) use of salivary molecules for field applications, including monitoring host exposure to sand flies and the risk of Leishmania transmission. Studies showed interesting differences between salivary proteins of Phlebotomus and Lutzomyia species, however, no data were ever published on salivary proteins of Sergentomyia species.
   Conclusions
   In the last 15 years, numerous studies have characterized sand fly salivary proteins and, in parallel, have addressed the impact of such molecules on the biology of the host-sand fly-parasite interaction. The results obtained shall pave the way for the development of field-application tools that could contribute to the management of leishmaniasis in endemic areas.
C1 [Lestinova, Tereza; Rohousova, Iva; Sima, Michal; Volf, Petr] Charles Univ Prague, Fac Sci, Dept Parasitol, Prague, Czech Republic.
   [de Oliveira, Camila I.] Fiocruz MS, Inst Goncalo Moniz, Salvador, BA, Brazil.
RP Lestinova, T (corresponding author), Charles Univ Prague, Fac Sci, Dept Parasitol, Prague, Czech Republic.
EM tereza.kratochvilova@natur.cuni.cz
RI Rohousova, Iva/B-4852-2011; Rohousova, Iva/AAL-9857-2020; Sima,
   Michal/F-2961-2016; Volf, Petr/C-4300-2012; de Oliveira, Camila
   I/B-4358-2009; Lestinova, Tereza/H-1121-2017
OI Rohousova, Iva/0000-0003-1830-0813; Rohousova, Iva/0000-0003-1830-0813;
   Sima, Michal/0000-0001-6927-8615; Volf, Petr/0000-0003-1790-1123; de
   Oliveira, Camila I/0000-0002-7868-5164; Lestinova,
   Tereza/0000-0001-5518-2268
FU Czech Science FoundationGrant Agency of the Czech Republic [17-103083
   S]; Grant Agency of Charles University [GAUK 1642314/2014, UNCE
   204017/2012]
FX This work was supported by Czech Science Foundation (project 17-103083
   S; https://gacr.cz/en/) - IR, MS, PV, Grant Agency of Charles University
   (GAUK 1642314/2014 - TL, IR, UNCE 204017/2012 - TL, MS). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Abdel-Badei NM, 2012, T ROY SOC TROP MED H, V106, P235, DOI 10.1016/j.trstmh.2012.01.006
   Abdeladhim M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004771
   Abdeladhim M, 2014, INFECT GENET EVOL, V28, P691, DOI 10.1016/j.meegid.2014.07.028
   Abdeladhim M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047347
   Abdeladhim M, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001345
   Adler S, 1926, PHLEBOTOMUS PAPATASI, P109
   Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
   Alvarenga PH, 2013, ARTERIOSCL THROM VAS, V33, P2759, DOI 10.1161/ATVBAHA.113.302482
   Alvarenga PH, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000547
   Andersen JF, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-102
   Anderson JM, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-52
   Andrade BB, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00121
   ANJILI CO, 1995, ACTA TROP, V60, P97, DOI 10.1016/0001-706X(95)00112-R
   Antinori S, 2012, EUR J CLIN MICROBIOL, V31, P109, DOI 10.1007/s10096-011-1276-0
   Aquino DMC, 2010, AM J TROP MED HYG, V83, P825, DOI 10.4269/ajtmh.2010.10-0182
   Araujo-Santos T, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000873
   Bahia D, 2007, PARASITOL RES, V100, P449, DOI 10.1007/s00436-006-0307-8
   Barral A, 2000, AM J TROP MED HYG, V62, P740, DOI 10.4269/ajtmh.2000.62.740
   Belkaid Y, 2000, P NATL ACAD SCI USA, V97, P6704, DOI 10.1073/pnas.97.12.6704
   Belkaid Y, 1998, J EXP MED, V188, P1941, DOI 10.1084/jem.188.10.1941
   Bezerra HSD, 2001, MEM I OSWALDO CRUZ, V96, P349
   Bozza PT, 2009, BBA-MOL CELL BIOL L, V1791, P540, DOI 10.1016/j.bbalip.2009.01.005
   Brodie TM, 2007, INFECT IMMUN, V75, P2359, DOI 10.1128/IAI.01812-06
   Calvo E, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-57
   Carvalho AM, 2015, J INFECT DIS, V212, P157, DOI 10.1093/infdis/jiv020
   Cerna P, 2002, INSECT BIOCHEM MOLEC, V32, P1691, DOI 10.1016/S0965-1748(02)00109-1
   Chagas AC, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003923
   CHAMPAGNE DE, 1995, P NATL ACAD SCI USA, V92, P694, DOI 10.1073/pnas.92.3.694
   Charlab R, 1999, P NATL ACAD SCI USA, V96, P15155, DOI 10.1073/pnas.96.26.15155
   Clements MF, 2010, AM J TROP MED HYG, V82, P801, DOI 10.4269/ajtmh.2010.09-0336
   Collin N, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000441
   Collin N, 2012, ARTERIOSCL THROM VAS, V32, P2185, DOI 10.1161/ATVBAHA.112.253906
   COLLIS MG, 1989, PHARMACOL THERAPEUT, V41, P143, DOI 10.1016/0163-7258(89)90104-6
   Costa DJ, 2004, INFECT IMMUN, V72, P1298, DOI 10.1128/IAI.72.3.1298-1305.2004
   Coutinho-Abreu IV, 2010, J MED ENTOMOL, V47, P1146, DOI 10.1603/ME10072
   Dama E, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002455
   de Moura TR, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000084
   de Moura TR, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002242
   de Moura TR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000712
   DIONISOTTI S, 1992, N-S ARCH PHARMACOL, V346, P673
   Dong ZY, 1995, J LEUKOCYTE BIOL, V58, P725
   Dostalova A, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-276
   Drahota J, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002597
   Drame PM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015596
   Duque GA, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00491
   EDLUND A, 1987, THROMB RES, V45, P183, DOI 10.1016/0049-3848(87)90172-1
   Francischetti IMB, 2010, TOXICON, V56, P1130, DOI 10.1016/j.toxicon.2009.12.003
   Gidwani K, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001296
   Gomes RB, 2002, J INFECT DIS, V186, P1530, DOI 10.1086/344733
   Gomes R, 2008, P NATL ACAD SCI USA, V105, P7845, DOI 10.1073/pnas.0712153105
   Gomes R, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005078
   Gomes R, 2012, J INVEST DERMATOL, V132, P2735, DOI 10.1038/jid.2012.205
   Gomes R, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00110
   Gomes RB, 2007, T ROY SOC TROP MED H, V101, P127, DOI 10.1016/j.trstmh.2006.06.002
   HALL LR, 1995, J IMMUNOL, V155, P3501
   Hasko G, 1998, EUR J PHARMACOL, V358, P261, DOI 10.1016/S0014-2999(98)00619-0
   Hasko G, 1996, J IMMUNOL, V157, P4634
   Horta Maria Fatima, 2012, J Parasitol Res, V2012, P203818, DOI 10.1155/2012/203818
   Hostomska J, 2008, VECTOR-BORNE ZOONOT, V8, P443, DOI 10.1089/vbz.2007.0214
   Hostomska J, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-282
   Hotez PJ, 2004, CLIN INFECT DIS, V38, P871, DOI 10.1086/382077
   Isawa H, 2002, J BIOL CHEM, V277, P27651, DOI 10.1074/jbc.M203505200
   Kamhawi S, 2000, SCIENCE, V290, P1351, DOI 10.1126/science.290.5495.1351
   Kato H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-226
   Kato H, 2013, INFECT GENET EVOL, V13, P56, DOI 10.1016/j.meegid.2012.08.024
   Katz O, 2000, AM J TROP MED HYG, V62, P145, DOI 10.4269/ajtmh.2000.62.145
   Killick-Kendrick R, 1999, CLIN DERMATOL, V17, P279, DOI 10.1016/S0738-081X(99)00046-2
   KLEIN J, 1997, IMMUNOLOGY
   Kostalova T, 2016, MED VET ENTOMOL
   Kostalova T, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003855
   Lanzaro GC, 1999, INSECT MOL BIOL, V8, P267, DOI 10.1046/j.1365-2583.1999.820267.x
   LeMoine O, 1996, J IMMUNOL, V156, P4408
   LERNER EA, 1991, J BIOL CHEM, V266, P11234
   Lestinova T, 2015, ACTA TROP, V144, P9, DOI 10.1016/j.actatropica.2015.01.005
   Link AA, 2000, J IMMUNOL, V164, P436, DOI 10.4049/jimmunol.164.1.436
   Londono-Renteria B, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1160-3
   Mans BJ, 2008, J BIOL CHEM, V283, P18721, DOI 10.1074/jbc.M800188200
   Mans BJ, 2007, J BIOL CHEM, V282, P36626, DOI 10.1074/jbc.M706410200
   Maroli M, 2013, MED VET ENTOMOL, V27, P123, DOI 10.1111/j.1365-2915.2012.01034.x
   Martin-Martin I, 2014, VET PARASITOL
   Martin-Martin I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140722
   Martin-Martin I, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/526069
   Martin-Martin I, 2012, ACTA TROP, V123, P22, DOI 10.1016/j.actatropica.2012.03.003
   Marzouki S, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003991
   Marzouki S, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001911
   Marzouki S, 2011, AM J TROP MED HYG, V84, P653, DOI 10.4269/ajtmh.2011.10-0598
   Mbow ML, 1998, J IMMUNOL, V161, P5571
   McDowell MA, 2015, TRENDS PARASITOL, V31, P363, DOI 10.1016/j.pt.2015.04.011
   Miles SA, 2005, J EXP MED, V201, P747, DOI 10.1084/jem.20041470
   Molina R, 2012, VET PARASITOL, V190, P268, DOI 10.1016/j.vetpar.2012.05.006
   Mondragon-Shem K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003449
   Monteiro MC, 2014, REV INST MED TROP SP, V56, P21
   Morris RV, 2001, J IMMUNOL, V167, P5226, DOI 10.4049/jimmunol.167.9.5226
   Loria-Cervera EN, 2014, REV INST MED TROP SP, V56, P1, DOI 10.1590/S0036-46652014000100001
   Norsworthy NB, 2004, INFECT IMMUN, V72, P1240, DOI 10.1128/IAI.72.3.1240-1247.2004
   Oliveira F, 2006, VACCINE, V24, P374, DOI 10.1016/j.vaccine.2005.07.085
   Oliveira F, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000226
   Oliveira F, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3043
   Oliveira MCG, 2007, NEUROSCIENCE, V145, P708, DOI 10.1016/j.neuroscience.2006.12.021
   Paesen GC, 1999, MOL CELL, V3, P661, DOI 10.1016/S1097-2765(00)80359-7
   Peters NC, 2008, SCIENCE, V321, P970, DOI 10.1126/science.1159194
   PIMENTA PFP, 1987, J SUBMICR CYTOL PATH, V19, P387
   Poinsignon A, 2010, TROP MED INT HEALTH, V15, P1198, DOI 10.1111/j.1365-3156.2010.02611.x
   Poinsignon A, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-198
   Poinsignon A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002472
   Prates DB, 2008, J MED ENTOMOL, V45, P409, DOI 10.1603/0022-2585(2008)45[409:CIAOTS]2.0.CO;2
   Prates DB, 2011, J LEUKOCYTE BIOL, V90, P575, DOI 10.1189/jlb.0211105
   Ramalho-Ortigao M, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0914-2
   Ribeiro JMC, 1999, J EXP BIOL, V202, P1551
   RIBEIRO JMC, 1986, COMP BIOCHEM PHYS A, V83, P683, DOI 10.1016/0300-9629(86)90709-7
   Ribeiro JMC, 2003, ANNU REV ENTOMOL, V48, P73, DOI 10.1146/annurev.ento.48.060402.102812
   Ribeiro JMC, 2010, INSECT BIOCHEM MOLEC, V40, P767, DOI 10.1016/j.ibmb.2010.08.002
   Ritter U, 2009, TRENDS PARASITOL, V25, P505, DOI 10.1016/j.pt.2009.08.003
   Rogers KA, 2003, PARASITE IMMUNOL, V25, P127, DOI 10.1046/j.1365-3024.2003.00623.x
   Rogers ME, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00223
   Rohousova I, 2005, PARASITOLOGY, V130, P493, DOI 10.1017/S003118200400681X
   Rohousova I, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0976-1
   Rohousova I, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001660
   Rohousova I, 2012, ACTA TROP, V122, P80, DOI 10.1016/j.actatropica.2011.12.004
   Rohousova I, 2011, INT J PARASITOL, V41, P481, DOI 10.1016/j.ijpara.2011.01.003
   Rossi E, 2008, ACTA TROP, V105, P158, DOI 10.1016/j.actatropica.2007.10.005
   SAMUELSON J, 1991, J EXP MED, V173, P49, DOI 10.1084/jem.173.1.49
   Savoia D, 2015, J INFECT DEV COUNTR, V9, P588, DOI 10.3855/jidc.6833
   Silva F, 2005, AM J TROP MED HYG, V72, P94, DOI 10.4269/ajtmh.2005.72.94
   Sima M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166191
   Sima M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004553
   SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127
   Soares BR, 2013, SCI REP-UK, V3, DOI 10.1038/srep02352
   Soares MBP, 1998, J IMMUNOL, V160, P1811
   Souza AP, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000649
   Tavares NM, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001169
   Teixeira C, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002781
   Teixeira C, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000638
   Teixeira CR, 2005, J IMMUNOL, V175, P8346, DOI 10.4049/jimmunol.175.12.8346
   THEODOS CM, 1991, INFECT IMMUN, V59, P1592, DOI 10.1128/IAI.59.5.1592-1598.1991
   Thiakaki M, 2005, MICROBES INFECT, V7, P760, DOI 10.1016/j.micinf.2005.01.013
   TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436
   Valenzuela JG, 2004, J EXP BIOL, V207, P3717, DOI 10.1242/jeb.01185
   Valenzuela JG, 1998, J BIOL CHEM, V273, P30583, DOI 10.1074/jbc.273.46.30583
   Valenzuela JG, 2001, J EXP MED, V194, P331, DOI 10.1084/jem.194.3.331
   Valenzuela JG, 2001, J EXP BIOL, V204, P229
   Van Assche T, 2011, FREE RADICAL BIO MED, V51, P337, DOI 10.1016/j.freeradbiomed.2011.05.011
   van Zandbergen G, 2004, J IMMUNOL, V173, P6521, DOI 10.4049/jimmunol.173.11.6521
   Vinhas V, 2007, EUR J IMMUNOL, V37, P3111, DOI 10.1002/eji.200737431
   Vlkova M, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002709
   Vlkova M, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001719
   Vlkova M, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001344
   Volf P, 2001, PARASITOLOGY, V122, P37, DOI 10.1017/S0031182000007046
   Volf P, 2000, MED VET ENTOMOL, V14, P251, DOI 10.1046/j.1365-2915.2000.00240.x
   Volfova V, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000294
   Waitumbi J, 1998, INFECT IMMUN, V66, P1534, DOI 10.1128/IAI.66.4.1534-1537.1998
   WARBURG A, 1994, PHILOS T R SOC B, V345, P223, DOI 10.1098/rstb.1994.0097
   Xanthos DN, 2008, PAIN, V137, P640, DOI 10.1016/j.pain.2007.10.031
   Xu XQ, 2013, ACTA CRYSTALLOGR D, V69, P105, DOI 10.1107/S0907444912043326
   Xu XQ, 2011, J BIOL CHEM, V286, P32383, DOI 10.1074/jbc.M111.268904
   Zer R, 2001, INT J PARASITOL, V31, P810, DOI 10.1016/S0020-7519(01)00190-4
NR 156
TC 49
Z9 49
U1 1
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUL
PY 2017
VL 11
IS 7
AR e0005600
DI 10.1371/journal.pntd.0005600
PG 26
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA FE2PD
UT WOS:000408057300005
PM 28704370
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Carvalho, AM
   Fukutani, KF
   Sharma, R
   Curvelo, RP
   Miranda, JC
   Barral, A
   Carvalho, EM
   Valenzuela, JG
   Oliveira, F
   de Oliveira, CI
AF Carvalho, Augusto M.
   Fukutani, Kiyoshi F.
   Sharma, Rohit
   Curvelo, Rebecca P.
   Miranda, Jose Carlos
   Barral, Aldina
   Carvalho, Edgar M.
   Valenzuela, Jesus G.
   Oliveira, Fabiano
   de Oliveira, Camila I.
TI Seroconversion to Lutzomyia intermedia LinB-13 as a biomarker for
   developing cutaneous leishmaniasis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID DELAYED-TYPE HYPERSENSITIVITY; SAND-FLY SALIVA; VISCERAL LEISHMANIASIS;
   PHLEBOTOMUS-PAPATASI; ANTIBODY-RESPONSE; IMMUNE-RESPONSE; BRAZILIENSIS
   INFECTION; LONGIPALPIS SALIVA; IGG4 ANTIBODIES; ENDEMIC AREAS
AB Sand flies inject saliva while feeding in the vertebrate host and anti-saliva antibodies can be used as biomarkers of exposure to Leishmania vectors. We expressed recombinant salivary proteins from Lutzomyia intermedia, a vector of Leishmania braziliensis, and evaluated the seroreactivity in exposed individuals in search for exposure markers. We found a strong correlation among positive serology to recombinant proteins LinB-13, 26, 15, 21 and to salivary proteins: rLinB-13 was the top performing molecule; IgG4 was the most predominant antibody subclass and antibodies to rLinB-13 did not cross react with Lu. longipalpis salivary proteins. By evaluating a cohort of contacts of CL patients, we confirmed that rLinB-13, an antigen 5-related protein, is a marker of exposure to Lu. intermedia with high degree of accuracy. In a 5-year follow up, we determined that individuals who developed CL presented higher anti-rLinB13 IgG responses, before the appearance of clinical symptoms. They also presented a lower frequency of cellular responses to the parasite (DTH). Our results show that seroconversion to a salivary molecule, rLinB-13, is a marker of risk for CL development caused by Leishmania braziliensis. This highlight the possibility of developing tools based on vector molecules to manage the disease in endemic areas.
C1 [Carvalho, Augusto M.; Fukutani, Kiyoshi F.; Sharma, Rohit; Curvelo, Rebecca P.; Miranda, Jose Carlos; Barral, Aldina; Carvalho, Edgar M.; de Oliveira, Camila I.] Fiocruz MS, Inst Goncalo Moniz, BR-40296710 Salvador, BA, Brazil.
   [Carvalho, Augusto M.; Barral, Aldina; Carvalho, Edgar M.; de Oliveira, Camila I.] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
   [Carvalho, Augusto M.; Carvalho, Edgar M.] Univ Fed Bahia, Serv Imunol Hosp Univ Prof Edgard Santos, Salvador, BA, Brazil.
   [Barral, Aldina; de Oliveira, Camila I.] INCT, Inst Invest Imunol III, Sao Paulo, Brazil.
   [Valenzuela, Jesus G.; Oliveira, Fabiano] NIAID, Vector Mol Biol Sect, Lab Malaria & Vector Res, NIH, Rockville, MD USA.
RP de Oliveira, CI (corresponding author), Fiocruz MS, Inst Goncalo Moniz, BR-40296710 Salvador, BA, Brazil.; de Oliveira, CI (corresponding author), Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.; de Oliveira, CI (corresponding author), INCT, Inst Invest Imunol III, Sao Paulo, Brazil.; Oliveira, F (corresponding author), NIAID, Vector Mol Biol Sect, Lab Malaria & Vector Res, NIH, Rockville, MD USA.
EM loliveira@niaid.nih.gov; camila@bahia.fiocruz.br
RI de Oliveira, Camila I/B-4358-2009; Fukutani, Kiyoshi/T-1630-2019;
   Oliveira, Fabiano/AAG-5388-2019; Fukutani, Kiyoshi/N-7905-2016
OI de Oliveira, Camila I/0000-0002-7868-5164; Oliveira,
   Fabiano/0000-0002-7924-8038; Fukutani, Kiyoshi/0000-0003-2223-0918
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI 30639]; Intramural
   Research Program of the NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; National Institute of
   Allergy and Infectious DiseasesUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq) [564689/2008-4];
   Fundacao de Amparo a Pesquisa da Bahia (FAPESB); NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, ZIAAI000932, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   ZIAAI000932, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   ZIAAI000932, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   ZIAAI000932, P50AI030639, ZIAAI000932, P50AI030639, ZIAAI000932,
   U01AI136032, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, ZIAAI000932, P50AI030639, P50AI030639, P50AI030639,
   ZIAAI000932, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, ZIAAI000932, P50AI030639, P50AI030639, P50AI030639,
   U01AI136032, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   ZIAAI000932, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, ZIAAI000932,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   U01AI136032, P50AI030639, P50AI030639] Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health (AI 30639
   to E.M.C.), by the Intramural Research Program of the NIH, National
   Institute of Allergy and Infectious Diseases (J.G.V., and F.O.), and by
   the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
   (564689/2008-4 to C.I.O.). E.M.C., A.B. and C.I.O. are senior
   researchers at CNPq. A.M.C. received fellowship from Fundacao de Amparo
   a Pesquisa da Bahia (FAPESB).
CR Abdeladhim M, 2014, INFECT GENET EVOL, V28, P691, DOI 10.1016/j.meegid.2014.07.028
   Abdeladhim M, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001345
   Aquino DMC, 2010, AM J TROP MED HYG, V83, P825, DOI 10.4269/ajtmh.2010.10-0182
   Barral A, 2000, AM J TROP MED HYG, V62, P740, DOI 10.4269/ajtmh.2000.62.740
   Ben Salah A, 2005, J INFECT DIS, V192, P1981, DOI 10.1086/498042
   BRUMMERKORVENKONTIO H, 1994, J ALLERGY CLIN IMMUN, V93, P551, DOI 10.1016/S0091-6749(94)70066-4
   Carvalho A. M., 2015, J INFECT DIS
   Castellucci L, 2011, GENES IMMUN, V12, P589, DOI 10.1038/gene.2011.37
   Castellucci L, 2006, J INFECT DIS, V194, P519, DOI 10.1086/505504
   Clements MF, 2010, AM J TROP MED HYG, V82, P801, DOI 10.4269/ajtmh.2010.09-0336
   Collin N, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000441
   de Moura TR, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000084
   de Moura TR, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002242
   de Moura TR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000712
   Drahota J, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002597
   Follador I, 2002, CLIN INFECT DIS, V34, pE54, DOI 10.1086/340261
   Geraci NS, 2014, AM J TROP MED HYG, V90, P923, DOI 10.4269/ajtmh.13-0130
   Gomes RB, 2002, J INFECT DIS, V186, P1530, DOI 10.1086/344733
   Gomes R, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00110
   Kamhawi S, 2000, SCIENCE, V290, P1351, DOI 10.1126/science.290.5495.1351
   Kostalova T, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003855
   Ma DY, 2015, ACTA CRYSTALLOGR F, V71, P643, DOI 10.1107/S2053230X1500271X
   Martin-Martin I, 2014, VET PARASITOL, V202, P207, DOI 10.1016/j.vetpar.2014.02.045
   Marzouki S, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003991
   Marzouki S, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001911
   Marzouki S, 2011, AM J TROP MED HYG, V84, P653, DOI 10.4269/ajtmh.2011.10-0598
   Mondragon-Shem K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003449
   Muniz A. C., 2016, J INFECT DIS
   Mussi ADH, 2007, ACTA TROP, V104, P108, DOI 10.1016/j.actatropica.2007.07.011
   Oliveira F, 2006, VACCINE, V24, P374, DOI 10.1016/j.vaccine.2005.07.085
   Oliveira F, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3043
   Oliveira F, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00375
   Orlandi-Pradines E, 2007, MICROBES INFECT, V9, P1454, DOI 10.1016/j.micinf.2007.07.012
   PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730
   Ramasawmy R, 2010, INFECT GENET EVOL, V10, P607, DOI 10.1016/j.meegid.2010.04.006
   REED SG, 1986, AM J TROP MED HYG, V35, P79, DOI 10.4269/ajtmh.1986.35.79
   REUNALA T, 1994, INT ARCH ALLERGY IMM, V104, P366, DOI 10.1159/000236693
   Rohousova I, 2005, PARASITOLOGY, V130, P493, DOI 10.1017/S003118200400681X
   Satoguina JS, 2005, J IMMUNOL, V174, P4718, DOI 10.4049/jimmunol.174.8.4718
   SCHWARTZ BS, 1991, AM J EPIDEMIOL, V134, P86, DOI 10.1093/oxfordjournals.aje.a115996
   Shan En-Zhi, 1995, Journal of Dermatology (Tokyo), V22, P411, DOI 10.1111/j.1346-8138.1995.tb03415.x
   Sima M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004553
   Souza AP, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000649
   Teixeira C, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000638
   Valenzuela JG, 2001, J EXP MED, V194, P331, DOI 10.1084/jem.194.3.331
   Vinhas V, 2007, EUR J IMMUNOL, V37, P3111, DOI 10.1002/eji.200737431
NR 46
TC 4
Z9 4
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 9
PY 2017
VL 7
AR 3149
DI 10.1038/s41598-017-03345-0
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EX1CM
UT WOS:000402957400030
PM 28600554
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Solana, JC
   Ramirez, L
   Corvo, L
   de Oliveira, CI
   Barral-Netto, M
   Requena, JM
   Iborra, S
   Soto, M
AF Carlos Solana, Jose
   Ramirez, Laura
   Corvo, Laura
   de Oliveira, Camila Indiani
   Barral-Netto, Manoel
   Maria Requena, Jose
   Iborra, Salvador
   Soto, Manuel
TI Vaccination with a Leishmania infantum HSP70-II null mutant confers
   long-term protective immunity against Leishmania major infection in two
   mice models
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID MEMORY T-CELLS; OLIGODEOXYNUCLEOTIDES INDUCES PROTECTION; CUTANEOUS
   LEISHMANIASIS; POSTTRANSCRIPTIONAL REGULATION; CONCOMITANT IMMUNITY;
   VISCERAL INFECTION; VACCINES; PERSISTENT; PARASITES; GENE
AB Background
   The immunization with genetically attenuated Leishmania cell lines has been associated to the induction of memory and effector T cell responses against Leishmania able to control subsequent challenges. A Leishmania infantum null mutant for the HSP70-II genes has been described, possessing a non-virulent phenotype.
   Methodology/Principal findings
   The L. infantum attenuated parasites (Li.HSP70-II) were inoculated in BALB/c (intravenously and subcutaneously) and C57BL/6 (subcutaneously) mice. An asymptomatic infection was generated and parasites diminished progressively to become undetectable in most of the analyzed organs. However, inoculation resulted in the long-term induction of parasite specific IFN-gamma responses able to control the disease caused by a challenge of L. major infective promastigotes. BALB/c susceptible mice showed very low lesion development and a drastic decrease in parasite burdens in the lymph nodes draining the site of infection and internal organs. C57BL/6 mice did not show clinical manifestation of disease, correlated to the rapid migration of Leishmania specific IFN-gamma producing T cells to the site of infection.
   Conclusion/Significance
   Inoculation of the Li.HSP70-II attenuated line activates mammalian immune system for inducing moderate pro-inflammatory responses. These responses are able to confer long-term protection in mice against the infection of L. major virulent parasites.
C1 [Carlos Solana, Jose; Ramirez, Laura; Corvo, Laura; Maria Requena, Jose; Iborra, Salvador; Soto, Manuel] Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, Dept Biol Mol Nicolas Cabrera 1, Madrid, Spain.
   [de Oliveira, Camila Indiani; Barral-Netto, Manoel] Fiocruz MS, Ctr Pesquisas Goncalo Moniz, Fundacao Oswaldo Cruz, Salvador, BA, Brazil.
RP Iborra, S (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, Dept Biol Mol Nicolas Cabrera 1, Madrid, Spain.
EM siborra@cnic.es; msoto@cbm.csic.es
RI de Oliveira, Camila I/B-4358-2009; Iborra, Salvador/J-2863-2015;
   Requena, Jose M/I-2022-2019; Iborra, Salvador/Y-9621-2019; Alvarez,
   Manuel Soto/Q-5234-2018; Ramirez, Laura/Q-5502-2018; Barral Netto,
   Manoel/B-3904-2009
OI de Oliveira, Camila I/0000-0002-7868-5164; Iborra,
   Salvador/0000-0002-1607-1749; Requena, Jose M/0000-0001-7550-0198;
   Iborra, Salvador/0000-0002-1607-1749; Alvarez, Manuel
   Soto/0000-0001-6825-841X; Ramirez, Laura/0000-0003-0597-400X; Solana,
   Jose Carlos/0000-0002-0485-6127; Corvo, Laura/0000-0001-5907-4993;
   Barral Netto, Manoel/0000-0002-5823-7903
FU Ministerio de Ciencia Innovacion from the Heath Institute Carlos III
   (ISCIII) [FISPI14/00366]; European Community Seventh Framework
   ProgrammeEuropean Union (EU)European Community (EC) [603181]; Fondo de
   Investigaciones SanitariasInstituto de Salud Carlos III
   [ISCIII-RETICRD16/0027/0008-FEDER]; CNPq within the Ciencia sem
   Fronteiras-PVE program [300174/2014-4]; EU 7th Framework
   ProgrammeEuropean Union (EU) [603181]; Fundacion Ramon Areces
FX The study was supported in Spain by grants from Ministerio de Ciencia
   Innovacion FISPI14/00366 (FEDER FUNDING) from the Heath Institute Carlos
   III (ISCIII). JCS was supported by the European Community Seventh
   Framework Programme under grant agreement No. 603181 Project
   MuLeVaClin), and LC was supported by a grant from Fondo de
   Investigaciones Sanitarias (ISCIII-RETICRD16/0027/0008-FEDER). A
   Brazilian grant from CNPq within the Ciencia sem Fronteiras-PVE program
   (Ref: 300174/2014-4) is also acknowledged. Finally, we also acknowledge
   the funding from the EU 7th Framework Programme under grant agreement
   No. 603181 (MuLeVaClin). A CBMSO institutional grant from Fundacion
   Ramon Areces is also acknowledged. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ahmed S, 2003, INFECT IMMUN, V71, P401, DOI 10.1128/IAI.71.1.401-410.2003
   Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
   Amaral VF, 2002, MEM I OSWALDO CRUZ, V97, P1041, DOI 10.1590/S0074-02762002000700019
   Belkaid Y, 2000, J IMMUNOL, V165, P969, DOI 10.4049/jimmunol.165.2.969
   Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152
   Belkaid Y, 2001, J EXP MED, V194, P1497, DOI 10.1084/jem.194.10.1497
   Brown SP, 2001, P ROY SOC B-BIOL SCI, V268, P2543, DOI 10.1098/rspb.2001.1821
   BUFFET PA, 1995, ANTIMICROB AGENTS CH, V39, P2167, DOI 10.1128/AAC.39.9.2167
   Carrion J, 2006, PARASITE IMMUNOL, V28, P173, DOI 10.1111/j.1365-3024.2006.00817.x
   Carrion J, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-150
   Davoudi N, 2005, VACCINE, V23, P1170, DOI 10.1016/j.vaccine.2004.08.032
   Davoudi N, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002785
   Dey R, 2013, J IMMUNOL, V190, P2138, DOI 10.4049/jimmunol.1202801
   Engwerda CR, 2000, IMMUNOL TODAY, V21, P73, DOI 10.1016/S0167-5699(99)01549-2
   Folgueira C, 2005, J BIOL CHEM, V280, P35172, DOI 10.1074/jbc.M505559200
   Folgueira C, 2008, INT MICROBIOL, V11, P81, DOI 10.2436/20.1501.01.47
   Garg R, 2006, INDIAN J MED RES, V123, P439
   Glennie ND, 2016, CELL IMMUNOL, V309, P50, DOI 10.1016/j.cellimm.2016.07.010
   Glennie ND, 2015, J EXP MED, V212, P1405, DOI 10.1084/jem.20142101
   Gomes R, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001610
   Greenwood B., 2017, LANCET INFECT DIS
   Gumy A, 2004, INT J PARASITOL, V34, P433, DOI 10.1016/j.ijpara.2003.11.021
   Helmbrecht K, 2000, CELL PROLIFERAT, V33, P341, DOI 10.1046/j.1365-2184.2000.00189.x
   Iborra S, 2005, INFECT IMMUN, V73, P5842, DOI 10.1128/IAI.73.9.5842-5852.2005
   Iborra S, 2004, VACCINE, V22, P3865, DOI 10.1016/j.vaccine.2004.04.015
   Iborra S, 2008, MICROBES INFECT, V10, P1133, DOI 10.1016/j.micinf.2008.06.002
   Ishizuka AS, 2016, NAT MED, V22, P614, DOI 10.1038/nm.4110
   Kebaier C, 2006, INFECT IMMUN, V74, P777, DOI 10.1128/IAI.74.1.777-780.2006
   Khamesipour A, 2005, VACCINE, V23, P3642, DOI 10.1016/j.vaccine.2005.02.015
   Khamesipour Ali, 2012, Indian J Dermatol, V57, P123, DOI 10.4103/0019-5154.94280
   Kublin JG, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aad9099
   Larsen MH, 2009, VACCINE, V27, P4709, DOI 10.1016/j.vaccine.2009.05.050
   LASKAY T, 1995, EUR J IMMUNOL, V25, P2220, DOI 10.1002/eji.1830250816
   Lauring AS, 2010, NAT BIOTECHNOL, V28, P573, DOI 10.1038/nbt.1635
   Lopes CS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162927
   Maroof A, 2008, IMMUNITY, V29, P295, DOI 10.1016/j.immuni.2008.06.012
   Melby PC, 1998, INFECT IMMUN, V66, P18, DOI 10.1128/IAI.66.1.18-27.1998
   Mendez A, 2002, VACCINE, V20, P3702, DOI 10.1016/S0264-410X(02)00376-6
   Mendez S, 2001, J IMMUNOL, V166, P5122, DOI 10.4049/jimmunol.166.8.5122
   Miles SA, 2005, J EXP MED, V201, P747, DOI 10.1084/jem.20041470
   Mou ZR, 2013, J IMMUNOL, V190, P3380, DOI 10.4049/jimmunol.1202537
   Murphy ML, 2001, EUR J IMMUNOL, V31, P2848, DOI 10.1002/1521-4141(2001010)31:10&lt;2848::AID-IMMU2848&gt;3.0.CO;2-T
   Nagill R, 2011, INT IMMUNOPHARMACOL, V11, P1464, DOI 10.1016/j.intimp.2011.05.008
   Nation CS, 2012, PARASITOL RES, V111, P1407, DOI 10.1007/s00436-012-2899-5
   Nylen S, 2007, J EXP MED, V204, P805, DOI 10.1084/jem.20061141
   Okwor I, 2008, IMMUNOL RES, V41, P123, DOI 10.1007/s12026-008-8016-2
   Okwor I, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00128
   Pagan AJ, 2013, EUR J IMMUNOL, V43, P427, DOI 10.1002/eji.201242715
   Peters NC, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004538
   Peters NC, 2012, J IMMUNOL, V189, P4832, DOI 10.4049/jimmunol.1201676
   Peters NC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000484
   Quijada L, 1997, J BIOL CHEM, V272, P4493, DOI 10.1074/jbc.272.7.4493
   Rajakumar S, 2006, J PARASITOL, V92, P41, DOI 10.1645/GE-3507.1
   REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.immunol.13.1.151
   Requena JM, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/301326
   Ribeiro-Gomes FL, 2014, INFECT IMMUN, V82, P2713, DOI 10.1128/IAI.01600-13
   Rittig MG, 2000, PARASITOL TODAY, V16, P292, DOI 10.1016/S0169-4758(00)01692-6
   Romano A, 2015, J IMMUNOL, V195, P3816, DOI 10.4049/jimmunol.1500752
   Russell PK, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004854
   Sacks DL, 2014, NAT IMMUNOL, V15, P403, DOI 10.1038/ni.2853
   Saljoughian N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00134
   Scott P, 2004, IMMUNOL REV, V201, P318, DOI 10.1111/j.0105-2896.2004.00198.x
   Scott P, 2016, NAT REV IMMUNOL, V16, P581, DOI 10.1038/nri.2016.72
   Seder RA, 2013, SCIENCE, V341, P1359, DOI 10.1126/science.1241800
   Selvapandiyan A, 2001, J BIOL CHEM, V276, P43253, DOI 10.1074/jbc.M106806200
   Selvapandiyan A, 2009, J IMMUNOL, V183, P1813, DOI 10.4049/jimmunol.0900276
   Silvestre R, 2007, J IMMUNOL
   Spath GF, 2004, INFECT IMMUN, V72, P3622, DOI 10.1128/IAI.72.6.3622-3627.2004
   Stephens R, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001208
   Stewart J, 2005, INT J PARASITOL, V35, P861, DOI 10.1016/j.ijpara.2005.03.008
   Stinson E, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftw079
   Struik SS, 2004, IMMUNOL REV, V201, P268, DOI 10.1111/j.0105-2896.2004.00181.x
   TITUS RG, 1995, P NATL ACAD SCI USA, V92, P10267, DOI 10.1073/pnas.92.22.10267
   Uzonna JE, 2004, J IMMUNOL, V172, P3793, DOI 10.4049/jimmunol.172.6.3793
   Zaph C, 2004, NAT MED, V10, P1104, DOI 10.1038/nm1108
   Zhang X, 2016, HUM VACC IMMUNOTHER, P1
NR 76
TC 10
Z9 10
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD MAY
PY 2017
VL 11
IS 5
AR e0005644
DI 10.1371/journal.pntd.0005644
PG 26
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA EX0RA
UT WOS:000402927300068
PM 28558043
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Florez, MM
   de Oliveira, CI
   Puerta, C
   Guzman, F
   Ayala, M
   Montoya, G
   Delgado, G
AF Melissa Florez, Magda
   Indiani de Oliveira, Camila
   Puerta, Concepcion
   Guzman, Fanny
   Ayala, Martha
   Montoya, Gladis
   Delgado, Gabriela
TI Synthetic Peptides Derived from Ribosomal Proteins of Leishmania spp. in
   Mucocutaneous Leishmaniasis: Diagnostic Usefulness
SO PROTEIN AND PEPTIDE LETTERS
LA English
DT Article
DE Mucocutaneous leishmaniasis; diagnosis; synthetic peptide; ribosomal
   protein; parasite; Leishmania braziliensis
ID LINKED-IMMUNOSORBENT-ASSAY; VISCERAL LEISHMANIASIS; TEGUMENTARY
   LEISHMANIASIS; SERODIAGNOSIS; ELISA; CANINE; IMMUNODIAGNOSIS;
   INFECTIONS; ANTIGENS
AB Background: The serological diagnostic methods currently available for mucocutaneous leishmaniasis (MCL) lack specificity when complete parasites are used; however, such specificity increases when protein fractions are used. Ribosomal proteins have been reported to induce antibodies in animal and humans infected with the parasite, making them a worth candidate to assess its diagnosis potential.
   Objective: This study was thus aimed at evaluating synthetic peptides derived from Leishmania braziliensis ribosomal proteins S25 and S5 as antigen candidates for diagnosing MCL by ELISA
   Methods: It was used 8 and 13 peptides derived from ribosomal proteins 25 and S5 respectively as antigens in order to detect IgG antibodies by ELISA in people with active MCL, Chagas disease (CH) and autoimmune disease (AID).
   Results: 4 of these 21 peptides (P4, P6, P19 and P21) had the greatest sensitivity (21.7%, 13.04%, 20% and 20%, respectively) as well as having 95%, 100%, 100% and 82.5% specificity, respectively.
   Conclusion: The study revealed the limited usefulness of the peptides being studied as a diagnostic tool in the conditions used here, because its low sensitivity, but it is worth highlighting that the use of peptides as antigen in the serodiagnosis of MCL may overcome the cross reaction presented with other antigens, thus avoiding false positives.
C1 [Melissa Florez, Magda; Delgado, Gabriela] Univ Nacl Colombia, Fac Ciencias, Dept Farm, Grp Invest Inmunotoxicol, Carrera 30 45-01, Bogota, Colombia.
   [Indiani de Oliveira, Camila] Fiocruz MS, Ctr Pesquisas Goncalo Moniz, Lab Inmunoparasitol, Salvador Bahia Rua Waldemar Falcao 121, Candeal Salvador, BA, Brazil.
   [Puerta, Concepcion] Pontificia Univ Javeriana, Fac Ciencias, Grp Invest Enfermedades Infecciosas, Carrera 7 40-62, Bogota, Colombia.
   [Guzman, Fanny] Pontificia Univ Catolica Valparaiso, Nucleo Biolotecnol Curauma, Ave Univ 330, Valparaiso, Chile.
   [Ayala, Martha] Inst Nacl Salud, Lab Parasitol, Ave Calle 26 51-20, Bogota, Colombia.
   [Montoya, Gladis] Univ Rosario, Ctr Estudio Enfermedades Autoinmunes, Carrera 26,63B-51, Bogota, Colombia.
RP Delgado, G (corresponding author), Univ Nacl Colombia, Fac Ciencias, Dept Farm, Grp Invest Inmunotoxicol, Carrera 30 45-01, Bogota, Colombia.
EM lgdelgadom@unal.edu.co
RI Guzman, Fanny fg/K-5592-2013; Puerta, Concepcion J/AAG-4912-2019; de
   Oliveira, Camila I/B-4358-2009
OI Guzman, Fanny fg/0000-0003-1537-0904; de Oliveira, Camila
   I/0000-0002-7868-5164; Delgado, Gabriela/0000-0003-2947-7796
FU Universidad Nacional de Colombia's Bogota Research Division (DIB)
   [16015]; Colombian Science, Technology and Innovation Department's
   (Colciencias) Young Researchers and Innovators programme "Virginia
   Gutierrez de Pineda"; Colombian Science, Technology and Innovation
   Department's (Colciencias) Grant [03092013, 57635945, 6]
FX This work was financed by the Universidad Nacional de Colombia's Bogota
   Research Division (DIB) project 16015, as well as a grant from the
   Colombian Science, Technology and Innovation Department's (Colciencias)
   Young Researchers and Innovators programme "Virginia Gutierrez de
   Pineda" (2012) and Colciencias Grant (contract number 03092013, code
   57635945-project 6). We Thank to National University of Colombia and its
   Master program on Microbiology. Thanks to Juqueline Cristal and to
   FAMETRA group by all their support in the development of the present
   work.
CR Abass E, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002322
   [Anonymous], NEW TECHN REP SER CO
   Barroso-Freitas APT, 2009, T ROY SOC TROP MED H, V103, P383, DOI 10.1016/j.trstmh.2008.12.019
   Bhattacharyya T, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002892
   Bottino CG, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-568
   Celeste BJ, 2014, AM J TROP MED HYG, V90, P860, DOI 10.4269/ajtmh.13-0623
   Celeste BI, 2004, BRAZ J MED BIOL RES, V37, P1591, DOI 10.1590/S0100-879X2004001100001
   Costa MM, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001622
   de Carvalho CA, 2013, ACTA TROP, V125, P128, DOI 10.1016/j.actatropica.2012.10.010
   Metz GE, 2014, J VIROL METHODS, V205, P3, DOI 10.1016/j.jviromet.2014.04.018
   Faria AR, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001310
   Goto H, 2010, EXPERT REV ANTI-INFE, V8, P419, DOI [10.1586/eri.10.19, 10.1586/ERI.10.19]
   GUIMARAES MCS, 1989, B WORLD HEALTH ORGAN, V67, P643
   Intapan PM, 2013, KOREAN J PARASITOL, V51, P763, DOI 10.3347/kjp.2013.51.6.763
   Kaur Jaspreet, 2013, J Parasit Dis, V37, P68, DOI 10.1007/s12639-012-0133-0
   Lakhal S, 2012, CLIN VACCINE IMMUNOL, V19, P1487, DOI 10.1128/CVI.00257-12
   MALCHIODI EL, 1994, CLIN EXP IMMUNOL, V97, P417, DOI 10.1111/j.1365-2249.1994.tb06104.x
   Montoya Y, 1997, T ROY SOC TROP MED H, V91, P674, DOI 10.1016/S0035-9203(97)90520-4
   Requena JM, 2000, PARASITOL TODAY, V16, P246, DOI 10.1016/S0169-4758(00)01651-3
   Romero GAS, 2005, ACTA TROP, V93, P49, DOI 10.1016/j.actatropica.2004.09.005
   Soto M, 1996, CLIN DIAGN LAB IMMUN, V3, P387, DOI 10.1128/CDLI.3.4.387-391.1996
   Souza AP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066110
   Vargas-Duarte Jimmy J, 2009, Rev. salud pública, V11, P641
NR 23
TC 5
Z9 5
U1 0
U2 1
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8665
EI 1875-5305
J9 PROTEIN PEPTIDE LETT
JI Protein Pept. Lett.
PY 2017
VL 24
IS 10
BP 982
EP 988
DI 10.2174/0929866524666170728143924
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA FS6JK
UT WOS:000419903500013
PM 28758598
DA 2020-12-08
ER

PT J
AU Reboucas-Silva, J
   Celes, FS
   Lima, JB
   Barud, HS
   de Oliveira, CI
   Berretta, AA
   Borges, VM
AF Reboucas-Silva, Jessica
   Celes, Fabiana S.
   Lima, Jonilson Berlink
   Barud, Hernane S.
   de Oliveira, Camila I.
   Berretta, Andresa A.
   Borges, Valeria M.
TI Parasite Killing of Leishmania (V) braziliensis by Standardized Propolis
   Extracts
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID ACID PHENETHYL ESTER; GROWTH-FACTOR-BETA; CUTANEOUS LEISHMANIASIS; GREEN
   PROPOLIS; CHEMICAL-COMPOSITION; PHENOLIC-COMPOUNDS; IN-VITRO; CELLS;
   DIVERSITY; APOPTOSIS
AB Treatments based on antimonials to cutaneous leishmaniasis (CL) entail a range of toxic side effects. Propolis, a natural compound widely used in traditional medical applications, exhibits a range of biological effects, including activity against infectious agents. The aim of this study was to test the potential leishmanicidal effects of different propolis extracts against Leishmania (Viannia) braziliensis promastigotes and intracellular amastigotes in vitro. Stationary-phase L. (V) braziliensis promastigotes were incubated with mediumalone or treated with dry, alcoholic, or glycolic propolis extract (10, 50, or 100 mu g/mL) for 96 h. Our data showed that all extracts exhibited a dose-dependent effect on the viability of L. (V) braziliensis promastigotes, while controlling the parasite burden inside infected macrophages. Dry propolis extract significantly modified the inflammatory profile of murine macrophages by downmodulating TGF-beta and IL-10 production, while upmodulating TNF-alpha All three types of propolis extractwere found to reduce nitric oxide and superoxide levels in activated L. braziliensis-infected macrophages. Altogether, our results showed that propolis extracts exhibited a leishmanicidal effect against both stages of L. (V) braziliensis. The low cell toxicity and efficient microbicidal effect of alcoholic or glycolic propolis extracts make them candidates to an additive treatment for cutaneous leishmaniasis.
C1 [Reboucas-Silva, Jessica; Celes, Fabiana S.; de Oliveira, Camila I.; Borges, Valeria M.] Fundacao Oswaldo Cruz, Inst Goncalo Moniz, Salvador, BA, Brazil.
   [Reboucas-Silva, Jessica; Borges, Valeria M.] Univ Fed Bahia, Salvador, BA, Brazil.
   [Lima, Jonilson Berlink] Univ Fed Oeste Bahia, Ctr Ciencias Biol & Saude, Barreiras, BA, Brazil.
   [Barud, Hernane S.] Univ Estadual Paulista, Inst Quim, Araraquara, SP, Brazil.
   [Barud, Hernane S.] Univ Araraquara, Programa Posgrad Biotecnol, Araraquara, SP, Brazil.
   [Berretta, Andresa A.] Apis Flora Ind & Comercial Ltda, Lab Pesquisa Desenvolvimento & Inovacao, Ribeirao Preto, SP, Brazil.
   [Berretta, Andresa A.] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Dept Ciencias Farmaceut, Ave Cafe S-N, BR-14049900 Ribeirao Preto, SP, Brazil.
RP Borges, VM (corresponding author), Fundacao Oswaldo Cruz, Inst Goncalo Moniz, Salvador, BA, Brazil.; Borges, VM (corresponding author), Univ Fed Bahia, Salvador, BA, Brazil.; Berretta, AA (corresponding author), Apis Flora Ind & Comercial Ltda, Lab Pesquisa Desenvolvimento & Inovacao, Ribeirao Preto, SP, Brazil.; Berretta, AA (corresponding author), Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Dept Ciencias Farmaceut, Ave Cafe S-N, BR-14049900 Ribeirao Preto, SP, Brazil.
EM andresa.berretta@apisflora.com.br; vborges@bahia.fiocruz.br
RI Lima, Jonilson Berlink/E-1531-2015; Borges, Val/N-6647-2019; de
   Oliveira, Camila I/B-4358-2009; Borges, Valeria/G-2009-2014
OI Lima, Jonilson Berlink/0000-0002-1403-4768; Borges,
   Val/0000-0002-2775-5409; de Oliveira, Camila I/0000-0002-7868-5164;
   Silva, Jessica/0000-0003-0062-7316
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico,
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [309988/2014-4]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo,
   FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2013/50496-2]; Financiadora de Estudos e Projetos, FINEPCiencia
   Tecnologia e Inovacao (FINEP) [03.12.0056.00]; Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES; CNPqNational
   Council for Scientific and Technological Development (CNPq)
FX The authors thank Andrezza Souza for technical and logistics support.
   They thank Dr. Fabio Formiga for their helpful discussions and Dr.
   Adriana Rangel and Dr. Claudio Figueira for their technical assistance
   with the electron microscopy. This work was supported by grants from
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, CNPq
   (Process no. 309988/2014-4 to Valeria M. Borges), Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo, FAPESP (Process no. 2013/50496-2 to
   Andresa A. Berretta), and Financiadora de Estudos e Projetos, FINEP
   (Process no. 03.12.0056.00 to Andresa A. Berretta). Valeria M. Borges,
   Andresa A. Berretta, and Camila I. de Oliveira are senior investigators
   from CNPq. Jessica Reboucas-Silva and Fabiana S. Celes have fellowships
   from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES). Hernane S. Barud has fellowship from CNPq.
CR Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
   Amarante MK, 2012, J PHARM PHARMACOL, V64, P154, DOI 10.1111/j.2042-7158.2011.01385.x
   Andrade CAS, 2009, COLLOID SURFACE B, V68, P7, DOI 10.1016/j.colsurfb.2008.08.020
   Ayres DC, 2007, MEM I OSWALDO CRUZ, V102, P215, DOI 10.1590/S0074-02762007005000020
   Ayres DC, 2011, REV INST MED TROP SP, V53, P329, DOI 10.1590/S0036-46652011000600006
   Bankova VS, 2000, APIDOLOGIE, V31, P3, DOI 10.1051/apido:2000102
   BARRAL A, 1995, AM J PATHOL, V147, P947
   BARRAL A, 1993, P NATL ACAD SCI USA, V90, P3442, DOI 10.1073/pnas.90.8.3442
   BARRALNETTO M, 1992, SCIENCE, V257, P545, DOI 10.1126/science.1636092
   Barud HS, 2013, EVID-BASED COMPL ALT, V2013
   Berretta AA, 2012, INT J BIOL SCI, V8, P512, DOI 10.7150/ijbs.3641
   Chavez-Fumagalli MA, 2015, REV SOC BRAS MED TRO, V48, P235, DOI 10.1590/0037-8682-0138-2015
   Chouhan G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00193
   da Silva AA, 2009, FITOTERAPIA, V80, P478, DOI 10.1016/j.fitote.2009.06.007
   da Silva NS, 2009, CAD SAUDE PUBLICA, V25, P1325, DOI 10.1590/S0102-311X2009000600015
   da Silva SS, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/673058
   de Castro PA, 2011, EUKARYOT CELL, V10, P398, DOI 10.1128/EC.00256-10
   de Castro PA, 2013, FUNGAL GENET BIOL, V60, P74, DOI 10.1016/j.fgb.2013.07.001
   Petersen ALDA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049496
   de Oliveira CI, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00145
   de Sa RA, 2013, BRAZ J MICROBIOL, V44, P993, DOI 10.1590/S1517-83822013005000062
   de Sousa JPB, 2007, J SEP SCI, V30, P2656, DOI 10.1002/jssc.200700228
   DeSmet PAGM, 1997, DRUGS, V54, P801, DOI 10.2165/00003495-199754060-00003
   Dezaki ES, 2016, PHARM BIOL, V54, P752, DOI 10.3109/13880209.2015.1079223
   do Nascimento TG, 2016, NANOSCALE RES LETT, V11, DOI 10.1186/s11671-016-1517-3
   ELSTNER EF, 1976, ANAL BIOCHEM, V70, P616, DOI 10.1016/0003-2697(76)90488-7
   Ferreira D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074499
   Ferreira FM, 2014, PARASITOL RES, V113, P533, DOI 10.1007/s00436-013-3685-8
   Hata T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048072
   Hori JI, 2013, EVID-BASED COMPL ALT, V2013, P1
   Khouri R, 2009, J IMMUNOL, V182, P2525, DOI 10.4049/jimmunol.0802860
   KROL W, 1993, ARZNEIMITTEL-FORSCH, V43-1, P607
   Kumar R, 2014, CLIN TRANSL IMMUNOL, V3, DOI 10.1038/cti.2014.4
   Kwon Tae Dong, 2014, J Exerc Nutrition Biochem, V18, P9, DOI 10.5717/jenb.2014.18.1.9
   Larki-Harchegani A, 2013, IRAN J BASIC MED SCI, V16, P850
   Layegh P, 2015, INDIAN J DERMATOL, V60, DOI 10.4103/0019-5154.152560
   Leitao DPD, 2004, BIOL PHARM BULL, V27, P1834, DOI 10.1248/bpb.27.1834
   Liu K, 2015, MED SCI MONIT BASIC, V21, P15, DOI 10.12659/MSMBR.893327
   Llanos-Cuentas A, 2008, CLIN INFECT DIS, V46, P223, DOI 10.1086/524042
   Machado J. L, 2012, EVID-BASED COMPL ALT, V2012, P10, DOI [10.1155/2012/157652, DOI 10.1155/2012/157652]
   Machado P, 2002, CLIN INFECT DIS, V34, pE69, DOI 10.1086/340526
   MARCUCCI MC, 1995, APIDOLOGIE, V26, P83, DOI 10.1051/apido:19950202
   Marcucci MC, 2001, J ETHNOPHARMACOL, V74, P105, DOI 10.1016/S0378-8741(00)00326-3
   Marinho FA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087659
   Ministerio da Saude, 2007, MAN VIG LEISHM TEG A, P180
   Miranda MM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125101
   Miranda Suelen, 2015, LEISHMANICIDAL ACTIV, V36, P25
   Novais FO, 2009, J IMMUNOL, V183, P8088, DOI 10.4049/jimmunol.0803720
   Oda J. M., 2011, SEMINA CIENCIAS BIOL, V32, P111
   Orsoilc N, 2005, BIOL PHARM BULL, V28, P1928, DOI 10.1248/bpb.28.1928
   Pace D, 2014, J INFECTION, V69, pS10, DOI 10.1016/j.jinf.2014.07.016
   Paulino N, 2008, EUR J PHARMACOL, V587, P296, DOI 10.1016/j.ejphar.2008.02.067
   Pontin K, 2008, PARASITOL RES, V103, P487, DOI 10.1007/s00436-008-0970-z
   Ribble D, 2005, BMC BIOTECHNOL, V5, DOI 10.1186/1472-6750-5-12
   Salgado VR, 2016, MEM I OSWALDO CRUZ, V111, P241, DOI 10.1590/0074-02760150436
   Salomao K, 2008, EVID-BASED COMPL ALT, V5, P317, DOI 10.1093/ecam/nem058
   Santos DM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003275
   Sen G, 2008, J ANTIMICROB CHEMOTH, V61, P1066, DOI 10.1093/jac/dkn053
   Siheri W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155355
   Sousa João P.B., 2007, Rev. bras. farmacogn., V17, P85, DOI 10.1590/S0102-695X2007000100017
   Machado BAS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145954
   Szliska E., 2013, EVID-BASED COMPL ALT, V2013
   Thomazelli A. P. F. dos Santos, 2016, CELL IMMUNOL, P10
   Vannier-Santos MA, 2009, CURR DRUG TARGETS, V10, P246, DOI 10.2174/138945009787581168
   Wali AF, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/393462
   WALKER P, 1987, APIDOLOGIE, V18, P327, DOI 10.1051/apido:19870404
   Washio K, 2015, BIOMED RES-TOKYO, V36, P343, DOI 10.2220/biomedres.36.343
   WHO, 2012, LEISHM WORLDW EP DRU
   Woisky RG, 1998, J APICULT RES, V37, P99, DOI 10.1080/00218839.1998.11100961
   Wu J, 2011, CANCER LETT, V308, P43, DOI 10.1016/j.canlet.2011.04.012
NR 70
TC 4
Z9 4
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2017
VL 2017
AR 6067172
DI 10.1155/2017/6067172
PG 14
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA EX4YA
UT WOS:000403240600001
PM 28690662
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Celes, FS
   Trovatti, E
   Khouri, R
   Van Weyenbergh, J
   Ribeiro, SJL
   Borges, VM
   Barud, HS
   de Oliveira, CI
AF Celes, Fabiana S.
   Trovatti, Eliane
   Khouri, Ricardo
   Van Weyenbergh, Johan
   Ribeiro, Sidney J. L.
   Borges, Valeria M.
   Barud, Hernane S.
   de Oliveira, Camila I.
TI DETC-based bacterial cellulose bio-curatives for topical treatment of
   cutaneous leishmaniasis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID NECROSIS-FACTOR-ALPHA; BIOCELLULOSE MEMBRANES; SYNTHESIZED CELLULOSE;
   MICROBIAL CELLULOSE; ENDOTHELIAL-CELLS; AMPHOTERICIN-B; IN-VITRO;
   INFECTION; BRAZILIENSIS; MILTEFOSINE
AB The treatment of leishmaniasis still relies on drugs with potentially serious adverse effects. Herein, we tested a topical formulation of bacterial cellulose (BC) membranes containing Diethyldithiocarbamate (DETC), a superoxide dismutase 1 inhibitor. Leishmania-infected macrophages exposed to BC-DETC resulted in parasite killing, without pronounced toxic effects to host cells. This outcome was associated with lower SOD1 activity and higher production of superoxide and cytokine mediators. Topical application of BC-DETC significantly decreased lesion size, parasite load and the inflammatory response at the infection site, as well as the production of both IFN-gamma and TNF. Combination of topical BC-DETC plus intraperitoneal Sb-v also significantly reduced disease development and parasite load. The leishmanicidal effect of BC-DETC was extended to human macrophages infected with L. braziliensis, highlighting the feasibility of BC-DETC as a topical formulation for chemotherapy of cutaneous leishmaniasis caused by L. braziliensis.
C1 [Celes, Fabiana S.; Khouri, Ricardo; Borges, Valeria M.; de Oliveira, Camila I.] Fiocruz MS, Inst Goncalo Moniz, Salvador, BA, Brazil.
   [Trovatti, Eliane; Ribeiro, Sidney J. L.; Barud, Hernane S.] Univ Estadual Paulista, Inst Quim, Araraquara, SP, Brazil.
   [Trovatti, Eliane; Barud, Hernane S.] Univ Araraquara UNIARA, Araraquara, SP, Brazil.
   [Van Weyenbergh, Johan] Katholieke Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, Leuven, Belgium.
   [de Oliveira, Camila I.] INCT, Inst Invest Imunol 3, Sao Paulo, Brazil.
RP de Oliveira, CI (corresponding author), Fiocruz MS, Inst Goncalo Moniz, Salvador, BA, Brazil.
EM camila@bahia.fiocruz.br
RI de Oliveira, Camila I/B-4358-2009; Borges, Val/N-6647-2019; Trovatti,
   Eliane/P-2263-2019; Borges, Valeria/G-2009-2014; Van Weyenbergh,
   Johan/Q-3829-2019; Trovatti, Eliane/B-9177-2012; Khouri,
   Ricardo/M-3184-2018; Van Weyenbergh, Johan/B-4187-2009; Ribeiro,
   Sidney/E-9864-2012
OI de Oliveira, Camila I/0000-0002-7868-5164; Borges,
   Val/0000-0002-2775-5409; Trovatti, Eliane/0000-0002-0495-8115; Van
   Weyenbergh, Johan/0000-0003-3234-8426; Khouri,
   Ricardo/0000-0001-5664-4436; Van Weyenbergh, Johan/0000-0003-3234-8426;
   Ribeiro, Sidney/0000-0002-8162-6747
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [482193/2012-3]; Fundacao Oswaldo Cruz - Programa de Apoio a
   Pesquisas Estrategicas (FIOCRUZ-PAPES IV) [407437/2012-6]; Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP); Coordenacao de Amparo a
   Pesquisa e Ensino Superior (CAPES); CNPqNational Council for Scientific
   and Technological Development (CNPq) [161535/2011-9]
FX We acknowledge the assistance of Lucas Menezes, Rebecca Curvelo and
   Laura Ramirez in mice treatment and parasite load assays. We thank
   Kiyoshi Fukutani and Bruno Bezerril for assistance in heatmap analysis
   and Fundacao Andre Tosello for the donation of ATCC cell line. We also
   acknowledge LMA-IQ for FEG-SEM facilities. SRB, VMB and CIO are senior
   researchers from CNPq. This work was supported by grants from Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
   (482193/2012-3), Fundacao Oswaldo Cruz - Programa de Apoio a Pesquisas
   Estrategicas (FIOCRUZ-PAPES IV) (407437/2012-6) and Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP). S.J.L, V.M.B and C.I.O are
   senior researchers CNPq. FSC received a fellowship from Coordenacao de
   Amparo a Pesquisa e Ensino Superior (CAPES). E.T. was the recipient of a
   postdoctoral grant 161535/2011-9 from CNPq.
CR Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
   Annaloro C, 2009, J ANTIMICROB CHEMOTH, V63, P625, DOI 10.1093/jac/dkn549
   Antonelli LRV, 2005, IMMUNOL LETT, V101, P226, DOI 10.1016/j.imlet.2005.06.004
   Avila HM, 2014, APPL MICROBIOL BIOT, V98, P7423, DOI 10.1007/s00253-014-5819-z
   Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   Barud Hda S., 2013, EVID-BASED COMPL ALT, V2013
   Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152
   Ben Salah A., 2009, PLOS NEGLECT TROP D, V3, P5
   Ben Salah A, 2013, NEW ENGL J MED, V368, P524, DOI 10.1056/NEJMoa1202657
   Bittencourt Achiléa, 2003, Braz J Infect Dis, V7, P229, DOI 10.1590/S1413-86702003000300009
   Carvalho AK, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/7068287
   CARVALHO EM, 1985, J IMMUNOL, V135, P4144
   Cecilio P, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00480
   Chavali AK, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752-0509-6-27
   Chawla PR, 2009, FOOD TECHNOL BIOTECH, V47, P107
   Chen YM, 2009, J BIOACT COMPAT POL, V24, P137, DOI 10.1177/0883911509102710
   COCCO D, 1981, J BIOL CHEM, V256, P8983
   Corda S, 2001, AM J RESP CELL MOL, V24, P762, DOI 10.1165/ajrcmb.24.6.4228
   Croft SL, 2003, TRENDS PARASITOL, V19, P502, DOI 10.1016/j.pt.2003.09.008
   Croft SL, 2006, INDIAN J MED RES, V123, P399
   Czaja WK, 2007, BIOMACROMOLECULES, V8, P1, DOI 10.1021/bm060620d
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   den Boer M, 2011, CLIN MICROBIOL INFEC, V17, P1471, DOI 10.1111/j.1469-0691.2011.03635.x
   Falcao SC, 2012, INT J PARASITOL, V42, P771, DOI 10.1016/j.ijpara.2012.05.006
   Haldar A. K., 2011, MOL BIOL INT, V2011
   Ho AWY, 2008, IMMUNOBIOLOGY, V213, P533, DOI 10.1016/j.imbio.2008.01.003
   Iguchi M, 2000, J MATER SCI, V35, P261, DOI 10.1023/A:1004775229149
   Jeong SI, 2010, MOL CELL TOXICOL, V6, P373, DOI 10.1007/s13273-010-0049-7
   Kanai K, 2011, J VET MED SCI, V73, P517, DOI 10.1292/jvms.10-0239
   Khouri R, 2014, J INFECT DIS, V210, P306, DOI 10.1093/infdis/jiu087
   Khouri R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014394
   Khouri R, 2009, J IMMUNOL, V182, P2525, DOI 10.4049/jimmunol.0802860
   Kim GD, 2013, BIOCHIP J, V7, P201, DOI 10.1007/s13206-013-7302-9
   Klemm D, 2005, ANGEW CHEM INT EDIT, V44, P3358, DOI 10.1002/anie.200460587
   Klemm D, 2011, ANGEW CHEM INT EDIT, V50, P5438, DOI 10.1002/anie.201001273
   LIEW FY, 1990, J IMMUNOL, V145, P4306
   Llanos-Cuentas A, 2008, CLIN INFECT DIS, V46, P223, DOI 10.1086/524042
   Machado PR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000912
   Marikovsky M, 2003, J IMMUNOL, V170, P2993, DOI 10.4049/jimmunol.170.6.2993
   MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539
   Mendez S, 2001, J IMMUNOL, V166, P5122, DOI 10.4049/jimmunol.166.8.5122
   Novais FO, 2014, J INFECT DIS, V209, P1288, DOI 10.1093/infdis/jiu013
   Novais FO, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003504
   Olliaro PL, 2010, CURR OPIN INFECT DIS, V23, P595, DOI 10.1097/QCO.0b013e32833fca9d
   Peters N, 2006, IMMUNOL REV, V213, P159, DOI 10.1111/j.1600-065X.2006.00432.x
   Ribeiro S. J. B. H., 2014, NANOCOMPOSITOS BIOCE
   Ribeiro-de-Jesus A, 1998, BRAZ J MED BIOL RES, V31, P143, DOI 10.1590/S0100-879X1998000100020
   Santos DM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003275
   Scherner M, 2014, J SURG RES, V189, P340, DOI 10.1016/j.jss.2014.02.011
   Sharlow ER, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000540
   Silva NHCS, 2014, CELLULOSE, V21, P665, DOI 10.1007/s10570-013-0114-1
   Sosa N, 2013, AM J TROP MED HYG, V89, P557, DOI 10.4269/ajtmh.12-0736
   Soto JM, 2002, AM J TROP MED HYG, V66, P147, DOI 10.4269/ajtmh.2002.66.147
   Trinconi CT, 2016, J ANTIMICROB CHEMOTH, V71, P1314, DOI 10.1093/jac/dkv495
   Trinconi CT, 2014, ANTIMICROB AGENTS CH, V58, P2608, DOI 10.1128/AAC.01315-13
   Trovatti E, 2012, INT J PHARMACEUT, V435, P83, DOI 10.1016/j.ijpharm.2012.01.002
   Trovatti E, 2011, BIOMACROMOLECULES, V12, P4162, DOI 10.1021/bm201303r
   Uzonna JE, 2001, J IMMUNOL, V167, P6967, DOI 10.4049/jimmunol.167.12.6967
   Wu SC, 2008, J MOL CATAL B-ENZYM, V54, P103, DOI 10.1016/j.molcatb.2007.12.021
NR 59
TC 10
Z9 10
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 6
PY 2016
VL 6
AR 38330
DI 10.1038/srep38330
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EE2OO
UT WOS:000389424300001
PM 27922065
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Carneiro, MW
   Fukutani, KF
   Andrade, BB
   Curvelo, RP
   Cristal, JR
   Carvalho, AM
   Barral, A
   Van Weyenbergh, J
   Barral-Netto, M
   de Oliveira, CI
AF Carneiro, Marcia W.
   Fukutani, Kiyoshi F.
   Andrade, Bruno B.
   Curvelo, Rebecca P.
   Cristal, Juqueline R.
   Carvalho, Augusto M.
   Barral, Aldina
   Van Weyenbergh, Johan
   Barral-Netto, Manoel
   de Oliveira, Camila I.
TI Gene Expression Profile of High IFN-gamma Producers Stimulated with
   Leishmania braziliensis Identifies Genes Associated with Cutaneous
   Leishmaniasis
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID MUCOSAL LEISHMANIASIS; IMMUNE-RESPONSE; TEGUMENTARY LEISHMANIASIS;
   DIFFERENTIAL REGULATION; T-CELLS; INFECTION; ALPHA; AMAZONENSIS;
   NEUTROPHILS; INHIBITION
AB Background
   The initial response to Leishmania parasites is essential in determining disease development or resistance. In vitro, a divergent response to Leishmania, characterized by high or low IFN-gamma production has been described as a potential tool to predict both vaccine response and disease susceptibility in vivo.
   Methods and findings
   We identified uninfected and healthy individuals that were shown to be either high-or low IFN-gamma producers (HPs and LPs, respectively) following stimulation of peripheral blood cells with Leishmania braziliensis. Following stimulation, RNA was processed for gene expression analysis using immune gene arrays. Both HPs and LPs were shown to upregulate the expression of CXCL10, IFI27, IL6 and LTA. Genes expressed in HPs only (CCL7, IL8, IFI44L and IL1B) were associated with pathways related to IL17 and TREM 1 signaling. In LPs, uniquely expressed genes (for example IL9, IFI44, IFIT1 and IL2RA) were associated with pathways related to pattern recognition receptors and interferon signaling. We then investigated whether the unique gene expression profiles described here could be recapitulated in vivo, in individuals with active Cutaneous Leishmaniasis or with subclinical infection. Indeed, using a set of six genes (TLR2, JAK2, IFI27, IFIT1, IRF1 and IL6) modulated in HPs and LPs, we could successfully discriminate these two clinical groups. Finally, we demonstrate that these six genes are significantly overexpressed in CL lesions.
   Conclusion
   Upon interrogation of the peripheral response of naive individuals with diverging IFN-gamma production to L. braziliensis, we identified differences in the innate response to the parasite that are recapitulated in vivo and that discriminate CL patients from individuals presenting a subclinical infection.
C1 [Carneiro, Marcia W.; Fukutani, Kiyoshi F.; Andrade, Bruno B.; Curvelo, Rebecca P.; Cristal, Juqueline R.; Carvalho, Augusto M.; Barral, Aldina; Barral-Netto, Manoel; de Oliveira, Camila I.] Fundacao Oswaldo Cruz FIOCRUZ, Inst Goncalo Moniz, Salvador, BA, Brazil.
   [Andrade, Bruno B.] Fundacao Jose Silveira, Multinat Org Network Sponsoring Translat & Epidem, Salvador, BA, Brazil.
   [Van Weyenbergh, Johan] Katholieke Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, Leuven, Belgium.
   [Barral, Aldina; Barral-Netto, Manoel] Univ Fed Bahia, Sch Med, Salvador, BA, Brazil.
   [Carneiro, Marcia W.] Univ Catolica Salvador, Salvador, BA, Brazil.
RP de Oliveira, CI (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Inst Goncalo Moniz, Salvador, BA, Brazil.
EM camila@bahia.fiocruz.br
RI Van Weyenbergh, Johan/B-4187-2009; Van Weyenbergh, Johan/Q-3829-2019;
   Fukutani, Kiyoshi/T-1630-2019; de Oliveira, Camila I/B-4358-2009;
   Andrade, Bruno/AAI-2248-2020; Barral Netto, Manoel/B-3904-2009
OI Van Weyenbergh, Johan/0000-0003-3234-8426; Van Weyenbergh,
   Johan/0000-0003-3234-8426; de Oliveira, Camila I/0000-0002-7868-5164;
   Fukutani, Kiyoshi/0000-0003-2223-0918; Barral Netto,
   Manoel/0000-0002-5823-7903; Weber Carneiro, Marcia/0000-0002-4220-5085
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [302464/2009-3]; Fundacao de Amparo a Pesquisa do Estado da Bahia
   (FAPESB); Coordenacao de Apoio a Pesquisa e Ensino Superior (CAPES)
FX This work was supported by the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq; grant 302464/2009-3 to M.BN and
   fellowship to MWC and KFF), Fundacao de Amparo a Pesquisa do Estado da
   Bahia (FAPESB) (fellowship to KFF) and Coordenacao de Apoio a Pesquisa e
   Ensino Superior (CAPES) (fellowship to JRC). AB, MBN, and MO are senior
   researchers at CNPq. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Antonelli LRV, 2005, IMMUNOL LETT, V101, P226, DOI 10.1016/j.imlet.2005.06.004
   Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   Bacellar O, 2009, J INFECT DIS, V200, P75, DOI 10.1086/599380
   Boaventura VS, 2010, EUR J IMMUNOL, V40, P2830, DOI 10.1002/eji.200940115
   Bouchon A, 2000, J IMMUNOL, V164, P4991, DOI 10.4049/jimmunol.164.10.4991
   Campanelli AP, 2010, HUM IMMUNOL, V71, P1220, DOI 10.1016/j.humimm.2010.09.002
   Carneiro MW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052296
   CARVALHO EM, 1985, J IMMUNOL, V135, P4144
   Carvalho LP, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00301
   Castellucci L, 2006, J INFECT DIS, V194, P519, DOI 10.1086/505504
   Castes M, 1993, Biol Res, V26, P233
   Coelho ZCB, 2010, BRAZ J INFECT DIS, V14, P476, DOI 10.1590/S1413-86702010000500009
   DaCruz AM, 1996, MEM I OSWALDO CRUZ, V91, P225, DOI 10.1590/S0074-02761996000200019
   DAVIES CR, 1995, EPIDEMIOL INFECT, V114, P297, DOI 10.1017/S0950268800057964
   de Oliveira CI, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00145
   Diehl S, 2002, J EXP MED, V196, P39, DOI 10.1084/jem.20020026
   Diehl S, 2000, IMMUNITY, V13, P805, DOI 10.1016/S1074-7613(00)00078-9
   Follador I, 2002, CLIN INFECT DIS, V34, pE54, DOI 10.1086/340261
   Franca-Costa J, 2016, J INFECT DIS, V213, P1143, DOI 10.1093/infdis/jiv548
   GESSNER A, 1993, IMMUNOBIOLOGY, V189, P419, DOI 10.1016/S0171-2985(11)80414-6
   Hardaker EL, 2004, FASEB J, V18, P191, DOI 10.1096/fj.03-0170fje
   Huang L, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003546
   Khouri R, 2014, J INFECT DIS, V210, P306, DOI 10.1093/infdis/jiu087
   Khouri R, 2009, J IMMUNOL, V182, P2525, DOI 10.4049/jimmunol.0802860
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Martensen PM, 2001, EUR J BIOCHEM, V268, P5947, DOI 10.1046/j.0014-2956.2001.02545.x
   Matikainen S, 2001, EUR J IMMUNOL, V31, P2236, DOI 10.1002/1521-4141(200107)31:7<2236::AID-IMMU2236>3.0.CO;2-G
   McKenna K, 2005, J VIROL, V79, P17, DOI 10.1128/JVI.79.1.17-27.2005
   Murray HW, 2008, INFECT IMMUN, V76, P4088, DOI 10.1128/IAI.00490-08
   Nagai Y, 2002, BLOOD, V99, P1699, DOI 10.1182/blood.V99.5.1699
   NANDAN D, 1995, INFECT IMMUN, V63, P4495, DOI 10.1128/IAI.63.11.4495-4500.1995
   Netea MG, 2006, J LEUKOCYTE BIOL, V80, P1454, DOI 10.1189/jlb.1205758
   Novais FO, 2014, J INVEST DERMATOL
   Oliveira PRS, 2015, J IMMUNOL, V194, P2664, DOI 10.4049/jimmunol.1402047
   Pompeu MML, 2001, INFECT IMMUN, V69, P7453, DOI 10.1128/IAI.69.12.7453-7460.2001
   Ribeiro-de-Jesus A, 1998, BRAZ J MED BIOL RES, V31, P143, DOI 10.1590/S0100-879X1998000100020
   Rogers KA, 2004, AM J TROP MED HYG, V71, P568, DOI 10.4269/ajtmh.2004.71.568
   Romagnani P, 2001, BLOOD, V97, P601, DOI 10.1182/blood.V97.3.601
   Schnorr D, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001947
   Temann UA, 2002, J CLIN INVEST, V109, P29, DOI 10.1172/JCI13696
   Weber B, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003900
NR 41
TC 9
Z9 9
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD NOV
PY 2016
VL 10
IS 11
AR 0005116
DI 10.1371/journal.pntd.0005116
PG 17
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA EI0HR
UT WOS:000392154400038
PM 27870860
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Gomes, R
   Cavalcanti, K
   Teixeira, C
   Carvalho, AM
   Mattos, PS
   Cristal, JR
   Muniz, AC
   Miranda, JC
   de Oliveira, CI
   Barral, A
AF Gomes, Regis
   Cavalcanti, Katrine
   Teixeira, Clarissa
   Carvalho, Augusto M.
   Mattos, Paulo S.
   Cristal, Juqueline R.
   Muniz, Aline C.
   Miranda, Jose Carlos
   de Oliveira, Camila I.
   Barral, Aldina
TI Immunity to Lutzomyia whitmani Saliva Protects against Experimental
   Leishmania braziliensis Infection
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID SAND FLY SALIVA; DELAYED-TYPE HYPERSENSITIVITY; REGULATORY T-CELLS;
   CUTANEOUS LEISHMANIASIS; LONGIPALPIS SALIVA; VISCERAL LEISHMANIASIS;
   VECTOR SALIVA; PHLEBOTOMUS-PAPATASI; ANTIBODY-RESPONSE; ENDEMIC AREAS
AB Background
   Previous works showed that immunization with saliva from Lutzomyia intermedia, a vector of Leishmania braziliensis, does not protect against experimental infection. However, L. braziliensis is also transmitted by Lutzomyia whitmani, a sand fly species closely related to Lu. intermedia. Herein we describe the immune response following immunization with Lu. whitmani saliva and the outcome of this response after L. braziliensis infection.
   Methods and findings
   BALB/c mice immunized with Lu. whitmani saliva developed robust humoral and cellular immune responses, the latter characterized by an intense cellular infiltrate and production of IFN-gamma and IL-10, by both CD4(+) and CD8(+) cells. Mice immunized as above and challenged with L. braziliensis plus Lu. whitmani saliva displayed significantly smaller lesions and parasite load at the challenge site. This protection was associated with a higher (p<0.05) IFN-gamma production in response to SLA stimulation. Long-term persisting immunity was also detected in mice immunized with Lu. whitmani saliva. Furthermore, individuals residing in an endemic area for cutaneous leishmaniasis (CL) presented antibody responses to Lu. whitmani saliva. However CL patients, with active lesions, displayed a lower humoral response to Lu. whitmani saliva compared to individuals with subclinical Leishmania infection.
   Conclusion Pre-exposure to Lu. whitmani saliva induces protection against L. braziliensis in a murine model. We also show that Lu. whitmani salivary proteins are immunogenic in naturally exposed individuals. Our results reinforce the importance of investigating the immunomodulatory effect of saliva from different species of closely related sand flies.
C1 [Gomes, Regis; Teixeira, Clarissa] Fundacao Oswaldo Cruz FIOCRUZ, Escritorio Tecn Reg, Teresina, Piaui, Brazil.
   [Cavalcanti, Katrine; Carvalho, Augusto M.; Mattos, Paulo S.; Cristal, Juqueline R.; Miranda, Jose Carlos; de Oliveira, Camila I.; Barral, Aldina] Fundacao Oswaldo Cruz FIOCRUZ, Inst Goncalo Moniz, Salvador, BA, Brazil.
   [Muniz, Aline C.] Univ Fed Bahia, Sch Med, Salvador, BA, Brazil.
   [de Oliveira, Camila I.; Barral, Aldina] INCT Inst Invest Imunol, Sao Paulo, Brazil.
   [Barral, Aldina] Univ Fed Bahia, Salvador, BA, Brazil.
RP de Oliveira, CI; Barral, A (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Inst Goncalo Moniz, Salvador, BA, Brazil.; de Oliveira, CI; Barral, A (corresponding author), INCT Inst Invest Imunol, Sao Paulo, Brazil.; Barral, A (corresponding author), Univ Fed Bahia, Salvador, BA, Brazil.
EM camila@bahia.fiocruz.br; abarral@bahia.fiocruz.br
RI de Oliveira, Camila I/B-4358-2009
OI de Oliveira, Camila I/0000-0002-7868-5164
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [400695/2012-0]; Fundacao de Amparo a Pesquisa da Bahia (FAPESB),
   Brazil [INT 0003/2013]
FX This work was funded in part by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq - 400695/2012-0) and Fundacao de Amparo a
   Pesquisa da Bahia (FAPESB INT 0003/2013), Brazil. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Abdeladhim M, 2014, INFECT GENET EVOL, V28, P691, DOI 10.1016/j.meegid.2014.07.028
   Aquino DMC, 2010, AM J TROP MED HYG, V83, P825, DOI 10.4269/ajtmh.2010.10-0182
   Atayde VD, 2015, CELL REP, V13, P957, DOI 10.1016/j.celrep.2015.09.058
   Barral A, 2000, AM J TROP MED HYG, V62, P740, DOI 10.4269/ajtmh.2000.62.740
   Belkaid Y, 1998, J EXP MED, V188, P1941, DOI 10.1084/jem.188.10.1941
   Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152
   Carregaro V, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-102
   Carvalho AM, 2015, J INFECT DIS, V212, P157, DOI 10.1093/infdis/jiv020
   de Moura TR, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000084
   de Moura TR, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002242
   Drahota J, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002597
   Falcao SC, 2012, INT J PARASITOL, V42, P771, DOI 10.1016/j.ijpara.2012.05.006
   Follador I, 2002, CLIN INFECT DIS, V34, pE54, DOI 10.1086/340261
   Gomes RB, 2002, J INFECT DIS, V186, P1530, DOI 10.1086/344733
   Gomes R, 2008, P NATL ACAD SCI USA, V105, P7845, DOI 10.1073/pnas.0712153105
   Gomes R, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00110
   Gonzalez-Lombana C, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003243
   Jirmanus L, 2012, AM J TROP MED HYG, V86, P426, DOI 10.4269/ajtmh.2012.11-0378
   Kamhawi S, 2000, SCIENCE, V290, P1351, DOI 10.1126/science.290.5495.1351
   Kamhawi S, 2000, MICROBES INFECT, V2, P1765, DOI 10.1016/S1286-4579(00)01331-9
   Lestinova T, 2015, ACTA TROP, V144, P9, DOI 10.1016/j.actatropica.2015.01.005
   Lima HC, 1996, INFECT IMMUN, V64, P5442, DOI 10.1128/IAI.64.12.5442-5445.1996
   Marzouki S, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003991
   Marzouki S, 2011, AM J TROP MED HYG, V84, P653, DOI 10.4269/ajtmh.2011.10-0598
   Mendez S, 2004, J EXP MED, V200, P201, DOI 10.1084/jem.20040298
   Miranda JC, 2002, MEM I OSWALDO CRUZ, V97, P185, DOI 10.1590/S0074-02762002000200006
   Norsworthy NB, 2004, INFECT IMMUN, V72, P1240, DOI 10.1128/IAI.72.3.1240-1247.2004
   Oliveira F, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000226
   Oliveira F, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3043
   Oliveira F, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00375
   Peters NC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000484
   RANGEL EF, 1990, MEM I OSWALDO CRUZ, V85, P39, DOI 10.1590/S0074-02761990000100006
   REED SG, 1986, AM J TROP MED HYG, V35, P79, DOI 10.4269/ajtmh.1986.35.79
   Rogers ME, 2004, NATURE, V430, P463, DOI 10.1038/nature02675
   Rohousova I, 2005, PARASITOLOGY, V130, P493, DOI 10.1017/S003118200400681X
   Rosales-Chilama M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004273
   Schnorr D, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001947
   Sima M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004553
   Souza AP, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000649
   Tavares NM, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001169
   Teixeira C, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002781
   Teixeira C, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000638
   Thiakaki M, 2005, MICROBES INFECT, V7, P760, DOI 10.1016/j.micinf.2005.01.013
   TITUS RG, 1990, PARASITOL TODAY, V6, P157, DOI 10.1016/0169-4758(90)90338-5
   Valenzuela JG, 2001, J EXP MED, V194, P331, DOI 10.1084/jem.194.3.331
   Weinkopff T, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002627
NR 46
TC 8
Z9 8
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD NOV
PY 2016
VL 10
IS 11
AR e0005078
DI 10.1371/journal.pntd.0005078
PG 15
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA EI0HR
UT WOS:000392154400018
PM 27812113
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Bouzas, ML
   Oliveira, JR
   Fukutani, KF
   Borges, IC
   Barral, A
   Van der Gucht, W
   Wollants, E
   Van Ranst, M
   de Oliveira, CI
   Van Weyenbergh, J
   Nascimento-Carvalho, CM
AF Bouzas, Maiara L.
   Oliveira, Juliana R.
   Fukutani, Kiyoshi F.
   Borges, Igor C.
   Barral, Aldina
   Van der Gucht, Winke
   Wollants, Elke
   Van Ranst, Marc
   de Oliveira, Camila I.
   Van Weyenbergh, Johan
   Nascimento-Carvalho, Cristiana M.
TI Respiratory syncytial virus a and b display different temporal patterns
   in a 4-year prospective cross-sectional study among children with acute
   respiratory infection in a tropical city
SO MEDICINE
LA English
DT Article
DE acute respiratory infection; immunoprophylaxis; palivizumab; RSV; RSVA;
   RSVB; seasonality
ID COMMUNITY-ACQUIRED PNEUMONIA; TRACT INFECTIONS; BRAZIL; SEASONALITY;
   PREVALENCE; EPIDEMIOLOGY; FREQUENCY; GENOTYPES; DYNAMICS; FEATURES
AB Respiratory syncytial virus (RSV) is one of the most common etiological agents of childhood respiratory infections globally. Information on seasonality of different antigenic groups is scarce. We aimed to describe the frequency, seasonality, and age of children infected by RSV antigenic groups A (RSVA) and B (RSVB) among children with ARI in a 4-year period.Children (6-23 months old) with respiratory infection for 7 days were enrolled in a prospective cross-sectional study, from September, 2009 to October, 2013, in Salvador, in a tropical region of Brazil. Upon recruitment, demographic, clinical data, and nasopharyngeal aspirates (NPA) were collected. A multiplex quantitative real-time polymerase chain reaction (RT-PCR) with a group-specific primer and probeset for RSVA and RSVB was used. Seasonal distribution of infection by RSV different antigenic groups was evaluated by Prais-Wisten regression.Of 560 cases, the mean age was 11.44.5 months and there were 287 (51.3%) girls. Overall, RSV was detected in 139 (24.8%; 95% CI: 21.4%-28.5%) cases, RSVA in 74 (13.2%; 95% CI: 10.6%-16.2%) cases, and RSVB in 67 (12.0%; 95% CI: 9.5%-14.9%) cases. Two (0.4%; 95% CI: 0.06%-1.2%) cases had coinfection. RSVA frequency was 9.6%, 18.4%, 21.6%, and 3.1% in 2010, 2011, 2012, and 2013, respectively. RSVB frequency was 19.2%, 0.7%, 1.4%, and 35.4% in the same years. RSVA was more frequently found from August to January than February to July (18.2% vs. 6.4%, P<0.001). RSVB was more frequently found (P<0.001) between March and June (36.0%) than July to October (1.0%) or November to February (1.6%). RSVB infection showed seasonal distribution and positive association with humidity (P = 0.02) whereas RSVA did not. RSVA was more common among children 1-year-old (17.8% vs. 1.8%; P = 0.02), as opposed to RSVB (11.5% vs. 12.2%; P = 0.8).One quarter of patients had RSV infection. RSVA compromised more frequently children aged 1 year. RSVA predominated in 2011 and 2012 whereas RSVB predominated in 2010 and 2013. In regard to months, RSVA was more frequent from August to January whereas RSVB was more often detected between March and June. Markedly different monthly as well as yearly patterns for RSVA and RSVB reveal independent RSV antigenic groups' epidemics.
C1 [Bouzas, Maiara L.; Oliveira, Juliana R.; Fukutani, Kiyoshi F.; Borges, Igor C.; Barral, Aldina; de Oliveira, Camila I.; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
   [Barral, Aldina; de Oliveira, Camila I.] Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisas Goncalo Moniz CPqGM, Salvador, BA, Brazil.
   [Barral, Aldina] Univ Fed Bahia, Sch Med, Dept Pathol, Salvador, BA, Brazil.
   [Van der Gucht, Winke; Wollants, Elke; Van Ranst, Marc; Van Weyenbergh, Johan] KU, Rega Inst Med Res, Lab Clin & Epidemiol Virol, Dept Microbiol & Immunol, Leuven, Belgium.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Rua Prof Aristides Novis,105-1201B, BR-40210630 Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Dept Pediat, Rua Prof Aristides Novis,105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI de Oliveira, Camila I/B-4358-2009; Van Weyenbergh, Johan/B-4187-2009;
   Van Weyenbergh, Johan/Q-3829-2019; Fukutani, Kiyoshi/T-1630-2019; Van
   Ranst, Marc/P-7522-2017; Borges, Igor Carmo/AAG-8531-2019
OI de Oliveira, Camila I/0000-0002-7868-5164; Van Weyenbergh,
   Johan/0000-0003-3234-8426; Van Weyenbergh, Johan/0000-0003-3234-8426;
   Van Ranst, Marc/0000-0002-1674-4157; Wollants, Elke/0000-0002-4057-2236;
   Carmo Borges, Igor/0000-0003-2749-0313; Fukutani,
   Kiyoshi/0000-0003-2223-0918
FU Bahia State Agency for Research Funding (FAPESB) [APP0045/2009,
   PNX0019/2009]
FX This work was supported by the Bahia State Agency for Research Funding
   (FAPESB) [grant numbers APP0045/2009 and PNX0019/2009]. FAPESB had no
   role in study design, data collection, data analysis, data
   interpretation, or writing of the report.
CR Aamir UB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074018
   Gardinassi LGA, 2012, VIRUSES-BASEL, V4, P2432, DOI 10.3390/v4112432
   Arbiza J, 2005, MEM I OSWALDO CRUZ, V100, P221, DOI 10.1590/S0074-02762005000300001
   Borchers AT, 2013, CLIN REV ALLERG IMMU, V45, P331, DOI 10.1007/s12016-013-8368-9
   Brady MT, 2014, PEDIATRICS, V134, P415, DOI 10.1542/peds.2014-1665
   Brazilian Ministry of Health, 2015, 052015 BRAZ MIN HLTH
   Calegari Tatiany, 2005, Braz J Infect Dis, V9, P156, DOI 10.1590/S1413-86702005000200006
   Cuevas LE, 2003, EMERG INFECT DIS, V9, P1626, DOI 10.3201/eid0912.030522
   Durigon GS, 2015, INT J INFECT DIS, V34, P3, DOI 10.1016/j.ijid.2015.03.003
   El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831
   Ferone EA, 2014, J PEDIAT-BRAZIL, V90, P42, DOI 10.1016/j.jped.2013.05.005
   Gurgel RQ, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003090
   Hacimustafaoglu M, 2013, TURKISH J PEDIATR, V55, P130
   Hara M, 2014, PEDIATR INFECT DIS J, V33, P687, DOI 10.1097/INF.0000000000000227
   Harris M, 2011, THORAX, V66, pII1, DOI 10.1136/thoraxjnl-2011-200598
   Haynes AK, 2013, J INFECT DIS, V208, pS246, DOI 10.1093/infdis/jit515
   Houspie L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060416
   Kimberlin DW, 2015, AM ACAD PEDIATRICSRE, P672
   Lamarao LM, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-119
   McCracken JP, 2013, J INFECT DIS, V208, pS197, DOI 10.1093/infdis/jit517
   Moore HC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100422
   Nair H, 2013, LANCET, V381, P1380, DOI 10.1016/S0140-6736(12)61901-1
   Nascimento-Carvalho CM, 2010, SCAND J INFECT DIS, V42, P839, DOI 10.3109/00365548.2010.498020
   Nolan T, 2015, CLIN INFECT DIS, V60, pE80, DOI 10.1093/cid/civ065
   Oliveira TFM, 2008, MEM I OSWALDO CRUZ, V103, P417, DOI 10.1590/S0074-02762008000500002
   Panayiotou C, 2014, EPIDEMIOL INFECT, V142, P2406, DOI 10.1017/S0950268814000028
   Sloan C, 2011, CTS-CLIN TRANSL SCI, V4, P48, DOI 10.1111/j.1752-8062.2010.00257.x
   White LJ, 2005, EPIDEMIOL INFECT, V133, P279, DOI 10.1017/S0950268804003450
   World Health Organization, 2008, 5032 WC WHO
   Zhang ZY, 2010, J CLIN MICROBIOL, V48, P1201, DOI 10.1128/JCM.02258-09
NR 30
TC 8
Z9 9
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD OCT
PY 2016
VL 95
IS 41
AR e5142
DI 10.1097/MD.0000000000005142
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA EA1LV
UT WOS:000386354700048
PM 27741144
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Scherer, MDD
   de Oliveira, CI
   Carvalho, WMDS
   Costa, MP
AF dos Anjos Scherer, Magda Duarte
   de Oliveira, Camila Izabela
   do Espirito Santo Carvalho, Wania Maria
   Costa, Marisa Pacini
TI Specialization training courses on Family Health: what can training
   change in the work?
SO INTERFACE-COMUNICACAO SAUDE EDUCACAO
LA English
DT Article
DE Work in health; Primary health care; Family health; Training; Ergology
ID CARE; EXPERIENCES; CHALLENGES; STRATEGY
AB The persistence of bio-medically oriented practices and the mismatch between training and work are identified as the challenges for the rolling out of Primary Health Care (PHC) in Brazil. This paper analyzes work changes in PHC after following specialization level training courses on community and family health, from the point of view of the trained professionals. It is a qualitative study carried on from 2011 to 2013 in the Federal District (DF) involving doctors, nurses and dentists. Data was collected with the use of digital questionnaires, semistructured interviews and focal groups. From the thematic content analysis, two categories emerged: "a universe of knowledge has opened up" and a "new way of doing things in an adverse working environment". The context of the PHC in DF is a constraint but the training had the potential to generate professional competences.
C1 [dos Anjos Scherer, Magda Duarte] Univ Brasilia, Nucleo Estudos Saude Publ, Fac Ciencias Saude, Dept Saude Colet, SCLN 406,Bloco A,2 Andar, BR-70847510 Brasilia, DF, Brazil.
   [de Oliveira, Camila Izabela] Secretaria Saude Dist Fed, Brasilia, DF, Brazil.
   [do Espirito Santo Carvalho, Wania Maria] Fdn Ensino & Pesquisa Dist Fed, Escola Aperfeicoamento SUS, Brasilia, DF, Brazil.
   [Costa, Marisa Pacini] Fdn Ensino & Pesquisa Distrito Fed, Brasilia, DF, Brazil.
RP Scherer, MDD (corresponding author), Univ Brasilia, Nucleo Estudos Saude Publ, Fac Ciencias Saude, Dept Saude Colet, SCLN 406,Bloco A,2 Andar, BR-70847510 Brasilia, DF, Brazil.
EM magdascherer@unb.br; camila_iza@hotmail.com; waniaescarvalho@gmail.com;
   marisa.pacini@gmail.com
RI SCHERER, MAGDA/P-2223-2017
OI SCHERER, MAGDA/0000-0002-1465-7949
FU Research Program for the Brazilian National Health System (PPSUS) of the
   Foundation for the Support of Research of the Federal District (FAPDF)
   [193.000.347/2010]
FX This article is the result of a research funded by the Research Program
   for the Brazilian National Health System (PPSUS) of the Foundation for
   the Support of Research of the Federal District (FAPDF) (Process number
   193.000.347/2010).
CR Bardin L., 2009, ANALISE CONTEUDO
   Bertoncini Judite Hennemann, 2011, Trab. educ. saúde, V9, P157, DOI 10.1590/S1981-77462011000400008
   Capozzolo AA, 2013, INTERFACE-BOTUCATU, V17, P357, DOI 10.1590/S1414-32832013000200009
   da Costa GD, 2009, REV BRAS ENFERM, V62, P113, DOI 10.1590/S0034-71672009000100017
   da Motta LB, 2011, CAD SAUDE PUBLICA, V27, P779, DOI 10.1590/S0102-311X2011000400017
   Araujo MBD, 2009, CIENC SAUDE COLETIVA, V14, P1439
   Dejours C., 1993, ED PERMANENTE, V116, P47
   Gottems LBD, 2009, CAD SAUDE PUBLICA, V25, P1409, DOI 10.1590/S0102-311X2009000600023
   Scherer MDD, 2013, CIENC SAUDE COLETIVA, V18, P3203
   dos Santos AM, 2012, CIENC SAUDE COLETIVA, V17, P2687, DOI 10.1590/S1413-81232012001000018
   Ellery Ana Ecilda Lima, 2013, Physis, V23, P415, DOI 10.1590/S0103-73312013000200006
   Gonçalves Rebeca Jesumary, 2009, Rev. bras. educ. med., V33, P382, DOI 10.1590/S0100-55022009000300009
   Graziano AP, 2012, REV ESC ENFERM USP, V46, P650, DOI 10.1590/S0080-62342012000300017
   Guerin F., 2001, COMPRENDRE TRAVAIL T
   Jobert G., 2010, RPS FORMATION ENJEUX
   de Mendonca MHM, 2010, CIENC SAUDE COLETIVA, V15, P2355, DOI 10.1590/S1413-81232010000500011
   Mendes EV, 2012, CUIDADO CONDICOES CR
   Minayo MCS, 2008, DESAFIO CONHECIMENTO
   Ministerio da Saude (BR). Secretaria de Atencao a Saude. Departamento da Atencao Basica, 2014, HIST COB SAUD FAM ES
   Ministerio da Saude (BR). Secretaria de Atencao a Saude. Departamento de Atencao Basica, 2012, POL NAC AT BAS PNAB
   Moura Bárbara Laisa Alves, 2010, Rev. Bras. Saude Mater. Infant., V10, ps69, DOI 10.1590/S1519-38292010000500007
   Maciel ELN, 2010, CIENC SAUDE COLETIVA, V15, P2021, DOI 10.1590/S1413-81232010000400016
   Peduzzi Marina, 2011, Physis, V21, P629, DOI 10.1590/S0103-73312011000200015
   Pinafo Elisangela, 2011, Trab. educ. saúde, V9, P201, DOI 10.1590/S1981-77462011000200003
   Reis MAS, 2002, INTERFACE-BOTUCATU, V11, P655
   Ronzani TM, 2008, CIENC SAUDE COLETIVA, V13, P23, DOI 10.1590/S1413-81232008000100007
   Schwartz Y., 2013, ED PERMAN, V197, P13
   Schwartz Y., 1998, EDUC SOC-CAMPINAS, V19, P101
   Schwartz Y, 2010, EDUC REAL, V35, P35
   Schwartz Y., 2000, PRO-POSICOES, V11, P34
   Secretaria de Saude do Distrito Federal (BR), 2010, PLAN DISTR REORG AT
NR 31
TC 3
Z9 6
U1 0
U2 4
PU UNIV ESTADUAL PAULISTA-UNESP
PI BOTUCATU
PA CAMPUS DE BOTUCATU, DIST RUBIAO JR S N, CAIXA POSTAL 592, BOTUCATU, SP
   18618-000, BRAZIL
SN 1414-3283
EI 1807-5762
J9 INTERFACE-BOTUCATU
JI Interface-Comun. Saude Educ.
PD JUL-SEP
PY 2016
VL 20
IS 58
BP 691
EP +
DI 10.1590/1807-57622015.0020
PG 20
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA VG0IF
UT WOS:000444349000014
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Salgado, VR
   de Queiroz, ATL
   Sanabani, SS
   de Oliveira, CI
   Carvalho, EM
   Costa, JML
   Barral-Netto, M
   Barral, A
AF Salgado, Vanessa R.
   de Queiroz, Artur T. L.
   Sanabani, Sabri S.
   de Oliveira, Camila I.
   Carvalho, Edgar M.
   Costa, Jackson M. L.
   Barral-Netto, Manoel
   Barral, Aldina
TI The microbiological signature of human cutaneous leishmaniasis lesions
   exhibits restricted bacterial diversity compared to healthy skin
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE microbiome; LCL; wound; healthy skin; high-throughput sequencing
ID AMERICAN TEGUMENTARY LEISHMANIASIS; ANTIMICROBIAL SUSCEPTIBILITY;
   PATHOGENIC BACTERIA; MICROBIAL-FLORA; CHRONIC WOUNDS; INFECTIONS; ULCER;
   IDENTIFICATION; BRAZIL; SENSITIVITY
AB Localised cutaneous leishmaniasis (LCL) is the most common form of cutaneous leishmaniasis characterised by single or multiple painless chronic ulcers, which commonly presents with secondary bacterial infection. Previous culture-based studies have found staphylococci, streptococci, and opportunistic pathogenic bacteria in LCL lesions, but there have been no comparisons to normal skin. In addition, this approach has strong bias for determining bacterial composition. The present study tested the hypothesis that bacterial communities in LCL lesions differ from those found on healthy skin (HS). Using a high throughput amplicon sequencing approach, which allows for better populational evaluation due to greater depth coverage and the Quantitative Insights Into Microbial Ecology pipeline, we compared the microbiological signature of LCL lesions with that of contralateral HS from the same individuals. Streptococcus, Staphylococcus, Fusobacterium and other strict or facultative anaerobic bacteria composed the LCL microbiome. Aerobic and facultative anaerobic bacteria found in HS, including environmental bacteria, were significantly decreased in LCL lesions (p < 0.01). This paper presents the first comprehensive microbiome identification from LCL lesions with next generation sequence methodology and shows a marked reduction of bacterial diversity in the lesions.
C1 [Salgado, Vanessa R.; de Queiroz, Artur T. L.; de Oliveira, Camila I.; Carvalho, Edgar M.; Costa, Jackson M. L.; Barral-Netto, Manoel; Barral, Aldina] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [de Queiroz, Artur T. L.; de Oliveira, Camila I.; Barral-Netto, Manoel; Barral, Aldina] Inst Invest Imunol, Sao Paulo, SP, Brazil.
   [Sanabani, Sabri S.] Univ Sao Paulo, Fac Med, Hosp Clin, Dept Patol, Sao Paulo, SP, Brazil.
   [Carvalho, Edgar M.] Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Imunol, Salvador, BA, Brazil.
   [Carvalho, Edgar M.] Inst Nacl Ciencia & Tecnol Doencas Tropicais, Salvador, BA, Brazil.
RP Barral, A (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.; Barral, A (corresponding author), Inst Invest Imunol, Sao Paulo, SP, Brazil.
EM abarral@bahia.fiocruz.br
RI Sanabani, Sabri Saeed/F-5600-2012; de Oliveira, Camila I/B-4358-2009;
   Barral-Netto, Manoel/B-3904-2009
OI Sanabani, Sabri Saeed/0000-0002-8876-8262; de Oliveira, Camila
   I/0000-0002-7868-5164; Barral-Netto, Manoel/0000-0002-5823-7903; de
   Queiroz, Artur Trancoso Lopo/0000-0003-4908-9993
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [479717/2011-7]; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI088650]; iii-INCT;
   INCT-D; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U01AI088650, U01AI088650, U01AI088650, U01AI088650,
   U01AI088650, U01AI088650, U01AI088650, U01AI088650, U01AI088650] Funding
   Source: NIH RePORTER
FX Financial support: CNPq (479717/2011-7), NIH (AI088650), iii-INCT,
   INCT-D
CR Alekseyenko AV, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-31
   Azeredo-Coutinho RBG, 2007, J PARASITOL, V93, P688, DOI 10.1645/GE-1031R.1
   Bertesteanu S, 2014, INT J PHARMACEUT, V463, P119, DOI 10.1016/j.ijpharm.2013.12.012
   BITTENCOURT A, 1989, MEM I OSWALDO CRUZ, V84, P585, DOI 10.1590/S0074-02761989000400022
   Caporaso JG, 2012, ISME J, V6, P1621, DOI 10.1038/ismej.2012.8
   Caporaso JG, 2011, P NATL ACAD SCI USA, V108, P4516, DOI 10.1073/pnas.1000080107
   Cogen AL, 2008, BRIT J DERMATOL, V158, P442, DOI 10.1111/j.1365-2133.2008.08437.x
   Costa JM, 2009, GM BAHIA, V79, P70
   DALTREY DC, 1981, J CLIN PATHOL, V34, P701, DOI 10.1136/jcp.34.7.701
   Das LM, 2014, J INVEST DERMATOL, V134, P2303, DOI 10.1038/jid.2014.232
   Davies CE, 2004, J CLIN MICROBIOL, V42, P3549, DOI 10.1128/JCM.42.8.3549-3557.2004
   Goncalves EDD, 2009, REV SOC BRAS MED TRO, V42, P219, DOI 10.1590/S0037-86822009000200027
   Dowd SE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003326
   Fontes CO, 2005, J MED MICROBIOL, V54, P1071, DOI 10.1099/jmm.0.46070-0
   Gardner SE, 2013, DIABETES, V62, P923, DOI 10.2337/db12-0771
   Gontcharova Viktoria, 2010, Open Microbiol J, V4, P8, DOI 10.2174/1874285801004010008
   Grice EA, 2011, NAT REV MICROBIOL, V9, P244, DOI 10.1038/nrmicro2537
   Grice EA, 2010, P NATL ACAD SCI USA, V107, P14799, DOI 10.1073/pnas.1004204107
   Grice EA, 2009, SCIENCE, V324, P1190, DOI 10.1126/science.1171700
   GRIMALDI G, 1989, AM J TROP MED HYG, V41, P687, DOI 10.4269/ajtmh.1989.41.687
   Halbert A R, 1992, Australas J Dermatol, V33, P75
   Han A, 2011, WOUND REPAIR REGEN, V19, P532, DOI 10.1111/j.1524-475X.2011.00720.x
   Isaac-Marquez AP, 2003, MEM I OSWALDO CRUZ, V98, P1093, DOI 10.1590/S0074-02762003000800021
   Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111
   Kong HH, 2012, J INVEST DERMATOL, V132, P933, DOI 10.1038/jid.2011.417
   Kuczynski J, 2012, CURR PROTOC MICROBIO, V1
   Lopes MEM, 2016, PARASITE IMMUNOL, V38, P37, DOI 10.1111/pim.12279
   Machado P, 2002, CLIN INFECT DIS, V34, pE69, DOI 10.1086/340526
   Mahnke A, 2014, J INVEST DERMATOL, V134, P2339, DOI 10.1038/jid.2014.121
   Mitropoulos P, 2010, J AM ACAD DERMATOL, V63, P309, DOI 10.1016/j.jaad.2009.06.088
   Naik S, 2012, SCIENCE, V337, P1115, DOI 10.1126/science.1225152
   Oliveira MR, 2005, PARASITOLOGY, V131, P477, DOI 10.1017/S0031182005008073
   Percival SL, 2010, INT WOUND J, V7, P169, DOI 10.1111/j.1742-481X.2010.00668.x
   Reithinger R, 2007, LANCET INFECT DIS, V7, P581, DOI 10.1016/S1473-3099(07)70209-8
   Rhoads DD, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-321
   ROSA AC, 1988, T ROY SOC TROP MED H, V82, P409, DOI 10.1016/0035-9203(88)90138-1
   Sadeghian G, 2011, Indian J Dermatol, V56, P37, DOI 10.4103/0019-5154.77549
   Salman SM, 1999, CLIN DERMATOL, V17, P291, DOI 10.1016/S0738-081X(99)00047-4
   Scales BS, 2013, J PATHOL, V229, P323, DOI 10.1002/path.4118
   Shirazi M H, 2007, Pak J Biol Sci, V10, P4555, DOI 10.3923/pjbs.2007.4555.4558
   Slover C. M., 2008, Clinical Microbiology Newsletter, V30, P23, DOI 10.1016/j.clinmicnews.2008.01.006
   Vera LA, 2006, REV SOC BRAS MED TRO, V39, P47, DOI 10.1590/S0037-86822006000100009
   Vera Luis Angel, 2002, Rev. Soc. Bras. Med. Trop., V35, P311, DOI 10.1590/S0037-86822002000400006
   Vieira LQ, 1998, BRAZ J MED BIOL RES, V31, P105, DOI 10.1590/S0100-879X1998000100013
   Weirather JL, 2011, J CLIN MICROBIOL, V49, P3892, DOI 10.1128/JCM.r00764-11
   Wolcott R D, 2009, J Wound Care, V18, P317
   Ziaei H, 2008, KOREAN J PARASITOL, V46, P191, DOI 10.3347/kjp.2008.46.3.191
NR 47
TC 11
Z9 11
U1 1
U2 12
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD APR
PY 2016
VL 111
IS 4
BP 241
EP 251
DI 10.1590/0074-02760150436
PG 11
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA DJ8TV
UT WOS:000374487000003
PM 27074253
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Perez, AP
   Altube, MJ
   Schilrreff, P
   Apezteguia, G
   Celes, FS
   Zacchino, S
   de Oliveira, CI
   Romero, EL
   Morilla, MJ
AF Paula Perez, Ana
   Julia Altube, Maria
   Schilrreff, Priscila
   Apezteguia, Gustavo
   Celes, Fabiana Santana
   Zacchino, Susana
   de Oliveira, Camila Indiani
   Lilia Romero, Eder
   Jose Morilla, Maria
TI Topical amphotericin B in ultradeformable liposomes: Formulation, skin
   penetration study, antifungal and antileishmanial activity in vitro
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Flexible liposomes; Skin delivery; Candida spp.; Leishmania
   braziliensis; Nanomedicine
ID DELIVERY; DRUG; LEISHMANIASIS; STABILITY; VESICLES; SYSTEMS; CARRIER;
   AGENTS
AB Aiming to improve the topical delivery of AmB to treat cutaneous fungal infections and leishmaniasis, ultradeformable liposomes containing amphotericin B (AmB-UDL) were prepared, and structural and functional characterized. The effect of different edge activators, phospholipid and AmB concentration, and phospholipid to edge activator ratio on liposomal deformability, as well as on AmB liposomal content, was tested. Liposomes having Tween 80 as edge activator resulted of maximal deformability and AmB/phospholipid ratio. These consisted of AmB-UDL of 107 f 8 nm diameter, 0.078-polydispersity index and-3 0.2 mV Z potential, exhibiting monomeric AmB encapsulated in the bilayer at a 75% encapsulation efficiency. After its cytotoxicity on keratinocytes (HaCaT cells) and macrophages (J774 cells) was determined, the in vitro antifungal activity of AmB-UDL was assayed. It was found that fungal strains (albicans and non-albicans Candida ATCC strains and clinical isolates of C. albicans) were more sensitive to AmB-UDL than mammal cells. Minimum inhibitory concentration values for AmB-UDL were 5-24 and 24-50 times lower than IC50 for J774 and HaCaT cells, respectively. AmB-UDL at 1.25 fig/m1 also displayed 100 and 75% anti-Leishmania braziliensis promastigote and amastigote activity, respectively. Finally, upon 1 h of non-occlusive incubation, the total accumulation of AmB in human skin was 40 times higher when applied as AmB-UDL than as AmBisome. AmB-UDL provided a profound AmB penetration toward deep epithelial layers, achieved without classical permeation enhancers. Because of that, topical treatments of cutaneous fungal infection and leishmaniasis with AmB-UDL may be regarded of potential of clinical significance. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Paula Perez, Ana; Julia Altube, Maria; Schilrreff, Priscila; Apezteguia, Gustavo; Lilia Romero, Eder; Jose Morilla, Maria] Univ Nacl Quilmes, Nanomed Res Program, Dept Ciencia & Tecnol, Roque Saenz Pena 352,Bernal B1876BXD, Buenos Aires, DF, Argentina.
   [Celes, Fabiana Santana; de Oliveira, Camila Indiani] Fiocruz MS, CPQGM, Ctr Pesquisas Goncalo Muniz, Salvador, BA, Brazil.
   [Zacchino, Susana] Fac Ciencias Bioquim & Farmaceut, Farmacognosia, Suipacha 531, RA-2000 Rosario, Santa Fe, Argentina.
RP Morilla, MJ (corresponding author), Univ Nacl Quilmes, Nanomed Res Program, Dept Ciencia & Tecnol, Roque Saenz Pena 352,Bernal B1876BXD, Buenos Aires, DF, Argentina.
EM jmorilla@unq.edu.ar
RI de Oliveira, Camila I/B-4358-2009
OI de Oliveira, Camila I/0000-0002-7868-5164; Schilrreff,
   Priscila/0000-0002-8003-2250; romero, eder lilia/0000-0003-3020-1746;
   Morilla, Maria Jose/0000-0003-3706-9207; Perez, Ana
   Paula/0000-0002-1290-6868
FU Secretaria de Investigaciones, Universidad Nacional de Quilmes; National
   Council for Scientific and Technological Research (CONICET)Consejo
   Nacional de Investigaciones Cientificas y Tecnicas (CONICET); 
   [PIP-2010-2012];  [893CONICET]
FX This work was supported by PIP-2010-2012 No 893CONICET and Secretaria de
   Investigaciones, Universidad Nacional de Quilmes. MJA and PS have a
   fellowship from National Council for Scientific and Technological
   Research (CONICET). ELR, MJM, APP are members of the Research Career
   Program from CONICET.
CR Adams ML, 2003, BIOMACROMOLECULES, V4, P750, DOI 10.1021/bm0257614
   BARWICZ J, 1993, J COLLOID INTERF SCI, V158, P71, DOI 10.1006/jcis.1993.1230
   BENEDICT S, 1994, CANCER NURS, V17, P411
   Bernuzzi F, 2009, CHEM-BIOL INTERACT, V177, P12, DOI 10.1016/j.cbi.2008.09.012
   BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X
   BOUDET G, 1979, BIOCHEM BIOPH RES CO, V88, P998, DOI 10.1016/0006-291X(79)91507-9
   Brajtburg J, 1996, CLIN MICROBIOL REV, V9, P512, DOI 10.1128/CMR.9.4.512
   Butani D, 2014, COLLOID SURFACE B, V116, P351, DOI 10.1016/j.colsurfb.2014.01.014
   Cevc G., 1995, HDB BIOL PHYSICS, V1
   Cevc G, 2012, J CONTROL RELEASE, V160, P135, DOI 10.1016/j.jconrel.2012.01.005
   CLSI, 2008, M27A3 CLSI, V28
   Devi M, 2011, INT J ADV PHARM RES, P37
   Egito EST, 2002, J PHARM SCI-US, V91, P2354, DOI 10.1002/jps.10223
   El Maghraby GMM, 2004, INT J PHARMACEUT, V276, P143, DOI 10.1016/j.ijpharm.2004.02.024
   Espuelas MS, 1998, COLLOID SURFACE B, V11, P141, DOI 10.1016/S0927-7765(98)00033-2
   HARRISON SM, 1984, J PHARM PHARMACOL, V36, P261, DOI 10.1111/j.2042-7158.1984.tb04363.x
   Hussain A, 2014, DRUG DEV IND PHARM, V40, P527, DOI 10.3109/03639045.2013.771647
   Kaminski DM, 2014, EUR BIOPHYS J BIOPHY, V43, P453, DOI 10.1007/s00249-014-0983-8
   Kaur IP, 2008, J OCUL PHARMACOL TH, V24, P481, DOI 10.1089/jop.2008.0031
   Kaur L., 2014, J LIPOSOME RES, P1
   Kumar A, 2012, DRUG DISCOV TODAY, V17, P1233, DOI 10.1016/j.drudis.2012.06.013
   Manosroi A, 2004, INT J PHARMACEUT, V270, P279, DOI 10.1016/j.ijpharm.2003.10.031
   Matsuoka S, 2003, BBA-BIOMEMBRANES, V1617, P109, DOI 10.1016/j.bbamem.2003.09.010
   Morand K, 2007, INT J PHARM, V344, P150, DOI 10.1016/j.ijpharm.2007.04.028
   Ramos LD, 2015, REV IBEROAM MICOL, V32, P122, DOI 10.1016/j.riam.2014.01.003
   Salerno C, 2013, COLLOID SURFACE B, V107, P160, DOI 10.1016/j.colsurfb.2013.02.001
   Sanchez DA, 2014, NANOMED-NANOTECHNOL, V10, P269, DOI 10.1016/j.nano.2013.06.002
   Santos CM, 2012, J BIOMED NANOTECHNOL, V8, P322, DOI 10.1166/jbn.2012.1385
   Sardao VA, 2009, CELL BIOL TOXICOL, V25, P227, DOI 10.1007/s10565-008-9070-1
   Schaefer U., 1996, PHARM RES, V13, P66
   Schram AM, 2014, CUTIS, V93, P204
   Selvam S, 2009, J PHARM SCI-US, V98, P4153, DOI 10.1002/jps.21718
   Singodia D, 2010, J BIOMED NANOTECHNOL, V6, P293, DOI 10.1166/jbn.2010.1121
   Torrado JJ, 2008, J PHARM SCI-US, V97, P2405, DOI 10.1002/jps.21179
   van den Bergh BAI, 2001, INT J PHARM, V217, P13, DOI 10.1016/S0378-5173(01)00576-2
   Wagner H, 2000, PHARM RES-DORDR, V17, P1475, DOI 10.1023/A:1007648807195
   Zhou WJ, 2013, INT J NANOMED, V8, P3715, DOI 10.2147/IJN.S51186
NR 37
TC 58
Z9 61
U1 1
U2 24
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
EI 1873-4367
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD MAR 1
PY 2016
VL 139
BP 190
EP 198
DI 10.1016/j.colsurfb.2015.12.003
PG 9
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA EE5ZK
UT WOS:000389687900024
PM 26709977
DA 2020-12-08
ER

PT J
AU Celes, FS
   Trovatti, E
   Khouri, R
   Van Weyenbergh, J
   Ribeiro, SJ
   Borges, VM
   Barud, H
   de Oliveira, CI
AF Celes, Fabiana S.
   Trovatti, Eliane
   Khouri, Ricardo
   Van Weyenbergh, Johan
   Ribeiro, Sidney J.
   Borges, Valeria M.
   Barud, Hernane
   de Oliveira, Camila I.
TI BACTERIAL CELLULOSE BIO-CURATIVES CONTAINING DIETHYLDITHIOCARBAMATE
   (DETC) FOR THE TOPICAL TREATMENT OF CUTANEOUS LEISHMANIASIS CAUSED BY
   LEISHMANIA BRAZILIENSIS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
C1 [Celes, Fabiana S.; Khouri, Ricardo; Borges, Valeria M.; de Oliveira, Camila I.] Ctr Pesquisas Goncalo Moniz FIOCRUZ BA, Salvador, BA, Brazil.
   [Trovatti, Eliane; Ribeiro, Sidney J.; Barud, Hernane] Univ Estadual Paulista, Inst Quim, Araraquara, SP, Brazil.
   [Van Weyenbergh, Johan] Katholieke Univ Leuven, Dept Microbiol & Immunol, Rega Inst Med Res, Leuven, Belgium.
RI Van Weyenbergh, Johan/Q-3829-2019; Trovatti, Eliane/P-2263-2019; Borges,
   Valeria/G-2009-2014; Van Weyenbergh, Johan/B-4187-2009; Trovatti,
   Eliane/B-9177-2012; Khouri, Ricardo/M-3184-2018
OI Van Weyenbergh, Johan/0000-0003-3234-8426; Trovatti,
   Eliane/0000-0002-0495-8115; Van Weyenbergh, Johan/0000-0003-3234-8426;
   Khouri, Ricardo/0000-0001-5664-4436
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD OCT
PY 2015
VL 93
IS 4
SU S
MA 1092
BP 333
EP 333
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA VB0ZJ
UT WOS:000412844103087
DA 2020-12-08
ER

PT J
AU Barud, HGO
   Barud, HD
   Cavicchioli, M
   do Amaral, TS
   de Oliveira, OB
   Santos, DM
   Petersen, ALDA
   Celes, F
   Borges, VM
   de Oliveira, CI
   de Oliveira, PF
   Furtado, RA
   Tavares, DC
   Ribeiro, SJL
AF Oliveira Barud, H. G.
   Barud, Hernane da S.
   Cavicchioli, Mauricio
   do Amaral, Thais Silva
   de Oliveira Junior, Osmir Batista
   Santos, Diego M.
   de Oliveira Almeida Petersen, Antonio Luis
   Celes, Fabiana
   Borges, Valeria Matos
   de Oliveira, Camila I.
   de Oliveira, Pollyanna Francielli
   Furtado, Ricardo Andrade
   Tavares, Denise Crispim
   Ribeiro, Sidney J. L.
TI Preparation and characterization of a bacterial cellulose/silk fibroin
   sponge scaffold for tissue regeneration
SO CARBOHYDRATE POLYMERS
LA English
DT Article
DE Bacterial cellulose; Silk fibroin; Biocompatible materials;
   Nanocomposites; Scaffold; Tissue engineering.
ID MESENCHYMAL STEM-CELLS; HUMAN BONE-MARROW; SILK FIBROIN; IN-VITRO;
   POLYURETHANE SCAFFOLDS; COMPOSITE; PROLIFERATION; MEMBRANES;
   DIFFERENTIATION; NANOCOMPOSITE
AB Bacterial cellulose (BC) and silk fibroin (SF) are natural biopolymers successfully applied in tissue engineering and biomedical fields. In this work nanocomposites based on BC and SF were prepared and characterized by scanning electron microscopy (SEM), infrared spectroscopy (FT-IR), X-ray diffraction (XRD) and thermogravimetric analysis (TGA). In addition, the investigation of cytocompatibility was done by KIT, XTT and Trypan Blue dye technique. Cellular adhesion and proliferation Were detected additionally. The evaluation of genotoxicity was realized by micronucleus assay. In vitro tests showed that the material is non-cytotoxic or genotoxic. SEM images revealed a greater number of cells attached at the BC/SF:50% scaffold surface than the pure BC one, suggesting that the,presence of fibroin improved cell attachment. This could be related to the SF amino acid sequence that acts as cell receptors facilitating cell adhesion and growth. Consequently, BC/SF:50% scaffolds configured an excellent option in bioengineering depicting its potential for tissue regeneration and cultivation of cells on nanocomposites. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Barud, Hernane da S.; Cavicchioli, Mauricio; do Amaral, Thais Silva; Ribeiro, Sidney J. L.] Sao Paulo State Univ Unesp, Inst Chem, BR-14801970 Araraquara, SP, Brazil.
   [Oliveira Barud, H. G.; de Oliveira Junior, Osmir Batista] Sao Paulo State Univ Unesp, Sch Dent Unesp, BR-14801903 Araraquara, SP, Brazil.
   [Santos, Diego M.; de Oliveira Almeida Petersen, Antonio Luis; Celes, Fabiana; Borges, Valeria Matos; de Oliveira, Camila I.] Fiocruz MS, Goncalo Moniz Res Ctr, BR-40296710 Salvador, BA, Brazil.
   [de Oliveira, Pollyanna Francielli; Furtado, Ricardo Andrade; Tavares, Denise Crispim] Univ Franca, BR-14404600 Franca, SP, Brazil.
   [Barud, Hernane da S.] Ctr Univ Araraquara UNIARA, Lab Quim Med & Med Regenerat QUIMMERA, Araraquara, SP, Brazil.
RP Barud, HD (corresponding author), Sao Paulo State Univ Unesp, Inst Chem, POB 355, BR-14801970 Araraquara, SP, Brazil.
EM hernane.barud@gmail.com
RI Borges, Val/N-6647-2019; Furtado, Ricardo A/B-3485-2013; Tavares, Denise
   C/C-3396-2012; Oliveira Junior, Osmir/C-2693-2016; Cavicchioli,
   Mauricio/A-3073-2008; de Oliveira, Camila I/B-4358-2009; Borges,
   Valeria/G-2009-2014; Ribeiro, Sidney/E-9864-2012
OI Borges, Val/0000-0002-2775-5409; Furtado, Ricardo A/0000-0003-1828-9706;
   Tavares, Denise C/0000-0003-4646-5914; Oliveira Junior,
   Osmir/0000-0002-2153-9887; Cavicchioli, Mauricio/0000-0002-6557-7391; de
   Oliveira, Camila I/0000-0002-7868-5164; Ribeiro,
   Sidney/0000-0002-8162-6747; Oliveira, Pollyanna/0000-0002-1646-0277
CR Alessandrino A, 2008, ENG LIFE SCI, V8, P219, DOI 10.1002/elsc.200700067
   Altman GH, 2003, BIOMATERIALS, V24, P401, DOI 10.1016/S0142-9612(02)00353-8
   Amsden JJ, 2010, ADV MATER, V22, P1746, DOI 10.1002/adma.200903166
   Backdahl H, 2006, BIOMATERIALS, V27, P2141, DOI 10.1016/j.biomaterials.2005.10.026
   Barnes CA, 2008, NANO LETT, V8, P3069, DOI 10.1021/nl801661w
   Barud HS, 2007, J THERM ANAL CALORIM, V87, P815, DOI 10.1007/s10973-006-8170-5
   Barud HS, 2012, COMPOS PART A-APPL S, V43, P973, DOI 10.1016/j.compositesa.2012.01.016
   Barud HS, 2008, THERMOCHIM ACTA, V471, P61, DOI 10.1016/j.tca.2008.02.009
   Barud HS, 2011, CARBOHYD POLYM, V83, P1279, DOI 10.1016/j.carbpol.2010.09.049
   Bhardwaj N, 2011, BIOMATERIALS, V32, P5773, DOI 10.1016/j.biomaterials.2011.04.061
   Bhardwaj N, 2011, CARBOHYD POLYM, V85, P325, DOI 10.1016/j.carbpol.2011.02.027
   Bodin A, 2010, BIOMATERIALS, V31, P8889, DOI 10.1016/j.biomaterials.2010.07.108
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Cai XJ, 2011, CYTOTECHNOLOGY, V63, P319, DOI 10.1007/s10616-011-9366-5
   Cattaneo I, 2013, INT J ARTIF ORGANS, V36, P166, DOI [10.5301/IJAO.5000185, 10.5301/ijao.5000185]
   Chen GP, 2002, MACROMOL BIOSCI, V2, P67, DOI 10.1002/1616-5195(20020201)2:2<67::AID-MABI67>3.3.CO;2-6
   Chiarini A, 2003, BIOMATERIALS, V24, P789, DOI 10.1016/S0142-9612(02)00417-9
   Choi Y., 2013, FIBERS POLYM, V14
   Czaja WK, 2007, BIOMACROMOLECULES, V8, P1, DOI 10.1021/bm060620d
   Dal Pra I, 2003, TISSUE ENG, V9, P1113, DOI 10.1089/10763270360728026
   De Salvi DTB, 2012, J SOL-GEL SCI TECHN, V63, P211, DOI 10.1007/s10971-012-2678-x
   EASTMOND DA, 1989, ENVIRON MOL MUTAGEN, V13, P34, DOI 10.1002/em.2850130104
   Enomoto S, 2010, J VASC SURG, V51, P155, DOI 10.1016/j.jvs.2009.09.005
   Fang B, 2009, TISSUE ENG PT A, V15, P1091, DOI 10.1089/ten.tea.2008.0110
   Fang Q, 2009, MAT SCI ENG C-BIO S, V29, P1527, DOI 10.1016/j.msec.2008.12.007
   Fenech M, 2000, MUTAT RES-FUND MOL M, V455, P81, DOI 10.1016/S0027-5107(00)00065-8
   FONTANA JD, 1990, APPL BIOCHEM BIOTECH, V24-5, P253, DOI 10.1007/BF02920250
   Fraser SA, 2008, J BIOMED MATER RES A, V86A, P725, DOI 10.1002/jbm.a.31519
   Fu LN, 2013, MAT SCI ENG C-MATER, V33, P2995, DOI 10.1016/j.msec.2013.03.026
   Gao CA, 2011, J POROUS MAT, V18, P139, DOI 10.1007/s10934-010-9364-6
   Grande CJ, 2009, ACTA BIOMATER, V5, P1605, DOI 10.1016/j.actbio.2009.01.022
   Helenius G, 2006, J BIOMED MATER RES A, V76A, P431, DOI 10.1002/jbm.a.30570
   Hutchens SA, 2006, BIOMATERIALS, V27, P4661, DOI 10.1016/j.biomaterials.2006.04.032
   Jonas R, 1998, POLYM DEGRAD STABIL, V59, P101, DOI 10.1016/S0141-3910(97)00197-3
   Kim H, 2009, TOXICOL LETT, V184, P13, DOI 10.1016/j.toxlet.2008.10.006
   Kim J, 2011, J POLYM RES, V18, P739, DOI 10.1007/s10965-010-9470-9
   Kim KH, 2005, J BIOTECHNOL, V120, P327, DOI 10.1016/j.jbiotec.2005.06.033
   Kim UJ, 2005, BIOMATERIALS, V26, P2775, DOI 10.1016/j.biomaterials.2004.07.044
   Klemm D, 2005, ANGEW CHEM INT EDIT, V44, P3358, DOI 10.1002/anie.200460587
   Klemm D, 2001, PROG POLYM SCI, V26, P1561, DOI 10.1016/S0079-6700(01)00021-1
   Kweon H, 2001, J APPL POLYM SCI, V80, P928, DOI 10.1002/app.1172
   Lee JM, 2013, JAMA OTOLARYNGOL, V139, P629, DOI 10.1001/jamaoto.2013.3044
   Li GH, 2011, J COLLOID INTERF SCI, V358, P307, DOI 10.1016/j.jcis.2011.02.053
   Lu QA, 2011, BIOMATERIALS, V32, P1059, DOI 10.1016/j.biomaterials.2010.09.072
   Luo HL, 2008, MATER CHEM PHYS, V110, P193, DOI 10.1016/j.matchemphys.2008.01.040
   Mandal BB, 2011, BIOMATERIALS, V32, P639, DOI 10.1016/j.biomaterials.2010.08.115
   Marelli B, 2009, MATER TECHNOL, V24, P52, DOI 10.1179/175355509X417945
   Marelli B, 2010, ACTA BIOMATER, V6, P4019, DOI 10.1016/j.actbio.2010.05.008
   Mauney JR, 2007, BIOMATERIALS, V28, P5280, DOI 10.1016/j.biomaterials.2007.08.017
   Ming JF, 2012, J APPL POLYM SCI, V125, P2148, DOI 10.1002/app.36354
   Mizuno S, 2004, BIOCHEM ENG J, V20, P203, DOI 10.1016/j.bej.2003.09.019
   Nazarov R, 2004, BIOMACROMOLECULES, V5, P718, DOI 10.1021/bm034327e
   Nogueira GM, 2009, J APPL POLYM SCI, V114, P617, DOI 10.1002/app.30627
   Omenetto FG, 2010, SCIENCE, V329, P528, DOI 10.1126/science.1188936
   Petrini P, 2001, J MATER SCI-MATER M, V12, P849, DOI 10.1023/A:1012847301850
   Rambo CR, 2008, MAT SCI ENG C-BIO S, V28, P549, DOI 10.1016/j.msec.2007.11.011
   Rockwood DN, 2011, NAT PROTOC, V6, P1612, DOI 10.1038/nprot.2011.379
   ROSS P, 1991, MICROBIOL REV, V55, P35, DOI 10.1128/MMBR.55.1.35-58.1991
   Sah M. K., 2010, International Journal of Environmental Science and Development, V1, P404
   Saska S, 2011, INT J BIOMATER, V2011, DOI 10.1155/2011/175362
   Saska S, 2012, J MATER CHEM, V22, P22102, DOI 10.1039/c2jm33762b
   SCHMITT DF, 1991, J AM COLL TOXICOL, V10, P541, DOI 10.3109/10915819109078651
   Shi LB, 2014, BIOMATERIALS, V35, P1519, DOI 10.1016/j.biomaterials.2013.11.025
   Shi Q, 2012, BIOMATERIALS, V33, P6644, DOI 10.1016/j.biomaterials.2012.05.071
   Sofia S, 2001, J BIOMED MATER RES, V54, P139, DOI 10.1002/1097-4636(200101)54:1<139::AID-JBM17>3.0.CO;2-7
   Svensson A, 2005, BIOMATERIALS, V26, P419, DOI 10.1016/j.biomaterials.2004.02.049
   Ul-Islam M, 2012, CARBOHYD POLYM, V88, P596, DOI 10.1016/j.carbpol.2012.01.006
   Wang YZ, 2006, BIOMATERIALS, V27, P4434, DOI 10.1016/j.biomaterials.2006.03.050
   Yang CX, 2011, J POROUS MAT, V18, P545, DOI 10.1007/s10934-010-9407-z
   Zeltinger J, 2001, TISSUE ENG, V7, P557, DOI 10.1089/107632701753213183
   Zhang YF, 2010, ACTA BIOMATER, V6, P3021, DOI 10.1016/j.actbio.2010.02.030
NR 71
TC 99
Z9 99
U1 1
U2 187
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0144-8617
EI 1879-1344
J9 CARBOHYD POLYM
JI Carbohydr. Polym.
PD SEP 5
PY 2015
VL 128
BP 41
EP 51
DI 10.1016/j.carbpol.2015.04.007
PG 11
WC Chemistry, Applied; Chemistry, Organic; Polymer Science
SC Chemistry; Polymer Science
GA CK4RC
UT WOS:000356209900005
PM 26005138
OA Bronze, Green Published
DA 2020-12-08
ER

PT J
AU Fukutani, KF
   Nascimento-Carvalho, CM
   Van der Gucht, W
   Wollants, E
   Khouri, R
   Dierckx, T
   Van Ranst, M
   Houspie, L
   Bouzas, ML
   Oliveira, JR
   Barral, A
   Van Weyenbergh, J
   de Oliveira, CI
AF Fukutani, Kiyoshi F.
   Nascimento-Carvalho, Cristiana M.
   Van der Gucht, Winke
   Wollants, Elke
   Khouri, Ricardo
   Dierckx, Tim
   Van Ranst, Marc
   Houspie, Lieselot
   Bouzas, Maiara L.
   Oliveira, Juliana R.
   Barral, Aldina
   Van Weyenbergh, Johan
   de Oliveira, Camila I.
TI Pathogen transcriptional profile in nasopharyngeal aspirates of children
   with acute respiratory tract infection
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE ARI; nCounter; Diagnostics; RSV
ID MESSENGER-RNA ABUNDANCE; RSV BRONCHIOLITIS; QUANTIFICATION; PULMONARY;
   VIRUSES; RISK
AB Background: Acute respiratory tract infections (ARI) present a significant morbidity and pose a global health burden. Patients are frequently treated with antibiotics although ARI are most commonly caused by virus, strengthening the need for improved diagnostic methods.
   Objectives: Detect viral and bacterial RNA in nasopharyngeal aspirates (NPA) from children aged 6-23 months with ARI using nCounter.
   Study design: A custom-designed nCounter probeset containing viral and bacterial targets was tested in NPA of ARI patients.
   Results: Initially, spiked control viral RNAs were detectable in >= 6.25 ng input RNA, indicating absence of inhibitors in NPA. nCounter applied to a larger NPA sample (n = 61) enabled the multiplex detection of different pathogens: RNA viruses Parainfluenza virus (PIV 1-3) and RSV A-B in 21%, Human metapneumovirus (hMPV) in 5%, Bocavirus (BoV), CoV, Influenza virus (IV) A in 3% and, Rhinovirus (RV) in 2% of samples, respectively. RSV A-B was confirmed by Real Time PCR (86.2-96.9% agreement). DNA virus (AV) was detected at RNAlevel, reflecting viral replication, in 10% of samples. Bacterial transcripts from Staphylococcus aureus, Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, Mycoplasma pneumoniae and Chlamydophila pneumoniae were detected in 77, 69, 26, 8, 3 and 2% of samples, respectively.
   Conclusion: nCounter is robust and sensitive for the simultaneous detection of viral (both RNA and DNA) and bacterial transcripts in NPA with low RNA input (< 10 ng). This medium-throughput technique will increase our understanding of ARI pathogenesis and may provide an evidence-based approach for the targeted and rational use of antibiotics in pediatric ARI. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Fukutani, Kiyoshi F.; Khouri, Ricardo; Barral, Aldina; de Oliveira, Camila I.] Ctr Pesquisas Goncalo Moniz CPqGM FIOCRUZ, Salvador, BA, Brazil.
   [Fukutani, Kiyoshi F.; Nascimento-Carvalho, Cristiana M.; Khouri, Ricardo; Bouzas, Maiara L.; Oliveira, Juliana R.; Barral, Aldina; de Oliveira, Camila I.] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
   [Van der Gucht, Winke; Wollants, Elke; Dierckx, Tim; Van Ranst, Marc; Houspie, Lieselot; Van Weyenbergh, Johan] Katholieke Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, Leuven, Belgium.
   [Barral, Aldina] Univ Fed Bahia, Sch Med, Dept Pathol, Salvador, BA, Brazil.
   [Barral, Aldina; de Oliveira, Camila I.] Inst Invest Imunol, Sao Paulo, SP, Brazil.
RP de Oliveira, CI (corresponding author), LIP CPqGM FIOCRUZ, Rua Waldemar Falcao 121, BR-40296710 Salvador, BA, Brazil.
EM camila@bahia.fiocruz.br
RI de Oliveira, Camila I/B-4358-2009; Khouri, Ricardo/M-3184-2018; Van
   Ranst, Marc/P-7522-2017; Van Weyenbergh, Johan/Q-3829-2019; Fukutani,
   Kiyoshi/N-7905-2016; Fukutani, Kiyoshi/T-1630-2019; Van Weyenbergh,
   Johan/B-4187-2009
OI de Oliveira, Camila I/0000-0002-7868-5164; Khouri,
   Ricardo/0000-0001-5664-4436; Van Ranst, Marc/0000-0002-1674-4157; Van
   Weyenbergh, Johan/0000-0003-3234-8426; Fukutani,
   Kiyoshi/0000-0003-2223-0918; Van Weyenbergh, Johan/0000-0003-3234-8426;
   Dierckx, Tim/0000-0002-1969-7974; Wollants, Elke/0000-0002-4057-2236
FU Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB)
   [PNX0019/2009]; Science without Borders (Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico; CNPQ); FAPESB; CNPqNational
   Council for Scientific and Technological Development (CNPq)
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado da
   Bahia (FAPESB; grant PNX0019/2009). KFF was supported by fellowships
   from Science without Borders (Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico; CNPQ) and FAPESB. RK was supported by a
   fellowship from CNPq. AB, CN-C and CIO are senior investigators from
   CNPq.
CR Barczak AK, 2012, P NATL ACAD SCI USA, V109, P6217, DOI 10.1073/pnas.1119540109
   Bouzas ML, 2014, PEDIAT ALLERG IMM-UK, V25, P198, DOI 10.1111/pai.12141
   Duttweiler L, 2004, ARCH DIS CHILD, V89, P1155, DOI 10.1136/adc.2004.049551
   Fahey T, 1998, ARCH DIS CHILD, V79, P225, DOI 10.1136/adc.79.3.225
   Fang RD, 2011, J IMMUNOL, V187, P4890, DOI 10.4049/jimmunol.1100381
   Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385
   Hishiki H, 2011, J INFECT CHEMOTHER, V17, P87, DOI 10.1007/s10156-010-0097-x
   Houspie L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060416
   Mahony JB, 2008, CLIN MICROBIOL REV, V21, P716, DOI 10.1128/CMR.00037-07
   Moens B, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-171
   Pavia AT, 2011, CLIN INFECT DIS, V52, pS284, DOI 10.1093/cid/cir043
   Payton JE, 2009, J CLIN INVEST, V119, P1714, DOI 10.1172/JCI38248
   Pettigrew MM, 2011, J CLIN MICROBIOL, V49, P3750, DOI 10.1128/JCM.01186-11
   Prokopec SD, 2013, RNA, V19, P51, DOI 10.1261/rna.034710.112
   Rde C. Silva, 2014, MEM I O CRUZ, V109, P229
   Resch B, 2007, ACTA PAEDIATR, V96, P495, DOI 10.1111/j.1651-2227.2007.00226.x
   Robinson Joan, 2004, Paediatr Child Health, V9, P21
   Segovia J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029695
   Thorburn K, 2006, THORAX, V61, P611, DOI 10.1136/thx.2005.048397
   Waggott D, 2012, BIOINFORMATICS, V28, P1546, DOI 10.1093/bioinformatics/bts188
   Yang S, 2004, LANCET INFECT DIS, V4, P337, DOI 10.1016/S1473-3099(04)01044-8
NR 21
TC 10
Z9 12
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD AUG
PY 2015
VL 69
BP 190
EP 196
DI 10.1016/j.jcv.2015.06.005
PG 7
WC Virology
SC Virology
GA CN3IH
UT WOS:000358318400039
PM 26209405
OA Green Published
DA 2020-12-08
ER

PT J
AU Carvalho, AM
   Cristal, JR
   Muniz, AC
   Carvalho, LP
   Gomes, R
   Miranda, JC
   Barral, A
   Carvalho, EM
   de Oliveira, CI
AF Carvalho, Augusto M.
   Cristal, Juqueline R.
   Muniz, Aline C.
   Carvalho, Lucas P.
   Gomes, Regis
   Miranda, Jose C.
   Barral, Aldina
   Carvalho, Edgar M.
   de Oliveira, Camila I.
TI Interleukin 10-Dominant Immune Response and Increased Risk of Cutaneous
   Leishmaniasis After Natural Exposure to Lutzomyia intermedia Sand Flies
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE sand fly saliva; L. braziliensis; cutaneous leishmaniasis; lutzomyia
   intermedia; ELISA; cytokines; chemokines; killing assay
ID DELAYED-TYPE HYPERSENSITIVITY; REGULATORY T-CELLS; VISCERAL
   LEISHMANIASIS; PHLEBOTOMUS-PAPATASI; LONGIPALPIS SALIVA; BRAZILIENSIS
   INFECTION; ANTIBODY-RESPONSE; ENDEMIC AREAS; FLY SALIVA; TNF-ALPHA
AB Background. Leishmaniasis is caused by parasites transmitted to the vertebrate host by infected sand flies. During transmission, the vertebrate host is also inoculated with sand fly saliva, which exerts powerful immunomodulatory effects on the host's immune response.
   Methods. We conducted a prospective cohort analysis to characterize the human immune response to Lutzomyia intermedia saliva in 264 individuals, from an area for cutaneous leishmaniasis (CL) caused by Leishmania braziliensis.
   Results. Antibodies were found in 150 individuals (56.8%); immunoglobulin G1 and G4 were the predominant subclasses. Recall responses to salivary gland sonicate showed elevated production of interleukin 10 (IL-10), interleukin 13, interferon gamma, CXCL9, and CCL2 compared with controls. CD4(+)CD25(+) T cells, including Foxp3(+) cells, were the main source of IL-10. L. braziliensis replication was increased (P <.05) in macrophages cocultured with saliva-stimulated lymphocytes from exposed individuals and addition of anti-IL-10 reverted this effect. Positive correlation between antibody response to saliva and cellular response to Leishmania was not found. Importantly, individuals seropositive to saliva are 2.1 times more likely to develop CL (relative risk, 2.1; 95% confidence interval, 1.07-4.2; P <.05).
   Conclusions. Exposure to L. intermedia sand flies skews the human immune response, facilitating L. braziliensis survival in vitro, and increases the risk of developing CL.
C1 [Carvalho, Augusto M.; Cristal, Juqueline R.; Gomes, Regis; Miranda, Jose C.; Barral, Aldina; de Oliveira, Camila I.] Univ Fed Bahia, Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [Muniz, Aline C.; Carvalho, Lucas P.; Carvalho, Edgar M.] Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Imunol, Salvador, BA, Brazil.
   [Carvalho, Lucas P.; Carvalho, Edgar M.] Inst Nacl Ciencia & Tecnol Doencas Trop, Salvador, BA, Brazil.
   [Barral, Aldina; de Oliveira, Camila I.] Inst Invest Imunol, Salvador, BA, Brazil.
RP de Oliveira, CI (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Muniz, Lab Imunoparasitol, Rua Waldemar Falcao 121, BR-40196710 Candeal Salvador, BA, Brazil.
EM camila@bahia.fiocruz.br
RI Carvalho, Lucas/AAP-1844-2020; de Oliveira, Camila I/B-4358-2009
OI de Oliveira, Camila I/0000-0002-7868-5164
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI 30639]; Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)National
   Council for Scientific and Technological Development (CNPq)
   [564689/2008-4]; Fundacao de Amparo a Pesquisa da Bahia; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639] Funding
   Source: NIH RePORTER
FX This work was supported by the National Institutes of Health (grant AI
   30639 to E. M. C.), the Conselho Nacional de Desenvolvimento Cientifico
   e Tecnologico (CNPq; grant 564689/2008-4 to C. I. d. O.), and Fundacao
   de Amparo a Pesquisa da Bahia (fellowships to A. M. C. and J. R. C.). A.
   B., E. M. C., and C. I. d. O. are senior researchers at CNPq.
CR Abdeladhim M, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001345
   Aquino DMC, 2010, AM J TROP MED HYG, V83, P825, DOI 10.4269/ajtmh.2010.10-0182
   Asseman C, 1999, J EXP MED, V190, P995, DOI 10.1084/jem.190.7.995
   Barral A, 2000, AM J TROP MED HYG, V62, P740, DOI 10.4269/ajtmh.2000.62.740
   Battaglia M, 2006, SEMIN IMMUNOL, V18, P120, DOI 10.1016/j.smim.2006.01.007
   Belkaid Y, 1998, J EXP MED, V188, P1941, DOI 10.1084/jem.188.10.1941
   Campanelli AP, 2006, J INFECT DIS, V193, P1313, DOI 10.1086/502980
   Collin N, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000441
   Costa DL, 2013, HUM IMMUNOL, V74, P1491, DOI 10.1016/j.humimm.2013.08.269
   CUENTAS EAL, 1984, T ROY SOC TROP MED H, V78, P845, DOI 10.1016/0035-9203(84)90043-9
   de Moura TR, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000084
   de Moura TR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000712
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   Gomes RB, 2002, J INFECT DIS, V186, P1530, DOI 10.1086/344733
   Gomes R, 2008, P NATL ACAD SCI USA, V105, P7845, DOI 10.1073/pnas.0712153105
   Gomes R, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00110
   Hasko G, 1996, J IMMUNOL, V157, P4634
   Hasko G, 2000, FASEB J, V14, P2065, DOI 10.1096/fj.99-0508com
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Kamhawi S, 2000, SCIENCE, V290, P1351, DOI 10.1126/science.290.5495.1351
   Katz O, 2000, AM J TROP MED HYG, V62, P145, DOI 10.4269/ajtmh.2000.62.145
   Marzouki S, 2011, AM J TROP MED HYG, V84, P653, DOI 10.4269/ajtmh.2011.10-0598
   Oliveira F, 2013, J INVEST DERMATOL, V133, P452, DOI 10.1038/jid.2012.315
   Peng ZK, 2004, J ALLERGY CLIN IMMUN, V114, P1189, DOI 10.1016/j.jaci.2004.08.014
   Pot C, 2009, J IMMUNOL, V183, P797, DOI 10.4049/jimmunol.0901233
   Ribeiro JMC, 1999, J EXP BIOL, V202, P1551
   Ritter U, 2002, PARASITE IMMUNOL, V24, P295, DOI 10.1046/j.1365-3024.2002.00467.x
   Rohousova I, 2005, PARASITOLOGY, V130, P493, DOI 10.1017/S003118200400681X
   Satoguina JS, 2005, J IMMUNOL, V174, P4718, DOI 10.4049/jimmunol.174.8.4718
   Schnorr D, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001947
   Souza AP, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000649
   Souza NA, 2005, J MED ENTOMOL, V42, P986, DOI 10.1603/0022-2585(2005)042[0986:NAROLI]2.0.CO;2
   Teixeira C, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000638
   Teixeira CR, 2005, J IMMUNOL, V175, P8346, DOI 10.4049/jimmunol.175.12.8346
   TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436
   Turetz ML, 2002, J INFECT DIS, V186, P1829, DOI 10.1086/345772
   Valenzuela JG, 2001, J EXP MED, V194, P331, DOI 10.1084/jem.194.3.331
   VANDERZEE JS, 1986, CLIN EXP IMMUNOL, V64, P415
   Vinhas V, 2007, EUR J IMMUNOL, V37, P3111, DOI 10.1002/eji.200737431
   Weinkopff T, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002627
NR 40
TC 15
Z9 15
U1 0
U2 12
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUL 1
PY 2015
VL 212
IS 1
BP 157
EP 165
DI 10.1093/infdis/jiv020
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CM6SA
UT WOS:000357818900019
PM 25596303
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Duarte, A
   Queiroz, ATL
   Tosta, R
   Carvalho, AM
   Barbosa, CH
   Bellio, M
   de Oliveira, CI
   Barral-Netto, M
AF Duarte, Angelo
   Queiroz, Artur T. L.
   Tosta, Rafael
   Carvalho, Augusto M.
   Barbosa, Carlos Henrique
   Bellio, Maria
   de Oliveira, Camila I.
   Barral-Netto, Manoel
TI Prediction of CD8(+) Epitopes in Leishmania braziliensis Proteins Using
   EPIBOT: In Silico Search and In Vivo Validation
SO PLOS ONE
LA English
DT Article
ID HUMAN CUTANEOUS LEISHMANIASIS; T-CELL RESPONSE; VACCINE CANDIDATES;
   BINDING PEPTIDES; INFECTION; NETWORKS; ANTIGENS; IMMUNITY; DATABASE;
   VIANNIA
AB Background
   Leishmaniasis is caused by intracellular Leishmania parasites that induce a T-cell mediated response associated with recognition of CD4(+) and CD8(+) T cell Line 1Lineepitopes. Identification of CD8(+) antigenic determinants is crucial for vaccine and therapy development. Herein, we developed an open-source software dedicated to search and compile data obtained from currently available on line prediction algorithms.
   Methodology/Principal Findings
   We developed a two-phase algorithm and implemented in an open source software called EPIBOT, that consolidates the results obtained with single prediction algorithms, generating a final output in which epitopes are ranked. EPIBOT was initially trained using a set of 831 known epitopes from 397 proteins from IEDB. We then screened 63 Leishmania braziliensis vaccine candidates with the EPIBOT trained tool to search for CD8(+) T cell epitopes. A proof-of-concept experiment was conducted with the top eight CD8(+) epitopes, elected by EPIBOT. To do this, the elected peptides were synthesized and validated for their in vivo cytotoxicity. Among the tested epitopes, three were able to induce lysis of pulsed-target cells.
   Conclusion
   Our results show that EPIBOT can successfully search across existing prediction tools, generating a compiled list of candidate CD8(+) epitopes. This software is fast and a simple search engine that can be customized to search over different MHC alleles or HLA haplotypes.
C1 [Duarte, Angelo; Tosta, Rafael] Univ Estadual Feira de Santana, Dept Tecnol, BR-44036900 Feira De Santana, BA, Brazil.
   [Queiroz, Artur T. L.; Carvalho, Augusto M.; de Oliveira, Camila I.; Barral-Netto, Manoel] CPqGM FIOCRUZ, BR-40296710 Salvador, BA, Brazil.
   [Barbosa, Carlos Henrique; Bellio, Maria] Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Microbiol Paulo de Goes, BR-21941902 Rio de Janeiro, RJ, Brazil.
   [de Oliveira, Camila I.; Barral-Netto, Manoel] Inst Invest Imunol, Sao Paulo, Brazil.
RP de Oliveira, CI (corresponding author), CPqGM FIOCRUZ, R Waldemar Falcao 121, BR-40296710 Salvador, BA, Brazil.
EM camila@bahia.fiocruz.br; mbarral@bahia.fiocruz.br
RI Barral-Netto, Manoel/B-3904-2009; de Oliveira, Camila I/B-4358-2009;
   BELLIO, MARIA/N-8525-2018
OI Barral-Netto, Manoel/0000-0002-5823-7903; de Oliveira, Camila
   I/0000-0002-7868-5164; BELLIO, MARIA/0000-0002-3360-2740
FU FAPESB (Fundacao de Amparo a Pesquisa da Bahia) [SUS0003/2009]
FX This work was supported with a grant from FAPESB (Fundacao de Amparo a
   Pesquisa da Bahia) (SUS0003/2009). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Agallou M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00268
   Alvar J, 2013, VACCINE, V31, pB244, DOI 10.1016/j.vaccine.2012.11.080
   Barber DL, 2003, J IMMUNOL, V171, P27, DOI 10.4049/jimmunol.171.1.27
   Brodskyn CI, 1997, J IMMUNOL, V159, P4467
   CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018
   CUENTAS EAL, 1984, T ROY SOC TROP MED H, V78, P845, DOI 10.1016/0035-9203(84)90043-9
   Davies MN, 2007, DRUG DISCOV TODAY, V12, P389, DOI 10.1016/j.drudis.2007.03.010
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   Donnes P, 2006, NUCLEIC ACIDS RES, V34, pW194, DOI 10.1093/nar/gkl284
   Guerfali FZ, 2009, INFECT GENET EVOL, V9, P344, DOI 10.1016/j.meegid.2008.02.011
   Gurunathan S, 1997, J EXP MED, V186, P1137, DOI 10.1084/jem.186.7.1137
   Harty JT, 2002, CURR OPIN IMMUNOL, V14, P360, DOI 10.1016/S0952-7915(02)00333-3
   Herrera-Najera C, 2009, PROTEOMICS, V9, P1293, DOI 10.1002/pmic.200800533
   Hughey R, 1996, COMPUT APPL BIOSCI, V12, P95
   Jayakumar A, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001204
   Kronenberg K, 2010, J INVEST DERMATOL, V130, P2602, DOI 10.1038/jid.2010.171
   Lin HH, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-8
   Lundegaard C, 2008, BIOINFORMATICS, V24, P1397, DOI 10.1093/bioinformatics/btn128
   Maroof A, 2012, J INFECT DIS, V205, P853, DOI 10.1093/infdis/jir842
   Costa CHN, 2011, PLOS NEGLECT TROP D, V5, DOI [10.1371/journal.pntd.0000943, 10.1371/journal.pntd.0000965]
   Noben-Trauth N, 2003, J IMMUNOL, V170, P5152, DOI 10.4049/jimmunol.170.10.5152
   Novais FO, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003504
   Okwor I, 2009, HUM VACCINES, V5, P291, DOI 10.4161/hv.5.5.7607
   PARKER KC, 1994, J IMMUNOL, V152, P163
   Peacock CS, 2007, NAT GENET, V39, P839, DOI 10.1038/ng2053
   PRESNELL SR, 1993, ANNU REV BIOPH BIOM, V22, P283, DOI 10.1146/annurev.bb.22.060193.001435
   Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595
   Resende DM, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-309
   Salay G, 2007, CLIN VACCINE IMMUNOL, V14, P1173, DOI 10.1128/CVI.00060-07
   Santos CDS, 2013, J INVEST DERMATOL, V133, P1533, DOI 10.1038/jid.2013.4
   Seyed N, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001295
   Tzelepis F, 2008, J IMMUNOL, V180, P1737, DOI 10.4049/jimmunol.180.3.1737
   Vita R, 2010, NUCLEIC ACIDS RES, V38, pD854, DOI 10.1093/nar/gkp1004
NR 33
TC 11
Z9 11
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 23
PY 2015
VL 10
IS 4
AR e0124786
DI 10.1371/journal.pone.0124786
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CG5KZ
UT WOS:000353332000089
PM 25905908
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Falcao, SAC
   Weinkopff, T
   Hurrell, BP
   Celes, FS
   Curvelo, RP
   Prates, DB
   Barral, A
   Borges, VM
   Tacchini-Cottier, F
   de Oliveira, CI
AF Falcao, Sarah A. C.
   Weinkopff, Tiffany
   Hurrell, Benjamin P.
   Celes, Fabiana S.
   Curvelo, Rebecca P.
   Prates, Deboraci B.
   Barral, Aldina
   Borges, Valeria M.
   Tacchini-Cottier, Fabienne
   de Oliveira, Camila I.
TI Exposure to Leishmania braziliensis Triggers Neutrophil Activation and
   Apoptosis
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID POLYMORPHONUCLEAR LEUKOCYTES; INTRACELLULAR PATHOGENS; MACROPHAGE
   INTERACTIONS; AMAZONENSIS INFECTION; MAJOR INFECTION; DENDRITIC CELLS;
   IN-VITRO; GRANULOCYTES; MECHANISMS; RECEPTOR
AB Background
   Neutrophils are the first line of defense against invading pathogens and are rapidly recruited to the sites of Leishmania inoculation. During Leishmania braziliensis infection, depletion of inflammatory cells significantly increases the parasite load whereas co-inoculation of neutrophils plus L. braziliensis had an opposite effect. Moreover, the co-culture of infected macrophages and neutrophils also induced parasite killing leading us to ask how neutrophils alone respond to an L. braziliensis exposure. Herein we focused on understanding the interaction between neutrophils and L. braziliensis, exploring cell activation and apoptotic fate.
   Methods and Findings
   Inoculation of serum-opsonized L. braziliensis promastigotes in mice induced neutrophil accumulation in vivo, peaking at 24 h. In vitro, exposure of thyoglycollate-elicited inflammatory or bone marrow neutrophils to L. braziliensis modulated the expression of surface molecules such as CD18 and CD62L, and induced the oxidative burst. Using mCherry-expressing L. braziliensis, we determined that such effects were mainly observed in infected and not in bystander cells. Neutrophil activation following contact with L. braziliensis was also confirmed by the release of TNF-alpha and neutrophil elastase. Lastly, neutrophils infected with L. braziliensis but not with L. major displayed markers of early apoptosis.
   Conclusions
   We show that L. braziliensis induces neutrophil recruitment in vivo and that neutrophils exposed to the parasite in vitro respond through activation and release of inflammatory mediators. This outcome may impact on parasite elimination, particularly at the early stages of infection.
C1 [Falcao, Sarah A. C.; Celes, Fabiana S.; Curvelo, Rebecca P.; Barral, Aldina; Borges, Valeria M.; de Oliveira, Camila I.] Fiocruz MS, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [Weinkopff, Tiffany; Hurrell, Benjamin P.; Tacchini-Cottier, Fabienne] Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland.
   [Weinkopff, Tiffany; Hurrell, Benjamin P.; Tacchini-Cottier, Fabienne] Univ Lausanne, WHO Immunol Res & Training Ctr, CH-1066 Epalinges, Switzerland.
   [Prates, Deboraci B.] Univ Fed Bahia, Inst Ciencias Saude, Dept Biomorfol, Salvador, BA, Brazil.
   [Barral, Aldina; Borges, Valeria M.; de Oliveira, Camila I.] Inst Invest Imunol, Salvador, BA, Brazil.
RP Falcao, SAC (corresponding author), Fiocruz MS, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
EM camila@bahia.fiocruz.br
RI Borges, Val/N-6647-2019; Borges, Valeria/G-2009-2014; de Oliveira,
   Camila I/B-4358-2009; Tacchini-Cottier, Fabienne M/H-2925-2012
OI Borges, Val/0000-0002-2775-5409; de Oliveira, Camila
   I/0000-0002-7868-5164; Tacchini-Cottier, Fabienne M/0000-0003-3561-0207;
   Falcao, Sarah/0000-0002-5458-7711
FU Brazilian-Swiss Research Program (BSJRP); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq); Fundacao de Amparo ao
   Estado da Bahia (FAPESB); Fundacao Oswaldo Cruz (FIOCRUZ), Brazil
FX This work was supported by the Brazilian-Swiss Research Program (BSJRP
   to FTC and AB), Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq), Fundacao de Amparo ao Estado da Bahia (FAPESB) and
   Fundacao Oswaldo Cruz (FIOCRUZ), Brazil. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aga E, 2002, J IMMUNOL, V169, P898, DOI 10.4049/jimmunol.169.2.898
   Appelberg R, 2007, TRENDS MICROBIOL, V15, P87, DOI 10.1016/j.tim.2006.11.009
   Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476
   Bennouna S, 2005, J IMMUNOL, V174, P4845, DOI 10.4049/jimmunol.174.8.4845
   Bennouna S, 2003, J IMMUNOL, V171, P6052, DOI 10.4049/jimmunol.171.11.6052
   BERG M, 1990, BLOOD, V76, P2381
   Bisti S, 2006, MICROBES INFECT, V8, P1464, DOI 10.1016/j.micinf.2006.01.014
   Borregaard N, 2007, TRENDS IMMUNOL, V28, P340, DOI 10.1016/j.it.2007.06.002
   Carlsen ED, 2013, INFECT IMMUN, V81, P3966, DOI 10.1128/IAI.00770-13
   Chagas AC, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003923
   CHANG KP, 1981, AM J TROP MED HYG, V30, P322, DOI 10.4269/ajtmh.1981.30.322
   Charmoy M, 2007, J LEUKOCYTE BIOL, V82, P288, DOI 10.1189/jlb.0706440
   Charmoy M, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/719361
   Charmoy M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000755
   Chen L, 2005, PARASITOL INT, V54, P109, DOI 10.1016/j.parint.2005.02.001
   Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   Fadeel B, 1998, BLOOD, V92, P4808, DOI 10.1182/blood.V92.12.4808.424k01_4808_4818
   Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112
   Faurschou M, 2003, MICROBES INFECT, V5, P1317, DOI 10.1016/j.micinf.2003.09.008
   Gueirard P, 2008, CELL MICROBIOL, V10, P100, DOI 10.1111/j.1462-5822.2007.01018.x
   Itou T, 2006, CLIN VACCINE IMMUNOL, V13, P575, DOI 10.1128/CVI.13.5.575-583.2006
   JUTILA MA, 1989, J IMMUNOL, V143, P3318
   Laskay T, 2003, TRENDS MICROBIOL, V11, P210, DOI 10.1016/S0966-842X(03)00075-1
   Laskay T, 2008, IMMUNOBIOLOGY, V213, P183, DOI 10.1016/j.imbio.2007.11.010
   Laufs H, 2002, INFECT IMMUN, V70, P826, DOI 10.1128/IAI.70.2.826-835.2002
   Lima GMAC, 1998, IMMUNOL LETT, V64, P145, DOI 10.1016/S0165-2478(98)00099-6
   Lorne E, 2008, AM J PHYSIOL-CELL PH, V294, pC985, DOI 10.1152/ajpcell.00454.2007
   McFarlane E, 2008, INFECT IMMUN, V76, P532, DOI 10.1128/IAI.01388-07
   Megiovanni AM, 2006, J LEUKOCYTE BIOL, V79, P977, DOI 10.1189/jlb.0905526
   Mitra S, 2006, BBA-MOL BASIS DIS, V1762, P732, DOI 10.1016/j.bbadis.2006.06.011
   Mollinedo F, 2010, J BIOL CHEM, V285, P34528, DOI 10.1074/jbc.M110.125302
   MOSSER DM, 1985, J IMMUNOL, V135, P2785
   Muller K, 2001, MED MICROBIOL IMMUN, V190, P73
   Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785
   Novais FO, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003504
   Novais FO, 2009, J IMMUNOL, V183, P8088, DOI 10.4049/jimmunol.0803720
   Okwor I, 2009, P NATL ACAD SCI USA, V106, P13951, DOI 10.1073/pnas.0905184106
   Onnheim K, 2008, IMMUNOLOGY, V125, P591, DOI 10.1111/j.1365-2567.2008.02873.x
   PALECANDA A, 1992, EUR J IMMUNOL, V22, P1279, DOI 10.1002/eji.1830220524
   Peters NC, 2008, SCIENCE, V321, P970, DOI 10.1126/science.1159194
   Prates DB, 2011, J LEUKOCYTE BIOL, V90, P575, DOI 10.1189/jlb.0211105
   Renshaw SA, 2000, J LEUKOCYTE BIOL, V67, P662
   Ribeiro-Gomes FL, 2004, J IMMUNOL, V172, P4454, DOI 10.4049/jimmunol.172.7.4454
   Ribeiro-Gomes FL, 2007, J IMMUNOL, V179, P3988, DOI 10.4049/jimmunol.179.6.3988
   Ribeiro-Gomes FL, 2014, INFECT IMMUN, V82, P2713, DOI 10.1128/IAI.01600-13
   Ribeiro-Gomes FL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002536
   Rosenthal LA, 1996, INFECT IMMUN, V64, P2206, DOI 10.1128/IAI.64.6.2206-2215.1996
   Rousseau D, 2001, BMC Microbiol, V1, P17, DOI 10.1186/1471-2180-1-17
   Sarkar A, 2013, MED MICROBIOL IMMUN, V202, P25, DOI 10.1007/s00430-012-0246-1
   SAVILL J, 1995, SEMIN CELL BIOL, V6, P385, DOI 10.1016/S1043-4682(05)80009-1
   SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970
   Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304
   Sousa LMA, 2014, PARASITE IMMUNOL, V36, P13, DOI 10.1111/pim.12078
   Spath GF, 2001, EXP PARASITOL, V99, P97, DOI 10.1006/expr.2001.4656
   Tacchini-Cottier F, 2000, J IMMUNOL, V165, P2628, DOI 10.4049/jimmunol.165.5.2628
   Tavares NM, 2014, J INFECT DIS, V210, P656, DOI 10.1093/infdis/jiu158
   Thalhofer CJ, 2011, INFECT IMMUN, V79, P108, DOI 10.1128/IAI.00338-10
   van Zandbergen G, 2004, J IMMUNOL, V173, P6521, DOI 10.4049/jimmunol.173.11.6521
   VONANDRIAN UH, 1993, BLOOD, V82, P182, DOI 10.1182/blood.V82.1.182.bloodjournal821182
   WOZENCRAFT AO, 1987, IMMUNOLOGY, V60, P559
   Zarbock A, 2008, AM J PATHOL, V172, P1, DOI 10.2353/ajpath.2008.070502
NR 62
TC 18
Z9 18
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD MAR
PY 2015
VL 9
IS 3
AR e0003601
DI 10.1371/journal.pntd.0003601
PG 19
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CE9YK
UT WOS:000352199400065
PM 25756874
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Pereira, L
   Abbehusen, M
   Teixeira, C
   Cunha, J
   Nascimento, IP
   Fukutani, K
   dos-Santos, W
   Barral, A
   de Oliveira, CI
   Barral-Netto, M
   Soto, M
   Brodskyn, CI
AF Pereira, Lais
   Abbehusen, Melissa
   Teixeira, Clarissa
   Cunha, Jurema
   Nascimento, Ivan P.
   Fukutani, Kyioshi
   dos-Santos, Washington
   Barral, Aldina
   de Oliveira, Camila Indiani
   Barral-Netto, Manoel
   Soto, Manoel
   Brodskyn, Claudia Ida
TI Vaccination with Leishmania infantum Acidic Ribosomal P0 but Not with
   Nucleosomal Histones Proteins Controls Leishmania infantum Infection in
   Hamsters
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID CANINE VISCERAL LEISHMANIASIS; CONFERS PROTECTION; DNA VACCINE;
   CUTANEOUS LEISHMANIASIS; SALIVARY PROTEIN; LYMPH-NODES; DONOVANI;
   IDENTIFICATION; PARASITE; DOGS
AB Background
   Several intracellular Leishmania antigens have been identified in order to find a potential vaccine capable of conferring long lasting protection against Leishmania infection. Histones and Acid Ribosomal proteins are already known to induce an effective immune response and have successfully been tested in the cutaneous leishmaniasis mouse model. Here, we investigate the protective ability of L. infantum nucleosomal histones (HIS) and ribosomal acidic protein P0 (LiP0) against L. infantum infection in the hamster model of visceral leishmaniasis using two different strategies: homologous (plasmid DNA only) or heterologous immunization (plasmid DNA plus recombinant protein and adjuvant).
   Methodology/Principal Findings
   Immunization with both antigens using the heterologous strategy presented a high antibody production level while the homologous strategy immunized group showed predominantly a cellular immune response with parasite load reduction. The pcDNA-LiP0 immunized group showed increased expression ratio of IFN-gamma/IL-10 and IFN-gamma/TGF-beta in the lymph nodes before challenge. Two months after infection hamsters immunized with the empty plasmid presented a pro-inflammatory immune response in the early stages of infection with increased expression ratio of IFN-gamma/IL-10 and IFN-gamma/TGF-beta, whereas hamsters immunized with pcDNA-HIS presented an increase only in the ratio IFN-gamma/TGF-beta. On the other hand, hamsters immunized with LiP0 did not present any increase in the IFN-gamma/TGF-beta and IFN-gamma/IL-10 ratio independently of the immunization strategy used. Conversely, five months after infection, hamsters immunized with HIS maintained a pro-inflammatory immune response (ratio IFN-gamma/IL-10) while pcDNA-LiP0 immunized hamsters continued showing a balanced cytokine profile of pro and anti-inflammatory cytokines. Moreover we observed a significant reduction in parasite load in the spleen, liver and lymph node in this group compared with controls.
   Conclusions/Significance
   Our results suggest that vaccination with L. infantum LiP0 antigen administered in a DNA formulation could be considered a potential component in a vaccine formulation against visceral leishmaniasis.
C1 [Pereira, Lais; Abbehusen, Melissa; Teixeira, Clarissa; Cunha, Jurema; Fukutani, Kyioshi; dos-Santos, Washington; Barral, Aldina; de Oliveira, Camila Indiani; Barral-Netto, Manoel; Brodskyn, Claudia Ida] FIOCRUZ BA, Ctr Pesquisa Goncalo Moniz, Salvador, BA, Brazil.
   [Nascimento, Ivan P.] Inst Butantan, Ctr Biotecnol, Sao Paulo, Brazil.
   [Barral, Aldina; Barral-Netto, Manoel] Univ Fed Bahia, Fac Med, BR-41170290 Salvador, BA, Brazil.
   [Barral, Aldina; de Oliveira, Camila Indiani; Barral-Netto, Manoel; Brodskyn, Claudia Ida] Inst Invest Imunol, Sao Paulo, Brazil.
   [Soto, Manoel] Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Madrid, Spain.
   [Brodskyn, Claudia Ida] Univ Fed Bahia, Inst Ciencias Saude, BR-41170290 Salvador, BA, Brazil.
RP Pereira, L (corresponding author), FIOCRUZ BA, Ctr Pesquisa Goncalo Moniz, Salvador, BA, Brazil.
EM brodskyn@bahia.fiocruz.br
RI Nascimento, Ivan/G-9520-2012; Fukutani, Kiyoshi/N-7905-2016; Fukutani,
   Kiyoshi/T-1630-2019; Alvarez, Manuel Soto/Q-5234-2018; Barral-Netto,
   Manoel/B-3904-2009; de Oliveira, Camila I/B-4358-2009; Nascimento,
   Ivan/G-9520-2012
OI Nascimento, Ivan/0000-0001-9843-1594; Fukutani,
   Kiyoshi/0000-0003-2223-0918; Alvarez, Manuel Soto/0000-0001-6825-841X;
   Barral-Netto, Manoel/0000-0002-5823-7903; de Oliveira, Camila
   I/0000-0002-7868-5164; de Melo e Cunha, Jurema/0000-0001-8039-8685;
   Nascimento, Ivan/0000-0002-5293-3967
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CYTED
FX This study was funded by CNPq and CYTED. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Agallou M, 2012, VACCINE, V30, P5086, DOI 10.1016/j.vaccine.2012.05.075
   Aguilar-Be I, 2005, INFECT IMMUN, V73, P812, DOI 10.1128/IAI.73.2.812-819.2005
   Alves CF, 2009, VET IMMUNOL IMMUNOP, V128, P349, DOI 10.1016/j.vetimm.2008.11.020
   Arora SK, 2005, EXP PARASITOL, V109, P163, DOI 10.1016/j.exppara.2004.12.009
   Baharia RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097911
   Basu R, 2005, J IMMUNOL, V174, P7160, DOI 10.4049/jimmunol.174.11.7160
   Borj-Cabrera GP, 2002, VACCINE, V20, P3277, DOI 10.1016/S0264-410X(02)00294-3
   Carcelen J, 2009, VACCINE, V27, P5964, DOI 10.1016/j.vaccine.2009.07.069
   Carneiro MW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052296
   Carrion J, 2007, MICROBES INFECT, V9, P735, DOI 10.1016/j.micinf.2007.02.018
   Chang KP, 2003, ACTA TROP, V85, P375, DOI 10.1016/S0001-706X(02)00238-3
   da Silva RAA, 2011, ACTA TROP, V120, P185, DOI 10.1016/j.actatropica.2011.08.007
   Dea-Ayuela MA, 2007, ACTA TROP, V103, P212, DOI 10.1016/j.actatropica.2007.06.008
   Fernandes AP, 2008, VACCINE, V26, P5888, DOI 10.1016/j.vaccine.2008.05.095
   Fernandes CB, 2014, VACCINE, V32, P1287, DOI 10.1016/j.vaccine.2013.12.046
   Gomes R, 2008, P NATL ACAD SCI USA, V105, P7845, DOI 10.1073/pnas.0712153105
   Handman E, 2001, CLIN MICROBIOL REV, V14, P229, DOI 10.1128/CMR.14.2.229-243.2001
   Iborra S, 2005, INFECT IMMUN, V73, P5842, DOI 10.1128/IAI.73.9.5842-5852.2005
   Iborra S, 2004, VACCINE, V22, P3865, DOI 10.1016/j.vaccine.2004.04.015
   Iborra S, 2003, INFECT IMMUN, V71, P6562, DOI 10.1128/IAI.71.11.6562-6572.2003
   MACFARLANE J, 1990, EUR J BIOCHEM, V190, P377, DOI 10.1111/j.1432-1033.1990.tb15586.x
   Melby PC, 2001, INFECT IMMUN, V69, P4719, DOI 10.1128/IAI.69.8.4719-4725.2001
   Molano I, 2003, VET IMMUNOL IMMUNOP, V92, P1, DOI 10.1016/S0165-2427(02)00315-X
   Nogueira FS, 2005, VACCINE, V23, P4805, DOI 10.1016/j.vaccine.2005.05.011
   Oxenius A, 1999, J VIROL, V73, P4120, DOI 10.1128/JVI.73.5.4120-4126.1999
   Pearson RD, 1996, CLIN INFECT DIS, V22, P1, DOI 10.1093/clinids/22.1.1
   Rajeshwari K, 2004, INFECT IMMUN, V72, P5515, DOI 10.1128/IAI.72.9.5515-5521.2004
   Ramos I, 2008, VACCINE, V26, P333, DOI 10.1016/j.vaccine.2007.11.021
   Requena JM, 2000, PARASITOL TODAY, V16, P246, DOI 10.1016/S0169-4758(00)01651-3
   Sane SA, 2010, J ANTIMICROB CHEMOTH, V65, P1448, DOI 10.1093/jac/dkq164
   Santarem N, 2007, J BIOMED BIOTECHNOL, DOI 10.1155/2007/85154
   Santos Diego M, 2012, Int J Nanomedicine, V7, P2115, DOI 10.2147/IJN.S30093
   Silverman JM, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-2-r35
   Singh S, 2002, MOL BIOCHEM PARASIT, V119, P121, DOI 10.1016/S0166-6851(01)00394-2
   SKEIKY YAW, 1994, INFECT IMMUN, V62, P1643, DOI 10.1128/IAI.62.5.1643-1651.1994
   Soto M, 1995, IMMUNOL LETT, V48, P23, DOI 10.1016/0165-2478(95)02436-0
   Soto M, 1998, J CLIN MICROBIOL, V36, P58, DOI 10.1128/JCM.36.1.58-63.1998
   Taylor A, 2006, IMMUNOLOGY, V117, P433, DOI 10.1111/j.1365-2567.2006.02321.x
   TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x
   Zhang HS, 2007, MOL BIOCHEM PARASIT, V153, P141, DOI 10.1016/j.molbiopara.2007.02.012
NR 40
TC 9
Z9 9
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD FEB
PY 2015
VL 9
IS 2
AR e0003490
DI 10.1371/journal.pntd.0003490
PG 16
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CD3PW
UT WOS:000350992500034
PM 25642946
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Santos, DM
   Petersen, ALOA
   Celes, FS
   Borges, VM
   Veras, PST
   de Oliveira, CI
AF Santos, Diego M.
   Petersen, Antonio L. O. A.
   Celes, Fabiana S.
   Borges, Valeria M.
   Veras, Patricia S. T.
   de Oliveira, Camila I.
TI Chemotherapeutic Potential of 17-AAG against Cutaneous Leishmaniasis
   Caused by Leishmania (Viannia) braziliensis
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID SHOCK-PROTEIN 90; NEW-WORLD; VISCERAL LEISHMANIASIS; INFLAMMATORY
   RESPONSES; MUCOSAL LEISHMANIASIS; MOLECULAR CHAPERONES; HSP90
   INHIBITION; IMMUNE-RESPONSE; CLINICAL CURE; MACROPHAGES
AB Background: Leishmaniasis remains a worldwide public health problem. The limited therapeutic options, drug toxicity and reports of resistance, reinforce the need for the development of new treatment options. Previously, we showed that 17( allylamino)-17-demethoxygeldanamycin (17-AAG), a Heat Shock Protein 90 (HSP90)-specific inhibitor, reduces L. (L.) amazonensis infection in vitro. Herein, we expand the current knowledge on the leishmanicidal activity of 17-AAG against cutaneous leishmaniasis, employing an experimental model of infection with L. (V.) braziliensis.
   Methodology/Principal findings: Exposure of axenic L. (V.) braziliensis promastigotes to 17-AAG resulted in direct dose-dependent parasite killing. These results were extended to L. (V.) braziliensis-infected macrophages, an effect that was dissociated from the production of nitric oxide (NO), superoxide (O-2) or inflammatory mediators such as TNF-alpha, IL-6 and MCP-1. The leishmanicidal effect was then demonstrated in vivo, employing BALB/c mice infected with L. braziliensis. In this model, 17-AAG treatment resulted in smaller skin lesions and parasite counts were also significantly reduced. Lastly, 17-AAG showed a similar effect to amphotericin B regarding the ability to reduce parasite viability.
   Conclusion/Significance: 17-AAG effectively inhibited the growth of L. braziliensis, both in vitro and in vivo. Given the chronicity of L. (V.) braziliensis infection and its association with mucocutaneous leishmaniasis, 17-AAG can be envisaged as a new chemotherapeutic alternative for cutaneous Leishmaniasis.
C1 [Santos, Diego M.; Petersen, Antonio L. O. A.; Celes, Fabiana S.; Borges, Valeria M.; Veras, Patricia S. T.; de Oliveira, Camila I.] Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [Borges, Valeria M.; de Oliveira, Camila I.] Inst Nacl Ciencia & Tecnol Invest Imunol III INCT, Salvador, BA, Brazil.
RP Santos, DM (corresponding author), Univ Fed Sergipe, Dept Educ Saude, Lagarto, Sergipe, Brazil.
EM camila@bahia.fiocruz.br
RI Borges, Val/N-6647-2019; Veras, Patricia S T Sampaio
   Tavares/I-9632-2014; Borges, Valeria/G-2009-2014; de Oliveira, Camila
   I/B-4358-2009
OI Borges, Val/0000-0002-2775-5409; Veras, Patricia S T Sampaio
   Tavares/0000-0001-8308-9263; de Oliveira, Camila I/0000-0002-7868-5164
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FIOCRUZ; CAPES fellowshipsCAPES; PIBIC/FIOCRUZ fellowship
FX This work was funded by grants from CNPq and FIOCRUZ. DMS and ALOAP
   received CAPES fellowships. FSC received a PIBIC/FIOCRUZ fellowship.
   VMB, PSTV and CIdO are senior investigators from CNPq. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
   Amato VS, 2007, AM J TROP MED HYG, V77, P266, DOI 10.4269/ajtmh.2007.77.266
   Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152
   Belkaid Y, 2001, J EXP MED, V194, P1497, DOI 10.1084/jem.194.10.1497
   Berman JD, 1997, CLIN INFECT DIS, V24, P684, DOI 10.1093/clind/24.4.684
   Besteiro S, 2006, J BIOL CHEM, V281, P11384, DOI 10.1074/jbc.M512307200
   Bittencourt Achiléa, 2003, Braz J Infect Dis, V7, P229, DOI 10.1590/S1413-86702003000300009
   Carvalho AK, 2012, PARASITE IMMUNOL, V34, P395, DOI 10.1111/j.1365-3024.2012.01370.x
   Carvalho LP, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00301
   Chatterjee A, 2007, AM J RESP CRIT CARE, V176, P667, DOI 10.1164/rccm.200702-291OC
   Chulay J D, 1988, Rev Soc Bras Med Trop, V21, P165, DOI 10.1590/S0037-86821988000400002
   COSTA JML, 1986, J TROP MED HYG, V89, P319
   Costa JML, 2005, GAZETA MED BAHIA, V75, P3
   Croft SL, 2003, TRENDS PARASITOL, V19, P502, DOI 10.1016/j.pt.2003.09.008
   de Morais-Teixeira E, 2014, J ANTIMICROB CHEMOTH, V69, P150, DOI 10.1093/jac/dkt318
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   Petersen ALDA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049496
   Dello Russo C, 2006, J NEUROCHEM, V99, P1351, DOI 10.1111/j.1471-4159.2006.04221.x
   den Boer M, 2011, CLIN MICROBIOL INFEC, V17, P1471, DOI 10.1111/j.1469-0691.2011.03635.x
   Devaney E, 2005, INT J PARASITOL, V35, P627, DOI 10.1016/j.ijpara.2005.01.007
   Egorin MJ, 2001, CANCER CHEMOTH PHARM, V47, P291, DOI 10.1007/s002800000242
   ELSTNER EF, 1976, ANAL BIOCHEM, V70, P616, DOI 10.1016/0003-2697(76)90488-7
   Falcao SC, 2012, INT J PARASITOL, V42, P771, DOI 10.1016/j.ijpara.2012.05.006
   Follador I, 2002, CLIN INFECT DIS, V34, pE54, DOI 10.1086/340261
   Goetz MP, 2003, ANN ONCOL, V14, P1169, DOI 10.1093/annonc/mdg316
   Gomes IN, 2003, MICROBES INFECT, V5, P251, DOI 10.1016/S1286-4579(03)00025-X
   Haldar A. K., 2011, MOL BIOL INT, V2011
   Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408
   Khouri R, 2009, J IMMUNOL, V182, P2525, DOI 10.4049/jimmunol.0802860
   Li QL, 2009, PARASITOL RES, V105, P1539, DOI 10.1007/s00436-009-1582-y
   Liese J, 2008, IMMUNOBIOLOGY, V213, P377, DOI 10.1016/j.imbio.2007.12.005
   Llanos-Cuentas A, 2008, CLIN INFECT DIS, V46, P223, DOI 10.1086/524042
   Luo SX, 2011, AM J PHYSIOL-CELL PH, V301, pC227, DOI 10.1152/ajpcell.00493.2010
   Machado P, 2002, CLIN INFECT DIS, V34, pE69, DOI 10.1086/340526
   Madrigal-Matute J, 2010, CARDIOVASC RES, V86, P330, DOI 10.1093/cvr/cvq046
   MARSDEN PD, 1986, T ROY SOC TROP MED H, V80, P859, DOI 10.1016/0035-9203(86)90243-9
   Matta NE, 2010, J PARASITOL, V96, P509, DOI 10.1645/GE-2241.1
   Mendonca MG, 2004, J INFECT DIS, V189, P1018, DOI 10.1086/382135
   Miranda KM, 2001, NITRIC OXIDE-BIOL CH, V5, P62, DOI 10.1006/niox.2000.0319
   Mishra J, 2007, CURR MED CHEM, V14, P1153, DOI 10.2174/092986707780362862
   Modabber Farrokh, 2007, Kinetoplastid Biol Dis, V6, P3, DOI 10.1186/1475-9292-6-3
   Morimoto RI, 1997, ESSAYS BIOCHEM, V32, P17
   Mout R, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-54
   Neckers L, 2012, CLIN CANCER RES, V18, P64, DOI 10.1158/1078-0432.CCR-11-1000
   Oliveira LF, 2011, ACTA TROP, V118, P87, DOI 10.1016/j.actatropica.2011.02.007
   Poulaki V, 2007, FASEB J, V21, P2113, DOI 10.1096/fj.06-7637com
   Rochani AK, 2013, CURR PHARM DESIGN, V19, P377
   Roy N, 2012, BBA-MOL CELL RES, V1823, P707, DOI 10.1016/j.bbamcr.2011.12.003
   Schubach A, 1998, AM J TROP MED HYG, V58, P824, DOI 10.4269/ajtmh.1998.58.824
   Schulte TW, 1998, CANCER CHEMOTH PHARM, V42, P273, DOI 10.1007/s002800050817
   Shimp SK, 2012, INFLAMM RES, V61, P521, DOI 10.1007/s00011-012-0442-x
   Solit DB, 2002, CLIN CANCER RES, V8, P986
   Sousa-Franco J, 2006, MICROBES INFECT, V8, P390, DOI 10.1016/j.micinf.2005.07.007
   Stauch A, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001973
   Trinconi CT, 2014, ANTIMICROB AGENTS CH
   Tuon FF, 2008, INT J DERMATOL, V47, P109, DOI 10.1111/j.1365-4632.2008.03417.x
   Usmani SZ, 2009, CURR MOL MED, V9, P654, DOI 10.2174/156652409788488757
   van Griensven J, 2010, LANCET INFECT DIS, V10, P184, DOI 10.1016/S1473-3099(10)70011-6
   Varela MR, 2013, ACTA TROP C, V131C, P32
   Wenkert D, 2010, J PARASITOLOGY RES, V2010
   Wiesgigl M, 2001, MED MICROBIOL IMMUN, V190, P27, DOI 10.1007/s004300100074
   Zhang JQ, 2013, MYCOPATHOLOGIA, V175, P273, DOI 10.1007/s11046-012-9612-1
NR 62
TC 13
Z9 14
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD OCT
PY 2014
VL 8
IS 10
AR e3275
DI 10.1371/journal.pntd.0003275
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AS9WJ
UT WOS:000344589000077
PM 25340794
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Fukutani, KF
   Figueiredo, V
   Celes, FS
   Cristal, JR
   Barral, A
   Barral-Netto, M
   de Oliveira, CI
AF Fukutani, Kiyoshi F.
   Figueiredo, Virginia
   Celes, Fabiana S.
   Cristal, Juqueline R.
   Barral, Aldina
   Barral-Netto, Manoel
   de Oliveira, Camila I.
TI Serological survey of Leishmania infection in blood donors in Salvador,
   Northeastern Brazil
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Leishmania; Blood supply; Asymptomatic infection; PCR; ELISA
ID POLYMERASE-CHAIN-REACTION; VISCERAL LEISHMANIASIS; FOLLOW-UP; CUTANEOUS
   LEISHMANIASIS; ASYMPTOMATIC INFECTION; TRANSPLANT RECIPIENTS; INFANTUM
   PARASITEMIA; KINETOPLAST DNA; SPP. INFECTION; LATIN-AMERICA
AB Background: Visceral Leishmaniasis is endemic to Brazil, where it is caused by Leishmania infantum (syn. Leishmania chagasi). Following parasite inoculation, individuals may experience asymptomatic infection, raising the possibility of parasite transmission through the transfusion of contaminated blood products. In the present work, we evaluated the prevalence of asymptomatic Leishmania infection among blood donors in Salvador, northeastern Brazil.
   Methods: Peripheral blood was collected from 700 blood donors attending the Blood Bank of Bahia (HEMOBA/SESAB), from January to September 2010. We evaluated anti-Leishmania serology by ELISA, employing Soluble Leishmania Antigen (sensitivity 90% and specificity 95%). The presence of parasite DNA was determined by qPCR, targeting a single copy gene (G6PD), and by end-point PCR, targeting multiple targets, namely a segment located in the Leishmania rRNA locus (ITS) and the conserved region of kinetoplastid DNA (kDNA) minicircles.
   Results: The blood-donor population was comprised of 74.5% of males with a mean age of 34 years. Anti-Leishmania serology by ELISA was positive in 5.4% (38/700) individuals. One individual was also positive for Chagas' disease and another tested positive for Syphilis. Employing qPCR, parasite DNA was not found in any of 38 seropositive samples. However, by ITS PCR, 8/38 (21%) samples were positive and this positivity increased to 26/38 (68%) when we targeted kDNA amplification. Agreement between both techniques (ITS and kDNA PCR) was fair (kappa = 0.219).
   Conclusions: These results indicate that asymptomatic infection is present among the blood donor population of Salvador, a finding that warrants a broader discussion regarding the need to implement specific screening strategies.
C1 [Fukutani, Kiyoshi F.; Celes, Fabiana S.; Cristal, Juqueline R.; Barral, Aldina; Barral-Netto, Manoel; de Oliveira, Camila I.] Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [Figueiredo, Virginia] Fundacao Hematol & Hemoterapia Bahia HEMOBA SESAB, Salvador, BA, Brazil.
   [Barral, Aldina; Barral-Netto, Manoel; de Oliveira, Camila I.] Inst Invest Imunol, Salvador, BA, Brazil.
RP de Oliveira, CI (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisas Goncalo Moniz, Rua Waldemar Falcao 121, Salvador, BA, Brazil.
EM camila@bahia.fiocruz.br
RI de Oliveira, Camila I/B-4358-2009; Fukutani, Kiyoshi/T-1630-2019;
   Barral-Netto, Manoel/B-3904-2009; Fukutani, Kiyoshi/N-7905-2016
OI de Oliveira, Camila I/0000-0002-7868-5164; Barral-Netto,
   Manoel/0000-0002-5823-7903; Fukutani, Kiyoshi/0000-0003-2223-0918
FU FIOCRUZ; CNPqNational Council for Scientific and Technological
   Development (CNPq); CAPES fellowshipCAPES; PIBIC/FIOCRUZ fellowship
FX This work was supported by grants from FIOCRUZ and CNPq. KFF was a
   recipient of a CAPES fellowship. FSC was a recipient of a PIBIC/FIOCRUZ
   fellowship. AB, MBN and CIO are senior investigators from CNPq.
CR Ates SC, 2012, FUTURE MICROBIOL, V7, P773, DOI [10.2217/FMB.12.46, 10.2217/fmb.12.46]
   BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003
   Basset D, 2005, MICROBES INFECT, V7, P1370, DOI 10.1016/j.micinf.2005.06.002
   Bastien P, 2008, J CLIN MICROBIOL, V46, P1897, DOI 10.1128/JCM.02258-07
   Boaventura VS, 2006, AM J TROP MED HYG, V75, P267, DOI 10.4269/ajtmh.2006.75.267
   Cardo LJ, 2006, TRANSFUS APHER SCI, V34, P233, DOI 10.1016/j.transci.2005.12.003
   Carranza-Tamayo CO, 2009, T ROY SOC TROP MED H, V103, P743, DOI 10.1016/j.trstmh.2009.01.014
   Castilho TM, 2008, AM J TROP MED HYG, V78, P122, DOI 10.4269/ajtmh.2008.78.122
   Castilho TM, 2003, J CLIN MICROBIOL, V41, P540, DOI 10.1128/JCM.41.2.540-546.2003
   Clemente WT, 2014, AM J TRANSPLANT, V14, P96, DOI 10.1111/ajt.12521
   COHEN C, 1991, LANCET, V338, P128, DOI 10.1016/0140-6736(91)90129-D
   Costa CHN, 2002, AM J TROP MED HYG, V66, P334, DOI 10.4269/ajtmh.2002.66.334
   Cruz I, 2002, LANCET, V359, P1124, DOI 10.1016/S0140-6736(02)08160-6
   CUMMINS D, 1995, ARCH DIS CHILD, V72, P235, DOI 10.1136/adc.72.3.235
   CUPOLILLO E, 1995, MOL BIOCHEM PARASIT, V73, P145, DOI 10.1016/0166-6851(95)00108-D
   de Oliveira CI, 2003, CLIN INFECT DIS, V37, pE149, DOI 10.1086/379610
   Dey A, 2006, Indian J Med Microbiol, V24, P165
   Marques LHD, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001955
   EVANS TG, 1995, AM J TROP MED HYG, V53, P360, DOI 10.4269/ajtmh.1995.53.360
   Franca AD, 2013, TRANSFUS APHER SCI, V49, P627, DOI 10.1016/j.transci.2013.07.009
   Harhay MO, 2011, TRENDS PARASITOL, V27, P403, DOI 10.1016/j.pt.2011.04.001
   Huda MM, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-62
   Kubar J, 1997, NAT MED, V3, P368, DOI 10.1038/nm0497-368
   Lachaud L, 2000, J CLIN MICROBIOL, V38, P236
   LAINSON R, 1978, NATURE, V273, P595, DOI 10.1038/273595a0
   le Fichoux Y, 1999, J CLIN MICROBIOL, V37, P1953, DOI 10.1128/JCM.37.6.1953-1957.1999
   Lima ID, 2012, AM J TROP MED HYG, V86, P99, DOI 10.4269/ajtmh.2012.10-0492
   Luz KG, 1997, AM J TROP MED HYG, V57, P168, DOI 10.4269/ajtmh.1997.57.168
   Martin-Sanchez J, 2004, AM J TROP MED HYG, V70, P545, DOI 10.4269/ajtmh.2004.70.545
   Mary C, 2006, AM J TROP MED HYG, V75, P858, DOI 10.4269/ajtmh.2006.75.858
   Michel G, 2011, ACTA TROP, V119, P69, DOI 10.1016/j.actatropica.2011.05.012
   Moreno EC, 2006, REV SOC BRAS MED TRO, V39, P421, DOI 10.1590/S0037-86822006000500001
   Mpaka MA, 2009, J INFECT DEV COUNTR, V3, P479, DOI 10.3855/jidc.422
   Oliveira JGS, 2005, ACTA TROP, V94, P55, DOI 10.1016/j.actatropica.2004.12.003
   Oliveira RA, 2008, TRANSPL INFECT DIS, V10, P364, DOI 10.1111/j.1399-3062.2008.00320.x
   Orsini M, 2012, T ROY SOC TROP MED H, V106, P283, DOI 10.1016/j.trstmh.2012.01.008
   Otero ACS, 2000, AM J TROP MED HYG, V62, P128, DOI 10.4269/ajtmh.2000.62.128
   Owens SD, 2001, J AM VET MED ASSOC, V219, P1076, DOI 10.2460/javma.2001.219.1076
   PalatnikdeSousa CB, 1996, BRAZ J MED BIOL RES, V29, P1311
   Riera C, 2008, TRANSFUSION, V48, P1383, DOI 10.1111/j.1537-2995.2008.01708.x
   RODGERS MR, 1990, EXP PARASITOL, V71, P267, DOI 10.1016/0014-4894(90)90031-7
   Romero GAS, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000584
   Saude MD, 2011, SERIE NORMAS MANUAIS, P78
   Scarlata F, 2008, T ROY SOC TROP MED H, V102, P394, DOI 10.1016/j.trstmh.2008.01.011
   Urias Elaine V. R., 2009, Rev. Bras. Hematol. Hemoter., V31, P348
NR 45
TC 13
Z9 13
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JUL 30
PY 2014
VL 14
AR 422
DI 10.1186/1471-2334-14-422
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA AM2HW
UT WOS:000339672300001
PM 25073468
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Ramirez, L
   Corvo, L
   Duarte, MC
   Chavez-Fumagalli, MA
   Valadares, DG
   Santos, DM
   de Oliveira, CI
   Escutia, MR
   Alonso, C
   Bonay, P
   Tavares, CAP
   Coelho, EAF
   Soto, M
AF Ramirez, Laura
   Corvo, Laura
   Duarte, Mariana C.
   Chavez-Fumagalli, Miguel A.
   Valadares, Diogo G.
   Santos, Diego M.
   de Oliveira, Camila I.
   Escutia, Marta R.
   Alonso, Carlos
   Bonay, Pedro
   Tavares, Carlos A. P.
   Coelho, Eduardo A. F.
   Soto, Manuel
TI Cross-protective effect of a combined L5 plus L3 Leishmania major
   ribosomal protein based vaccine combined with a Th1 adjuvant in murine
   cutaneous and visceral leishmaniasis
SO PARASITES & VECTORS
LA English
DT Article
DE Leishmania parasites; L3 and L5 ribosomal proteins; BALB/c mice;
   Experimental infection; Vaccines; Visceral leishmaniasis; Cutaneous
   leishmaniasis
ID OLIGODEOXYNUCLEOTIDES INDUCES PROTECTION; CD4(+) T-CELLS;
   IMMUNE-RESPONSES; BALB/C MICE; AMAZONENSIS INFECTION; AMASTIGOTE
   ANTIGENS; CHAGASI INFECTION; C57BL/6 MICE; EFFICACY; INFANTUM
AB Background: Two Leishmania major ribosomal proteins L3 (LmL3) and L5 (LmL5) have been described as protective molecules against cutaneous leishmaniasis due to infection with L. major and Leishmania braziliensis in BALB/c mice when immunized with a Th1 adjuvant (non-methylated CpG-oligodeoxynucleotides; CpG-ODN). In the present study we analyzed the cross-protective efficacy of an LmL3-LmL5-CpG ODN combined vaccine against infection with Leishmania amazonensis and Leishmania chagasi (syn. Leishmania infantum) the etiologic agents of different clinical forms of human leishmaniasis in South America.
   Methods: The combined vaccine was administered subcutaneously to BALB/c mice. After immunization the cellular and humoral responses elicited were analyzed. Mice were independently challenged with L. amazonensis and L. chagasi. The size of the cutaneous lesions caused by the infection with the first species, the parasite loads and the immune response in both infection models were analyzed nine weeks after challenge.
   Results: Mice vaccinated with the combined vaccine showed a Th1-like response against LmL3 and LmL5. Vaccinated mice were able to delay lesion development due to L. amazonensis infection and to control parasite loads in the site of infection. A reduction of the parasite burden in the lymph nodes draining the site of infection and in the liver and spleen was observed in the vaccinated mice after a subcutaneous infection with L. chagasi. In both models of infection, protection was correlated to parasite antigen-specific production of IFN-gamma and down-regulation of parasite-mediated IL-4 and IL-10 responses.
   Conclusions: The data presented here demonstrate the potential use of L. major L3 and L5 recombinant ribosomal proteins for the development of vaccines against various Leishmania species.
C1 [Ramirez, Laura; Corvo, Laura; Alonso, Carlos; Bonay, Pedro; Soto, Manuel] Univ Autonoma Madrid, Dept Biol Mol, Ctr Biol Mol Severo Ochoa CSIC UAM, E-28049 Madrid, Spain.
   [Duarte, Mariana C.; Chavez-Fumagalli, Miguel A.; Coelho, Eduardo A. F.] Univ Fed Minas Gerais, Fac Med, Programa Posgrad Ciencias Saude Infectol & Med Tr, Belo Horizonte, MG, Brazil.
   [Valadares, Diogo G.; Tavares, Carlos A. P.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, Belo Horizonte, MG, Brazil.
   [Santos, Diego M.; de Oliveira, Camila I.] Fiocruz MS, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [Escutia, Marta R.] Labs LETI S L u, Dept Res & Dev, Madrid 28760, Spain.
   [Coelho, Eduardo A. F.] Univ Fed Minas Gerais, COLTEC, Dept Patol Clin, Belo Horizonte, MG, Brazil.
RP Soto, M (corresponding author), Univ Autonoma Madrid, Dept Biol Mol, Ctr Biol Mol Severo Ochoa CSIC UAM, Nicolas Cabrera 1, E-28049 Madrid, Spain.
EM msoto@cbm.uam.es
RI Alvarez, Manuel Soto/Q-5234-2018; Chavez Fumagalli, Miguel
   Angel/I-6756-2016; Fumagalli, Miguel Angel Chavez/AAI-9413-2020;
   Ramirez, Laura/Q-5502-2018; de Oliveira, Camila I/B-4358-2009
OI Alvarez, Manuel Soto/0000-0001-6825-841X; Chavez Fumagalli, Miguel
   Angel/0000-0002-8394-4802; Fumagalli, Miguel Angel
   Chavez/0000-0002-8394-4802; Ramirez, Laura/0000-0003-0597-400X; de
   Oliveira, Camila I/0000-0002-7868-5164; Corvo, Laura/0000-0001-5907-4993
FU Laboratorios LETI S.L.u-Fundacion Severo Ochoa; Ministerio de Ciencia e
   InnovacionInstituto de Salud Carlos IIISpanish Government [FIS/PI080101,
   FIS PI11/00095]; Instituto de Salud Carlos III within the Network of
   Tropical Diseases Research (VI P I + D + I, ISCIII -Subdireccion General
   de Redes y Centros de Investigacion Cooperativa) [RD12/0018/0009];
   Instituto Nacional de Ciencia e Tecnologia em Nano-Bbiofarmaceutica;
   FAPEMIGMinas Gerais State Research Foundation (FAPEMIG)
   [CBB-APQ-00496-11, CBB-APQ-00819-12]; CNPqNational Council for
   Scientific and Technological Development (CNPq) [APQ-472090/2011-9,
   APQ-482976/2012-8]; CAPES/FAPEMIG; Fundacion Ramon Areces
FX The study was supported in Spain by grants from Laboratorios LETI
   S.L.u-Fundacion Severo Ochoa, from Ministerio de Ciencia e Innovacion
   FIS/PI080101 and FIS PI11/00095 and from the Instituto de Salud Carlos
   III within the Network of Tropical Diseases Research (VI P I + D + I
   2008-2011, ISCIII -Subdireccion General de Redes y Centros de
   Investigacion Cooperativa (RD12/0018/0009)). This work was also, in
   part, supported by grants from Instituto Nacional de Ciencia e
   Tecnologia em Nano-Bbiofarmaceutica, FAPEMIG (CBB-APQ-00496-11 and
   CBB-APQ-00819-12), and CNPq (APQ-472090/2011-9 and APQ-482976/2012-8).
   EAFC is a grant recipient of CNPq. MACF is a grant recipient of
   CAPES/FAPEMIG. A CBMSO institutional grant from Fundacion Ramon Areces
   is also acknowledged.
CR Ahmed S, 2003, INFECT IMMUN, V71, P401, DOI 10.1128/IAI.71.1.401-410.2003
   Awasthi A, 2004, INDIAN J MED RES, V119, P238
   Beattie L, 2008, PARASITE IMMUNOL, V30, P255, DOI 10.1111/j.1365-3024.2008.01020.x
   Beaumier CM, 2013, TRANSL RES, V162, P144, DOI 10.1016/j.trsl.2013.03.006
   Bertholet S, 2009, VACCINE, V27, P7036, DOI 10.1016/j.vaccine.2009.09.066
   BUFFET PA, 1995, ANTIMICROB AGENTS CH, V39, P2167, DOI 10.1128/AAC.39.9.2167
   Calvopina M, 2006, VACCINE, V24, P5645, DOI 10.1016/j.vaccine.2006.03.023
   Campbell M, 2003, INFECT IMMUN, V71, P6270, DOI 10.1128/IAI.71.11.6270-6278.2003
   Carrion J, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-150
   Chavez-Fumagalli MA, 2010, MICROBES INFECT, V12, P967, DOI 10.1016/j.micinf.2010.06.008
   Coelho EAF, 2003, INFECT IMMUN, V71, P3988, DOI 10.1128/IAI.71.7.3988-3994.2003
   COFFMAN RL, 1993, ANN NY ACAD SCI, V681, P25, DOI 10.1111/j.1749-6632.1993.tb22865.x
   Coler RN, 2007, INFECT IMMUN, V75, P4648, DOI 10.1128/IAI.00394-07
   Guedes HLD, 2010, VACCINE, V28, P5491, DOI 10.1016/j.vaccine.2010.04.109
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   Duthie MS, 2012, VACCINE, V30, P134, DOI 10.1016/j.vaccine.2011.11.005
   Farajnia S, 2005, CLIN EXP IMMUNOL, V139, P498, DOI 10.1111/j.1365-2249.2004.02702.x
   Fernandes AP, 2012, CURR OPIN MICROBIOL, V15, P476, DOI 10.1016/j.mib.2012.05.002
   Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495
   Grenfell RFQ, 2010, MEM I OSWALDO CRUZ, V105, P818, DOI 10.1590/S0074-02762010000600015
   Handman E, 2001, CLIN MICROBIOL REV, V14, P229, DOI 10.1128/CMR.14.2.229-243.2001
   Hernandez  MX, 2006, IMMUNOL LETT, V105, P38, DOI 10.1016/j.imlet.2005.12.002
   Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2
   Iborra S, 2005, INFECT IMMUN, V73, P5842, DOI 10.1128/IAI.73.9.5842-5852.2005
   Iborra S, 2008, MICROBES INFECT, V10, P1133, DOI 10.1016/j.micinf.2008.06.002
   Kaye PM, 2004, IMMUNOL REV, V201, P239, DOI 10.1111/j.0105-2896.2004.00188.x
   Kedzierski L, 2011, HUM VACCINES, V7, P1204, DOI 10.4161/hv.7.11.17752
   Marcondes M, 2011, VET PARASITOL, V181, P153, DOI 10.1016/j.vetpar.2011.04.004
   Martins VT, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002148
   Mauricio IL, 2000, PARASITOL TODAY, V16, P188, DOI 10.1016/S0169-4758(00)01637-9
   Meddeb-Garnaoui A, 2010, VACCINE, V28, P1881, DOI 10.1016/j.vaccine.2009.11.075
   Moreno J, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001683
   Murphy ML, 2001, EUR J IMMUNOL, V31, P2848, DOI 10.1002/1521-4141(2001010)31:10&lt;2848::AID-IMMU2848&gt;3.0.CO;2-T
   Murray HW, 2002, INFECT IMMUN, V70, P6284, DOI 10.1128/IAI.70.11.6284-6293.2002
   Mutiso JM, 2013, J BIOMED RES, V27, P85, DOI [10.7555/BR.27.20120064, 10.7555/JBR.27.20120064]
   Oliveira DM, 2012, PARASITOL RES, V110, P1277, DOI 10.1007/s00436-011-2628-5
   Passero LFD, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-64
   Pinto EF, 2004, INFECT IMMUN, V72, P4521, DOI 10.1128/IAI.72.8.4521-4527.2004
   Pinto EF, 2003, VACCINE, V21, P3534, DOI 10.1016/S0264-410X(03)00427-4
   Probst P, 2001, J IMMUNOL, V166, P498, DOI 10.4049/jimmunol.166.1.498
   Ramirez L, 2013, VACCINE, V31, P1312, DOI 10.1016/j.vaccine.2012.12.071
   Ramirez L, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/181690
   Requena JM, 2000, PARASITOL TODAY, V16, P246, DOI 10.1016/S0169-4758(00)01651-3
   Resende DM, 2008, VACCINE, V26, P4585, DOI 10.1016/j.vaccine.2008.05.091
   Rhee EG, 2002, J EXP MED, V195, P1565, DOI 10.1084/jem.20020147
   Pereira BAS, 2008, VET PARASITOL, V158, P239, DOI 10.1016/j.vetpar.2008.09.015
   Shi PY, 1997, BIOTECHNIQUES, V23, P1036, DOI 10.2144/97236bm15
   Silvestre R, 2007, J IMMUNOL, V179, P3161, DOI 10.4049/jimmunol.179.5.3161
   Soong L, 1997, J IMMUNOL, V158, P5374
   SOONG L, 1995, INFECT IMMUN, V63, P3559, DOI 10.1128/IAI.63.9.3559-3566.1995
   Soong L, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00058
   Soto M, 2009, SCHOLARLY RES EXCHAN, V2009, DOI [/10. 3814/2009/173039., DOI 10.3814/2009/173039]
   Ulevitch RJ, 2004, NAT REV IMMUNOL, V4, P512, DOI 10.1038/nri1396
   Valadares DG, 2012, PARASITOL RES, V111, P1807, DOI 10.1007/s00436-012-3028-1
   Wilson ME, 2005, MICROB PATHOGENESIS, V38, P147, DOI 10.1016/j.micpath.2004.11.002
   Zanin FHC, 2007, MICROBES INFECT, V9, P1070, DOI 10.1016/j.micinf.2007.05.012
NR 56
TC 27
Z9 27
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-3305
J9 PARASITE VECTOR
JI Parasites Vectors
PD JAN 2
PY 2014
VL 7
AR 3
DI 10.1186/1756-3305-7-3
PG 11
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA AF3RA
UT WOS:000334628600001
PM 24382098
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Weinkopff, T
   de Oliveira, CI
   de Carvalho, AM
   Hauyon-La Torre, Y
   Muniz, AC
   Miranda, JC
   Barral, A
   Tacchini-Cottier, F
AF Weinkopff, Tiffany
   de Oliveira, Camila I.
   de Carvalho, Augusto M.
   Hauyon-La Torre, Yazmin
   Muniz, Aline C.
   Miranda, Jose Carlos
   Barral, Aldina
   Tacchini-Cottier, Fabienne
TI Repeated Exposure to Lutzomyia intermedia Sand Fly Saliva Induces Local
   Expression of Interferon-Inducible Genes Both at the Site of Injection
   in Mice and in Human Blood
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID LEISHMANIA-BRAZILIENSIS INFECTION; IMMUNITY-RELATED GTPASES;
   INTRACELLULAR PATHOGENS; CUTANEOUS LEISHMANIASIS; VIANNIA BRAZILIENSIS;
   RESISTANCE MECHANISM; HOST-RESISTANCE; P47 GTPASES; TRANSMISSION;
   PROTEIN
AB During a blood meal, Lutzomyia intermedia sand flies transmit Leishmania braziliensis, a parasite causing tegumentary leishmaniasis. In experimental leishmaniasis, pre-exposure to saliva of most blood-feeding sand flies results in parasite establishment in absence of any skin damages in mice challenged with dermotropic Leishmania species together with saliva. In contrast, pre-immunization with Lu. intermedia salivary gland sonicate (SGS) results in enhanced skin inflammatory exacerbation upon co-inoculation of Lu. intermedia SGS and L. braziliensis. These data highlight potential unique features of both L. braziliensis and Lu. intermedia. In this study, we investigated the genes modulated by Lu. intermedia SGS immunization to understand their potential impact on the subsequent cutaneous immune response following inoculation of both SGS and L. braziliensis. The cellular recruitment and global gene expression profile was analyzed in mice repeatedly inoculated or not with Lu. intermedia. Microarray gene analysis revealed the upregulation of a distinct set of IFN-inducible genes, an immune signature not seen to the same extent in control animals. Of note this INF-inducible gene set was not induced in SGS pre-immunized mice subsequently co-inoculated with SGS and L. braziliensis. These data suggest the parasite prevented the upregulation of this Lu. intermedia saliva-related immune signature. The presence of these IFN-inducible genes was further analyzed in peripheral blood mononuclear cells (PBMCs) sampled from uninfected human individuals living in a L. braziliensis-endemic region of Brazil thus regularly exposed to Lu. intermedia bites. PBMCs were cultured in presence or absence of Lu. intermedia SGS. Using qRT-PCR we established that the IFN-inducible genes induced in the skin of SGS pre-immunized mice, were also upregulated by SGS in PBMCs from human individuals regularly exposed to Lu. intermedia bites, but not in PBMCs of control subjects. These data demonstrate that repeated exposure to Lu. intermedia SGS induces the expression of potentially host-protective IFN-inducible genes.
C1 [Weinkopff, Tiffany; Hauyon-La Torre, Yazmin; Tacchini-Cottier, Fabienne] Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland.
   [Weinkopff, Tiffany; Hauyon-La Torre, Yazmin; Tacchini-Cottier, Fabienne] Univ Lausanne, WHO Immunol Res & Training Ctr, CH-1066 Epalinges, Switzerland.
   [de Oliveira, Camila I.; de Carvalho, Augusto M.; Miranda, Jose Carlos; Barral, Aldina] Fiocruz MS, Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [de Oliveira, Camila I.; Barral, Aldina] Inst Nacl Ciencia & Tecnol Invest Imunol iii INCT, Salvador, BA, Brazil.
   [de Carvalho, Augusto M.] Natl Inst Sci & Technol Trop Dis CNPq, Salvador, BA, Brazil.
   [Muniz, Aline C.] Univ Fed Bahia, Serv Imunol, Complexo Hosp Univ Prof Edgar Santos, Salvador, BA, Brazil.
RP Weinkopff, T (corresponding author), Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland.
EM Fabienne.Tacchini-Cottier@unil.ch
RI Tacchini-Cottier, Fabienne M/H-2925-2012; de Oliveira, Camila
   I/B-4358-2009
OI Tacchini-Cottier, Fabienne M/0000-0003-3561-0207; de Oliveira, Camila
   I/0000-0002-7868-5164
FU Brazilian-Swiss Research Program [BSJRP 011007]; Swiss National
   FoundationSwiss National Science Foundation (SNSF) [3100030-129852]
FX This work was supported by the Brazilian-Swiss Research Program [BSJRP
   011007 to FTC and AB] and the Swiss National Foundation [3100030-129852
   to FTC]. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Andrade BB, 2007, SCAND J IMMUNOL, V66, P122, DOI 10.1111/j.1365-3083.2007.01964.x
   Andrade BB, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00121
   Bates PA, 2007, INT J PARASITOL, V37, P1097, DOI 10.1016/j.ijpara.2007.04.003
   Bekpen C, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-11-r92
   Belkaid Y, 1998, J EXP MED, V188, P1941, DOI 10.1084/jem.188.10.1941
   Charmoy M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000755
   CHILDS GE, 1984, ANN TROP MED PARASIT, V78, P25, DOI 10.1080/00034983.1984.11811769
   Collazo CM, 2001, J EXP MED, V194, P181, DOI 10.1084/jem.194.2.181
   Colpitts SL, 2009, J IMMUNOL, V182, P5702, DOI 10.4049/jimmunol.0803450
   de Moura TR, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000084
   de Moura TR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000712
   de Oliveira CI, 2004, MICROBES INFECT, V6, P977, DOI 10.1016/j.micinf.2004.05.009
   de Souza-Neto SM, 2004, MEM I OSWALDO CRUZ, V99, P289, DOI 10.1590/S0074-02762004000300009
   DeKrey GK, 1998, INFECT IMMUN, V66, P827, DOI 10.1128/IAI.66.2.827-829.1998
   Groom JR, 2011, IMMUNOL CELL BIOL, V89, P207, DOI 10.1038/icb.2010.158
   Howard JC, 2011, CURR OPIN MICROBIOL, V14, P414, DOI 10.1016/j.mib.2011.07.002
   Hunn JP, 2011, MAMM GENOME, V22, P43, DOI 10.1007/s00335-010-9293-3
   Jirmanus L, 2012, AM J TROP MED HYG, V86, P426, DOI 10.4269/ajtmh.2012.11-0378
   Kamhawi S, 2000, SCIENCE, V290, P1351, DOI 10.1126/science.290.5495.1351
   Lee HH, 1996, CYTOGENET CELL GENET, V74, P255, DOI 10.1159/000134428
   Lee LF, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002400
   Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maioli TU, 2004, PARASITOL RES, V94, P207, DOI 10.1007/s00436-004-1193-6
   Miranda JC, 2002, MEM I OSWALDO CRUZ, V97, P185, DOI 10.1590/S0074-02762002000200006
   Naik S, 2012, SCIENCE, V337, P1115, DOI 10.1126/science.1225152
   NEAL RA, 1983, PARASITOLOGY, V87, P7, DOI 10.1017/S0031182000052379
   Oliveira F, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000226
   Pichlmair A, 2011, NAT IMMUNOL, V12, P624, DOI 10.1038/ni.2048
   RANGEL E F, 1986, Memorias do Instituto Oswaldo Cruz, V81, P347, DOI 10.1590/S0074-02761986000300013
   RANGEL EF, 1990, MEM I OSWALDO CRUZ, V85, P39, DOI 10.1590/S0074-02761990000100006
   Rocha FJS, 2007, INFECT IMMUN, V75, P3823, DOI 10.1128/IAI.01335-06
   Rogers ME, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00223
   SAMUELSON J, 1991, J EXP MED, V173, P49, DOI 10.1084/jem.173.1.49
   Santiago HC, 2005, J IMMUNOL, V175, P8165, DOI 10.4049/jimmunol.175.12.8165
   Schnorr D, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001947
   Singh SB, 2006, SCIENCE, V313, P1438, DOI 10.1126/science.1129577
   Taylor GA, 2004, NAT REV IMMUNOL, V4, P100, DOI 10.1038/nri1270
   Taylor GA, 2007, MICROBES INFECT, V9, P1644, DOI 10.1016/j.micinf.2007.09.004
   Taylor GA, 2007, CELL MICROBIOL, V9, P1099, DOI 10.1111/j.1462-5822.2007.00916.x
   TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436
   Valenzuela JG, 2001, J EXP MED, V194, P331, DOI 10.1084/jem.194.3.331
   Weinkopff T, 2013, INFECT IMMUN, V81, P1575, DOI 10.1128/IAI.01401-12
   Young DG, 1994, GUIDE IDENTIFICATION, V54
NR 44
TC 9
Z9 9
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JAN
PY 2014
VL 8
IS 1
AR e2627
DI 10.1371/journal.pntd.0002627
PG 10
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AJ8SI
UT WOS:000337977300026
PM 24421912
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Santos, DM
   Carneiro, MW
   de Moura, TR
   Soto, M
   Luz, NF
   Prates, DB
   Irache, JM
   Brodskyn, C
   Barral, A
   Barral-Netto, M
   Espuelas, S
   Borges, VM
   de Oliveira, CI
AF Santos, Diego M.
   Carneiro, Marcia W.
   de Moura, Tatiana R.
   Soto, Manuel
   Luz, Nivea F.
   Prates, Deboraci B.
   Manuel Irache, Juan
   Brodskyn, Claudia
   Barral, Aldina
   Barral-Netto, Manoel
   Espuelas, Socorro
   Borges, Valeria M.
   de Oliveira, Camila I.
TI PLGA nanoparticles loaded with KMP-11 stimulate innate immunity and
   induce the killing of Leishmania
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Leishmania; PLGA; Nanoparticle; Macrophage; Innate response
ID KINETOPLASTID MEMBRANE PROTEIN-11; TUMOR-NECROSIS-FACTOR; BIODEGRADABLE
   MICROSPHERES; DENDRITIC CELLS; HUMAN MONOCYTES; NITRIC-OXIDE; PLASMID
   DNA; IFN-GAMMA; IN-VITRO; DELIVERY
AB We recently demonstrated that immunization with polyester poly(lactide-co-glycolide acid) (PLGA) nanoparticles loaded with the 11-kDa Leishmania vaccine candidate kinetoplastid membrane protein 11 (KMP-11) significantly reduced parasite load in vivo. Presently, we explored the ability of the recombinant PLGA nanoparticles to stimulate innate responses in macrophages and the outcome of infection with Leishmania braziliensis in vitro. Incubation of macrophages with KMP-11-loaded PLGA nanoparticles significantly decreased parasite load. In parallel, we observed the augmented production of nitric oxide, superoxide, TNF-alpha and IL-6. An increased release of CCL2/MCP-1 and CXCL1/KC was also observed, resulting in macrophage and neutrophil recruitment in vitro. Lastly, the incubation of macrophages with KMP-11-loaded PLGA nanoparticles triggered the activation of caspase-1 and the secretion of IL-1 beta and IL-18, suggesting inflammasome participation. Inhibition of caspase-1 significantly increased the parasite load. We conclude that KMP-11-loaded PLGA nanoparticles promote the killing of intracellular Leishmania parasites through the induction of potent innate responses. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Santos, Diego M.; Carneiro, Marcia W.; de Moura, Tatiana R.; Luz, Nivea F.; Prates, Deboraci B.; Brodskyn, Claudia; Barral, Aldina; Barral-Netto, Manoel; Borges, Valeria M.; de Oliveira, Camila I.] Fiocruz MS, Ctr Pesquisas Goncalo Moniz, BR-40196710 Salvador, BA, Brazil.
   [Soto, Manuel] Univ Autonoma Madrid, Dept Biol Mol, Consejo Super Invest Cient, Ctr Biol Mol Severo Ochoa, Madrid, Spain.
   [Manuel Irache, Juan] Univ Navarra, Inst Salud Trop, E-31080 Pamplona, Spain.
   [Brodskyn, Claudia; Barral, Aldina; Barral-Netto, Manoel; de Oliveira, Camila I.] Inst Invest Imunol, Salvador, BA, Brazil.
   [Espuelas, Socorro] Univ Navarra, Fac Farm, Dept Farm & Tecnol Farmaceut, E-31080 Pamplona, Spain.
RP de Oliveira, CI (corresponding author), Fiocruz MS, CPqGM, LIP, Rua Waldemar Falcao,121 Candeal, BR-40196710 Salvador, BA, Brazil.
EM camila@bahia.fiocruz.br
RI Borges, Val/N-6647-2019; Espuelas, Socorro/F-6881-2016; ,
   Tatiana/AAN-1194-2020; Alvarez, Manuel Soto/Q-5234-2018; Borges,
   Valeria/G-2009-2014; de Oliveira, Camila I/B-4358-2009; Irache, Juan
   Manuel/T-3516-2017; Barral-Netto, Manoel/B-3904-2009; Irache, Juan
   M./U-3851-2019
OI Borges, Val/0000-0002-2775-5409; , Tatiana/0000-0002-7442-4434; Alvarez,
   Manuel Soto/0000-0001-6825-841X; de Oliveira, Camila
   I/0000-0002-7868-5164; Irache, Juan Manuel/0000-0001-9687-3436;
   Barral-Netto, Manoel/0000-0002-5823-7903; Farias Luz,
   Nivea/0000-0003-1958-7043; Weber Carneiro, Marcia/0000-0002-4220-5085;
   Espuelas, Socorro/0000-0002-7352-1523
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); AECID (Spain); CAN Foundation (Navarra); CYTED; CAPESCAPES
FX This work was supported by grants from CNPq, AECID (Spain), CAN
   Foundation (Navarra) and CYTED. D.M. Santos and T.R. de Moura were
   supported by CAPES fellowships. M.W. Carneiro, N.F. Luz and D.B. Prates
   were supported by CNPq fellowships. C. Brodskyn, A. Barral, M.
   Barral-Netto, V.M. Borges and C.I. de Oliveira are senior investigators
   from CNPq.
CR ASSREUY J, 1994, EUR J IMMUNOL, V24, P672, DOI 10.1002/eji.1830240328
   Audran R, 2003, VACCINE, V21, P1250, DOI 10.1016/S0264-410X(02)00521-2
   Basu R, 2005, J IMMUNOL, V174, P7160, DOI 10.4049/jimmunol.174.11.7160
   Basu R, 2007, J INFECT DIS, V195, P1373, DOI 10.1086/513439
   Bhaumik S, 2009, VACCINE, V27, P1306, DOI 10.1016/j.vaccine.2008.12.053
   BITTENCOURT AL, 1995, TROPICAL PATHOLOGY, P597
   BOZIC CR, 1995, J IMMUNOL, V154, P6048
   Carcaboso AM, 2004, VACCINE, V22, P1423, DOI 10.1016/j.vaccine.2003.10.020
   Chong CSW, 2005, J CONTROL RELEASE, V102, P85, DOI 10.1016/j.jconrel.2004.09.014
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   del Barrio GG, 2003, J CONTROL RELEASE, V86, P123
   Doroud D, 2011, PARASITE IMMUNOL, V33, P335, DOI 10.1111/j.1365-3024.2011.01289.x
   Doroud D, 2011, J CONTROL RELEASE, V153, P154, DOI 10.1016/j.jconrel.2011.04.011
   dos Santos DF, 2011, EUR J PHARM SCI, V44, P580, DOI 10.1016/j.ejps.2011.10.005
   Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939
   Elamanchili P, 2004, VACCINE, V22, P2406, DOI 10.1016/j.vaccine.2003.12.032
   Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710
   Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579
   Fukuhara Y, 2007, J PHARM SCI-US, V96, P1576, DOI 10.1002/jps.20816
   Hamdy S, 2008, VACCINE, V26, P5046, DOI 10.1016/j.vaccine.2008.07.035
   Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725
   JARDIM A, 1995, BIOCHEM J, V305, P307, DOI 10.1042/bj3050307
   Jensen ATR, 1998, SCAND J IMMUNOL, V48, P103
   Khouri R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014394
   Kobayashi Y, 2008, FRONT BIOSCI-LANDMRK, V13, P2400, DOI 10.2741/2853
   LIEW FY, 1990, J IMMUNOL, V145, P4306
   Lonez C, 2012, ADV DRUG DELIVER REV, V64, P1749, DOI 10.1016/j.addr.2012.05.009
   Lutsiak MEC, 2006, J PHARM PHARMACOL, V58, P739, DOI 10.1211/jpp.58.6.0004
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   Meunier E, 2012, NANOMED-NANOTECHNOL, V8, P987, DOI 10.1016/j.nano.2011.11.004
   Miranda KM, 2001, NITRIC OXIDE-BIOL CH, V5, P62, DOI 10.1006/niox.2000.0319
   Nicolete R, 2011, INT IMMUNOPHARMACOL, V11, P1557, DOI 10.1016/j.intimp.2011.05.014
   OKADA H, 1995, CRIT REV THER DRUG, V12, P1
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Prates DB, 2011, J LEUKOCYTE BIOL, V90, P575, DOI 10.1189/jlb.0211105
   Rathinam VAK, 2010, NAT IMMUNOL, V11, P395, DOI 10.1038/ni.1864
   Reddy ST, 2006, J CONTROL RELEASE, V112, P26, DOI 10.1016/j.jconrel.2006.01.006
   Ritter U, 2000, EUR J IMMUNOL, V30, P3111, DOI 10.1002/1521-4141(200011)30:11&lt;3111::AID-IMMU3111&gt;3.0.CO;2-O
   ROLLINS BJ, 1991, BLOOD, V78, P1112
   Roman BS, 2008, EUR J PHARM BIOPHARM, V70, P98, DOI 10.1016/j.ejpb.2008.03.015
   Santos Diego M, 2012, Int J Nanomedicine, V7, P2115, DOI 10.2147/IJN.S30093
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Sharp FA, 2009, P NATL ACAD SCI USA, V106, P870, DOI 10.1073/pnas.0804897106
   Storni T, 2005, ADV DRUG DELIVER REV, V57, P333, DOI 10.1016/j.addr.2004.09.008
   Svensjo E, 2012, MICROVASC RES, V83, P185, DOI 10.1016/j.mvr.2011.10.003
   Tafaghodi M, 2011, PARASITOL RES, V108, P1265, DOI 10.1007/s00436-010-2176-4
   THEODOS CM, 1991, INFECT IMMUN, V59, P2839, DOI 10.1128/IAI.59.8.2839-2842.1991
   Thomas MC, 2000, DNA CELL BIOL, V19, P47, DOI 10.1089/104454900314708
   van Zandbergen G, 2004, J IMMUNOL, V173, P6521, DOI 10.4049/jimmunol.173.11.6521
   Yan WL, 2007, MOL IMMUNOL, V44, P3672, DOI 10.1016/j.molimm.2007.04.009
NR 50
TC 31
Z9 32
U1 0
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
EI 1549-9642
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD OCT
PY 2013
VL 9
IS 7
BP 985
EP 995
DI 10.1016/j.nano.2013.04.003
PG 11
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 219PU
UT WOS:000324520900016
PM 23603355
OA Green Published
DA 2020-12-08
ER

PT J
AU Soares, BR
   Souza, APA
   Prates, DB
   de Oliveira, CI
   Barral-Netto, M
   Miranda, JC
   Barral, A
AF Soares, Barbara Ribeiro
   Almeida Souza, Ana Paula
   Prates, Deboraci Brito
   de Oliveira, Camila I.
   Barral-Netto, Manoel
   Miranda, Jose Carlos
   Barral, Aldina
TI Seroconversion of sentinel chickens as a biomarker for monitoring
   exposure to visceral Leishmaniasis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID LUTZOMYIA-LONGIPALPIS SALIVA; FEEDING PREFERENCE; GLAND ANTIGENS; SAND
   FLIES; BRAZIL; PROTEINS; CHAGASI; PSYCHODIDAE; CALIFORNIA; DIPTERA
AB Leishmania infantum chagasi causes visceral leishmaniasis (VL); it is transmitted by the sand fly Lutzomyia longipalpis that injects saliva and parasites into the host's skin during a blood meal. Chickens represent an important blood source for sand flies and their presence in the endemic area is often cited as a risk factor for VL transmission. However, the role of chickens in VL epidemiology has not been well defined. Here, we tested if chicken antibodies against Lu. longipalpis salivary gland sonicate (SGS) could be used as markers of exposure to sand fly bites. All naturally exposed chickens in a VL endemic area in Brazil developed anti-SGS IgY antibodies. Interestingly, Lu. longipalpis recombinant salivary proteins rLJM17 and rLJM11 were also able to detect anti-SGS IgY antibodies. Taken together, these results show that chickens can be used to monitor the presence of Lu. longipalpis in the peri-domiciliary area in VL endemic regions, when used as sentinel animals.
C1 [Soares, Barbara Ribeiro; Almeida Souza, Ana Paula; de Oliveira, Camila I.; Barral-Netto, Manoel; Miranda, Jose Carlos; Barral, Aldina] Fundacao Oswaldo Cruz FIOCRUZ Salvador, Ctr Pesquisas Goncalo Moniz, BR-40296710 Salvador, BA, Brazil.
   [Prates, Deboraci Brito] Univ Fed Bahia, Inst Ciencias Saude, Dept Biomorfol, BR-40110100 Salvador, BA, Brazil.
   [Barral-Netto, Manoel; Barral, Aldina] Univ Fed Bahia, Fac Med, BR-40110100 Salvador, BA, Brazil.
   [Barral-Netto, Manoel; Barral, Aldina] Inst Nacl Ciencia & Tecnol, Inst Invest Imunol 3, Salvador, BA, Brazil.
RP Barral, A (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ Salvador, Ctr Pesquisas Goncalo Moniz, Rua Waldemar Falcao 121, BR-40296710 Salvador, BA, Brazil.
EM abarral@bahia.fiocruz.br
RI de Oliveira, Camila I/B-4358-2009; Barral Netto, Manoel/B-3904-2009
OI de Oliveira, Camila I/0000-0002-7868-5164; Barral Netto,
   Manoel/0000-0002-5823-7903
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPESB
FX We gratefully acknowledge the technical assistance of Mr. Edvaldo Passos
   with the sand fly colony, and Edna Oliveira Santos in the endemic area.
   We thank Dr. Jesus Valenzuela for providing the sand fly saliva
   recombinant antigens and Mr. Gilmar Ribeiro for providing sera from
   chickens exposed to Aedes aegypti or to triatomine bites. This work was
   supported by CNPq and FAPESB. The funders had no role in the study
   design, data collection and analysis, decision to publish or preparation
   of the manuscript. We thank Global Science Editing, UK for their English
   language editing services.
CR Alexander B, 2002, EMERG INFECT DIS, V8, P1480, DOI 10.3201/eid0812.010485
   Barker CM, 2010, AM J TROP MED HYG, V82, P1185, DOI 10.4269/ajtmh.2010.09-0324
   Barral A, 2000, AM J TROP MED HYG, V62, P740, DOI 10.4269/ajtmh.2000.62.740
   Brazil R.P., 1991, Parassitologia (Rome), V33, P113
   Caldas AJM, 2002, T ROY SOC TROP MED H, V96, P21, DOI 10.1016/S0035-9203(02)90227-0
   Charlab R, 2001, GENE, V267, P13, DOI 10.1016/S0378-1119(01)00393-6
   Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004
   Dias Flávio de Oliveira Passos, 2003, Cad. Saúde Pública, V19, P1373, DOI 10.1590/S0102-311X2003000500015
   Gomes RB, 2002, J INFECT DIS, V186, P1530, DOI 10.1086/344733
   Gomes RB, 2007, T ROY SOC TROP MED H, V101, P127, DOI 10.1016/j.trstmh.2006.06.002
   JERONIMO SMB, 1994, T ROY SOC TROP MED H, V88, P386, DOI 10.1016/0035-9203(94)90393-X
   Kwan JL, 2010, AM J TROP MED HYG, V83, P1137, DOI 10.4269/ajtmh.2010.10-0078
   Lainson R, 2005, MEM I OSWALDO CRUZ, V100, P811, DOI 10.1590/S0074-02762005000800001
   Nery LCD, 2004, MEM I OSWALDO CRUZ, V99, P571, DOI 10.1590/S0074-02762004000600006
   Oliveira-Pereira YN, 2008, CAD SAUDE PUBLICA, V24, P2183, DOI 10.1590/S0102-311X2008000900024
   Otranto D, 2010, ACTA TROP, V113, P80, DOI 10.1016/j.actatropica.2009.09.014
   Prates DB, 2008, J MED ENTOMOL, V45, P409, DOI 10.1603/0022-2585(2008)45[409:CIAOTS]2.0.CO;2
   Rangel EF, 2008, CAD SAUDE PUBLICA, V24, P2948, DOI 10.1590/S0102-311X2008001200025
   REISEN WK, 1990, AM J TROP MED HYG, V43, P419, DOI 10.4269/ajtmh.1990.43.419
   Sant'Anna MRV, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-3
   Schwarz A, 2010, INT J PARASITOL, V40, P1295, DOI 10.1016/j.ijpara.2010.03.013
   Schwarz A, 2009, INT J PARASITOL, V39, P1021, DOI 10.1016/j.ijpara.2009.01.010
   Silva F, 2005, AM J TROP MED HYG, V72, P94, DOI 10.4269/ajtmh.2005.72.94
   SINGH N, 2012, INDIA J PARASITOL, DOI DOI 10.1645/GE-3085.1
   Souza AP, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000649
   Teixeira C, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000638
   Trevejo RT, 2005, J AM MOSQUITO CONTR, V21, P39, DOI 10.2987/8756-971X(2005)21[39:DOCATM]2.0.CO;2
   Valenzuela JG, 2004, J EXP BIOL, V207, P3717, DOI 10.1242/jeb.01185
   Valenzuela JG, 2002, INSECT BIOCHEM MOLEC, V32, P1101, DOI 10.1016/S0965-1748(02)00047-4
   Volf P, 2000, MED VET ENTOMOL, V14, P251, DOI 10.1046/j.1365-2915.2000.00240.x
   WARBURG A, 1994, PHILOS T R SOC B, V345, P223, DOI 10.1098/rstb.1994.0097
NR 31
TC 13
Z9 13
U1 0
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 5
PY 2013
VL 3
AR 2352
DI 10.1038/srep02352
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 195JR
UT WOS:000322698700002
PM 23912591
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Novais, FO
   Carvalho, LP
   Graff, JW
   Beiting, DP
   Ruthel, G
   Roos, DS
   Betts, MR
   Goldschmidt, MH
   Wilson, ME
   de Oliveira, CI
   Scott, P
AF Novais, Fernanda O.
   Carvalho, Lucas P.
   Graff, Joel W.
   Beiting, Daniel P.
   Ruthel, Gordon
   Roos, David S.
   Betts, Michael R.
   Goldschmidt, Michael H.
   Wilson, Mary E.
   de Oliveira, Camila I.
   Scott, Phillip
TI Cytotoxic T Cells Mediate Pathology and Metastasis in Cutaneous
   Leishmaniasis
SO PLOS PATHOGENS
LA English
DT Article
ID EXPERIMENTAL VISCERAL LEISHMANIASIS; EXPERIMENTAL CEREBRAL MALARIA;
   CD8(+) T; INFECTED MACROPHAGES; MUCOSAL LEISHMANIASIS; MUCOCUTANEOUS
   LEISHMANIASIS; COGNATE ANTIGEN; IMMUNE-SYSTEM; DYING CELLS; MICE
AB Disease progression in response to infection can be strongly influenced by both pathogen burden and infection-induced immunopathology. While current therapeutics focus on augmenting protective immune responses, identifying therapeutics that reduce infection-induced immunopathology are clearly warranted. Despite the apparent protective role for murine CD8+ T cells following infection with the intracellular parasite Leishmania, CD8+ T cells have been paradoxically linked to immunopathological responses in human cutaneous leishmaniasis. Transcriptome analysis of lesions from Leishmania braziliensis patients revealed that genes associated with the cytolytic pathway are highly expressed and CD8+ T cells from lesions exhibited a cytolytic phenotype. To determine if CD8+ T cells play a causal role in disease, we turned to a murine model. These studies revealed that disease progression and metastasis in L. braziliensis infected mice was independent of parasite burden and was instead directly associated with the presence of CD8+ T cells. In mice with severe pathology, we visualized CD8+ T cell degranulation and lysis of L. braziliensis infected cells. Finally, in contrast to wild-type CD8+ T cells, perforin-deficient cells failed to induce disease. Thus, we show for the first time that cytolytic CD8+ T cells mediate immunopathology and drive the development of metastatic lesions in cutaneous leishmaniasis.
C1 [Novais, Fernanda O.; Ruthel, Gordon; Goldschmidt, Michael H.; Scott, Phillip] Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA.
   [Carvalho, Lucas P.] Univ Fed Bahia, INCT DT, CNPq, MCT,Serv Imunol,Hosp Univ Prof Edgard Santos, Salvador, BA, Brazil.
   [Graff, Joel W.; Wilson, Mary E.] Iowa City VA Med Ctr, Iowa City, IA USA.
   [Beiting, Daniel P.; Roos, David S.] Univ Penn, Dept Biol, Philadelphia, PA 19104 USA.
   [Betts, Michael R.] Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [de Oliveira, Camila I.] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
RP Scott, P (corresponding author), Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA.
EM pscott@vet.upenn.edu
RI Beiting, Daniel/AAG-6275-2019; de Oliveira, Camila I/B-4358-2009;
   Carvalho, Lucas/AAP-1844-2020
OI de Oliveira, Camila I/0000-0002-7868-5164; Goldschmidt,
   Michael/0000-0001-9515-0535; Roos, David/0000-0001-6725-4089; Wilson,
   Mary/0000-0001-8680-7275
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [RO176257];
   International Centers for Infectious Disease Research grant [U01-AUI
   088650]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq), BrazilNational Council for Scientific and Technological
   Development (CNPq); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U01AI088650, U01AI088650, U01AI088650,
   R01AI076257, U01AI088650, U01AI088650, R01AI076257, R01AI076257,
   R01AI076257, R01AI076257, R01AI076257, U01AI088650, U01AI088650,
   U01AI088650, U01AI088650] Funding Source: NIH RePORTER
FX These studies were funded in part by the National Institutes of Health:
   (RO176257, http://grants.nih.gov/grants/oer.htm); International Centers
   for Infectious Disease Research grant (U01-AUI 088650), Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq,
   http://www.cnpq.br/), Brazil. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Anderson CF, 2007, J EXP MED, V204, P285, DOI 10.1084/jem.20061886
   BARRALNETTO M, 1995, PARASITE IMMUNOL, V17, P21, DOI 10.1111/j.1365-3024.1995.tb00962.x
   Belkaid Y, 2002, J IMMUNOL, V168, P3992, DOI 10.4049/jimmunol.168.8.3992
   Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152
   Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5
   Bonilla WV, 2012, SCIENCE, V335, P984, DOI 10.1126/science.1215418
   Brodskyn CI, 1997, J IMMUNOL, V159, P4467
   Carvalho LP, 2007, PARASITE IMMUNOL, V29, P251, DOI 10.1111/j.1365-3024.2007.00940.x
   Chen ML, 2005, P NATL ACAD SCI USA, V102, P419, DOI 10.1073/pnas.0408197102
   David CV, 2009, DERMATOL THER, V22, P491, DOI 10.1111/j.1529-8019.2009.01272.x
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   de Oliveira CI, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00145
   Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004
   Falcao SC, 2012, INT J PARASITOL, V42, P771, DOI 10.1016/j.ijpara.2012.05.006
   Faria DR, 2009, PARASITE IMMUNOL, V31, P432, DOI 10.1111/j.1365-3024.2009.01125.x
   Faria DR, 2005, INFECT IMMUN, V73, P7853, DOI 10.1128/IAI.73.12.7853-7859.2005
   Gebhard JR, 1998, AM J PATHOL, V153, P417, DOI 10.1016/S0002-9440(10)65585-X
   Gonzalez S, 2008, TRENDS IMMUNOL, V29, P397, DOI 10.1016/j.it.2008.04.007
   Gunderson AJ, 2012, J INVESTIGATIVE DERM
   Gurunathan S, 1997, J EXP MED, V186, P1137, DOI 10.1084/jem.186.7.1137
   Haque A, 2011, J IMMUNOL, V186, P6148, DOI 10.4049/jimmunol.1003955
   Ives A, 2011, SCIENCE, V331, P775, DOI 10.1126/science.1199326
   Jayakumar A, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001204
   Jordan KA, 2010, EXP PARASITOL, V126, P318, DOI 10.1016/j.exppara.2010.05.008
   Kaye P, 2011, NAT REV MICROBIOL, V9, P604, DOI 10.1038/nrmicro2608
   KAYE PM, 1992, EUR J IMMUNOL, V22, P357, DOI 10.1002/eji.1830220211
   Kima PE, 1997, J IMMUNOL, V159, P1828
   Kono H, 2008, NAT REV IMMUNOL, V8, P279, DOI 10.1038/nri2215
   Kronenberg K, 2010, J INVEST DERMATOL, V130, P2602, DOI 10.1038/jid.2010.171
   Maroof A, 2012, J INFECT DIS, V205, P853, DOI 10.1093/infdis/jir842
   Mempel TR, 2006, IMMUNITY, V25, P129, DOI 10.1016/j.immuni.2006.04.015
   MULLER I, 1991, INT IMMUNOL, V3, P587, DOI 10.1093/intimm/3.6.587
   Nitcheu J, 2003, J IMMUNOL, V170, P2221, DOI 10.4049/jimmunol.170.4.2221
   Novoa R, 2011, PARASITE IMMUNOL, V33, P132, DOI 10.1111/j.1365-3024.2010.01256.x
   Ortega C, 2009, J LEUKOCYTE BIOL, V86, P435, DOI [10.1189/JLB.0109046, 10.1189/jlb.0109046]
   PINELLI E, 1995, EUR J IMMUNOL, V25, P1594, DOI 10.1002/eji.1830250619
   Polley R, 2006, INFECT IMMUN, V74, P773, DOI 10.1128/IAI.74.1.773-776.2006
   Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500
   Res PCM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014108
   Rocha FJS, 2007, INFECT IMMUN, V75, P3823, DOI 10.1128/IAI.01335-06
   Russo DM, 1999, EXP PARASITOL, V93, P161, DOI 10.1006/expr.1999.4452
   Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933
   Sanchez-Sampedro L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038859
   Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957
   Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991
   Silva C, 2013, J INVESTIGA IN PRESS
   Silverio JC, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002645
   SMITH LE, 1991, J EXP MED, V174, P499, DOI 10.1084/jem.174.3.499
   Smyth MJ, 2001, J LEUKOCYTE BIOL, V70, P18
   Soong L, 1997, J IMMUNOL, V158, P5374
   Soudja SM, 2012, IMMUNITY, V37, P549, DOI 10.1016/j.immuni.2012.05.029
   Spath GF, 2001, EXP PARASITOL, V99, P97, DOI 10.1006/expr.2001.4656
   Stager S, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00005
   STERN JJ, 1988, J IMMUNOL, V140, P3971
   TARLETON RL, 1992, NATURE, V356, P338, DOI 10.1038/356338a0
   Tsagozis P, 2003, PARASITE IMMUNOL, V25, P569, DOI 10.1111/j.0141-9838.2004.00672.x
   Uzonna JE, 2004, J EXP MED, V199, P1559, DOI 10.1084/jem.20040172
   Winau F, 2006, IMMUNITY, V24, P105, DOI 10.1016/j.immuni.2005.12.001
NR 58
TC 77
Z9 77
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD JUL
PY 2013
VL 9
IS 7
AR e1003504
DI 10.1371/journal.ppat.1003504
PG 11
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 190CX
UT WOS:000322316700044
PM 23874205
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Souza, AP
   Soto, M
   Costa, JML
   Boaventura, VS
   de Oliveira, CI
   Cristal, JR
   Barral-Netto, M
   Barral, A
AF Souza, Ana Paula
   Soto, Manuel
   Costa, Jackson M. L.
   Boaventura, Viviane S.
   de Oliveira, Camila I.
   Cristal, Juqueline R.
   Barral-Netto, Manoel
   Barral, Aldina
TI Towards a More Precise Serological Diagnosis of Human Tegumentary
   Leishmaniasis Using Leishmania Recombinant Proteins
SO PLOS ONE
LA English
DT Article
ID AMERICAN CUTANEOUS LEISHMANIASIS; CANINE VISCERAL LEISHMANIASIS;
   POLYMERASE-CHAIN-REACTION; HEAT-SHOCK PROTEINS; KINETOPLASTID MEMBRANE
   PROTEIN-11; IMMUNE-RESPONSE; ANTIGENIC DETERMINANTS; VIANNIA
   BRAZILIENSIS; MUCOCUTANEOUS LEISHMANIASIS; MUCOSAL LEISHMANIASIS
AB Background: Exposure to Leishmania induces a humoral immune response that can be used as a marker of parasite exposure.
   Methodology/Principal Findings: Herein, ELISA was used to screen sera from patients with Tegumentary Leishmaniasis (TL) against different L. infantum-chagasi-derived recombinant proteins (rHSP70, rH2A, rH2B, rH3, rH4 and rKMP11). Among the recombinant proteins, rHSP70 and rH2A showed the best reactivity against human sera obtained from endemic areas of TL. Receiver-Operator Characteristics (ROC) curve analysis was used to identify the effectiveness of these proteins for serodiagnosis of TL. ROC curves confirmed the superior performance of rHSP70 and rH2A, in comparison to the other tested recombinant proteins. Additionally, we evaluated the specificity of the response to rHSP70 and rH2A by testing sera obtained from patients with Chagas' disease, Tuberculosis, Leprosy or Systemic Lupus Erythematosus. In this case, rHSP70 displayed an increased ability to discriminate diseases, in comparison to SLA.
   Conclusion: Our results raise possibility of using rHSP70 for the serodiagnosis of TL
C1 [Souza, Ana Paula; Costa, Jackson M. L.; Boaventura, Viviane S.; de Oliveira, Camila I.; Cristal, Juqueline R.; Barral-Netto, Manoel; Barral, Aldina] Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisas Goncalo Moniz CPqGM, Salvador, BA, Brazil.
   [Soto, Manuel] Univ Autonoma Madrid, Ctr Biol Mol, Ctr Biol Mol Severo Ochoa CSIC UAM, E-28049 Madrid, Spain.
   [Boaventura, Viviane S.; de Oliveira, Camila I.; Barral-Netto, Manoel; Barral, Aldina] Univ Fed Bahia UFBA, Fac Med Bahia, Salvador, BA, Brazil.
   [de Oliveira, Camila I.; Barral-Netto, Manoel; Barral, Aldina] Inst Nacl Ciencia & Tecnol Invest Imunol Iii INCT, Salvador, BA, Brazil.
RP Barral, A (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisas Goncalo Moniz CPqGM, Salvador, BA, Brazil.
EM abarral@bahia.fiocruz.br
RI Alvarez, Manuel Soto/Q-5234-2018; Boaventura, Viviane S/H-9165-2015; de
   Oliveira, Camila I/B-4358-2009; Barral Netto, Manoel/B-3904-2009
OI Alvarez, Manuel Soto/0000-0001-6825-841X; de Oliveira, Camila
   I/0000-0002-7868-5164; Barral Netto, Manoel/0000-0002-5823-7903
FU Pronex: CNPq/FAPESBNational Council for Scientific and Technological
   Development (CNPq); Ministerio de Economia y CompetitividadSpanish
   Government [FIS PI11/00095]; CNPqNational Council for Scientific and
   Technological Development (CNPq)
FX The research and publication process was supported by grants from from
   Pronex: CNPq/FAPESB. This study was in part supported in Spain by grant
   FIS PI11/00095 from Ministerio de Economia y Competitividad. APS
   received fellowship from CNPq. JML, CIO, MB-N and AB are senior
   investigators from CNPq. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR ANTHONY RL, 1987, AM J TROP MED HYG, V37, P271, DOI 10.4269/ajtmh.1987.37.271
   ARDESHIR F, 1987, EMBO J, V6, P493, DOI 10.1002/j.1460-2075.1987.tb04780.x
   BARRAL A, 1987, Memorias do Instituto Oswaldo Cruz, V82, P579, DOI 10.1590/S0074-02761987000400018
   Barral A, 2000, AM J TROP MED HYG, V62, P740, DOI 10.4269/ajtmh.2000.62.740
   Boarino A, 2005, CLIN DIAGN LAB IMMUN, V12, P647, DOI 10.1128/CDLI.12.5.647-653.2005
   Boaventura VS, 2010, EUR J IMMUNOL, V40, P2830, DOI 10.1002/eji.200940115
   Boggild AK, 2010, CLIN INFECT DIS, V50, pE1, DOI 10.1086/648730
   Braz RFS, 2002, AM J TROP MED HYG, V67, P344, DOI 10.4269/ajtmh.2002.67.344
   Carmelo E, 2002, CLIN DIAGN LAB IMMUN, V9, P808, DOI 10.1128/CDLI.9.4.808-811.2002
   Carrillo E, 2008, VACCINE, V26, P1902, DOI 10.1016/j.vaccine.2008.01.042
   CARVALHO EM, 1995, AM J TROP MED HYG, V53, P273, DOI 10.4269/ajtmh.1995.53.273
   Cataldo JI, 2010, J CLIN LAB ANAL, V24, P289, DOI 10.1002/jcla.20402
   Celeste BI, 2004, BRAZ J MED BIOL RES, V37, P1591, DOI 10.1590/S0100-879X2004001100001
   Coelho EAF, 2009, CLIN VACCINE IMMUNOL, V16, P1774, DOI 10.1128/CVI.00295-09
   de Carvalho LP, 2003, MICROBES INFECT, V5, P7, DOI 10.1016/S1286-4579(02)00051-5
   de Oliveira CI, 2009, PARASITOL INT, V58, P319, DOI 10.1016/j.parint.2009.07.013
   de Oliveira CI, 2003, CLIN INFECT DIS, V37, pE149, DOI 10.1086/379610
   De Souza CM, 2012, PARASITE IMMUNOL, V34, P1, DOI 10.1111/j.1365-3024.2011.01334.x
   DEANDRADE CR, 1992, J CLIN MICROBIOL, V30, P330, DOI 10.1128/JCM.30.2.330-335.1992
   Dias SD, 2005, AM J TROP MED HYG, V72, P126, DOI 10.4269/ajtmh.2005.72.126
   Fagundes A, 2010, MEM I OSWALDO CRUZ, V105, P109, DOI 10.1590/S0074-02762010000100018
   Fuertes MA, 2001, J BIOL INORG CHEM, V6, P107, DOI 10.1007/s007750000175
   Goto H, 2010, EXPERT REV ANTI-INFE, V8, P419, DOI [10.1586/eri.10.19, 10.1586/ERI.10.19]
   GUIMARAES MCS, 1991, REV I MED TROP, V33, P503, DOI 10.1590/S0036-46651991000600012
   HEDSTROM R, 1987, J EXP MED, V165, P1430, DOI 10.1084/jem.165.5.1430
   Iborra S, 2004, VACCINE, V22, P3865, DOI 10.1016/j.vaccine.2004.04.015
   Iniesta L, 2002, CLIN DIAGN LAB IMMUN, V9, P1137, DOI 10.1128/CDLI.9.5.1137-1141.2002
   JONES TC, 1987, J INFECT DIS, V156, P73, DOI 10.1093/infdis/156.1.73
   KALTER DC, 1994, DERMATOL CLIN, V12, P37, DOI 10.1016/S0733-8635(18)30200-6
   Kubar J, 2005, LANCET INFECT DIS, V5, P107, DOI 10.1016/S1473-3099(05)70085-2
   Lunedo SN, 2012, ACTA HISTOCHEM, V114, P252, DOI 10.1016/j.acthis.2011.06.002
   LYNCH NR, 1986, T ROY SOC TROP MED H, V80, P6, DOI 10.1016/0035-9203(86)90183-5
   Maalej IA, 2003, AM J TROP MED HYG, V68, P312, DOI 10.4269/ajtmh.2003.68.312
   Mabey D, 2004, NAT REV MICROBIOL, V2, P231, DOI 10.1038/nrmicro841
   Meddeb-Garnaoui A, 2010, VACCINE, V28, P1881, DOI 10.1016/j.vaccine.2009.11.075
   Montoya Y, 1997, T ROY SOC TROP MED H, V91, P674, DOI 10.1016/S0035-9203(97)90520-4
   Ndao M., 2009, Interdisciplinary Perspectives on Infectious Diseases, V2009, P278246, DOI 10.1155/2009/278246
   Oliveira F, 2011, AM J TROP MED HYG, V85, P70, DOI 10.4269/ajtmh.2011.10-0680
   Oliveira JGS, 2005, ACTA TROP, V94, P55, DOI 10.1016/j.actatropica.2004.12.003
   Passos S, 2005, CLIN DIAGN LAB IMMUN, V12, P1164, DOI 10.1128/CDLI.12.10.1164-1167.2005
   Perinoto AC, 2010, ANAL CHEM, V82, P9763, DOI 10.1021/ac101920t
   Luz ZMP, 2009, MEM I OSWALDO CRUZ, V104, P62, DOI 10.1590/S0074-02762009000100010
   Quijada L, 1998, IMMUNOL LETT, V63, P169, DOI 10.1016/S0165-2478(98)00071-6
   Quijada L, 1996, PARASITOLOGY, V112, P277, DOI 10.1017/S0031182000065793
   Rafati S, 2006, CLIN VACCINE IMMUNOL, V13, P1104, DOI 10.1128/CVI.00188-06
   Requena JM, 2000, PARASITOL TODAY, V16, P246, DOI 10.1016/S0169-4758(00)01651-3
   ReyLadino JA, 1997, EXP PARASITOL, V85, P249, DOI 10.1006/expr.1996.4137
   ROFFI J, 1980, AM J TROP MED HYG, V29, P183, DOI 10.4269/ajtmh.1980.29.183
   Romero GAS, 2005, ACTA TROP, V93, P49, DOI 10.1016/j.actatropica.2004.09.005
   SARAVIA NG, 1989, J INFECT DIS, V159, P725, DOI 10.1093/infdis/159.4.725
   SKEIKY YAW, 1995, INFECT IMMUN, V63, P4105, DOI 10.1128/IAI.63.10.4105-4114.1995
   Skeiky YAW, 1997, INFECT IMMUN, V65, P5368, DOI 10.1128/IAI.65.12.5368-5370.1997
   Soto M, 1996, CLIN EXP IMMUNOL, V106, P454, DOI 10.1046/j.1365-2249.1996.d01-865.x
   Soto M, 1996, CLIN DIAGN LAB IMMUN, V3, P387, DOI 10.1128/CDLI.3.4.387-391.1996
   Soto M, 1995, IMMUNOL LETT, V48, P209, DOI 10.1016/0165-2478(95)02473-5
   Soto M, 1998, J CLIN MICROBIOL, V36, P58, DOI 10.1128/JCM.36.1.58-63.1998
   Trujillo C, 1999, IMMUNOL LETT, V70, P203
   WEIGLE KA, 1987, AM J TROP MED HYG, V36, P489, DOI 10.4269/ajtmh.1987.36.489
   Weigle KA, 2002, J CLIN MICROBIOL, V40, P601, DOI 10.1128/JCM.40.2.601-606.2002
   Zugel U, 1999, IMMUNOBIOLOGY, V201, P22
   Zurita AI, 2003, J PARASITOL, V89, P372, DOI 10.1645/0022-3395(2003)089[0372:CACOTL]2.0.CO;2
NR 61
TC 31
Z9 32
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 12
PY 2013
VL 8
IS 6
AR e66110
DI 10.1371/journal.pone.0066110
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 163FW
UT WOS:000320322400082
PM 23776617
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Santos, CDS
   Boaventura, V
   Cardoso, CR
   Tavares, N
   Lordelo, MJ
   Noronha, A
   Costa, J
   Borges, VM
   de Oliveira, CI
   Van Weyenbergh, J
   Barral, A
   Barral-Netto, M
   Brodskyn, CI
AF Santos, Claire da Silva
   Boaventura, Viviane
   Cardoso, Cristina Ribeiro
   Tavares, Natalia
   Lordelo, Morgana J.
   Noronha, Almerio
   Costa, Jackson
   Borges, Valeria M.
   de Oliveira, Camila I.
   Van Weyenbergh, Johan
   Barral, Aldina
   Barral-Netto, Manoel
   Brodskyn, Claudia Ida
TI CD8(+) Granzyme B+-Mediated Tissue Injury vs. CD4(+)IFN
   gamma(+)-Mediated Parasite Killing in Human Cutaneous Leishmaniasis
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Article
ID T-CELLS; MUCOSAL LEISHMANIASIS; IN-VITRO; CYTOTOXICITY; EXPRESSION;
   RESPONSES; RECRUITMENT; ACTIVATION; RECEPTOR
AB A protective or deleterious role of CD8(+)T cells in human cutaneous leishmaniasis (CL) has been debated. The present report explores the participation of CD8(+)T cells in disease pathogenesis as well as in parasite killing. CD8(+)T cells accumulated in CL lesions as suggested by a higher frequency of CD8(+)CD45RO(+)T cells and CD8(+)CLA(+)T cells compared with peripheral blood mononuclear cells. Upon Leishmania braziliensis restimulation, most of the CD8(+)T cells from the lesion expressed cytolytic markers, CD107a and granzyme B. Granzyme B expression in CL lesions positively correlated with lesion size and percentage of TUNEL-positive cells. We also observed a significantly higher percentage of TUNEL-positive cells and granzyme B expression in the biopsies of patients showing a more intense necrotic process. Furthermore, coculture of infected macrophages and CD8(+) T lymphocytes resulted in the release of granzyme B, and the use of granzyme B inhibitor, as well as z-VAD, Fas:Fc, or anti-IFN-gamma, had no effect upon parasite killing. However, coculture of infected macrophages with CD4(+)T cells strongly increased parasite killing, which was completely reversed by anti-IFN-gamma. Our results reveal a dichotomy in human CL: CD8(+) granzyme B+T cells mediate tissue injury, whereas CD4(+)IFN-gamma T+ cells mediate parasite killing.
C1 [Santos, Claire da Silva; Boaventura, Viviane; Tavares, Natalia; Lordelo, Morgana J.; Barral, Aldina; Barral-Netto, Manoel] Univ Fed Bahia, Fac Med Bahia, Salvador, BA, Brazil.
   [Santos, Claire da Silva; Boaventura, Viviane; Tavares, Natalia; Lordelo, Morgana J.; Noronha, Almerio; Costa, Jackson; Borges, Valeria M.; de Oliveira, Camila I.; Van Weyenbergh, Johan; Barral, Aldina; Barral-Netto, Manoel; Brodskyn, Claudia Ida] Fundacao Oswaldo Cruz, FIOCRUZ, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [Cardoso, Cristina Ribeiro] Univ Sao Paulo, Dept Anal Clin Toxicol & Bromatol, Fac Ciencias Farmaceut Ribeirao Preto, Sao Paulo, Brazil.
   [Borges, Valeria M.; de Oliveira, Camila I.; Van Weyenbergh, Johan; Barral, Aldina; Barral-Netto, Manoel; Brodskyn, Claudia Ida] Inst Invest Imunol, Sao Paulo, Brazil.
   [Brodskyn, Claudia Ida] Univ Fed Bahia, Inst Ciencias Saude, Salvador, BA, Brazil.
RP Brodskyn, CI (corresponding author), Ctr Pesquisas Goncalo Moniz, Lab Integrado Microbiol & Imunorregulacao, Rua Waldemar Falcao 121, BR-40295001 Salvador, BA, Brazil.
EM brodskyn@bahia.fiocruz.br
RI de Oliveira, Camila I/B-4358-2009; de Barros Cardoso, Cristina
   Ribeiro/L-8396-2017; Boaventura, Viviane S/H-9165-2015; Van Weyenbergh,
   Johan/Q-3829-2019; Van Weyenbergh, Johan/B-4187-2009; Barral-Netto,
   Manoel/B-3904-2009; Borges, Val/N-6647-2019; Tavares,
   Natalia/AAQ-1527-2020; Borges, Valeria/G-2009-2014
OI de Oliveira, Camila I/0000-0002-7868-5164; de Barros Cardoso, Cristina
   Ribeiro/0000-0002-6156-3144; Van Weyenbergh, Johan/0000-0003-3234-8426;
   Van Weyenbergh, Johan/0000-0003-3234-8426; Barral-Netto,
   Manoel/0000-0002-5823-7903; Borges, Val/0000-0002-2775-5409; Machado
   Tavares, Natalia/0000-0002-4026-679X
FU Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB) e/Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
   [SUS0025/2009]; Pronex (FAPESB/CNPq)National Council for Scientific and
   Technological Development (CNPq) [738712006]; Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), BrazilCAPES; CNPq
   BrazilNational Council for Scientific and Technological Development
   (CNPq)
FX The authors are grateful to all patients and control subjects who
   participated in this study. This study was supported by grants from
   Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB) e/Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq grant number
   PPSUS # SUS0025/2009) and from Pronex (FAPESB/CNPq grant number
   738712006). CdaSS has a fellowship from Coordenacao de Aperfeicoamento
   de Pessoal de Nivel Superior (CAPES), Brazil; NT and MJL receive
   fellowships from CNPq Brazil and CIdO, VMB, JvW, AB, MB-N, and CIB are
   senior investigators of CNPq.
CR Akdis M, 1999, J IMMUNOL, V163, P466
   Antonelli LRV, 2005, IMMUNOL LETT, V101, P226, DOI 10.1016/j.imlet.2005.06.004
   Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   BARRALNETTO M, 1995, PARASITE IMMUNOL, V17, P21, DOI 10.1111/j.1365-3024.1995.tb00962.x
   Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5
   Bourreau E, 2007, MICROBES INFECT, V9, P1034, DOI 10.1016/j.micinf.2007.04.009
   Bousoffara T, 2004, J INFECT DIS, V189, P1265, DOI 10.1086/382031
   Brodskyn CI, 1997, J IMMUNOL, V159, P4467
   Carvalho LP, 2007, PARASITE IMMUNOL, V29, P251, DOI 10.1111/j.1365-3024.2007.00940.x
   Carvalho LP, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00301
   Costa RP, 2003, IMMUNOL LETT, V90, P155, DOI 10.1016/j.imlet.2003.09.001
   Da-Cruz AM, 2005, BRIT J DERMATOL, V153, P537, DOI 10.1111/j.1365-2133.2005.06647.x
   Faria DR, 2009, PARASITE IMMUNOL, V31, P432, DOI 10.1111/j.1365-3024.2009.01125.x
   Faria DR, 2005, INFECT IMMUN, V73, P7853, DOI 10.1128/IAI.73.12.7853-7859.2005
   Haque A, 2011, J IMMUNOL, V186, P6148, DOI 10.4049/jimmunol.1003955
   Hernandez-Ruiz J, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000871
   Jayakumar A, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001204
   Jordan KA, 2010, EXP PARASITOL, V126, P318, DOI 10.1016/j.exppara.2010.05.008
   Kaye P, 2011, NAT REV MICROBIOL, V9, P604, DOI 10.1038/nrmicro2608
   Lieberman J, 2010, IMMUNOL REV, V235, P5, DOI 10.1111/j.0105-2896.2010.00914.x
   Lord SJ, 2003, IMMUNOL REV, V193, P31, DOI 10.1034/j.1600-065X.2003.00044.x
   McConville MJ, 2011, ANNU REV MICROBIOL, V65, P543, DOI 10.1146/annurev-micro-090110-102913
   Mendes-Aguiar CD, 2009, CLIN EXP IMMUNOL, V157, P377, DOI 10.1111/j.1365-2249.2009.03970.x
   Mougneau E, 2011, IMMUNOL REV, V240, P286, DOI 10.1111/j.1600-065X.2010.00983.x
   Pompeu MML, 2001, INFECT IMMUN, V69, P7453, DOI 10.1128/IAI.69.12.7453-7460.2001
   Ribeiro-de-Jesus A, 1998, BRAZ J MED BIOL RES, V31, P143, DOI 10.1590/S0100-879X1998000100020
   Ribeiro-Gomes FL, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00059
   Rostami MN, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000845
   Sallusto F, 2004, CURR OPIN IMMUNOL, V16, P724, DOI 10.1016/j.coi.2004.09.012
   Sharron M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041549
NR 30
TC 73
Z9 75
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD JUN
PY 2013
VL 133
IS 6
BP 1533
EP 1540
DI 10.1038/jid.2013.4
PG 8
WC Dermatology
SC Dermatology
GA 146VE
UT WOS:000319121500018
OA Other Gold, Green Published
DA 2020-12-08
ER

PT J
AU de Moura, TR
   Oliveira, F
   Carneiro, MW
   Miranda, JC
   Clarencio, J
   Barral-Netto, M
   Brodskyn, C
   Barral, A
   Ribeiro, JMC
   Valenzuela, JG
   de Oliveira, CI
AF de Moura, Tatiana R.
   Oliveira, Fabiano
   Carneiro, Marcia W.
   Miranda, Jose Carlos
   Clarencio, Jorge
   Barral-Netto, Manoel
   Brodskyn, Claudia
   Barral, Aldina
   Ribeiro, Jose M. C.
   Valenzuela, Jesus G.
   de Oliveira, Camila I.
TI Functional Transcriptomics of Wild-Caught Lutzomyia intermedia Salivary
   Glands: Identification of a Protective Salivary Protein against
   Leishmania braziliensis Infection
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID SAND FLY VECTOR; CUTANEOUS LEISHMANIASIS; VISCERAL LEISHMANIASIS;
   SEQUENCE ALIGNMENT; CIMEX-LECTULARIUS; INFANTUM-CHAGASI; BED BUG;
   LONGIPALPIS; MAXADILAN; IMMUNITY
AB Background: Leishmania parasites are transmitted in the presence of sand fly saliva. Together with the parasite, the sand fly injects salivary components that change the environment at the feeding site. Mice immunized with Phlebotomus papatasi salivary gland (SG) homogenate are protected against Leishmania major infection, while immunity to Lutzomyia intermedia SG homogenate exacerbated experimental Leishmania braziliensis infection. In humans, antibodies to Lu. intermedia saliva are associated with risk of acquiring L. braziliensis infection. Despite these important findings, there is no information regarding the repertoire of Lu. intermedia salivary proteins.
   Methods and Findings: A cDNA library from the Salivary Glands (SGs) of wild-caught Lu. intermedia was constructed, sequenced, and complemented by a proteomic approach based on 1D SDS PAGE and mass/mass spectrometry to validate the transcripts present in this cDNA library. We identified the most abundant transcripts and proteins reported in other sand fly species as well as novel proteins such as neurotoxin-like proteins, peptides with ML domain, and three small peptides found so far only in this sand fly species. DNA plasmids coding for ten selected transcripts were constructed and used to immunize BALB/c mice to study their immunogenicity. Plasmid Linb-11-coding for a 4.5-kDa protein-induced a cellular immune response and conferred protection against L. braziliensis infection. This protection correlated with a decreased parasite load and an increased frequency of IFN-c-producing cells.
   Conclusions: We identified the most abundant and novel proteins present in the SGs of Lu. intermedia, a vector of cutaneous leishmaniasis in the Americas. We also show for the first time that immunity to a single salivary protein from Lu. intermedia can protect against cutaneous leishmaniasis caused by L. braziliensis.
C1 [de Moura, Tatiana R.; Carneiro, Marcia W.; Miranda, Jose Carlos; Clarencio, Jorge; Barral-Netto, Manoel; Brodskyn, Claudia; Barral, Aldina; de Oliveira, Camila I.] Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [Oliveira, Fabiano; Valenzuela, Jesus G.] NIAID, Vector Mol Biol Sect, Lab Malaria & Vector Res, NIH, Rockville, MD USA.
   [Barral-Netto, Manoel; Brodskyn, Claudia; Barral, Aldina] Univ Fed Bahia, Salvador, BA, Brazil.
   [Barral-Netto, Manoel; Brodskyn, Claudia; Barral, Aldina; de Oliveira, Camila I.] Inst Nacl Ciencia & Tecnol Invest Imunol III INCT, Salvador, BA, Brazil.
   [Ribeiro, Jose M. C.] NIAID, Vector Biol Sect, Lab Malaria & Vector Res, NIH, Rockville, MD USA.
RP de Moura, TR (corresponding author), Univ Fed Sergipe, Ctr Ciencias Biol & Saude, Aracaju, Sergipe, Brazil.
EM jvalenzuela@niaid.nih.gov; camila@bahia.fiocruz.br
RI Oliveira, Fabiano/AAG-5388-2019; , Tatiana/AAN-1194-2020; de Oliveira,
   Camila I/B-4358-2009; Ribeiro, Jose/J-7011-2015; Barral Netto,
   Manoel/B-3904-2009
OI Oliveira, Fabiano/0000-0002-7924-8038; , Tatiana/0000-0002-7442-4434; de
   Oliveira, Camila I/0000-0002-7868-5164; Clarencio,
   Jorge/0000-0002-4289-5450; Ribeiro, Jose/0000-0002-9107-0818; Barral
   Netto, Manoel/0000-0002-5823-7903; Weber Carneiro,
   Marcia/0000-0002-4220-5085
FU Intramural Research Program of the Division of Intramural Research,
   National Institute of Allergy and Infectious Diseases, National
   Institutes of Health, USA; Fundacao de Amparo a Pesquisa da Bahia
   (FAPESB); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq), BrazilNational Council for Scientific and Technological
   Development (CNPq); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [ZIAAI000932, ZIAAI000932, ZIAAI000932,
   ZIAAI000810, ZIAAI000810, ZIAAI000932, ZIAAI000932, ZIAAI000932,
   ZIAAI000932, ZIAAI000810, ZIAAI000810, ZIAAI000810, ZIAAI000810,
   ZIAAI000810, ZIAAI000810, ZIAAI000810, ZIAAI000932, ZIAAI000932,
   ZIAAI000932, ZIAAI000810] Funding Source: NIH RePORTER
FX This work was funded in part by the Intramural Research Program of the
   Division of Intramural Research, National Institute of Allergy and
   Infectious Diseases, National Institutes of Health, USA, and by the
   Fundacao de Amparo a Pesquisa da Bahia (FAPESB) and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Abdeladhim M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047347
   Anderson JM, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-52
   Assumpcao TCF, 2012, AM J TROP MED HYG, V86, P1005, DOI 10.4269/ajtmh.2012.11-0690
   Belkaid Y, 2001, J EXP MED, V194, P1497, DOI 10.1084/jem.194.10.1497
   BITTENCOURT AL, 1995, TROPICAL PATHOLOGY, P597
   Calvete JJ, 2007, CURR PHARM DESIGN, V13, P2853, DOI 10.2174/138161207782023766
   CHAMPAGNE DE, 1995, P NATL ACAD SCI USA, V92, P694, DOI 10.1073/pnas.92.3.694
   Charlab R, 1999, P NATL ACAD SCI USA, V96, P15155, DOI 10.1073/pnas.96.26.15155
   Collin N, 2012, ARTERIOSCL THROM VAS, V32, P2185, DOI 10.1161/ATVBAHA.112.253906
   Costa DJ, 2004, INFECT IMMUN, V72, P1298, DOI 10.1128/IAI.72.3.1298-1305.2004
   de Moura TR, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000084
   de Moura TR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000712
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   Francischetti IMB, 2010, J PROTEOME RES, V9, P3820, DOI 10.1021/pr1000169
   Francischetti IMB, 2009, FRONT BIOSCI-LANDMRK, V14, P2051, DOI 10.2741/3363
   Gomes R, 2008, P NATL ACAD SCI USA, V105, P7845, DOI 10.1073/pnas.0712153105
   Gomes R, 2012, J INVEST DERMATOL, V132, P2735, DOI 10.1038/jid.2012.205
   GREVELINK SA, 1995, J PHARMACOL EXP THER, V272, P33
   HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7
   Hostomska J, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-282
   Huang XQ, 1999, GENOME RES, V9, P868, DOI 10.1101/gr.9.9.868
   Jackson TS, 1996, AM J PHYSIOL-HEART C, V271, pH924
   Jochim RC, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-15
   Kamhawi S, 2000, SCIENCE, V290, P1351, DOI 10.1126/science.290.5495.1351
   Kato H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-226
   Kato H, 2013, INFECT GENET EVOL, V13, P56, DOI 10.1016/j.meegid.2012.08.024
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   Lanzaro GC, 1999, INSECT MOL BIOL, V8, P267, DOI 10.1046/j.1365-2583.1999.820267.x
   MCLANE MA, 1994, BIOCHEM J, V301, P429, DOI 10.1042/bj3010429
   Milleron RS, 2004, AM J TROP MED HYG, V70, P278, DOI 10.4269/ajtmh.2004.70.278
   NIEWIAROWSKI S, 1994, SEMIN HEMATOL, V31, P289
   Oliveira F, 2006, VACCINE, V24, P374, DOI 10.1016/j.vaccine.2005.07.085
   Oliveira F, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000226
   Peters NC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000484
   Qureshi AA, 1996, AM J TROP MED HYG, V54, P665, DOI 10.4269/ajtmh.1996.54.665
   Ribeiro JMC, 2010, INSECT BIOCHEM MOLEC, V40, P767, DOI 10.1016/j.ibmb.2010.08.002
   Rohousova I, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001660
   Silva F, 2005, AM J TROP MED HYG, V72, P94, DOI 10.4269/ajtmh.2005.72.94
   Soares MBP, 1998, J IMMUNOL, V160, P1811
   TASWELL C, 1984, J IMMUNOL METHODS, V72, P29, DOI 10.1016/0022-1759(84)90430-7
   Teixeira C, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000638
   Teixeira CR, 2005, J IMMUNOL, V175, P8346, DOI 10.4049/jimmunol.175.12.8346
   Valenzuela JG, 2004, J EXP BIOL, V207, P3717, DOI 10.1242/jeb.01185
   Valenzuela JG, 1998, J BIOL CHEM, V273, P30583, DOI 10.1074/jbc.273.46.30583
   Valenzuela JG, 2001, J EXP MED, V194, P331, DOI 10.1084/jem.194.3.331
   WARBURG A, 1994, PHILOS T R SOC B, V345, P223, DOI 10.1098/rstb.1994.0097
   Xu XQ, 2011, J BIOL CHEM, V286, P32383, DOI 10.1074/jbc.M111.268904
NR 47
TC 36
Z9 36
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD MAY
PY 2013
VL 7
IS 5
AR e2242
DI 10.1371/journal.pntd.0002242
PG 16
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 158SW
UT WOS:000319994400042
PM 23717705
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Costa, DJ
   Carvalho, RMD
   Abbehusen, M
   Teixeira, C
   Pitombo, M
   Trigo, J
   Nascimento, F
   Amorim, L
   Abreu-Silva, AL
   Cruz, MDP
   Miranda, JC
   Fukutani, K
   de Oliveira, CI
   Barral, A
   Barral-Netto, M
   Brodskyn, C
AF Costa, Dirceu Joaquim
   de Araujo Carvalho, Rayssa M.
   Abbehusen, Melissa
   Teixeira, Clarissa
   Pitombo, Maiana
   Trigo, Joelma
   Nascimento, Flavia
   Amorim, Lucilene
   Abreu-Silva, Ana Lucia
   Pires Cruz, Maria do Socorro
   Miranda, Jose Carlos
   Fukutani, Kyoshi
   de Oliveira, Camila I.
   Barral, Aldina
   Barral-Netto, Manoel
   Brodskyn, Claudia
TI Experimental Infection of Dogs with Leishmania and Saliva as a Model to
   Study Canine Visceral Leishmaniasis
SO PLOS ONE
LA English
DT Article
ID SAND FLY SALIVA; ASYMPTOMATIC DOGS; IMMUNE-RESPONSE; IGG2 ANTIBODY;
   CUTANEOUS LEISHMANIASIS; PROTECTIVE IMMUNITY; VECTOR SALIVA; NATURAL
   MODEL; MURINE MODEL; INFANTUM
AB Background: Canine Visceral Leishmaniasis (CVL) is a zoonotic disease caused by Leishmania infantum, transmitted by the bite of Lutzomyia longipalpis sand flies. Dogs are the main domestic reservoir of the parasite. The establishment of an experimental model that partially reproduces natural infection in dogs is very important to test vaccine candidates, mainly regarding those that use salivary proteins from the vector and new therapeutical approaches.
   Methodology/Principal Findings: In this report, we describe an experimental infection in dogs, using intradermal injection of Leishmania infantum plus salivary gland homogenate (SGH) of Lutzomyia longipalpis. Thirty-five dogs were infected with 1 x 10(7) parasites combined with five pairs of Lutzomyia longipalpis salivary glands and followed for 450 days after infection and clinical, immunological and parasitological parameters were evaluated. Two hundred and ten days after infection we observed that 31,4% of dogs did not display detectable levels of anti-Leishmania antibodies but all presented different numbers of parasites in the lymph nodes. Animals with a positive xenodiagnosis had at least 3,35 x 10(5) parasites in their lymph nodes. An increase of IFN-gamma and IL-10 levels was detected during infection. Twenty two percent of dogs developed symptoms of CVL during infection.
   Conclusion: The infection model described here shows some degree of similarity when compared with naturally infected dogs opening new perspectives for the study of CVL using an experimental model that employs the combination of parasites and sand fly saliva both present during natural transmission.
C1 [Costa, Dirceu Joaquim; de Araujo Carvalho, Rayssa M.; Abbehusen, Melissa; Teixeira, Clarissa; Pitombo, Maiana; Trigo, Joelma; Miranda, Jose Carlos; Fukutani, Kyoshi; de Oliveira, Camila I.; Barral, Aldina; Barral-Netto, Manoel; Brodskyn, Claudia] FIOCRUZ BA, Ctr Pesquisa Goncalo Moniz, Salvador, BA, Brazil.
   [Barral, Aldina; Barral-Netto, Manoel] Univ Fed Bahia, Fac Med, BR-41170290 Salvador, BA, Brazil.
   [Brodskyn, Claudia] Univ Fed Bahia, Inst Ciencias Saude, BR-41170290 Salvador, BA, Brazil.
   [Pires Cruz, Maria do Socorro; Brodskyn, Claudia] Univ Fed Piaui, Ctr Ciencias Agr, Dept Morfofisiol Vet, Teresina, Piaui, Brazil.
   [de Oliveira, Camila I.; Barral, Aldina; Barral-Netto, Manoel] Inst Invest Imunol, Sao Paulo, Brazil.
RP Brodskyn, C (corresponding author), FIOCRUZ BA, Ctr Pesquisa Goncalo Moniz, Salvador, BA, Brazil.
EM brodskyn@bahia.fiocruz.br
RI Barral-Netto, Manoel/B-3904-2009; de Oliveira, Camila I/B-4358-2009;
   Fukutani, Kiyoshi/T-1630-2019; COSTA, DIRCEU/W-8832-2019; CRUZ, MARIA
   S/AAD-9243-2020; Silva, Ana Lucia Abreu/AAR-9739-2020; Fukutani,
   Kiyoshi/N-7905-2016; Nascimento, Flavia/F-8173-2016
OI Barral-Netto, Manoel/0000-0002-5823-7903; de Oliveira, Camila
   I/0000-0002-7868-5164; COSTA, DIRCEU/0000-0002-0334-3899; Fukutani,
   Kiyoshi/0000-0003-2223-0918; Abreu-Silva, Ana Lucia/0000-0003-2167-3725;
   Nascimento, Flavia/0000-0001-9328-1806
FU RENORBIO/CNPqNational Council for Scientific and Technological
   Development (CNPq) [554753/2006-5]
FX The work was funded by RENORBIO/CNPq, number 554753/2006-5. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Almeida MAO, 2005, VET IMMUNOL IMMUNOP, V106, P151, DOI 10.1016/j.vetimm.2004.08.024
   Alves CF, 2009, VET IMMUNOL IMMUNOP, V128, P349, DOI 10.1016/j.vetimm.2008.11.020
   Andrade BB, 2007, SCAND J IMMUNOL, V66, P122, DOI 10.1111/j.1365-3083.2007.01964.x
   Belkaid Y, 1998, J EXP MED, V188, P1941, DOI 10.1084/jem.188.10.1941
   Belkaid Y, 2000, J IMMUNOL, V165, P969, DOI 10.4049/jimmunol.165.2.969
   Boggiatto PM, 2010, CLIN VACCINE IMMUNOL, V17, P267, DOI 10.1128/CVI.00456-09
   Bourdoiseau G, 1997, VET IMMUNOL IMMUNOP, V59, P21, DOI 10.1016/S0165-2427(97)00072-X
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Campino L, 2000, VET PARASITOL, V92, P269, DOI 10.1016/S0304-4017(00)00313-7
   Cavalcanti MD, 2009, VET J, V182, P356, DOI 10.1016/j.tvjl.2008.05.018
   Collin N, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000441
   DEPLAZES P, 1995, PARASITE IMMUNOL, V17, P451, DOI 10.1111/j.1365-3024.1995.tb00914.x
   Dos-Santos WLC, 2008, VET IMMUNOL IMMUNOP, V123, P251, DOI 10.1016/j.vetimm.2008.02.004
   DYE C, 1992, PARASITOLOGY, V105, P35, DOI 10.1017/S0031182000073662
   Dye C, 1996, AM J TROP MED HYG, V55, P125, DOI 10.4269/ajtmh.1996.55.125
   Ferreira JFL, 2008, VACCINE, V26, P677, DOI 10.1016/j.vaccine.2007.11.044
   Gomes R, 2008, P NATL ACAD SCI USA, V105, P7845, DOI 10.1073/pnas.0712153105
   Gramiccia M, 2005, INT J PARASITOL, V35, P1169, DOI 10.1016/j.ijpara.2005.07.001
   Leandro C, 2001, VET IMMUNOL IMMUNOP, V79, P273, DOI 10.1016/S0165-2427(01)00270-7
   Lemesre JL, 2005, VACCINE, V23, P2825, DOI 10.1016/j.vaccine.2004.11.061
   Lima HC, 1996, INFECT IMMUN, V64, P5442, DOI 10.1128/IAI.64.12.5442-5445.1996
   Manna L, 2009, RES VET SCI, V87, P76, DOI 10.1016/j.rvsc.2008.12.009
   Mauricio IL, 2000, PARASITOL TODAY, V16, P188, DOI 10.1016/S0169-4758(00)01637-9
   Michalsky EM, 2007, VET PARASITOL, V147, P67, DOI 10.1016/j.vetpar.2007.03.004
   Nieto CG, 1999, VET IMMUNOL IMMUNOP, V67, P117, DOI 10.1016/S0165-2427(98)00213-X
   PINELLI E, 1994, INFECT IMMUN, V62, P229, DOI 10.1128/IAI.62.1.229-235.1994
   Pinelli E, 1999, IMMUNOGENETICS, V49, P696, DOI 10.1007/s002510050667
   Reis AB, 2006, VET IMMUNOL IMMUNOP, V112, P102, DOI 10.1016/j.vetimm.2006.02.001
   RIBEIRO JMC, 1995, INFECT AGENT DIS, V4, P143
   Riera C, 1999, VET PARASITOL, V84, P33, DOI 10.1016/S0304-4017(99)00084-9
   Roatt BM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049780
   Sanchez MA, 2004, AM J TROP MED HYG, V70, P618, DOI 10.4269/ajtmh.2004.70.618
   Santos-Gomes GM, 2002, VET IMMUNOL IMMUNOP, V88, P21, DOI 10.1016/S0165-2427(02)00134-4
   SCOTT P, 1987, J IMMUNOL, V139, P221
   Sherlock IA, 1996, MEM I OSWALDO CRUZ, V91, P671, DOI 10.1590/S0074-02761996000600003
   Silvestre R, 2007, J IMMUNOL, V179, P3161, DOI 10.4049/jimmunol.179.5.3161
   Solano-Gallego L, 2001, VET PARASITOL, V102, P163, DOI 10.1016/S0304-4017(01)00527-1
   Solano-Gallego L, 2000, VET PARASITOL, V90, P37, DOI 10.1016/S0304-4017(00)00223-5
   Tafuri Wagner Luiz, 1996, Revista do Instituto de Medicina Tropical de Sao Paulo, V38, P81, DOI 10.1590/S0036-46651996000200001
   Tafuri WL, 2004, J IMMUNOL METHODS, V292, P17, DOI 10.1016/j.jim.2004.05.009
   THEODOS CM, 1991, INFECT IMMUN, V59, P1592, DOI 10.1128/IAI.59.5.1592-1598.1991
   Thiakaki M, 2005, MICROBES INFECT, V7, P760, DOI 10.1016/j.micinf.2005.01.013
   TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436
   Travi BL, 2001, AM J TROP MED HYG, V64, P119, DOI 10.4269/ajtmh.2001.64.119
   Travi BL, 2009, AM J TROP MED HYG, V81, P994, DOI 10.4269/ajtmh.2009.09-0229
   Vercosa BLA, 2008, BMC VET RES, V4, DOI 10.1186/1746-6148-4-45
   Volpini AC, 2001, PARASITOL RES, V87, P1056
   Zer R, 2001, INT J PARASITOL, V31, P810, DOI 10.1016/S0020-7519(01)00190-4
NR 48
TC 18
Z9 18
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 5
PY 2013
VL 8
IS 4
AR e60535
DI 10.1371/journal.pone.0060535
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 146RZ
UT WOS:000319109800061
PM 23577121
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Ramirez, L
   Santos, DM
   Souza, AP
   Coelho, EAF
   Barral, A
   Alonso, C
   Escutia, MR
   Bonay, P
   de Oliveira, CI
   Soto, M
AF Ramirez, Laura
   Santos, Diego M.
   Souza, Ana P.
   Coelho, Eduardo A. F.
   Barral, Aldina
   Alonso, Carlos
   Escutia, Marta R.
   Bonay, Pedro
   de Oliveira, Camila I.
   Soto, Manuel
TI Evaluation of immune responses and analysis of the effect of vaccination
   of the Leishmania major recombinant ribosomal proteins L3 or L5 in two
   different murine models of cutaneous leishmaniasis
SO VACCINE
LA English
DT Article
DE Leishmania; BALB/c mice; Th1/Th2 Immune responses; Recombinant ribosomal
   proteins; Vaccines
ID CPG OLIGODEOXYNUCLEOTIDES; BALB/C MICE; VISCEROCUTANEOUS LEISHMANIASIS;
   VISCERAL LEISHMANIASIS; MOUSE MODEL; BRAZILIENSIS; PROTECTION;
   INFECTION; INFANTUM; IDENTIFICATION
AB Four new antigenic proteins located in Leishmania ribosomes have been characterized: S4, S6, L3 and L5. Recombinant versions of the four ribosomal proteins from Leishmania major were recognized by sera from human and canine patients suffering different clinical forms of leishmaniasis. The prophylactic properties of these proteins were first studied in the experimental model of cutaneous leishmaniasis caused by L. major inoculation into BALB/c mice. The administration of two of them, LmL3 or LmL5 combined with CpG-oligodeoxynucleotides (CpG-ODN) was able to protect BALB/c mice against L. major infection. Vaccinated mice showed smaller lesions and parasite burden compared to mice inoculated with vaccine diluent or vaccine adjuvant. Protection was correlated with an antigen-specific increased production of IFN-gamma paralleled by a decrease of the antigen-specific IL-10 mediated response in protected mice relative to non-protected controls. Further, it was demonstrated that BALB/c mice vaccinated with recombinant LmL3 or LmL5 plus CpG-ODN were also protected against the development of cutaneous lesions following inoculation of L. braziliensis. Together, data presented here indicate that LmL3 or LmL5 ribosomal proteins combined with Th1 inducing adjuvants, may be relevant components of a vaccine against cutaneous leishmaniasis caused by distinct species. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Ramirez, Laura; Alonso, Carlos; Bonay, Pedro; Soto, Manuel] Univ Autonoma Madrid, Dept Biol Mol, Ctr Biol Mol Severo Ochoa CSIC UAM, E-28049 Madrid, Spain.
   [Santos, Diego M.; Souza, Ana P.; Barral, Aldina; de Oliveira, Camila I.] Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisas Goncalo Moniz, BR-40296710 Salvador, BA, Brazil.
   [Coelho, Eduardo A. F.] Univ Fed Minas Gerais, COLTEC, Fac Med, Programa Posgrad Ciencias Saude Infectol & Med Tr, BR-31270901 Belo Horizonte, MG, Brazil.
   [Coelho, Eduardo A. F.] Univ Fed Minas Gerais, COLTEC, Dept Patol Clin, BR-31270901 Belo Horizonte, MG, Brazil.
   [Escutia, Marta R.] Labs LETI SLu, Dept Res & Dev, Madrid 28760, Spain.
RP Soto, M (corresponding author), Univ Autonoma Madrid, Dept Biol Mol, Ctr Biol Mol Severo Ochoa CSIC UAM, Nicolas Cabrera 1, E-28049 Madrid, Spain.
EM msoto@cbm.uam.es
RI Ramirez, Laura/Q-5502-2018; Alvarez, Manuel Soto/Q-5234-2018; de
   Oliveira, Camila I/B-4358-2009
OI Ramirez, Laura/0000-0003-0597-400X; Alvarez, Manuel
   Soto/0000-0001-6825-841X; de Oliveira, Camila I/0000-0002-7868-5164
FU Laboratorios LETI S.L.u; Ministerio de Ciencia e InnovacionInstituto de
   Salud Carlos IIISpanish Government [FIS/PI080101, FIS PI11/00095];
   Instituto de Salud Carlos III within the Network of Tropical Diseases
   ResearchInstituto de Salud Carlos III [RICET RD06/0021/0008];
   FAPEMIGMinas Gerais State Research Foundation (FAPEMIG)
   [CBB-APQ-00496-11]; CNPqNational Council for Scientific and
   Technological Development (CNPq) [APQ-472090/2011-9]; INCT NANO-BIOFAR;
   Fundacion Ramon Areces
FX We thank Dr Manoel Barral-Netto for critically discussing the project.
   We thank Libertad Teresa and Maria Vega for her technical support. We
   thank Dr Julian de la Horra and Dr. Jose M Requena for critically
   discussing the manuscript during the revision process. The study was
   supported in Spain by grants from Laboratorios LETI S.L.u, from
   Ministerio de Ciencia e Innovacion FIS/PI080101 and FIS PI11/00095 and
   from the Instituto de Salud Carlos III within the Network of Tropical
   Diseases Research (RICET RD06/0021/0008). This work was also partially
   supported by grants from FAPEMIG (CBB-APQ-00496-11), CNPq
   (APQ-472090/2011-9) and INCT NANO-BIOFAR. EAFC is a grant recipient of
   CNPq. A CBMSO institutional grant from Fundacion Ramon Areces is also
   acknowledged.
CR Badiee A, 2008, CLIN VACCINE IMMUNOL, V15, P668, DOI 10.1128/CVI.00413-07
   BUFFET PA, 1995, ANTIMICROB AGENTS CH, V39, P2167, DOI 10.1128/AAC.39.9.2167
   Chavez-Fumagalli MA, 2010, MICROBES INFECT, V12, P967, DOI 10.1016/j.micinf.2010.06.008
   Coelho EAF, 2009, CLIN VACCINE IMMUNOL, V16, P1774, DOI 10.1128/CVI.00295-09
   Coelho VTS, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001430
   de Moura TR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000712
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   Goto Y, 2009, VET PARASITOL, V160, P215, DOI 10.1016/j.vetpar.2008.10.097
   Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2
   Iborra S, 2005, INFECT IMMUN, V73, P5842, DOI 10.1128/IAI.73.9.5842-5852.2005
   Iborra S, 2008, MICROBES INFECT, V10, P1133, DOI 10.1016/j.micinf.2008.06.002
   Kaye P, 2011, NAT REV MICROBIOL, V9, P604, DOI 10.1038/nrmicro2608
   Mager WH, 1997, NUCLEIC ACIDS RES, V25, P4872, DOI 10.1093/nar/25.24.4872
   Nylen S, 2010, J GLOB INFECT DIS, V2, P135, DOI 10.4103/0974-777X.62876
   Ramirez L, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/181690
   Rhee EG, 2002, J EXP MED, V195, P1565, DOI 10.1084/jem.20020147
   Salay G, 2007, CLIN VACCINE IMMUNOL, V14, P1173, DOI 10.1128/CVI.00060-07
   SAMUELSON J, 1991, J EXP MED, V173, P49, DOI 10.1084/jem.173.1.49
   Santos Diego M, 2012, Int J Nanomedicine, V7, P2115, DOI 10.2147/IJN.S30093
   Shi PY, 1997, BIOTECHNIQUES, V23, P1036, DOI 10.2144/97236bm15
   SKEIKY YAW, 1994, INFECT IMMUN, V62, P1643, DOI 10.1128/IAI.62.5.1643-1651.1994
   SOTO M, 1995, CLIN EXP IMMUNOL, V100, P246
   Soto M, 1995, IMMUNOL LETT, V48, P23, DOI 10.1016/0165-2478(95)02436-0
   Soto M, 1999, CLIN EXP IMMUNOL, V115, P342, DOI 10.1046/j.1365-2249.1999.00796.x
   Soto M, 2009, SCHOLARLY RES EXCHAN, V2009, DOI [/10. 3814/2009/173039., DOI 10.3814/2009/173039]
   Stober CB, 2006, VACCINE, V24, P2602, DOI 10.1016/j.vaccine.2005.12.012
   Thomas MC, 2004, J PARASITOL, V90, P908, DOI 10.1645/GE-3297RN
   Tonui WK, 2007, AM J TROP MED HYG, V76, P579, DOI 10.4269/ajtmh.2007.76.579
NR 28
TC 32
Z9 35
U1 0
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2013
VL 31
IS 9
BP 1312
EP 1319
DI 10.1016/j.vaccine.2012.12.071
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 095CP
UT WOS:000315312600010
PM 23313653
OA Green Published
DA 2020-12-08
ER

PT J
AU Oliveira, F
   de Carvalho, AM
   de Oliveira, CI
AF Oliveira, Fabiano
   de Carvalho, Augusto M.
   de Oliveira, Camila I.
TI Sand-fly saliva-Leishmania-man: the trigger trio
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE sand-fly; saliva; Leishmania; vaccine; leishmaniasis
AB Leishmaniases are worldwide diseases transmitted to the vertebrate host by the bite of an infected sand-fly. Sand-fly biting and parasite inoculation are accompanied by the injection of salivary molecules, whose immunomodulatory properties are actively being studied. This mini review focuses on how the interactions between sand-fly saliva and the immune system may shape the outcome of infection, given its immunomodulatory properties, in experimental models and in the endemic area. Additionally, we approach the recent contributions regarding the identification of individual salivary components and how these are currently being considered as additional components of a vaccine against leishmaniasis.
C1 [Oliveira, Fabiano] NIAID, Vector Biol Sect, Lab Malaria & Vector Res, NIH, Rockville, MD USA.
   [de Carvalho, Augusto M.; de Oliveira, Camila I.] FlOCRUZ, Lab Imunoparasitol, Ctr Pesquisas Goncalo Moniz, BR-40196710 Salvador, BA, Brazil.
   [de Oliveira, Camila I.] Inst Nacl Ciencia & Tecnol Invest Imunol Iii INCT, Salvador, BA, Brazil.
RP de Oliveira, CI (corresponding author), FlOCRUZ, Lab Imunoparasitol, Ctr Pesquisas Goncalo Moniz, Rua Waldemar Falcao,121 Candeal, BR-40196710 Salvador, BA, Brazil.
EM camila@bahia.fiocruz.br
RI de Oliveira, Camila I/B-4358-2009; Oliveira, Fabiano/AAG-5388-2019
OI de Oliveira, Camila I/0000-0002-7868-5164; Oliveira,
   Fabiano/0000-0002-7924-8038
FU Division of Intramural Research, National Institute of Allergy and
   Infectious Diseases, National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
FX This work was supported by the Intramural Research Program of the
   Division of Intramural Research, National Institute of Allergy and
   Infectious Diseases, National Institutes of Health. We thank Brenda Rae
   Marshall, DPSS, NIAID, for editing. Because Fabiano Oliveira is a
   government employe and this is a government work, the work is in the
   public domain in the U.S. Notwithstanding any other agreements, the NIH
   reserves the right to provide the work to Pub Med Central for display
   and use by the public, and Pub Med Central may tag or modify the work
   consistent with its customary practices. You can establish rights
   outside of the U.S. subject to a government use license.
CR Abdeladhim M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047347
   Abdeladhim M, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001345
   Alvarenga PH, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000547
   Anderson JM, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-52
   ANJILI CO, 1995, ACTA TROP, V60, P97, DOI 10.1016/0001-706X(95)00112-R
   Aquino DMC, 2010, AM J TROP MED HYG, V83, P825, DOI 10.4269/ajtmh.2010.10-0182
   Araujo-Santos T, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000873
   Barral A, 2000, AM J TROP MED HYG, V62, P740, DOI 10.4269/ajtmh.2000.62.740
   Basu R, 2005, J IMMUNOL, V174, P7160, DOI 10.4049/jimmunol.174.11.7160
   Belkaid Y, 1998, J EXP MED, V188, P1941, DOI 10.1084/jem.188.10.1941
   Bertholet S, 2009, VACCINE, V27, P7036, DOI 10.1016/j.vaccine.2009.09.066
   Bezerra HSD, 2001, MEM I OSWALDO CRUZ, V96, P349
   Bozza M, 1998, EUR J IMMUNOL, V28, P3120, DOI 10.1002/(SICI)1521-4141(199810)28:10<3120::AID-IMMU3120>3.0.CO;2-3
   Brodie TM, 2007, INFECT IMMUN, V75, P2359, DOI 10.1128/IAI.01812-06
   Calvo E, 2006, J EXP BIOL, V209, P2651, DOI 10.1242/jeb.02267
   Calvo E, 2009, P NATL ACAD SCI USA, V106, P3728, DOI 10.1073/pnas.0813190106
   Carregaro V, 2008, J LEUKOCYTE BIOL, V84, P104, DOI 10.1189/jlb.1107797
   Carregaro V, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-102
   Carregaro V, 2011, J IMMUNOL, V187, P4347, DOI 10.4049/jimmunol.1003404
   CHAMPAGNE DE, 1995, P NATL ACAD SCI USA, V92, P694, DOI 10.1073/pnas.92.3.694
   Clements MF, 2010, AM J TROP MED HYG, V82, P801, DOI 10.4269/ajtmh.2010.09-0336
   Collin N, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000441
   Collin N, 2012, ARTERIOSCL THROM VAS, V32, P2185, DOI 10.1161/ATVBAHA.112.253906
   Costa DJ, 2004, INFECT IMMUN, V72, P1298, DOI 10.1128/IAI.72.3.1298-1305.2004
   da Silva RAA, 2011, ACTA TROP, V120, P185, DOI 10.1016/j.actatropica.2011.08.007
   Daifalla NS, 2012, EXP PARASITOL, V131, P317, DOI 10.1016/j.exppara.2012.05.002
   de Moura TR, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000084
   de Moura TR, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002242
   Donnelly KB, 1998, J PARASITOL, V84, P97, DOI 10.2307/3284537
   Gomes RB, 2002, J INFECT DIS, V186, P1530, DOI 10.1086/344733
   Gomes R, 2008, P NATL ACAD SCI USA, V105, P7845, DOI 10.1073/pnas.0712153105
   Gomes R, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001610
   Gomes R, 2012, J INVEST DERMATOL, V132, P2735, DOI 10.1038/jid.2012.205
   Gomes R, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00110
   Goto Y, 2011, CLIN VACCINE IMMUNOL, V18, P1118, DOI 10.1128/CVI.05024-11
   Grespan R, 2012, INT IMMUNOPHARMACOL, V12, P603, DOI 10.1016/j.intimp.2012.02.004
   HALL LR, 1995, J IMMUNOL, V155, P3501
   Hostomska J, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-282
   Kamhawi S, 2000, SCIENCE, V290, P1351, DOI 10.1126/science.290.5495.1351
   Kato H, 2013, INFECT GENET EVOL, V13, P56, DOI 10.1016/j.meegid.2012.08.024
   LERNER EA, 1991, J BIOL CHEM, V266, P11234
   Lima HC, 1996, INFECT IMMUN, V64, P5442, DOI 10.1128/IAI.64.12.5442-5445.1996
   Lombardo F, 2000, J BIOL CHEM, V275, P23861, DOI 10.1074/jbc.M909547199
   LONARDONI MVC, 1994, MEDIAT INFLAMM, V3, P137, DOI 10.1155/S0962935194000177
   Mans BJ, 1998, EXP APPL ACAROL, V22, P353, DOI 10.1023/A:1024517209621
   Marzouki S, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001911
   Marzouki S, 2011, AM J TROP MED HYG, V84, P653, DOI 10.4269/ajtmh.2011.10-0598
   Mathews GV, 1996, AM J TROP MED HYG, V55, P417, DOI 10.4269/ajtmh.1996.55.417
   Mbow ML, 1998, J IMMUNOL, V161, P5571
   Menezes MJ, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-12
   Monteiro MC, 2007, AM J TROP MED HYG, V76, P88, DOI 10.4269/ajtmh.2007.76.88
   Monteiro MC, 2005, EUR J IMMUNOL, V35, P2424, DOI 10.1002/eji.200526160
   Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683
   Morris RV, 2001, J IMMUNOL, V167, P5226, DOI 10.4049/jimmunol.167.9.5226
   Norsworthy NB, 2004, INFECT IMMUN, V72, P1240, DOI 10.1128/IAI.72.3.1240-1247.2004
   Oliveira F, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000226
   Oliveira F, 2013, J INVEST DERMATOL, V133, P452, DOI 10.1038/jid.2012.315
   Peters NC, 2008, SCIENCE, V321, P970, DOI 10.1126/science.1159194
   Peters NC, 2012, J IMMUNOL, V189, P4832, DOI 10.4049/jimmunol.1201676
   Peters NC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000484
   Petersen TN, 2011, NAT METHODS, V8, P785, DOI 10.1038/nmeth.1701
   Prates DB, 2011, J LEUKOCYTE BIOL, V90, P575, DOI 10.1189/jlb.0211105
   Qureshi AA, 1996, AM J TROP MED HYG, V54, P665, DOI 10.4269/ajtmh.1996.54.665
   Reno HE, 2005, AM J TROP MED HYG, V73, P541, DOI 10.4269/ajtmh.2005.73.541
   RIBEIRO JMC, 1990, COMP BIOCHEM PHYS B, V95, P215, DOI 10.1016/0305-0491(90)90067-4
   Ribeiro JMC, 1999, J EXP BIOL, V202, P1551
   RIBEIRO JMC, 1987, ANNU REV ENTOMOL, V32, P463, DOI 10.1146/annurev.en.32.010187.002335
   RIBEIRO JMC, 1984, COMP BIOCHEM PHYS B, V79, P81, DOI 10.1016/0305-0491(84)90081-6
   RIBEIRO JMC, 1989, EXP PARASITOL, V69, P104, DOI 10.1016/0014-4894(89)90177-X
   RIBEIRO JMC, 1991, COMP BIOCHEM PHYS A, V100, P109, DOI 10.1016/0300-9629(91)90190-N
   Ribeiro JMC, 2010, INSECT BIOCHEM MOLEC, V40, P767, DOI 10.1016/j.ibmb.2010.08.002
   Rogers KA, 2003, PARASITE IMMUNOL, V25, P127, DOI 10.1046/j.1365-3024.2003.00623.x
   Rohousova I, 2005, PARASITOLOGY, V130, P493, DOI 10.1017/S003118200400681X
   Rohousova I, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001660
   Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933
   SAMUELSON J, 1991, J EXP MED, V173, P49, DOI 10.1084/jem.173.1.49
   SARKIS JJF, 1986, BIOCHEM J, V233, P885, DOI 10.1042/bj2330885
   Silva F, 2005, AM J TROP MED HYG, V72, P94, DOI 10.4269/ajtmh.2005.72.94
   Soares BR, 2013, SCI REP-UK, V3, DOI 10.1038/srep02352
   Soares MBP, 1998, J IMMUNOL, V160, P1811
   Souza AP, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000649
   Tavares NM, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001169
   Teixeira C, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000638
   Teixeira CR, 2005, J IMMUNOL, V175, P8346, DOI 10.4049/jimmunol.175.12.8346
   THEODOS CM, 1991, INFECT IMMUN, V59, P1592, DOI 10.1128/IAI.59.5.1592-1598.1991
   TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436
   Valenzuela JG, 2004, J EXP BIOL, V207, P3717, DOI 10.1242/jeb.01185
   Valenzuela JG, 2001, J EXP MED, V194, P331, DOI 10.1084/jem.194.3.331
   Valenzuela JG, 2001, J EXP BIOL, V204, P229
   Vinhas V, 2007, EUR J IMMUNOL, V37, P3111, DOI 10.1002/eji.200737431
   Waitumbi J, 1998, INFECT IMMUN, V66, P1534, DOI 10.1128/IAI.66.4.1534-1537.1998
   Xu XQ, 2011, J BIOL CHEM, V286, P32383, DOI 10.1074/jbc.M111.268904
   Zer R, 2001, INT J PARASITOL, V31, P810, DOI 10.1016/S0020-7519(01)00190-4
NR 93
TC 28
Z9 28
U1 0
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PY 2013
VL 4
AR 375
DI 10.3389/fimmu.2013.00375
PG 8
WC Immunology
SC Immunology
GA V38WS
UT WOS:000209374100366
PM 24312093
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Carneiro, MW
   Santos, DM
   Fukutani, KF
   Clarencio, J
   Miranda, JC
   Brodskyn, C
   Barral, A
   Barral-Netto, M
   Soto, M
   de Oliveira, CI
AF Carneiro, Marcia W.
   Santos, Diego M.
   Fukutani, Kiyoshi F.
   Clarencio, Jorge
   Miranda, Jose Carlos
   Brodskyn, Claudia
   Barral, Aldina
   Barral-Netto, Manoel
   Soto, Manuel
   de Oliveira, Camila I.
TI Vaccination with L. infantum chagasi Nucleosomal Histones Confers
   Protection against New World Cutaneous Leishmaniasis Caused by
   Leishmania braziliensis
SO PLOS ONE
LA English
DT Article
ID MURINE VISCERAL LEISHMANIASIS; PRIME-BOOST VACCINATION; SAND FLY SALIVA;
   IMMUNE-RESPONSE; BALB/C MICE; ANTIGENIC DETERMINANTS;
   LUTZOMYIA-LONGIPALPIS; DENDRITIC CELLS; CONSERVED PROTEINS; GLAND LYSATE
AB Background: Nucleosomal histones are intracellular proteins that are highly conserved among Leishmania species. After parasite destruction or spontaneous lysis, exposure to these proteins elicits a strong host immune response. In the present study, we analyzed the protective capability of Leishmania infantum chagasi nucleosomal histones against L. braziliensis infection using different immunization strategies.
   Methodology/Principal Findings: BALB/c mice were immunized with either a plasmid DNA cocktail (DNA) containing four Leishmania nucleosomal histones or with the DNA cocktail followed by the corresponding recombinant proteins plus CpG (DNA/Protein). Mice were later challenged with L. braziliensis, in the presence of sand fly saliva. Lesion development, parasite load and the cellular immune response were analyzed five weeks after challenge. Immunization with either DNA alone or with DNA/Protein was able to inhibit lesion development. This finding was highlighted by the absence of infected macrophages in tissue sections. Further, parasite load at the infection site and in the draining lymph nodes was also significantly lower in vaccinated animals. This outcome was associated with increased expression of IFN-gamma and down regulation of IL-4 at the infection site.
   Conclusion: The data presented here demonstrate the potential use of L. infantum chagasi nucleosomal histones as targets for the development of vaccines against infection with L. braziliensis, as shown by the significant inhibition of disease development following a live challenge.
C1 [Carneiro, Marcia W.; Santos, Diego M.; Fukutani, Kiyoshi F.; Clarencio, Jorge; Miranda, Jose Carlos; Brodskyn, Claudia; Barral, Aldina; Barral-Netto, Manoel; de Oliveira, Camila I.] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [Brodskyn, Claudia; Barral, Aldina; Barral-Netto, Manoel; de Oliveira, Camila I.] Inst Invest Imunol, Salvador, BA, Brazil.
   [Soto, Manuel] Univ Autonoma Madrid, Dept Biol Mol, Ctr Biol Mol Severo Ochoa, Consejo Super Invest Cient, Madrid, Spain.
RP de Oliveira, CI (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
EM camila@bahia.fiocruz.br
RI Fukutani, Kiyoshi/N-7905-2016; Alvarez, Manuel Soto/Q-5234-2018;
   Fukutani, Kiyoshi/T-1630-2019; de Oliveira, Camila I/B-4358-2009;
   Barral-Netto, Manoel/B-3904-2009
OI Fukutani, Kiyoshi/0000-0003-2223-0918; Alvarez, Manuel
   Soto/0000-0001-6825-841X; de Oliveira, Camila I/0000-0002-7868-5164;
   Barral-Netto, Manoel/0000-0002-5823-7903; Weber Carneiro,
   Marcia/0000-0002-4220-5085; Clarencio, Jorge/0000-0002-4289-5450
FU Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational
   Council for Scientific and Technological Development (CNPq); CYTED;
   CAPESCAPES
FX This work was supported by grants from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico and CYTED. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.; We thank Dr Almerio Noronha for help
   with histopathology analysis and documentation. MWC, DMS and KFF were
   supported by CAPES fellowships. MBN, AB, CB and CIO are senior
   investigators from CNPq.
CR Abdian N, 2011, EXP PARASITOL, V127, P627, DOI 10.1016/j.exppara.2010.12.007
   Agallou M, 2012, VACCINE, V30, P5086, DOI 10.1016/j.vaccine.2012.05.075
   Andrade BB, 2007, SCAND J IMMUNOL, V66, P122, DOI 10.1111/j.1365-3083.2007.01964.x
   Belkaid Y, 2001, J EXP MED, V194, P1497, DOI 10.1084/jem.194.10.1497
   Bittencourt Achiléa, 2003, Braz J Infect Dis, V7, P229, DOI 10.1590/S1413-86702003000300009
   Carmelo E, 2006, PARASITE, V13, P231, DOI 10.1051/parasite/2006133231
   Carmelo E, 2002, CLIN DIAGN LAB IMMUN, V9, P808, DOI 10.1128/CDLI.9.4.808-811.2002
   Carrion J, 2008, VACCINE, V26, P1155, DOI 10.1016/j.vaccine.2007.12.051
   Carrion J, 2008, VACCINE, V26, P2537, DOI 10.1016/j.vaccine.2008.03.003
   Carrion J, 2007, MICROBES INFECT, V9, P735, DOI 10.1016/j.micinf.2007.02.018
   Cerna P, 2002, INSECT BIOCHEM MOLEC, V32, P1691, DOI 10.1016/S0965-1748(02)00109-1
   Charlab R, 1999, P NATL ACAD SCI USA, V96, P15155, DOI 10.1073/pnas.96.26.15155
   Chenik M, 2006, VACCINE, V24, P2521, DOI 10.1016/j.vaccine.2005.12.027
   Costa DL, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000965
   de Carvalho LP, 2003, MICROBES INFECT, V5, P7, DOI 10.1016/S1286-4579(02)00051-5
   de Moura TR, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000084
   de Moura TR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000712
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   de Oliveira CI, 2009, PARASITOL INT, V58, P319, DOI 10.1016/j.parint.2009.07.013
   Dondji B, 2005, INFECT IMMUN, V73, P5286, DOI 10.1128/IAI.73.8.5286-5289.2005
   Donnelly KB, 1998, J PARASITOL, V84, P97, DOI 10.2307/3284537
   Falcao SC, 2012, INT J PARASITOL, V42, P771, DOI 10.1016/j.ijpara.2012.05.006
   Galanti N, 1998, PARASITOL TODAY, V14, P64, DOI 10.1016/S0169-4758(97)01162-9
   Gomes R, 2008, P NATL ACAD SCI USA, V105, P7845, DOI 10.1073/pnas.0712153105
   Gomes R, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001610
   Gonzalo RM, 2002, VACCINE, V20, P1226, DOI 10.1016/S0264-410X(01)00427-3
   Goto Y, 2011, CLIN VACCINE IMMUNOL, V18, P1118, DOI 10.1128/CVI.05024-11
   Iborra S, 2004, VACCINE, V22, P3865, DOI 10.1016/j.vaccine.2004.04.015
   Klinman DM, 1997, J IMMUNOL, V158, P3635
   Klinman DM, 2000, SPRINGER SEMIN IMMUN, V22, P173, DOI 10.1007/s002810050027
   Launois P, 2008, EXPERT REV VACCINES, V7, P1277, DOI 10.1586/14760584.7.8.1277
   LERNER EA, 1991, J BIOL CHEM, V266, P11234
   LIEW FY, 1990, J IMMUNOL, V145, P4306
   Lima HC, 1996, INFECT IMMUN, V64, P5442, DOI 10.1128/IAI.64.12.5442-5445.1996
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Masina S, 2003, J INFECT DIS, V188, P1250, DOI 10.1086/378677
   Mazumder S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014644
   Meddeb-Garnaoui A, 2010, VACCINE, V28, P1881, DOI 10.1016/j.vaccine.2009.11.075
   Costa CHN, 2011, PLOS NEGLECT TROP D, V5, DOI [10.1371/journal.pntd.0000943, 10.1371/journal.pntd.0000965]
   Norsworthy NB, 2004, INFECT IMMUN, V72, P1240, DOI 10.1128/IAI.72.3.1240-1247.2004
   Okwor I, 2009, HUM VACCINES, V5, P291, DOI 10.4161/hv.5.5.7607
   Peters NC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000484
   Probst P, 2001, J IMMUNOL, V166, P498, DOI 10.4049/jimmunol.166.1.498
   Rafati S, 2006, VACCINE, V24, P2169, DOI 10.1016/j.vaccine.2005.11.011
   Ramshaw IA, 2000, IMMUNOL TODAY, V21, P163, DOI 10.1016/S0167-5699(00)01612-1
   Requena JM, 2000, PARASITOL TODAY, V16, P246, DOI 10.1016/S0169-4758(00)01651-3
   Rohousova I, 2005, PARASITE IMMUNOL, V27, P469, DOI 10.1111/j.1365-3024.2005.00787.x
   Salay G, 2007, CLIN VACCINE IMMUNOL, V14, P1173, DOI 10.1128/CVI.00060-07
   SAMUELSON J, 1991, J EXP MED, V173, P49, DOI 10.1084/jem.173.1.49
   Santarem N, 2007, J BIOMED BIOTECHNOL, DOI 10.1155/2007/85154
   Shi PY, 1997, BIOTECHNIQUES, V23, P1036, DOI 10.2144/97236bm15
   Solioz N, 1999, VACCINE, V18, P850, DOI 10.1016/S0264-410X(99)00340-0
   Soto M, 1996, CLIN EXP IMMUNOL, V106, P454, DOI 10.1046/j.1365-2249.1996.d01-865.x
   Soto M, 1999, CLIN EXP IMMUNOL, V115, P342, DOI 10.1046/j.1365-2249.1999.00796.x
   Soto M, 1995, IMMUNOL LETT, V48, P209, DOI 10.1016/0165-2478(95)02473-5
   Tapia E, 2003, MICROBES INFECT, V5, P73, DOI 10.1016/S1286-4579(02)00077-1
   Tavares NM, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001169
   Tewary P, 2005, J INFECT DIS, V191, P2130, DOI 10.1086/430348
   TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x
   Valenzuela JG, 2001, J EXP MED, V194, P331, DOI 10.1084/jem.194.3.331
NR 60
TC 10
Z9 11
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 20
PY 2012
VL 7
IS 12
AR e52296
DI 10.1371/journal.pone.0052296
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 060RA
UT WOS:000312794500137
PM 23284976
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Falcao, SC
   de Moura, TR
   Clarencio, J
   Brodskyn, C
   Barral, A
   de Oliveira, CI
AF Falcao, Sarah C.
   de Moura, Tatiana R.
   Clarencio, Jorge
   Brodskyn, Claudia
   Barral, Aldina
   de Oliveira, Camila I.
TI The presence of Tregs does not preclude immunity to reinfection with
   Leishmania braziliensis
SO INTERNATIONAL JOURNAL FOR PARASITOLOGY
LA English
DT Article
DE Leishmania braziliensis; Treg; CD4(+)CD25(+)
ID REGULATORY T-CELLS; IMMUNOLOGICAL SELF-TOLERANCE; CUTANEOUS
   LEISHMANIASIS; MAJOR INFECTION; VIANNIA BRAZILIENSIS; BALB/C MICE;
   DISEASE; PARASITES; EFFECTOR; FOXP3
AB Leishmania spp. cause a broad spectrum of diseases collectively known as leishmaniasis. Leishmania braziliensis is the main etiological agent of American cutaneous leishmaniasis and mucocutaneous leishmaniasis. During experimental infection with L. braziliensis, BALB/c mice develop an adaptive immune response that is associated with lesion healing and, in parallel, parasite persistence within draining lymph nodes (dLNs). In the Leishmania major model of cutaneous leishmaniasis, regulatory T cells (Tregs) play an important role in immune regulation, preventing pathological immune responses but at the same time precluding sterile cure. In this study we investigated the role of Tregs during experimental infection with L. braziliensis. CD4(+)CD25(+) T cells were detected throughout the duration of clinical disease both at the ear and in dLNs of infected mice. These cells expressed Treg markers such as glucocorticoid-induced TNF-receptor-related protein (GITR), the alpha chain of the alpha epsilon beta 7 integrin (CD103), and the forkhead/winged helix transcription factor, Foxp3, and were able to suppress the proliferation of CD4(+)CD25(-) cells. Importantly, a high frequency of Foxp3(+) cells accumulated at the site of infection and in dLNs. We next investigated the outcome of a reinfection with L. braziliensis in terms of Treg distribution and disease reactivation. Interestingly, a secondary inoculation with L. braziliensis did not preclude an efficient recall response to L. braziliensis at a distal site, despite the presence of Tregs. Within dLNs, reinfection did not promote parasite dissemination or a differential recruitment of either CD4(+)CD25(+)Foxp3(+) or CD4(+)IL-10(+) T cells. On the contrary, parasites were mainly detected in the LN draining the primary infection site where a high frequency of CD4(+)IFN-gamma(+) T cells was also present. Collectively these data show that during experimental infection, Tregs are present in healed mice but this population does not compromise an effective immune response upon reinfection with L braziliensis. (C) 2012 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Falcao, Sarah C.; de Moura, Tatiana R.; Clarencio, Jorge; Brodskyn, Claudia; Barral, Aldina; de Oliveira, Camila I.] Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [Brodskyn, Claudia; Barral, Aldina] Univ Fed Bahia, Salvador, BA, Brazil.
RP de Oliveira, CI (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisas Goncalo Moniz, Rua Waldemar Falcao 121, Salvador, BA, Brazil.
EM camila@bahia.fiocruz.br
RI , Tatiana/AAN-1194-2020; Clarencio, Jorge/H-3940-2012; de Oliveira,
   Camila I/B-4358-2009
OI , Tatiana/0000-0002-7442-4434; de Oliveira, Camila
   I/0000-0002-7868-5164; Clarencio, Jorge/0000-0002-4289-5450; Falcao,
   Sarah/0000-0002-5458-7711
CR Anderson CF, 2007, J EXP MED, V204, P285, DOI 10.1084/jem.20061886
   Aseffa A, 2002, J IMMUNOL, V169, P3232, DOI 10.4049/jimmunol.169.6.3232
   Belkaid Y, 2003, EXPERT OPIN BIOL TH, V3, P875, DOI 10.1517/14712598.3.6.875
   Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152
   Belkaid Y, 2001, J EXP MED, V194, P1497, DOI 10.1084/jem.194.10.1497
   Belkaid Y, 2006, CURR OPIN IMMUNOL, V18, P406, DOI 10.1016/j.coi.2006.05.014
   Belkaid Y, 2006, IMMUNOL REV, V212, P287, DOI 10.1111/j.0105-2896.2006.00409.x
   BITTENCOURT AL, 1995, TROPICAL PATHOLOGY, P597
   Bogdan C, 2000, J EXP MED, V191, P2121, DOI 10.1084/jem.191.12.2121
   Bopp T, 2007, J EXP MED, V204, P1303, DOI 10.1084/jem.20062129
   Bourreau E, 2009, INFECT IMMUN, V77, P1465, DOI 10.1128/IAI.01398-08
   Campanelli AP, 2006, J INFECT DIS, V193, P1313, DOI 10.1086/502980
   Collison LW, 2007, NATURE, V450, P566, DOI 10.1038/nature06306
   Colpitts SL, 2010, J IMMUNOL, V185, P2416, DOI 10.4049/jimmunol.1000483
   Costa DL, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000965
   Coutinho S.G., 2002, T ROY SOC TROP MED H, pS173
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904
   Hesse M, 2004, J IMMUNOL, V172, P3157, DOI 10.4049/jimmunol.172.5.3157
   Hori S, 2002, EUR J IMMUNOL, V32, P1282, DOI 10.1002/1521-4141(200205)32:5<1282::AID-IMMU1282>3.0.CO;2-#
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Hsu AC, 2007, J IMMUNOL, V179, P8200, DOI 10.4049/jimmunol.179.12.8200
   Jankovic D, 2007, J EXP MED, V204, P273, DOI 10.1084/jem.20062175
   Ji JX, 2005, J IMMUNOL, V174, P7147, DOI 10.4049/jimmunol.174.11.7147
   Kane MM, 2001, J IMMUNOL, V166, P1141, DOI 10.4049/jimmunol.166.2.1141
   Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909
   Kullberg MC, 2002, J EXP MED, V196, P505, DOI 10.1084/jem.20020556
   Lages CS, 2008, J IMMUNOL, V181, P1835, DOI 10.4049/jimmunol.181.3.1835
   LOCKSLEY RM, 1991, RES IMMUNOL, V142, P28, DOI 10.1016/0923-2494(91)90007-6
   Makala LHC, 2011, J INFECT DIS, V203, P715, DOI 10.1093/infdis/jiq095
   Mendez S, 2004, J EXP MED, V200, P201, DOI 10.1084/jem.20040298
   Moll H, 1995, ADV EXP MED BIOL, V378, P507
   Murray HW, 1999, J EXP MED, V189, P741, DOI 10.1084/jem.189.4.741
   Nylen S, 2007, J EXP MED, V204, P805, DOI 10.1084/jem.20061141
   Okwor I, 2009, HUM VACCINES, V5, P291, DOI 10.4161/hv.5.5.7607
   Pandiyan P, 2007, NAT IMMUNOL, V8, P1353, DOI 10.1038/ni1536
   Peters NC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000484
   Piccirillo CA, 2001, J IMMUNOL, V167, P1137, DOI 10.4049/jimmunol.167.3.1137
   Powrie Fiona, 2003, Novartis Found Symp, V252, P92
   Ramirez JL, 1997, MEM I OSWALDO CRUZ, V92, P333, DOI 10.1590/S0074-02761997000300006
   Rocha FJS, 2007, INFECT IMMUN, V75, P3823, DOI 10.1128/IAI.01335-06
   Rodrigues OR, 2009, IMMUNOBIOLOGY, V214, P101, DOI 10.1016/j.imbio.2008.07.001
   Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122
   SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151
   SCOTT P, 1989, IMMUNOL REV, V112, P161, DOI 10.1111/j.1600-065X.1989.tb00557.x
   Stager S, 2006, EUR J IMMUNOL, V36, P1764, DOI 10.1002/eji.200635937
   Suffia IJ, 2006, J EXP MED, V203, P777, DOI 10.1084/jem.20052056
   Tabbara KS, 2005, INFECT IMMUN, V73, P4714, DOI 10.1128/IAI.73.8.4714-4722.2005
   Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303
   Tang QZ, 2008, NAT IMMUNOL, V9, P239, DOI 10.1038/ni1572
   Xu DM, 2003, J IMMUNOL, V170, P394, DOI 10.4049/jimmunol.170.1.394
NR 51
TC 13
Z9 13
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020-7519
EI 1879-0135
J9 INT J PARASITOL
JI Int. J. Parasit.
PD JUL
PY 2012
VL 42
IS 8
BP 771
EP 780
DI 10.1016/j.ijpara.2012.05.006
PG 10
WC Parasitology
SC Parasitology
GA 987KS
UT WOS:000307416400008
PM 22705204
OA Green Published
DA 2020-12-08
ER

PT J
AU Silva, JS
   Andrade, AC
   Santana, CC
   Santos, LQ
   de Oliveira, CI
   Veras, PST
   Vassallo, J
   Dos-Santos, WLC
AF Silva, Joselli S.
   Andrade, Alan C.
   Santana, Claudia C.
   Santos, Leina Q.
   de Oliveira, Camila I.
   Veras, Patricia S. T.
   Vassallo, Jose
   dos-Santos, Washington L. C.
TI Low CXCL13 Expression, Splenic Lymphoid Tissue Atrophy and Germinal
   Center Disruption in Severe Canine Visceral Leishmaniasis
SO PLOS ONE
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; FOLLICULAR DENDRITIC CELLS; MARGINAL ZONE;
   DONOVANI INFECTION; SPLEEN; DOGS; CHAGASI; BRAZIL; MICE; PCR
AB Visceral leishmaniasis is associated with atrophy and histological disorganization of splenic compartments. In this paper, we compared organized and disorganized splenic lymphoid tissue from dogs naturally infected with Leishmania infantum assessing the size of the white pulp compartments, the distribution of T, B and S100(+) dendritic cells, using immunohistochemistry and morphometry and the expression of CCR7 and the cytokines, CXCL13, lymphotoxin (LT)-alpha, LT-beta, CCL19, CCL21, TNF-alpha, IL-10, IFN-gamma and TGF-beta, using by real time RT-PCR. The lymphoid follicles and marginal zones were smaller (3.2 and 1.9 times, respectively; Mann-Whitney, P<0.02) in animals with disorganized splenic tissue in comparison to those with organized splenic lymphoid tissue. In spleens with disorganized lymphoid tissue, the numbers of T cells and S100(+) dendritic cells were decreased in the follicles, and the numbers of B cells were reduced in both the follicles and marginal zones. CXCL13 mRNA expression was lower in animals with disorganized lymphoid tissue (0.5+/-0.4) compared to those with organized lymphoid tissue (2.7+/-2.9, both relative to 18S expression, P = 0.01). These changes in the spleen were associated with higher frequency of severe disease (7/12) in the animals with disorganized than in animals with organized (2/13, Chi-square, P = 0.01) splenic lymphoid tissue. The data presented herein suggest that natural infection with Leishmania infantum is associated with the impairment of follicular dendritic cells, CXCL13 expression, B cell migration and germinal center formation and associates these changes with severe clinical forms of visceral leishmaniasis. Furthermore the fact that this work uses dogs naturally infected with Leishmania infantum emphasizes the relevance of the data presented herein for the knowledge on the canine and human visceral leishmaniasis.
C1 [Silva, Joselli S.; Andrade, Alan C.; Santos, Leina Q.; de Oliveira, Camila I.; Veras, Patricia S. T.; dos-Santos, Washington L. C.] Ctr Pesquisas Goncalo Moniz, Fundacao Oswaldo Cruz, Salvador, BA, Brazil.
   [Santana, Claudia C.] Escola Bahiana Med & Saude Publ Biomed, Salvador, BA, Brazil.
   [Vassallo, Jose] Univ Estadual Campinas, Fac Ciencias Med, Campinas, SP, Brazil.
RP Dos-Santos, WLC (corresponding author), Ctr Pesquisas Goncalo Moniz, Fundacao Oswaldo Cruz, Salvador, BA, Brazil.
EM wluis@bahia.fiocruz.br
RI DOS-SANTOS, WASHINGTON/B-4173-2009; DoenAas Tropicais, Inct/K-2308-2013;
   de Oliveira, Camila I/B-4358-2009; Cronemberger-Andrade,
   Alan/V-5047-2019; Veras, Patricia S T Sampaio Tavares/I-9632-2014
OI DOS-SANTOS, WASHINGTON/0000-0003-1445-2318; de Oliveira, Camila
   I/0000-0002-7868-5164; Cronemberger-Andrade, Alan/0000-0003-1645-0500;
   Veras, Patricia S T Sampaio Tavares/0000-0001-8308-9263; VASSALLO,
   JOSE/0000-0002-2192-4865; Santana, Cesar/0000-0002-8962-173X
FU Fundacao de Amparo a Pesquisa do Estado da Bahia (Fapesb)
   [APR0434/2005]; Fundacao Oswaldo Cruz (Fiocruz) PAPES V [403470/2008-0]
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado da
   Bahia (Fapesb) grant no. APR0434/2005 and Fundacao Oswaldo Cruz
   (Fiocruz) PAPES V grant 403470/2008-0. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR ANDRADE TM, 1990, J INFECT DIS, V162, P1354, DOI 10.1093/infdis/162.6.1354
   ANDRADE ZILTON A., 1966, REV INST MED TROP SAO PAULO, V8, P259
   Ansel KM, 2000, NATURE, V406, P309
   Ato M, 2004, J IMMUNOL, V173, P4815, DOI 10.4049/jimmunol.173.8.4815
   Ato M, 2002, NAT IMMUNOL, V3, P1185, DOI 10.1038/ni861
   Ato M, 2006, J IMMUNOL, V176, P5486, DOI 10.4049/jimmunol.176.9.5486
   BADARO R, 1986, J INFECT DIS, V154, P639, DOI 10.1093/infdis/154.4.639
   BARRALNETTO M, 1991, J INFECT DIS, V163, P853, DOI 10.1093/infdis/163.4.853
   Benedict CA, 2006, PLOS PATHOG, V2, P164, DOI 10.1371/journal.ppat.0020016
   Bossolasco S, 2003, J CLIN MICROBIOL, V41, P5080, DOI 10.1128/JCM.41.11.5080-5084.2003
   CARBONE A, 1988, HUM PATHOL, V19, P51, DOI 10.1016/S0046-8177(88)80315-0
   Carrion J, 2006, PARASITE IMMUNOL, V28, P173, DOI 10.1111/j.1365-3024.2006.00817.x
   Cesta MF, 2006, TOXICOL PATHOL, V34, P455, DOI 10.1080/01926230600867743
   Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748
   Cinamon G, 2004, NAT IMMUNOL, V5, P713, DOI 10.1038/ni1083
   COCCHIA D, 1983, CELL TISSUE RES, V230, P95
   Dos-Santos WLC, 2008, VET IMMUNOL IMMUNOP, V123, P251, DOI 10.1016/j.vetimm.2008.02.004
   Dye C, 1996, AM J TROP MED HYG, V55, P125, DOI 10.4269/ajtmh.1996.55.125
   Engwerda CR, 2002, AM J PATHOL, V161, P429, DOI 10.1016/S0002-9440(10)64199-5
   Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5
   Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261
   GLANTZ SA, 1997, PRIMER BIOSTATISTICS, P1
   Glantz SA, 1997, PRIMER BIOSTATISTICS
   Hansen K, 2001, PEDIATR DEVEL PATHOL, V4, P105, DOI 10.1007/s100240010145
   JANOSSY G, 1985, CLIN EXP IMMUNOL, V59, P257
   KEENAN CM, 1984, VET PATHOL, V21, P80, DOI 10.1177/030098588402100114
   Kemming G, 2004, EUR SURG RES, V36, P198, DOI 10.1159/000078853
   Lage RS, 2007, VET IMMUNOL IMMUNOP, V115, P135, DOI 10.1016/j.vetimm.2006.10.001
   Mebius RE, 2005, NAT REV IMMUNOL, V5, P606, DOI 10.1038/nri1669
   Melby PC, 2001, EXP PARASITOL, V99, P17, DOI 10.1006/expr.2001.4640
   Melby PC, 2001, J IMMUNOL, V166, P1912, DOI 10.4049/jimmunol.166.3.1912
   Ministerio da Saude do Brasil, 2006, MAN VIG CONTR LEISHM
   Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403
   ParanhosSilva M, 1996, AM J TROP MED HYG, V55, P39, DOI 10.4269/ajtmh.1996.55.39
   Quinnell RJ, 2009, PARASITOLOGY, V136, P1915, DOI 10.1017/S0031182009991156
   Quinnell RJ, 1997, PARASITOLOGY, V115, P143, DOI 10.1017/S0031182097001200
   Reis AB, 2006, VET IMMUNOL IMMUNOP, V112, P102, DOI 10.1016/j.vetimm.2006.02.001
   Ruiz Felipe Sueiro, 2005, J. Bras. Patol. Med. Lab., V41, P263, DOI 10.1590/S1676-24442005000400008
   Machado CJS, 2009, SCIENCE, V324, P1643, DOI 10.1126/science.324_1643
   Santana CC, 2008, PARASITE IMMUNOL, V30, P515, DOI 10.1111/j.1365-3024.2008.01051.x
   Shi KR, 2001, J IMMUNOL, V166, P650, DOI 10.4049/jimmunol.166.1.650
   Silva ES, 2001, MEM I OSWALDO CRUZ, V96, P285, DOI 10.1590/S0074-02762001000300002
   Smelt SC, 1997, J IMMUNOL, V158, P3813
   Solano-Gallego L, 2008, VET PARASITOL, V157, P211, DOI 10.1016/j.vetpar.2008.07.024
   Steiniger B, 1999, MICROANATOMY FUNCTIO
   Rodrigues CAT, 2009, VET IMMUNOL IMMUNOP, V127, P382, DOI 10.1016/j.vetimm.2008.10.324
   TRYPHONAS L, 1977, CAN J COMP MED, V41, P1
   VERESS B, 1983, BRIT J EXP PATHOL, V64, P505
   VERESS B, 1977, IMMUNOLOGY, V33, P605
NR 49
TC 24
Z9 25
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 5
PY 2012
VL 7
IS 1
AR e29103
DI 10.1371/journal.pone.0029103
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 058VE
UT WOS:000312662100013
PM 22242159
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU de Oliveira, CI
   Brodskyn, CI
AF de Oliveira, Camila I.
   Brodskyn, Claudia I.
TI The immunobiology of Leishmania braziliensis infection
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE Leishmania braziliensis; innate immunity; human adaptive immunology;
   animal models
AB Leishmaniases are a group of diseases caused by protozoa of the genus Leishmania that affect millions of people worldwide. These diseases are caused by distinct Leishmania species, of which L. braziliensis, a New World representative of the Leishmania genus, has been the least studied. Although leishmaniasis caused by L. braziliensis induces a range of clinical manifestations ranging from mild localized lesions to severe mucosal involvement, few studies have focused on elucidating the immune mechanisms behind this pathology. In this review, we focus on the immunobiology of L. braziliensis infection, emphasizing the innate and adaptive immune responses and taking into consideration both studies performed in endemic areas and experimental models of infection. Additionally, we address recent findings regarding the role of sand fly saliva in disease immunopathogenesis and vaccine development.
C1 [de Oliveira, Camila I.; Brodskyn, Claudia I.] Fiocruz MS, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [de Oliveira, Camila I.; Brodskyn, Claudia I.] Inst Invest Imunol, Salvador, BA, Brazil.
RP de Oliveira, CI (corresponding author), CPqGM FIOCRUZ, Ctr Pesquisas Goncalo Moniz, Rua Waldemar Falcao 121, Salvador, BA, Brazil.
EM camila@bahia.fiocruz.br; brodskyn@bahia.fiocruz.br
RI de Oliveira, Camila I/B-4358-2009
OI de Oliveira, Camila I/0000-0002-7868-5164
CR Afonso L, 2008, J LEUKOCYTE BIOL, V84, P389, DOI 10.1189/jlb.0108018
   Anderson CF, 2007, J EXP MED, V204, P285, DOI 10.1084/jem.20061886
   Antonelli LRV, 2005, IMMUNOL LETT, V101, P226, DOI 10.1016/j.imlet.2005.06.004
   Antonelli LRV, 2004, CLIN EXP IMMUNOL, V136, P341, DOI 10.1111/j.1365-2249.2004.02426.x
   Bafica A, 2003, INT J DERMATOL, V42, P203, DOI 10.1046/j.1365-4362.2003.01868.x
   BARRAL A, 1995, AM J TROP MED HYG, V53, P256, DOI 10.4269/ajtmh.1995.53.256
   BARRAL A, 1992, AM J TROP MED HYG, V47, P587, DOI 10.4269/ajtmh.1992.47.587
   BARRAL A, 1983, AM J TROP MED HYG, V32, P277, DOI 10.4269/ajtmh.1983.32.277
   BARRAL A, 1995, AM J PATHOL, V147, P947
   BARRALNETTO M, 1992, SCIENCE, V257, P545, DOI 10.1126/science.1636092
   Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152
   Belkaid Y, 2001, J EXP MED, V194, P1497, DOI 10.1084/jem.194.10.1497
   Bezerra HSD, 2001, MEM I OSWALDO CRUZ, V96, P349
   Bittar RC, 2007, MEM I OSWALDO CRUZ, V102, P625, DOI 10.1590/S0074-02762007005000069
   Boaventura VS, 2010, EUR J IMMUNOL, V40, P2830, DOI 10.1002/eji.200940115
   Bomfim G, 2007, AM J TROP MED HYG, V77, P854, DOI 10.4269/ajtmh.2007.77.854
   Bottrel RLA, 2001, INFECT IMMUN, V69, P3232, DOI 10.1128/IAI.69.5.3232-3239.2001
   Brodskyn CI, 1997, J IMMUNOL, V159, P4467
   Campanelli AP, 2006, J INFECT DIS, V193, P1313, DOI 10.1086/502980
   Carvalho LP, 2008, J IMMUNOL, V181, P6473, DOI 10.4049/jimmunol.181.9.6473
   CHILDS GE, 1984, ANN TROP MED PARASIT, V78, P25, DOI 10.1080/00034983.1984.11811769
   Clarencio J, 2006, INFECT IMMUN, V74, P4757, DOI 10.1128/IAI.00265-06
   CONVIT J, 1962, BRIT J DERMATOL, V74, P132, DOI 10.1111/j.1365-2133.1962.tb13475.x
   Costa DL, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000965
   COSTA JML, 1986, J TROP MED HYG, V89, P319
   de Moura TR, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000084
   de Moura TR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000712
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   de Oliveira CI, 2004, MICROBES INFECT, V6, P977, DOI 10.1016/j.micinf.2004.05.009
   de Souza-Neto SM, 2004, MEM I OSWALDO CRUZ, V99, P289, DOI 10.1590/S0074-02762004000300009
   DeKrey GK, 1998, INFECT IMMUN, V66, P827, DOI 10.1128/IAI.66.2.827-829.1998
   Falcao S. C., 2012, INT J PARAS IN PRESS
   Faria DR, 2009, PARASITE IMMUNOL, V31, P432, DOI 10.1111/j.1365-3024.2009.01125.x
   Faria DR, 2005, INFECT IMMUN, V73, P7853, DOI 10.1128/IAI.73.12.7853-7859.2005
   Figueroa RA, 2009, J INFECT DIS, V200, P638, DOI 10.1086/600109
   Follador I, 2002, CLIN INFECT DIS, V34, pE54, DOI 10.1086/340261
   Gaze ST, 2006, SCAND J IMMUNOL, V63, P70, DOI 10.1111/j.1365-3083.2005.01707.x
   Gomes R, 2008, P NATL ACAD SCI USA, V105, P7845, DOI 10.1073/pnas.0712153105
   Guimaraes-Costa AB, 2009, P NATL ACAD SCI USA, V106, P6748, DOI 10.1073/pnas.0900226106
   Ives A, 2011, SCIENCE, V331, P775, DOI 10.1126/science.1199326
   JONES TC, 1987, J INFECT DIS, V156, P73, DOI 10.1093/infdis/156.1.73
   Keesen TSL, 2011, CLIN EXP IMMUNOL, V165, P338, DOI 10.1111/j.1365-2249.2011.04430.x
   Khouri R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014394
   Khouri R, 2009, J IMMUNOL, V182, P2525, DOI 10.4049/jimmunol.0802860
   Lessa HA, 2001, AM J TROP MED HYG, V65, P87, DOI 10.4269/ajtmh.2001.65.87
   Lima HC, 1996, INFECT IMMUN, V64, P5442, DOI 10.1128/IAI.64.12.5442-5445.1996
   Lye LF, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001161
   Rebelo JMM, 2010, CAD SAUDE PUBLICA, V26, P195, DOI 10.1590/S0102-311X2010000100020
   Machado P, 2002, EUR J DERMATOL, V12, P449
   Maioli TU, 2004, PARASITOL RES, V94, P207, DOI 10.1007/s00436-004-1193-6
   Maretti-Mira AC, 2011, ACTA TROP, V119, P160, DOI 10.1016/j.actatropica.2011.05.009
   Maroof A, 2008, IMMUNITY, V29, P295, DOI 10.1016/j.immuni.2008.06.012
   MARSDEN PD, 1990, BRIT MED J, V301, P656, DOI 10.1136/bmj.301.6753.656
   Martins L, 2010, REV SAUDE PUBL, V44, P571, DOI 10.1590/S0034-89102010005000004
   McFarlane E, 2008, INFECT IMMUN, V76, P532, DOI 10.1128/IAI.01388-07
   Mendes-Aguiar Cde O., 2009, CLIN EXP IMMUNOL, V157, P377
   Mendonca MG, 2004, J INFECT DIS, V189, P1018, DOI 10.1086/382135
   Menezes MJ, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-12
   Miles SA, 2005, J EXP MED, V201, P747, DOI 10.1084/jem.20041470
   Miranda JC, 2002, MEM I OSWALDO CRUZ, V97, P185, DOI 10.1590/S0074-02762002000200006
   Norsworthy NB, 2004, INFECT IMMUN, V72, P1240, DOI 10.1128/IAI.72.3.1240-1247.2004
   Novais FO, 2009, J IMMUNOL, V183, P8088, DOI 10.4049/jimmunol.0803720
   Novoa R, 2011, PARASITE IMMUNOL, V33, P132, DOI 10.1111/j.1365-3024.2010.01256.x
   Nylen S, 2007, J EXP MED, V204, P805, DOI 10.1084/jem.20061141
   Oliveira F, 2011, AM J TROP MED HYG, V85, P70, DOI 10.4269/ajtmh.2011.10-0680
   PATTERSON JL, 1993, PARASITOL TODAY, V9, P135, DOI 10.1016/0169-4758(93)90178-I
   Peacock CS, 2007, NAT GENET, V39, P839, DOI 10.1038/ng2053
   Pompeu MML, 2001, INFECT IMMUN, V69, P7453, DOI 10.1128/IAI.69.12.7453-7460.2001
   Ribeiro-de-Jesus A, 1998, BRAZ J MED BIOL RES, V31, P143, DOI 10.1590/S0100-879X1998000100020
   Rocha FJS, 2007, INFECT IMMUN, V75, P3823, DOI 10.1128/IAI.01335-06
   Rohousova I, 2005, PARASITOLOGY, V130, P493, DOI 10.1017/S003118200400681X
   Ronet C, 2010, J IMMUNOL, V184, P886, DOI 10.4049/jimmunol.0901114
   Salay G, 2007, CLIN VACCINE IMMUNOL, V14, P1173, DOI 10.1128/CVI.00060-07
   SAMUELSON J, 1991, J EXP MED, V173, P49, DOI 10.1084/jem.173.1.49
   Schubach A, 1998, J INFECT DIS, V178, P911, DOI 10.1086/515355
   Shi HF, 2004, EUKARYOT CELL, V3, P1445, DOI 10.1128/EC.3.6.1445-1453.2004
   SOUSA AD, 1995, AM J TROP MED HYG, V53, P380
   Stager S, 2006, EUR J IMMUNOL, V36, P1764, DOI 10.1002/eji.200635937
   Svensson M, 2004, IMMUNITY, V21, P805, DOI 10.1016/j.immuni.2004.10.012
   TARR PI, 1988, P NATL ACAD SCI USA, V85, P9572, DOI 10.1073/pnas.85.24.9572
   Tavares NM, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001169
   Teixeira MJ, 2005, INFECT IMMUN, V73, P1191, DOI 10.1128/IAI.73.2.1191-1195.2005
   Thiakaki M, 2005, MICROBES INFECT, V7, P760, DOI 10.1016/j.micinf.2005.01.013
   Trinchieri G, 2003, IMMUNITY, V19, P641, DOI 10.1016/S1074-7613(03)00296-6
   Valenzuela JG, 2001, J EXP MED, V194, P331, DOI 10.1084/jem.194.3.331
   Vargas-Inchaustegui DA, 2008, J IMMUNOL, V180, P7537, DOI DOI 10.4049/JIMMUNOL.180.11.7537
   Vargas-Inchaustegui DA, 2010, INFECT IMMUN, V78, P301, DOI 10.1128/IAI.00959-09
   Vargas-Inchaustegui DA, 2009, INFECT IMMUN, V77, P2948, DOI 10.1128/IAI.00154-09
   Yoshimura T, 2006, J IMMUNOL, V177, P5377, DOI 10.4049/jimmunol.177.8.5377
NR 89
TC 37
Z9 38
U1 0
U2 0
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PY 2012
VL 3
AR 145
DI 10.3389/fimmu.2012.00145
PG 9
WC Immunology
SC Immunology
GA V40TQ
UT WOS:000209501300142
PM 22701117
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU da Silva, RAA
   Tavares, NM
   Costa, D
   Pitombo, M
   Barbosa, L
   Fukutani, K
   Miranda, JC
   de Oliveira, CI
   Valenzuela, JG
   Barral, A
   Soto, M
   Barral-Netto, M
   Brodskyn, C
AF da Silva, Robson A. A.
   Tavares, Natalia M.
   Costa, Dirceu
   Pitombo, Maiana
   Barbosa, Larissa
   Fukutani, Kyioshi
   Miranda, Jose C.
   de Oliveira, Camila I.
   Valenzuela, Jesus G.
   Barral, Aldina
   Soto, Manuel
   Barral-Netto, Manoel
   Brodskyn, Claudia
TI DNA vaccination with KMP11 and Lutzomyia longipalpis salivary protein
   protects hamsters against visceral leishmaniasis
SO ACTA TROPICA
LA English
DT Article
DE Hamster; Leishmonia chagasi; Visceral leishmaniasis; Saliva; DNA
   plasmids; Protection
ID KINETOPLASTID MEMBRANE PROTEIN-11; SAND FLY SALIVA; IMMUNE-RESPONSE;
   BALB/C MICE; CUTANEOUS LEISHMANIASIS; VECTOR SALIVA; MESSENGER-RNA;
   NITRIC-OXIDE; MODEL; MACROPHAGES
AB It was recently shown that immunization of hamsters with DNA plasmids coding LJM19, a sand fly salivary protein, partially protected against a challenge with Leishmania chagasi, whereas immunization with KMP11 DNA plasmid, a Leishmania antigen, induced protection against L donovani infection. In the present study, we evaluated the protective effect of immunization with both LJM19 and KMP11 DNA plasmid together. Concerning the protection against an infection by L chagasi, immunization with DNA plasmids coding LJM19 or KMP11, as well as with both plasmids combined, induced IFN-gamma production in draining lymph nodes at 7, 14 and 21 days post-immunization. Immunized hamsters challenged with L chagasi plus Salivary Gland Sonicate (SGS) from Lutzomyia longipalpis showed an enhancement of IFN-gamma/IL-10 and IFN-gamma/TGF-beta in draining lymph nodes after 7 and 14 days of infection. Two and five months after challenge, immunized animals showed reduced parasite load in the liver and spleen, as well as increased IFN-gamma/IL-10 and IFN-gamma/TGF-beta ratios in the spleen. Furthermore, immunized animals remained with a normal hematological profile even five months after the challenge, whereas L chagasi in unimmunized hamsters lead to a significant anemia. The protection observed with LJM19 or KMP11 DNA plasmids used alone was very similar to the protection obtained by the combination of both plasmids. (C) 2011 Elsevier B.V. All rights reserved.
C1 [da Silva, Robson A. A.; Tavares, Natalia M.; Costa, Dirceu; Pitombo, Maiana; Barbosa, Larissa; Fukutani, Kyioshi; Miranda, Jose C.; de Oliveira, Camila I.; Barral, Aldina; Barral-Netto, Manoel] Fiocruz MS, Ctr Pesquisas Goncalo Moniz CPqGM, BR-40296710 Salvador, BA, Brazil.
   [da Silva, Robson A. A.] Univ Fed Bahia UFBA, Inst Multidisciplinar Saude, Vitoria Da Conquista, BA, Brazil.
   [da Silva, Robson A. A.] Inst Ciencias Saude, Salvador, BA, Brazil.
   [da Silva, Robson A. A.] Fac Med, Salvador, BA, Brazil.
   [Brodskyn, Claudia] Inst Nacl Ciencia & Tecnol Invest Imunol Iii INCT, Sao Paulo, Brazil.
   [Soto, Manuel] Univ Autonoma Madrid, Dept Biol Mol, Ctr Biol Mol Severo Ochoa SCIC UAM, E-28049 Madrid, Spain.
   [Valenzuela, Jesus G.] NIAID, Vector Mol Biol Sect, Lab Malaria & Vector Res, NIH, Bethesda, MD USA.
RP Brodskyn, C (corresponding author), Fiocruz MS, Lab Imunoregulacao LIMI, Ctr Pesquisas Goncalo Moniz, Rua Waldemar Falcao 121, BR-40296710 Salvador, BA, Brazil.
EM brodskyn@bahia.fiocruz.br
RI Barral-Netto, Manoel/B-3904-2009; Silva, Robson A A/N-8801-2018;
   Fukutani, Kiyoshi/N-7905-2016; Costa, Dirceu/D-7993-2013; Alvarez,
   Manuel Soto/Q-5234-2018; Fukutani, Kiyoshi/T-1630-2019; de Oliveira,
   Camila I/B-4358-2009; Tavares, Natalia/AAQ-1527-2020
OI Barral-Netto, Manoel/0000-0002-5823-7903; Fukutani,
   Kiyoshi/0000-0003-2223-0918; Costa, Dirceu/0000-0002-0334-3899; Alvarez,
   Manuel Soto/0000-0001-6825-841X; de Oliveira, Camila
   I/0000-0002-7868-5164; Machado Tavares, Natalia/0000-0002-4026-679X
FU FAPESB; CNPqNational Council for Scientific and Technological
   Development (CNPq); CAPESCAPES
FX We thank Edivaldo Passos for technical assistance. This research was
   supported by FAPESB, CNPq and CAPES. CB, AB, CIO and MB-N are senior
   investigators of CNPq-Brasil. RAAS received a fellowship from CNPq.
CR Andrade BB, 2007, SCAND J IMMUNOL, V66, P122, DOI 10.1111/j.1365-3083.2007.01964.x
   Barral A, 2000, AM J TROP MED HYG, V62, P740, DOI 10.4269/ajtmh.2000.62.740
   Basu R, 2005, J IMMUNOL, V174, P7160, DOI 10.4049/jimmunol.174.11.7160
   Basu R, 2007, J INFECT DIS, V195, P1373, DOI 10.1086/513439
   Belkaid Y, 1998, J EXP MED, V188, P1941, DOI 10.1084/jem.188.10.1941
   Caldas AJM, 2006, ACTA TROP, V97, P252, DOI 10.1016/j.actatropica.2005.09.010
   Costa DJ, 2004, INFECT IMMUN, V72, P1298, DOI 10.1128/IAI.72.3.1298-1305.2004
   Dondji B, 2005, INFECT IMMUN, V73, P5286, DOI 10.1128/IAI.73.8.5286-5289.2005
   Fernandez-Guerrero ML, 2004, ACTA TROP, V90, P11, DOI 10.1016/j.actatropica.2003.09.009
   Fuertes MA, 2001, J BIOL INORG CHEM, V6, P107, DOI 10.1007/s007750000175
   Gantt KR, 2003, J IMMUNOL, V170, P2613, DOI 10.4049/jimmunol.170.5.2613
   Gomes R, 2008, P NATL ACAD SCI USA, V105, P7845, DOI 10.1073/pnas.0712153105
   Greenland JR, 2007, VACCINE, V25, P3731, DOI 10.1016/j.vaccine.2007.01.120
   Guilpin VO, 2002, PARASITE IMMUNOL, V24, P437, DOI 10.1046/j.1365-3024.2002.00484.x
   Kamhawi S, 2000, SCIENCE, V290, P1351, DOI 10.1126/science.290.5495.1351
   Lima HC, 1997, PARASITOL TODAY, V13, P80, DOI 10.1016/S0169-4758(96)40010-2
   Lima HC, 1996, INFECT IMMUN, V64, P5442, DOI 10.1128/IAI.64.12.5442-5445.1996
   Melby PC, 1998, INFECT IMMUN, V66, P2135, DOI 10.1128/IAI.66.5.2135-2142.1998
   Melby PC, 2001, J IMMUNOL, V166, P1912, DOI 10.4049/jimmunol.166.3.1912
   Moreno J, 2007, VACCINE, V25, P5290, DOI 10.1016/j.vaccine.2007.05.010
   Morris RV, 2001, J IMMUNOL, V167, P5226, DOI 10.4049/jimmunol.167.9.5226
   Nylen S, 2007, J EXP MED, V204, P805, DOI 10.1084/jem.20061141
   Oliveira F, 2006, VACCINE, V24, P374, DOI 10.1016/j.vaccine.2005.07.085
   Olivier M, 2005, CLIN MICROBIOL REV, V18, P293, DOI 10.1128/CMR.18.2.293-305.2005
   Pastorino Antonio C., 2002, J. Pediatr. (Rio J.), V78, P120, DOI 10.1590/S0021-75572002000200010
   Ramirez JR, 2001, VACCINE, V20, P455, DOI 10.1016/S0264-410X(01)00341-3
   RIBEIRO JMC, 1995, INFECT AGENT DIS, V4, P143
   Ribeiro JMC, 2001, J PARASITOL, V87, P915, DOI 10.1645/0022-3395(2001)087[0915:TSAACO]2.0.CO;2
   Sharma G, 2006, J DRUG TARGET, V14, P301, DOI 10.1080/10611860600809112
   Silva F, 2005, AM J TROP MED HYG, V72, P94, DOI 10.4269/ajtmh.2005.72.94
   THEODOS CM, 1991, INFECT IMMUN, V59, P1592, DOI 10.1128/IAI.59.5.1592-1598.1991
   TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436
   Valenzuela JG, 2001, J EXP MED, V194, P331, DOI 10.1084/jem.194.3.331
   Yarali N, 2002, AM J HEMATOL, V71, P191, DOI 10.1002/ajh.10200
NR 34
TC 23
Z9 24
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PD DEC
PY 2011
VL 120
IS 3
BP 185
EP 190
DI 10.1016/j.actatropica.2011.08.007
PG 6
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 853LS
UT WOS:000297428400006
PM 21875567
OA Green Accepted, Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Tavares, NM
   Silva, RA
   Costa, DJ
   Pitombo, MA
   Fukutani, KF
   Miranda, JC
   Valenzuela, JG
   Barral, A
   de Oliveira, CI
   Barral-Netto, M
   Brodskyn, C
AF Tavares, Natalia M.
   Silva, Robson A.
   Costa, Dirceu J.
   Pitombo, Maiana A.
   Fukutani, Kiyoshi F.
   Miranda, Jose C.
   Valenzuela, Jesus G.
   Barral, Aldina
   de Oliveira, Camila I.
   Barral-Netto, Manoel
   Brodskyn, Claudia
TI Lutzomyia longipalpis Saliva or Salivary Protein LJM19 Protects against
   Leishmania braziliensis and the Saliva of Its Vector, Lutzomyia
   intermedia
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID CUTANEOUS LEISHMANIASIS; IMMUNE-RESPONSE; MODEL; IDENTIFICATION;
   EXPRESSION; MICE
AB Background: Leishmania transmission occurs in the presence of insect saliva. Immunity to Phlebotomus papatasi or Lutzomyia longipalpis saliva or salivary components confers protection against an infection by Leishmania in the presence of the homologous saliva. However, immunization with Lutzomyia intermedia saliva did not protect mice against Leishmania braziliensis plus Lu. intermedia saliva. In the present study, we have studied whether the immunization with Lu. longipalpis saliva or a DNA plasmid coding for LJM19 salivary protein would be protective against L. braziliensis infection in the presence of Lu. intermedia saliva, the natural vector for L. braziliensis.
   Methodology/Principal Findings: Immunization with Lu. longipalpis saliva or with LJM19 DNA plasmid induced a Delayed-Type Hypersensitivity (DTH) response against Lu. longipalpis as well as against a Lu. intermedia saliva challenge. Immunized and unimmunized control hamsters were then intradermally infected in the ears with L. braziliensis in the presence of Lu. longipalpis or Lu. intermedia saliva. Animals immunized with Lu. longipalpis saliva exhibited smaller lesion sizes as well as reduced disease burdens both at lesion site and in the draining lymph nodes. These alterations were associated with a significant decrease in the expression levels of IL-10 and TGF-beta. Animals immunized with LJM19 DNA plasmid presented similar findings in protection and immune response and additionally increased IFN-gamma expression.
   Conclusions/Significance: Immunization with Lu. longipalpis saliva or with a DNA plasmid coding LJM19 salivary protein induced protection in hamsters challenged with L. braziliensis plus Lu. intermedia saliva. These findings point out an important role of immune response against saliva components, suggesting the possibility to develop a vaccine using a single component of Lu. longipalpis saliva to generate protection against different species of Leishmania, even those transmitted by a different vector.
C1 [Tavares, Natalia M.; Costa, Dirceu J.; Pitombo, Maiana A.; Fukutani, Kiyoshi F.; Miranda, Jose C.; Barral, Aldina; de Oliveira, Camila I.; Barral-Netto, Manoel; Brodskyn, Claudia] Fiocruz MS, Ctr Pesquisa Goncalo Moniz, Salvador, BA, Brazil.
   [Silva, Robson A.] Univ Fed Bahia, Inst Multidisciplinar Saude, Vitoria Da Conquista, BA, Brazil.
   [Valenzuela, Jesus G.] NIAID, Vector Mol Biol Unit, Lab Malaria & Vector Res, NIH, Rockville, MD USA.
   [Barral, Aldina; de Oliveira, Camila I.; Barral-Netto, Manoel; Brodskyn, Claudia] Inst Invest Imunol, Sao Paulo, Brazil.
RP Tavares, NM (corresponding author), Fiocruz MS, Ctr Pesquisa Goncalo Moniz, Salvador, BA, Brazil.
EM brodskyn@bahia.fiocruz.br
RI Barral-Netto, Manoel/B-3904-2009; Silva, Robson A A/N-8801-2018; de
   Oliveira, Camila I/B-4358-2009; Tavares, Natalia/AAQ-1527-2020;
   Fukutani, Kiyoshi/N-7905-2016; Fukutani, Kiyoshi/T-1630-2019
OI Barral-Netto, Manoel/0000-0002-5823-7903; de Oliveira, Camila
   I/0000-0002-7868-5164; Fukutani, Kiyoshi/0000-0003-2223-0918; Machado
   Tavares, Natalia/0000-0002-4026-679X
FU FAPESB; Renorbio [554753/2006-5]; CNPqNational Council for Scientific
   and Technological Development (CNPq) [472973/2006-1]; NATIONAL INSTITUTE
   OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [ZIAAI000932,
   ZIAAI000932, ZIAAI000932, ZIAAI000932, ZIAAI000932, ZIAAI000932,
   ZIAAI000932, ZIAAI000932, ZIAAI000932, ZIAAI000932] Funding Source: NIH
   RePORTER
FX This work was supported by FAPESB, Renorbio (554753/2006-5) and CNPq
   (472973/2006-1). AB, CIO, MB-N and CB are senior investigators from
   CNPq. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Andrade BB, 2007, SCAND J IMMUNOL, V66, P122, DOI 10.1111/j.1365-3083.2007.01964.x
   Araujo-Santos T, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000873
   Belkaid Y, 1998, J EXP MED, V188, P1941, DOI 10.1084/jem.188.10.1941
   BITTENCOURT AL, 1991, MEM I OSWALDO CRUZ, V86, P51, DOI 10.1590/S0074-02761991000100009
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Collin N, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000441
   Costa DJ, 2004, INFECT IMMUN, V72, P1298, DOI 10.1128/IAI.72.3.1298-1305.2004
   de Moura TR, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000084
   de Moura TR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000712
   de Oliveira CI, 2004, MICROBES INFECT, V6, P977, DOI 10.1016/j.micinf.2004.05.009
   Gomes R, 2008, P NATL ACAD SCI USA, V105, P7845, DOI 10.1073/pnas.0712153105
   HERRER A, 1979, EXP PARASITOL, V48, P359, DOI 10.1016/0014-4894(79)90120-6
   Kamhawi S, 2000, SCIENCE, V290, P1351, DOI 10.1126/science.290.5495.1351
   LABUDA M, 1993, MED VET ENTOMOL, V7, P193, DOI 10.1111/j.1365-2915.1993.tb00674.x
   Lima HC, 1996, INFECT IMMUN, V64, P5442, DOI 10.1128/IAI.64.12.5442-5445.1996
   Melby PC, 2001, EXP PARASITOL, V99, P17, DOI 10.1006/expr.2001.4640
   Oliveira F, 2006, VACCINE, V24, P374, DOI 10.1016/j.vaccine.2005.07.085
   Ribeiro JMC, 2001, J EXP BIOL, V204, P2001
   Teixeira MJ, 2005, INFECT IMMUN, V73, P1191, DOI 10.1128/IAI.73.2.1191-1195.2005
   Thiakaki M, 2005, MICROBES INFECT, V7, P760, DOI 10.1016/j.micinf.2005.01.013
   TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436
   TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x
   Valenzuela JG, 2004, J EXP BIOL, V207, P3717, DOI 10.1242/jeb.01185
   Valenzuela JG, 2001, J EXP MED, V194, P331, DOI 10.1084/jem.194.3.331
   WILSON HR, 1979, EXP PARASITOL, V47, P270, DOI 10.1016/0014-4894(79)90079-1
NR 25
TC 44
Z9 45
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD MAY
PY 2011
VL 5
IS 5
AR e1169
DI 10.1371/journal.pntd.0001169
PG 11
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 770OZ
UT WOS:000291099100037
PM 21655303
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Khouri, R
   Novais, F
   Santana, G
   de Oliveira, CI
   dos Santos, MAV
   Barral, A
   Barral-Netto, M
   Van Weyenbergh, J
AF Khouri, Ricardo
   Novais, Fernanda
   Santana, Giselia
   de Oliveira, Camila Indiani
   Vannier dos Santos, Marcos Andre
   Barral, Aldina
   Barral-Netto, Manoel
   Van Weyenbergh, Johan
TI DETC Induces Leishmania Parasite Killing in Human In Vitro and Murine In
   Vivo Models: A Promising Therapeutic Alternative in Leishmaniasis
SO PLOS ONE
LA English
DT Article
ID DIFFUSE CUTANEOUS LEISHMANIASIS; NITRIC-OXIDE SYNTHASE;
   ACETYL-L-CYSTEINE; FACTOR-KAPPA-B; SUPEROXIDE-DISMUTASE;
   IMMUNE-RESPONSE; MAJOR INFECTION; BALB/C MICE; DIETHYLDITHIOCARBAMATE;
   SURVIVAL
AB Background: Chemotherapy remains the primary tool for treatment and control of human leishmaniasis. However, currently available drugs present serious problems regarding side-effects, variable efficacy, and cost. Affordable and less toxic drugs are urgently needed for leishmaniasis.
   Methodology/Principal Findings: We demonstrate, by microscopy and viability assays, that superoxide dismutase inhibitor diethyldithiocarbamate (DETC) dose-dependently induces parasite killing (p<0.001) and is able to "sterilize'' Leishmania amazonensis infection at 2 mM in human macrophages in vitro. We also show that DETC-induced superoxide production (p < 0.001) and parasite destruction (p < 0.05) were reverted by the addition of the antioxidant N-acetylcysteine, indicating that DETC-induced killing occurs through oxidative damage. Furthermore, ultrastructural analysis by electron microscopy demonstrates a rapid and highly selective destruction of amastigotes in the phagosome upon DETC treatment, without any apparent damage to the host cell, including its mitochondria. In addition, DETC significantly induced parasite killing in Leishmania promastigotes in axenic culture. In murine macrophages infected with Leishmania braziliensis, DETC significantly induced in vitro superoxide production (p = 0.0049) and parasite killing (p = 0.0043). In vivo treatment with DETC in BALB/C mice infected with Leishmania braziliensis caused a significant decrease in lesion size (p<0.0001), paralleled by a 100-fold decrease (p = 0.0087) in parasite burden.
   Conclusions/Significance: Due to its strong leishmanicidal effect in human macrophages in vitro, its in vivo effectiveness in a murine model, and its previously demonstrated in vivo safety profile in HIV treatment, DETC treatment might be considered as a valuable therapeutic option in human leishmaniasis, including HIV/Leishmania co-infection.
C1 [Khouri, Ricardo; Novais, Fernanda; Santana, Giselia; de Oliveira, Camila Indiani; Vannier dos Santos, Marcos Andre; Barral, Aldina; Barral-Netto, Manoel; Van Weyenbergh, Johan] Fundacao Oswaldo Cruz FIOCRUZ, LIMI, Ctr Pesquisa Goncalo Moniz, LIP,LBP, Salvador, BA, Brazil.
   [Barral, Aldina; Barral-Netto, Manoel; Van Weyenbergh, Johan] INCT, Inst Invest Immunol, Sao Paulo, Brazil.
RP Khouri, R (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, LIMI, Ctr Pesquisa Goncalo Moniz, LIP,LBP, Salvador, BA, Brazil.
EM johan@bahia.fiocruz.br
RI Vannier-Santos, Marcos A/L-3649-2013; Khouri, Ricardo/M-3184-2018;
   Vannier-Santos, Marcos/G-5517-2012; Barral-Netto, Manoel/B-3904-2009;
   Barral, Aldina/B-4191-2009; Van Weyenbergh, Johan/B-4187-2009; de
   Oliveira, Camila I/B-4358-2009; Van Weyenbergh, Johan/Q-3829-2019
OI Khouri, Ricardo/0000-0001-5664-4436; Barral-Netto,
   Manoel/0000-0002-5823-7903; Barral, Aldina/0000-0002-7177-464X; Van
   Weyenbergh, Johan/0000-0003-3234-8426; de Oliveira, Camila
   I/0000-0002-7868-5164; Van Weyenbergh, Johan/0000-0003-3234-8426;
   Vannier-Santos, Marcos/0000-0001-9241-2261
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES; European UnionEuropean Union (EU) [E06D103200BR]
FX This work was supported by CNPq (AB and MBN are CNPq senior
   investigators), CAPES and Alban Program, European Union Program of High
   Level Scholarship for Latin America, scholarship no. E06D103200BR. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Amato VS, 2007, AM J TROP MED HYG, V77, P266, DOI 10.4269/ajtmh.2007.77.266
   BARRAL A, 1995, INT J DERMATOL, V34, P474, DOI 10.1111/j.1365-4362.1995.tb00613.x
   Blos M, 2003, EUR J IMMUNOL, V33, P1224, DOI 10.1002/eji.200323825
   COCCO D, 1981, J BIOL CHEM, V256, P8983
   Cruz KK, 2008, PARASITE IMMUNOL, V30, P171, DOI 10.1111/j.1365-3024.2007.01014.x
   Cvek B, 2007, CURR PHARM DESIGN, V13, P3155, DOI 10.2174/138161207782110390
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004
   Desjeux P, 2004, NAT REV MICROBIOL, V2, P692, DOI 10.1038/nrmicro981
   ELSTNER EF, 1976, ANAL BIOCHEM, V70, P616, DOI 10.1016/0003-2697(76)90488-7
   Gantt KR, 2001, J IMMUNOL, V167, P893, DOI 10.4049/jimmunol.167.2.893
   Getachew F, 2007, MOL BIOCHEM PARASIT, V154, P62, DOI 10.1016/j.molbiopara.2007.04.007
   Ghosh S, 2003, BIOCHEM J, V369, P447, DOI 10.1042/BJ20021684
   Hothersall JS, 1997, BIOCHEM J, V322, P477, DOI 10.1042/bj3220477
   HUBNER L, 1991, INT J IMMUNOPHARMACO, V13, P1067, DOI 10.1016/0192-0561(91)90157-3
   Khouri R, 2009, J IMMUNOL, V182, P2525, DOI 10.4049/jimmunol.0802860
   Liese J, 2008, IMMUNOBIOLOGY, V213, P377, DOI 10.1016/j.imbio.2007.12.005
   Llanos-Cuentas A, 2008, CLIN INFECT DIS, V46, P223, DOI 10.1086/524042
   Marikovsky M, 2003, J IMMUNOL, V170, P2993, DOI 10.4049/jimmunol.170.6.2993
   Menezes D, 2006, PARASITOL RES, V98, P99, DOI 10.1007/s00436-005-0010-1
   Mikoyan VD, 1997, BBA-GEN SUBJECTS, V1336, P225, DOI 10.1016/S0304-4165(97)00032-9
   Miranda KM, 2001, NITRIC OXIDE-BIOL CH, V5, P62, DOI 10.1006/niox.2000.0319
   Modabber Farrokh, 2007, Kinetoplastid Biol Dis, V6, P3, DOI 10.1186/1475-9292-6-3
   Monteiro MC, 2008, PARASITOL RES, V102, P801, DOI 10.1007/s00436-007-0827-x
   Murray HW, 2005, LANCET, V366, P1561, DOI 10.1016/S0140-6736(05)67629-5
   Murray HW, 1999, J EXP MED, V189, P741, DOI 10.1084/jem.189.4.741
   Novais FO, 2009, J IMMUNOL, V183, P8088, DOI 10.4049/jimmunol.0803720
   Obminska-Mrukowicz Bozena, 2005, J Vet Sci, V6, P25
   REISINGER EC, 1990, LANCET, V335, P679, DOI 10.1016/0140-6736(90)90802-C
   Reithinger R, 2007, LANCET INFECT DIS, V7, P581, DOI 10.1016/S1473-3099(07)70209-8
   Rocha-Vieira E, 2003, IMMUNOLOGY, V108, P401, DOI 10.1046/j.1365-2567.2003.01582.x
   SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181
   TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x
   Tuon FF, 2008, INT J DERMATOL, V47, P109, DOI 10.1111/j.1365-4632.2008.03417.x
   Vannier-Santos MA, 2009, CURR DRUG TARGETS, V10, P246, DOI 10.2174/138945009787581168
   Vannier-Santos MA, 1999, MICROBIOL-UK, V145, P3213, DOI 10.1099/00221287-145-11-3213
   Vannier-Santos MA, 2008, MICROBIOL-SGM, V154, P3104, DOI 10.1099/mic.0.2007/013896-0
   Vannier-Santos Marcos A., 2001, Biological Procedures Online, V3, P8, DOI 10.1251/bpo19
   Zerpa O, 2007, BRIT J DERMATOL, V156, P1328, DOI 10.1111/j.1365-2133.2007.07872.x
   Zhang K, 2005, MOL MICROBIOL, V55, P1566, DOI 10.1111/j.1365-2958.2005.04493.x
NR 40
TC 20
Z9 22
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 21
PY 2010
VL 5
IS 12
AR e14394
DI 10.1371/journal.pone.0014394
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 698EY
UT WOS:000285576900009
PM 21200432
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Campanelli, AP
   Brodskyn, CI
   Boaventura, V
   Silva, C
   Roselino, AM
   Costa, J
   Saldanha, AC
   de Freitas, LAR
   de Oliveira, CI
   Barral-Netto, M
   Silva, JS
   Barral, A
AF Campanelli, Ana P.
   Brodskyn, Claudia I.
   Boaventura, Viviane
   Silva, Claire
   Roselino, Ana M.
   Costa, Jackson
   Saldanha, Ana Cristina
   Rodrigues de Freitas, Luiz Antonio
   de Oliveira, Camila Indiani
   Barral-Netto, Manoel
   Silva, Joao S.
   Barral, Aldina
TI Chemokines and chemokine receptors coordinate the inflammatory immune
   response in human cutaneous leishmaniasis
SO HUMAN IMMUNOLOGY
LA English
DT Article
DE Chemokines; Cutaneous leishmaniasis; Inflammation
ID DIFFERENTIAL EXPRESSION; T-CELLS; CYTOKINES; RESPONSIVENESS;
   RECRUITMENT; MACROPHAGES; MATURATION; PATTERNS; LESIONS
AB Cutaneous leishmaniasis (CL) includes different clinical manifestations displaying diverse intensities of dermal Inflammatory infiltrate Diffuse CL (DCL) cases are hyporesponsive and lesions show very few lymphocytes and a predominance of macrophages In contrast localized CL (LCL) cases are responsive to leishmanial antigen and lesions exhibit granulocytes and mononuclear cell infiltration in the early phases changing to a pattern with numerous lymphocytes and macrophages later in the lesion Therefore different chemokines may affect the predominance of cell infiltration in distinct clinical manifestations In lesions from LCL patients we examined by flow cytometry the presence of different chemokines and their receptors in T cells and we verified a higher expression of CXCR3 in the early stages of LCL (less than 30 days of infection) and a higher expression of CCR4 in the late stages of disease (more than 60 days of infection) We also observed a higher frequency of T cells producing IL-10 in the late stage of LCL Using immunohistochemistry we observed a higher expression of CCL7 CCL17 in lesions from late LCL as well as CCR4 suggesting a preferential recruitment of regulatory T cells in the late LCL Comparing lesions from LCL and DCL patients we observed a higher frequency of CCL7 in DCL lesions These results point out the Importance of the chemokines defining the different types of cells recruited to the site of the infection which could be related to the outcome of infection as well as the clinical form observed (C) 2010 American Society for Histocompatibility and Immunogenetics Published by Elsevier Inc All rights reserved
C1 [Brodskyn, Claudia I.; Boaventura, Viviane; Silva, Claire; Costa, Jackson; Saldanha, Ana Cristina; Rodrigues de Freitas, Luiz Antonio; de Oliveira, Camila Indiani; Barral-Netto, Manoel; Barral, Aldina] FIOCRUZ BA, Ctr Pesquisa Goncalo Moniz, Salvador, BA, Brazil.
   [Campanelli, Ana P.; Silva, Joao S.] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Biochem & Immunol, BR-05508 Sao Paulo, Brazil.
   [Roselino, Ana M.] Univ Sao Paulo, Sch Med Ribeirao Preto, Div Dermatol, BR-05508 Sao Paulo, Brazil.
   [Campanelli, Ana P.] Univ Sao Paulo, Dept Biol Sci, Bauru Dent Sch, BR-05508 Sao Paulo, Brazil.
   [Brodskyn, Claudia I.; Barral-Netto, Manoel; Barral, Aldina] Univ Fed Bahia, Salvador, BA, Brazil.
   [Brodskyn, Claudia I.; Barral-Netto, Manoel; Barral, Aldina] INCT, Inst Invest Imunol, Sao Paulo, Brazil.
RP Brodskyn, CI (corresponding author), FIOCRUZ BA, Ctr Pesquisa Goncalo Moniz, Salvador, BA, Brazil.
RI Boaventura, Viviane S/H-9165-2015; de Oliveira, Camila I/B-4358-2009;
   Roselino, Ana M. F./F-7487-2010; Barral-Netto, Manoel/B-3904-2009;
   Campanelli, Ana Paula/B-9144-2012; Barral, Aldina/B-4191-2009; Silva,
   Joao S/A-4484-2008
OI de Oliveira, Camila I/0000-0002-7868-5164; Roselino, Ana M.
   F./0000-0002-2709-1825; Barral-Netto, Manoel/0000-0002-5823-7903;
   Barral, Aldina/0000-0002-7177-464X; Silva, Joao S/0000-0002-3410-3927;
   Campanelli, Ana Paula/0000-0002-0536-5469
FU Conselho Nacional de Pesquisa (CNPq)National Council for Scientific and
   Technological Development (CNPq); FAPESB; FAPESPFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP)
FX We thank the patients for donation of tissue and blood samples and
   Alexandra V R Dias for expertise with flow cytometry This work was
   supported in part by Conselho Nacional de Pesquisa (CNPq) and FAPESB A B
   J C CB MB-N L A R F and J S S are CNPq Senior Investigators A PC
   received a scholarship from FAPESP
CR Aliberti JCS, 1999, INFECT IMMUN, V67, P4819, DOI 10.1128/IAI.67.9.4819-4826.1999
   BARRAL A, 1995, INT J DERMATOL, V34, P474, DOI 10.1111/j.1365-4362.1995.tb00613.x
   Bomfim G, 1996, EXP PARASITOL, V84, P188, DOI 10.1006/expr.1996.0104
   Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129
   Brodskyn Claudia, 2003, Expert Rev Vaccines, V2, P705, DOI 10.1586/14760584.2.5.705
   Campanelli AP, 2006, J INFECT DIS, V193, P1313, DOI 10.1086/502980
   Conrad SM, 2007, INFECT IMMUN, V75, P653, DOI 10.1128/IAI.01314-06
   Costa JML, 2009, GMBAHIA, V79, P19
   Diaz NL, 2002, EXP DERMATOL, V11, P34, DOI 10.1034/j.1600-0625.2002.110104.x
   Faria DR, 2009, PARASITE IMMUNOL, V31, P432, DOI 10.1111/j.1365-3024.2009.01125.x
   Forster R, 2008, NAT REV IMMUNOL, V8, P362, DOI 10.1038/nri2297
   Ha HJ, 2002, J AM SOC NEPHROL, V13
   Katzman SD, 2008, J CLIN INVEST, V118, P801, DOI 10.1172/JCI33174
   Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706
   Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298
   Menten P, 2001, EUR CYTOKINE NETW, V12, P554
   Oo YH, 2010, J IMMUNOL, V184, P2886, DOI 10.4049/jimmunol.0901216
   PIRMEZ C, 1990, J IMMUNOL, V145, P3100
   Ritter U, 2002, PARASITE IMMUNOL, V24, P295, DOI 10.1046/j.1365-3024.2002.00467.x
   Ritter U, 1996, J INFECT DIS, V173, P699, DOI 10.1093/infdis/173.3.699
   Romagnani S, 2002, MOL IMMUNOL, V38, P881, DOI 10.1016/S0161-5890(02)00013-5
   Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N
   TAN JQ, 1995, J IMMUNOL, V154, P3742
   Teixeira MJ, 2006, TRENDS PARASITOL, V22, P32, DOI 10.1016/j.pt.2005.11.010
   Teixeira MJ, 2005, INFECT IMMUN, V73, P1191, DOI 10.1128/IAI.73.2.1191-1195.2005
   Yanagihara S, 1998, J IMMUNOL, V161, P3096
   Zou WP, 2000, J IMMUNOL, V165, P4388, DOI 10.4049/jimmunol.165.8.4388
NR 27
TC 21
Z9 22
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0198-8859
EI 1879-1166
J9 HUM IMMUNOL
JI Hum. Immunol.
PD DEC
PY 2010
VL 71
IS 12
BP 1220
EP 1227
DI 10.1016/j.humimm.2010.09.002
PG 8
WC Immunology
SC Immunology
GA 684NL
UT WOS:000284556500010
PM 20854864
OA Green Published
DA 2020-12-08
ER

PT J
AU de Moura, TR
   Oliveira, F
   Rodrigues, GC
   Carneiro, MW
   Fukutani, KF
   Novais, FO
   Miranda, JC
   Barral-Netto, M
   Brodskyn, C
   Barral, A
   de Oliveira, CI
AF de Moura, Tatiana R.
   Oliveira, Fabiano
   Rodrigues, Gabriele C.
   Carneiro, Marcia W.
   Fukutani, Kiyoshi F.
   Novais, Fernanda O.
   Miranda, Jose Carlos
   Barral-Netto, Manoel
   Brodskyn, Claudia
   Barral, Aldina
   de Oliveira, Camila I.
TI Immunity to Lutzomyia intermedia Saliva Modulates the Inflammatory
   Environment Induced by Leishmania braziliensis
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID PAPATASI SAND FLY; CUTANEOUS LEISHMANIASIS; NEUTROPHIL MIGRATION; MAJOR
   INFECTION; HUMAN MONOCYTES; VECTOR SALIVA; NATURAL MODEL; IN-VIVO;
   EXPRESSION; MICE
AB Background: During blood feeding, sand flies inject Leishmania parasites in the presence of saliva. The types and functions of cells present at the first host-parasite contact are critical to the outcome on infection and sand fly saliva has been shown to play an important role in this setting. Herein, we investigated the in vivo chemotactic effects of Lutzomyia intermedia saliva, the vector of Leishmania braziliensis, combined or not with the parasite.
   Methods and Findings: We tested the initial response induced by Lutzomyia intermedia salivary gland sonicate (SGS) in BALB/c mice employing the air pouch model of inflammation. L. intermedia SGS induced a rapid influx of macrophages and neutrophils. In mice that were pre-sensitized with L. intermedia saliva, injection of SGS was associated with increased neutrophil recruitment and a significant up-regulation of CXCL1, CCL2, CCL4 and TNF-alpha expression. Surprisingly, in mice that were pre-exposed to SGS, a combination of SGS and L. braziliensis induced a significant migration of neutrophils and an important modulation in cytokine and chemokine expression as shown by decreased CXCL10 expression and increased IL-10 expression.
   Conclusion: These results confirm that sand fly saliva modulates the initial host response. More importantly, pre-exposure to L. intermedia saliva significantly modifies the host's response to L. braziliensis, in terms of cellular recruitment and expression of cytokines and chemokines. This particular immune modulation may, in turn, favor parasite multiplication.
C1 [de Moura, Tatiana R.; Rodrigues, Gabriele C.; Carneiro, Marcia W.; Fukutani, Kiyoshi F.; Novais, Fernanda O.; Miranda, Jose Carlos; Barral-Netto, Manoel; Brodskyn, Claudia; Barral, Aldina; de Oliveira, Camila I.] Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [Oliveira, Fabiano] NIAID, Vector Mol Biol Unit, NIH, Bethesda, MD 20892 USA.
   [Barral-Netto, Manoel; Brodskyn, Claudia; Barral, Aldina] Univ Fed Bahia, Salvador, BA, Brazil.
   [Barral-Netto, Manoel; Brodskyn, Claudia; Barral, Aldina; de Oliveira, Camila I.] Inst Nacl Ciencia & Tecnol Invest Imunol, Sao Paulo, Brazil.
RP de Moura, TR (corresponding author), Univ Fed Sergipe, Ctr Ciencias Biol & Saude, Aracaju, Brazil.
EM camila@bahia.fiocruz.br
RI Fukutani, Kiyoshi/N-7905-2016; Oliveira, Fabiano/AAG-5388-2019;
   Fukutani, Kiyoshi/T-1630-2019; Barral-Netto, Manoel/B-3904-2009; de
   Oliveira, Camila I/B-4358-2009; Barral, Aldina/B-4191-2009; ,
   Tatiana/AAN-1194-2020
OI Fukutani, Kiyoshi/0000-0003-2223-0918; Oliveira,
   Fabiano/0000-0002-7924-8038; Barral-Netto, Manoel/0000-0002-5823-7903;
   de Oliveira, Camila I/0000-0002-7868-5164; Barral,
   Aldina/0000-0002-7177-464X; , Tatiana/0000-0002-7442-4434; Weber
   Carneiro, Marcia/0000-0002-4220-5085
FU FAPESB; PAPES/FIOCRUZ; CNPqNational Council for Scientific and
   Technological Development (CNPq)
FX This work was supported by grants from FAPESB, PAPES/FIOCRUZ, and CNPq.
   TRdM was supported by a CNPq fellowship. MB-N, CB, AB, and CIdO are
   senior investigators from CNPq. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Aga E, 2002, J IMMUNOL, V169, P898, DOI 10.4049/jimmunol.169.2.898
   Andrade BB, 2007, SCAND J IMMUNOL, V66, P122, DOI 10.1111/j.1365-3083.2007.01964.x
   ANJILI CO, 1995, ACTA TROP, V60, P97, DOI 10.1016/0001-706X(95)00112-R
   Belkaid Y, 2000, P NATL ACAD SCI USA, V97, P6704, DOI 10.1073/pnas.97.12.6704
   Belkaid Y, 1998, J EXP MED, V188, P1941, DOI 10.1084/jem.188.10.1941
   Belkaid Y, 2000, J IMMUNOL, V165, P969, DOI 10.4049/jimmunol.165.2.969
   Belkaid Y, 2001, J EXP MED, V194, P1497, DOI 10.1084/jem.194.10.1497
   BOZIC CR, 1995, J IMMUNOL, V154, P6048
   Canetti C, 2001, BRIT J PHARMACOL, V134, P1619, DOI 10.1038/sj.bjp.0704403
   Cerna P, 2002, INSECT BIOCHEM MOLEC, V32, P1691, DOI 10.1016/S0965-1748(02)00109-1
   Costa DJ, 2004, INFECT IMMUN, V72, P1298, DOI 10.1128/IAI.72.3.1298-1305.2004
   de Moura TR, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000084
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   Dufour JH, 2002, J IMMUNOL, V168, P3195, DOI 10.4049/jimmunol.168.7.3195
   Gomes R, 2008, P NATL ACAD SCI USA, V105, P7845, DOI 10.1073/pnas.0712153105
   Kamhawi S, 2000, SCIENCE, V290, P1351, DOI 10.1126/science.290.5495.1351
   Kane MM, 2001, J IMMUNOL, V166, P1141, DOI 10.4049/jimmunol.166.2.1141
   KLEIN A, 1995, IMMUNOLOGY, V84, P577
   Kobayashi Y, 2008, FRONT BIOSCI-LANDMRK, V13, P2400, DOI 10.2741/2853
   Lainson R, 2005, TOPLEY WILSONS MICRO, P313
   Lima HC, 1996, INFECT IMMUN, V64, P5442, DOI 10.1128/IAI.64.12.5442-5445.1996
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Matte C, 2002, J INFECT DIS, V185, P673, DOI 10.1086/339260
   Menezes MJ, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-12
   Monteiro MC, 2007, AM J TROP MED HYG, V76, P88, DOI 10.4269/ajtmh.2007.76.88
   Muller K, 2001, MED MICROBIOL IMMUN, V190, P73
   NOVAIS FO, 2009, J IMMUNOL
   Oliveira F, 2006, VACCINE, V24, P374, DOI 10.1016/j.vaccine.2005.07.085
   Peters NC, 2008, SCIENCE, V321, P970, DOI 10.1126/science.1159194
   Ramos CDL, 2005, J LEUKOCYTE BIOL, V78, P167, DOI 10.1189/jlb.0404237
   Rangel EF, 2003, FLEBOTOMINEOS BRASIL, P291
   REICHEL CA, 2009, ARTERIOSCLER THROMB
   RIBEIRO JMC, 1995, INFECT AGENT DIS, V4, P143
   Rogers KA, 2003, PARASITE IMMUNOL, V25, P127, DOI 10.1046/j.1365-3024.2003.00623.x
   Rogers M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000555
   Rogers ME, 2004, NATURE, V430, P463, DOI 10.1038/nature02675
   Rohousova I, 2005, PARASITOLOGY, V130, P493, DOI 10.1017/S003118200400681X
   Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933
   SAMUELSON J, 1991, J EXP MED, V173, P49, DOI 10.1084/jem.173.1.49
   Schrum S, 1996, J IMMUNOL, V157, P3598
   Silva F, 2005, AM J TROP MED HYG, V72, P94, DOI 10.4269/ajtmh.2005.72.94
   Teixeira CR, 2005, J IMMUNOL, V175, P8346, DOI 10.4049/jimmunol.175.12.8346
   Teixeira MJ, 2005, INFECT IMMUN, V73, P1191, DOI 10.1128/IAI.73.2.1191-1195.2005
   THEODOS CM, 1991, INFECT IMMUN, V59, P1592, DOI 10.1128/IAI.59.5.1592-1598.1991
   Thiakaki M, 2005, MICROBES INFECT, V7, P760, DOI 10.1016/j.micinf.2005.01.013
   TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436
   Titus RG, 1998, EXP PARASITOL, V89, P133, DOI 10.1006/expr.1998.4272
   Valenzuela JG, 2001, J EXP MED, V194, P331, DOI 10.1084/jem.194.3.331
   van Zandbergen G, 2004, J IMMUNOL, V173, P6521, DOI 10.4049/jimmunol.173.11.6521
   VARGASINCHAUSTE.DA, 2009, CXCL10 PRODUCTION HU
   Volfova V, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000294
   WARBURG A, 1994, PHILOS T R SOC B, V345, P223, DOI 10.1098/rstb.1994.0097
   YOSHINO S, 1985, AM J PATHOL, V121, P327
NR 53
TC 37
Z9 37
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUN
PY 2010
VL 4
IS 6
AR e712
DI 10.1371/journal.pntd.0000712
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 618HD
UT WOS:000279341300020
PM 20559550
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Brodskyn, C
   Afonso, L
   Khoury, R
   Santos, T
   Clarencio, J
   de Oliveira, C
   Barral, A
   Barral-Netto, M
   Borges, V
AF Brodskyn, Claudia
   Afonso, Lilian
   Khoury, Ricardo
   Santos, Theo
   Clarencio, Jorge
   de Oliveira, Camila
   Barral, Aldina
   Barral-Netto, Manoel
   Borges, Valeria
TI Activated human neutrophil control macrophage infection by L-amazonensis
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [Brodskyn, Claudia; Afonso, Lilian; Khoury, Ricardo; Santos, Theo; Clarencio, Jorge; de Oliveira, Camila; Barral, Aldina; Barral-Netto, Manoel; Borges, Valeria] FIOCRUZ BA, Ctr Pesquisa Goncalo Moniz, Lab Immunoregulatioj, Salvador, BA, Brazil.
   [Brodskyn, Claudia; Barral, Aldina; Barral-Netto, Manoel] Univ Fed Bahia, Salvador, BA, Brazil.
RI Borges, Valeria/G-2009-2014; de Oliveira, Camila I/B-4358-2009
OI de Oliveira, Camila I/0000-0002-7868-5164
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD APR 1
PY 2010
VL 184
SU 1
MA 37.14
PG 1
WC Immunology
SC Immunology
GA V44OM
UT WOS:000209758300104
DA 2020-12-08
ER

PT J
AU de Oliveira, C
   Novais, F
   Santiago, R
   Brodskyn, C
   Barral-Netto, M
   Barral, A
AF de Oliveira, Camila
   Novais, Fernanda
   Santiago, Romulo
   Brodskyn, Claudia
   Barral-Netto, Manoel
   Barral, Aldina
TI The role of CD8+T cells in cutaneous leishmaniasis caused by Leishmania
   braziliensis
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [de Oliveira, Camila; Novais, Fernanda; Santiago, Romulo; Brodskyn, Claudia; Barral-Netto, Manoel; Barral, Aldina] CPqGM FlOCRUZ, Salvador, BA, Brazil.
   [de Oliveira, Camila; Brodskyn, Claudia; Barral-Netto, Manoel; Barral, Aldina] INCT, Sao Paulo, Brazil.
RI de Oliveira, Camila I/B-4358-2009
OI de Oliveira, Camila I/0000-0002-7868-5164
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD APR 1
PY 2010
VL 184
SU 1
MA 40.9
PG 1
WC Immunology
SC Immunology
GA V44OM
UT WOS:000209758300206
DA 2020-12-08
ER

PT J
AU Souza, AP
   Andrade, BB
   Aquino, D
   Entringer, P
   Miranda, JC
   Alcantara, R
   Ruiz, D
   Soto, M
   Teixeira, CR
   Valenzuela, JG
   de Oliveira, CI
   Brodskyn, CI
   Barral-Netto, M
   Barral, A
AF Souza, Ana Paula
   Andrade, Bruno Bezerril
   Aquino, Dorlene
   Entringer, Petter
   Miranda, Jose Carlos
   Alcantara, Ruan
   Ruiz, Daniel
   Soto, Manuel
   Teixeira, Clarissa R.
   Valenzuela, Jesus G.
   de Oliveira, Camila Indiani
   Brodskyn, Claudia Ida
   Barral-Netto, Manoel
   Barral, Aldina
TI Using Recombinant Proteins from Lutzomyia longipalpis Saliva to Estimate
   Human Vector Exposure in Visceral Leishmaniasis Endemic Areas
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID PHLEBOTOMINE SANDFLIES; BRAZILIENSIS INFECTION; IMMUNE-RESPONSE;
   PSYCHODIDAE; ANTIGENS; ANTIBODY; CHAGASI; DIPTERA; GLANDS; MARKER
AB Background: Leishmania is transmitted by female sand flies and deposited together with saliva, which contains a vast repertoire of pharmacologically active molecules that contribute to the establishment of the infection. The exposure to vector saliva induces an immune response against its components that can be used as a marker of exposure to the vector. Performing large-scale serological studies to detect vector exposure has been limited by the difficulty in obtaining sand fly saliva. Here, we validate the use of two sand fly salivary recombinant proteins as markers for vector exposure.
   Methodology/principal findings: ELISA was used to screen human sera, collected in an area endemic for visceral leishmaniasis, against the salivary gland sonicate (SGS) or two recombinant proteins (rLJM11 and rLJM17) from Lutzomyia longipalpis saliva. Antibody levels before and after SGS seroconversion (n=26) were compared using the Wilcoxon signed rank paired test. Human sera from an area endemic for VL which recognize Lu. longipalpis saliva in ELISA also recognize a combination of rLJM17 and rLJM11. We then extended the analysis to include 40 sera from individuals who were seropositive and 40 seronegative to Lu. longipalpis SGS. Each recombinant protein was able to detect anti-saliva seroconversion, whereas the two proteins combined increased the detection significantly. Additionally, we evaluated the specificity of the anti-Lu. longipalpis response by testing 40 sera positive to Lutzomyia intermedia SGS, and very limited (2/40) cross-reactivity was observed. Receiver-operator characteristics (ROC) curve analysis was used to identify the effectiveness of these proteins for the prediction of anti-SGS positivity. These ROC curves evidenced the superior performance of rLJM17+rLJM11. Predicted threshold levels were confirmed for rLJM17+rLJM11 using a large panel of 1,077 serum samples.
   Conclusion: Our results show the possibility of substituting Lu. longipalpis SGS for two recombinant proteins, LJM17 and LJM11, in order to probe for vector exposure in individuals residing in endemic areas.
C1 [Souza, Ana Paula; Andrade, Bruno Bezerril; Aquino, Dorlene; Entringer, Petter; Miranda, Jose Carlos; Alcantara, Ruan; de Oliveira, Camila Indiani; Brodskyn, Claudia Ida; Barral-Netto, Manoel; Barral, Aldina] Fiocruz MS, Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [Aquino, Dorlene] Univ Fed Maranhao, Dept Enfermagem, Sao Luis, Brazil.
   [Ruiz, Daniel; Soto, Manuel] Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, Dept Biol Mol, Madrid, Spain.
   [Teixeira, Clarissa R.; Valenzuela, Jesus G.] NIAID, Vector Mol Biol Sect, Lab Malaria & Vector Res, NIH, Rockville, MD USA.
   [de Oliveira, Camila Indiani; Brodskyn, Claudia Ida; Barral-Netto, Manoel; Barral, Aldina] INCT, Inst Invest Imunol, Sao Paulo, Brazil.
RP Souza, AP (corresponding author), Fiocruz MS, Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
EM abarral@bahia.fiocruz.br
RI Barral, Aldina/B-4191-2009; Barral-Netto, Manoel/B-3904-2009; Andrade,
   Bruno/J-9111-2012; de Oliveira, Camila I/B-4358-2009; Andrade,
   Bruno/AAI-2248-2020; Alvarez, Manuel Soto/Q-5234-2018
OI Barral, Aldina/0000-0002-7177-464X; Barral-Netto,
   Manoel/0000-0002-5823-7903; Andrade, Bruno/0000-0001-6833-3811; de
   Oliveira, Camila I/0000-0002-7868-5164; Alvarez, Manuel
   Soto/0000-0001-6825-841X
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CYTED; CAPESCAPES; Renorbio/CNPqNational Council for Scientific
   and Technological Development (CNPq); Division of Intramural Research,
   National Institute of Allergy and Infectious Diseases, National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID); FIOCRUZ; FAPESB; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [ZIAAI000932, ZIAAI000932, ZIAAI000932, ZIAAI000932, ZIAAI000932,
   ZIAAI000932, ZIAAI000932, ZIAAI000932, ZIAAI000932, ZIAAI000932] Funding
   Source: NIH RePORTER
FX This work was supported by grants from CNPq, CYTED, CAPES, and
   Renorbio/CNPq. This work was partially supported by the Intramural
   Research Program of the Division of Intramural Research, National
   Institute of Allergy and Infectious Diseases, National Institutes of
   Health. BBA was supported by CNPq. APS and RA were supported by CAPES
   fellowships. PE was supported by a FIOCRUZ fellowship. DR was supported
   by a FAPESB fellowship. CIdO, CIB, MBN, and AB are senior investigators
   from CNPq. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript
CR Andrade BB, 2007, SCAND J IMMUNOL, V66, P122, DOI 10.1111/j.1365-3083.2007.01964.x
   Barral A, 2000, AM J TROP MED HYG, V62, P740, DOI 10.4269/ajtmh.2000.62.740
   BRUMMERKORVENKONTIO H, 1994, J ALLERGY CLIN IMMUN, V93, P551, DOI 10.1016/S0091-6749(94)70066-4
   de Moura TR, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000084
   Follador I, 1999, Rev Soc Bras Med Trop, V32, P497, DOI 10.1590/S0037-86821999000500005
   Follador I, 2002, CLIN INFECT DIS, V34, pE54, DOI 10.1086/340261
   Gomes RB, 2002, J INFECT DIS, V186, P1530, DOI 10.1086/344733
   MODI GB, 1983, J MED ENTOMOL, V20, P568, DOI 10.1093/jmedent/20.5.568
   Prates DB, 2008, J MED ENTOMOL, V45, P409, DOI 10.1603/0022-2585(2008)45[409:CIAOTS]2.0.CO;2
   Rebelo J M, 1999, Rev Soc Bras Med Trop, V32, P247, DOI 10.1590/S0037-86821999000300005
   Rohousova I, 2005, PARASITOLOGY, V130, P493, DOI 10.1017/S003118200400681X
   SCHWARTZ BS, 1991, AM J EPIDEMIOL, V134, P86, DOI 10.1093/oxfordjournals.aje.a115996
   Valenzuela JG, 2004, J EXP BIOL, V207, P3717, DOI 10.1242/jeb.01185
   Vinhas V, 2007, EUR J IMMUNOL, V37, P3111, DOI 10.1002/eji.200737431
   Volf P, 2001, PARASITOLOGY, V122, P37, DOI 10.1017/S0031182000007046
   Volf P, 2000, MED VET ENTOMOL, V14, P251, DOI 10.1046/j.1365-2915.2000.00240.x
   Wikel SK, 1996, ANNU REV ENTOMOL, V41, P1, DOI 10.1146/annurev.en.41.010196.000245
NR 17
TC 57
Z9 57
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1935-2727
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD MAR
PY 2010
VL 4
IS 3
AR e649
DI 10.1371/journal.pntd.0000649
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 578RG
UT WOS:000276312200015
PM 20351785
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Teixeira, C
   Gomes, R
   Collin, N
   Reynoso, D
   Jochim, R
   Oliveira, F
   Seitz, A
   Elnaiem, DE
   Caldas, A
   de Souza, AP
   Brodskyn, CI
   de Oliveira, CI
   Mendonca, I
   Costa, CHN
   Volf, P
   Barral, A
   Kamhawi, S
   Valenzuela, JG
AF Teixeira, Clarissa
   Gomes, Regis
   Collin, Nicolas
   Reynoso, David
   Jochim, Ryan
   Oliveira, Fabiano
   Seitz, Amy
   Elnaiem, Dia-Eldin
   Caldas, Arlene
   de Souza, Ana Paula
   Brodskyn, Claudia I.
   de Oliveira, Camila Indiani
   Mendonca, Ivete
   Costa, Carlos H. N.
   Volf, Petr
   Barral, Aldina
   Kamhawi, Shaden
   Valenzuela, Jesus G.
TI Discovery of Markers of Exposure Specific to Bites of Lutzomyia
   longipalpis, the Vector of Leishmania infantum chagasi in Latin America
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID CANINE VISCERAL LEISHMANIASIS; ANTITICK SALIVA ANTIBODY; SAND FLIES;
   EPIDEMIOLOGIC MARKER; IMMUNE-RESPONSE; TICK BITE; FLY; TRANSCRIPTOME;
   PROTEINS; ANTIGENS
AB Background: Sand flies deliver Leishmania parasites to a host alongside salivary molecules that affect infection outcomes. Though some proteins are immunogenic and have potential as markers of vector exposure, their identity and vector specificity remain elusive.
   Methodology/Principal Findings: We screened human, dog, and fox sera from endemic areas of visceral leishmaniasis to identify potential markers of specific exposure to saliva of Lutzomyia longipalpis. Human and dog sera were further tested against additional sand fly species. Recombinant proteins of nine transcripts encoding secreted salivary molecules of Lu. longipalpis were produced, purified, and tested for antigenicity and specificity. Use of recombinant proteins corresponding to immunogenic molecules in Lu. longipalpis saliva identified LJM17 and LJM11 as potential markers of exposure. LJM17 was recognized by human, dog, and fox sera; LJM11 by humans and dogs. Notably, LJM17 and LJM11 were specifically recognized by humans exposed to Lu. longipalpis but not by individuals exposed to Lu. intermedia.
   Conclusions/Significance: Salivary recombinant proteins are of value as markers of vector exposure. In humans, LJM17 and LJM11 emerged as potential markers of specific exposure to Lu. longipalpis, the vector of Leishmania infantum chagasi in Latin America. In dogs, LJM17, LJM11, LJL13, LJL23, and LJL143 emerged as potential markers of sand fly exposure. Testing these recombinant proteins in large scale studies will validate their usefulness as specific markers of Lu. longipalpis exposure in humans and of sand fly exposure in dogs.
C1 [Teixeira, Clarissa; Gomes, Regis; Collin, Nicolas; Reynoso, David; Jochim, Ryan; Oliveira, Fabiano; Seitz, Amy; Kamhawi, Shaden; Valenzuela, Jesus G.] NIAID, Vector Mol Biol Sect, Lab Malaria & Vector Res, NIH, Rockville, MD USA.
   [Elnaiem, Dia-Eldin] Univ Maryland Eastern Shore, Dept Nat Sci, Princess Anne, MD USA.
   [Caldas, Arlene] Univ Fed Maranhao, Sao Luis, Maranhao, Brazil.
   [de Souza, Ana Paula; Brodskyn, Claudia I.; de Oliveira, Camila Indiani; Barral, Aldina] Fiocruz MS, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [Mendonca, Ivete; Costa, Carlos H. N.] Inst Doencas Tropicais Natan Portella, Teresina, Piaui, Brazil.
   [Mendonca, Ivete; Costa, Carlos H. N.] Univ Fed Piaui, Teresina, Piaui, Brazil.
   [Volf, Petr] Charles Univ Prague, Dept Parasitol, Fac Sci, Prague, Czech Republic.
RP Teixeira, C (corresponding author), NIAID, Vector Mol Biol Sect, Lab Malaria & Vector Res, NIH, Rockville, MD USA.
EM jvalenzuela@niaid.nih.gov
RI Jochim, Ryan/C-6756-2013; Oliveira, Fabiano/B-4251-2009; Oliveira,
   Fabiano/AAG-5388-2019; Volf, Petr/C-4300-2012; de Oliveira, Camila
   I/B-4358-2009; Barral, Aldina/B-4191-2009
OI Oliveira, Fabiano/0000-0002-7924-8038; Oliveira,
   Fabiano/0000-0002-7924-8038; Volf, Petr/0000-0003-1790-1123; de
   Oliveira, Camila I/0000-0002-7868-5164; Barral,
   Aldina/0000-0002-7177-464X; Mendonca, Ivete/0000-0002-4000-4781
FU Division of Intramural Research, National Institute of Allergy and
   Infectious Diseases, US National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID);
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [ZIAAI000932, ZIAAI000932, ZIAAI000932, ZIAAI000932, ZIAAI000932,
   ZIAAI000932, ZIAAI000932, ZIAAI000932, ZIAAI000932, ZIAAI000932] Funding
   Source: NIH RePORTER
FX This work was supported by the Intramural Research Program of the
   Division of Intramural Research, National Institute of Allergy and
   Infectious Diseases, US National Institutes of Health. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Alarcon-Chaidez F, 2006, CLIN VACCINE IMMUNOL, V13, P1217, DOI 10.1128/CVI.00201-06
   Andersen JF, 2009, J PROTEOME RES, V8, P1474, DOI 10.1021/pr8008429
   Anderson JM, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-52
   Andrade BB, 2007, SCAND J IMMUNOL, V66, P122, DOI 10.1111/j.1365-3083.2007.01964.x
   Assumpcao TCF, 2008, INSECT BIOCHEM MOLEC, V38, P213, DOI 10.1016/j.ibmb.2007.11.001
   Bahia D, 2007, PARASITOL RES, V100, P449, DOI 10.1007/s00436-006-0307-8
   Barral A, 2000, AM J TROP MED HYG, V62, P740, DOI 10.4269/ajtmh.2000.62.740
   Calvo E, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-57
   Cornelie S, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-75
   DAVIES CR, 1993, T ROY SOC TROP MED H, V87, P603, DOI 10.1016/0035-9203(93)90103-W
   de Moura TR, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000084
   Silva JGDE, 2007, CAD SAUDE PUBLICA, V23, P1715, DOI 10.1590/S0102-311X2007000700024
   Fenech FF, 1997, ANN TROP MED PARASIT, V91, P747, DOI 10.1080/00034989760491
   Follador I, 1999, Rev Soc Bras Med Trop, V32, P497, DOI 10.1590/S0037-86821999000500005
   Gomes RB, 2002, J INFECT DIS, V186, P1530, DOI 10.1086/344733
   Gomes RB, 2007, T ROY SOC TROP MED H, V101, P127, DOI 10.1016/j.trstmh.2006.06.002
   Hostomska J, 2008, VECTOR-BORNE ZOONOT, V8, P443, DOI 10.1089/vbz.2007.0214
   Maroli M, 2008, TROP MED INT HEALTH, V13, P256, DOI [10.1111/j.1365-3156.2007.01998.x, 10.1111/j.1365-3156.2007.01998]
   Oliveira F, 2006, VACCINE, V24, P374, DOI 10.1016/j.vaccine.2005.07.085
   Oliveira F, 2009, PARASITOL INT, V58, P1, DOI 10.1016/j.parint.2008.07.004
   Poinsignon A, 2008, AM J TROP MED HYG, V78, P750, DOI 10.4269/ajtmh.2008.78.750
   Queiroz PVS, 2009, RES VET SCI, V86, P267, DOI 10.1016/j.rvsc.2008.07.014
   Rebelo J M, 1999, Cad Saude Publica, V15, P623, DOI 10.1590/S0102-311X1999000300020
   Remoue F, 2006, T ROY SOC TROP MED H, V100, P363, DOI 10.1016/j.trstmh.2005.06.032
   Ribeiro JMC, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-6
   Rohousova I, 2005, PARASITOLOGY, V130, P493, DOI 10.1017/S003118200400681X
   SACKS DL, 1994, PARASITOLOGY, V108, P55
   SCHWARTZ BS, 1991, AM J EPIDEMIOL, V134, P86, DOI 10.1093/oxfordjournals.aje.a115996
   SCHWARTZ BS, 1993, AM J TROP MED HYG, V48, P50, DOI 10.4269/ajtmh.1993.48.50
   Schwarz A, 2009, INT J PARASITOL, V39, P1021, DOI 10.1016/j.ijpara.2009.01.010
   Silva F, 2005, AM J TROP MED HYG, V72, P94, DOI 10.4269/ajtmh.2005.72.94
   Titus RG, 2006, PARASITE IMMUNOL, V28, P131, DOI 10.1111/j.1365-3024.2006.00807.x
   Valenzuela JG, 2001, J EXP MED, V194, P331, DOI 10.1084/jem.194.3.331
   Vinhas V, 2007, EUR J IMMUNOL, V37, P3111, DOI 10.1002/eji.200737431
   Ximenes MDFD, 2000, J MED ENTOMOL, V37, P162, DOI 10.1603/0022-2585-37.1.162
NR 35
TC 82
Z9 83
U1 0
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1935-2727
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD MAR
PY 2010
VL 4
IS 3
AR e638
DI 10.1371/journal.pntd.0000638
PG 10
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 578RG
UT WOS:000276312200011
PM 20351786
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Novais, FO
   Santiago, RC
   Bafica, A
   Khouri, R
   Afonso, L
   Borges, VM
   Brodskyn, C
   Barral-Netto, M
   Barral, A
   de Oliveira, CI
AF Novais, Fernanda O.
   Santiago, Romulo C.
   Bafica, Andre
   Khouri, Ricardo
   Afonso, Lilian
   Borges, Valeria M.
   Brodskyn, Claudia
   Barral-Netto, Manoel
   Barral, Aldina
   de Oliveira, Camila I.
TI Neutrophils and Macrophages Cooperate in Host Resistance against
   Leishmania braziliensis Infection
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID CUTANEOUS LEISHMANIASIS; IMMUNE-RESPONSE; INTRACELLULAR PATHOGENS;
   EXPERIMENTAL-MODEL; MAJOR INFECTION; GR-1(+) CELLS; IN-VIVO; MICE;
   PROMASTIGOTES; AMAZONENSIS
AB Neutrophils play an active role in the control of infections caused by intracellular pathogens such as Leishmania. In the present study, we investigated the effect of neutrophil depletion at the time of Leishmania braziliensis infection of BALB/c mice and how neutrophils interact with the infected macrophage to promote parasite elimination. The in vivo depletion of neutrophils led to a significant increase in parasite load and enhanced the Th1-Th2 immune response in this experimental model of infection. BALB/c mice coinoculated with both parasites and live neutrophils displayed lower parasite burdens at the site of infection and in the draining lymph nodes. In vitro, we observed that live neutrophils significantly reduced the parasite load in L. braziliensis-infected murine macrophages, an effect not observed with Leishmania major. L. braziliensis elimination was dependent on the interaction between neutrophils and macrophages and was associated with TNF-alpha as well as superoxide production. Furthermore, cooperation between neutrophils and macrophages toward parasite elimination was also observed in experiments performed with L. braziliensis-infected human cells and, importantly, with two other New World Leishmania species. These results indicate that neutrophils play an important and previously unappreciated role in L. braziliensis infection, favoring the induction of a protective immune response. The Journal of Immunology, 2009, 183: 8088-8098.
C1 [Novais, Fernanda O.; Santiago, Romulo C.; Khouri, Ricardo; Afonso, Lilian; Borges, Valeria M.; Brodskyn, Claudia; Barral-Netto, Manoel; Barral, Aldina; de Oliveira, Camila I.] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [Bafica, Andre] Univ Fed Santa Catarina, Dept Microbiol Imunol & Parasitol, Florianopolis, SC, Brazil.
   [Borges, Valeria M.; Brodskyn, Claudia; Barral-Netto, Manoel; Barral, Aldina; de Oliveira, Camila I.] Inst Invest Imunol, Salvador, BA, Brazil.
   [Brodskyn, Claudia; Barral-Netto, Manoel; Barral, Aldina] Univ Fed Bahia, Salvador, BA, Brazil.
RP de Oliveira, CI (corresponding author), Rua Waldemar Falcao 121, BR-40296710 Salvador, BA, Brazil.
EM camila@bahia.fiocruz.br
RI Borges, Val/N-6647-2019; Khouri, Ricardo/M-3184-2018; Barral-Netto,
   Manoel/B-3904-2009; Borges, Valeria/G-2009-2014; Brodskyn,
   Claudia/A-9970-2010; de Oliveira, Camila I/B-4358-2009; Bafica,
   Andre/ABF-5986-2020
OI Borges, Val/0000-0002-2775-5409; Khouri, Ricardo/0000-0001-5664-4436;
   Barral-Netto, Manoel/0000-0002-5823-7903; de Oliveira, Camila
   I/0000-0002-7868-5164; Bafica, Andre/0000-0002-5148-600X
FU Programa Estrategico de Apoio a Pesquisa cm Saude (PAPES)/Fundacao
   Oswaldo Cruz; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologica (CNPq)National Council for Scientific and Technological
   Development (CNPq); Commissao de Aperfeicoamento de Pessoal Nival
   Superior; Instituto de Investigacao em Imunologia
FX This work was supported by grants from Programa Estrategico de Apoio a
   Pesquisa cm Saude (PAPES)/Fundacao Oswaldo Cruz and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologica (CNPq). F.O.N. was supported by
   a Commissao de Aperfeicoamento de Pessoal Nival Superior fellowship and
   R.S. and L.A. were supported by CNPq fellowships. A. Bafica, V.M.B.,
   C.B.. M.B.N., A. Barral, and C.I.O. are senior investigators from CNPq
   and Instituto de Investigacao em Imunologia (iii).
CR Afonso L, 2008, J LEUKOCYTE BIOL, V84, P389, DOI 10.1189/jlb.0108018
   Allenbach C, 2006, J IMMUNOL, V176, P6656, DOI 10.4049/jimmunol.176.11.6656
   Appelberg R, 2007, TRENDS MICROBIOL, V15, P87, DOI 10.1016/j.tim.2006.11.009
   Asgharpour A, 2005, INFECT IMMUN, V73, P4522, DOI 10.1128/IAI.73.8.4522-4529.2005
   Bittencourt Achiléa, 2003, Braz J Infect Dis, V7, P229, DOI 10.1590/S1413-86702003000300009
   Bomfim G, 2007, AM J TROP MED HYG, V77, P854, DOI 10.4269/ajtmh.2007.77.854
   CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2
   Charmoy M, 2007, J LEUKOCYTE BIOL, V82, P288, DOI 10.1189/jlb.0706440
   Chen L, 2005, PARASITOL INT, V54, P109, DOI 10.1016/j.parint.2005.02.001
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   DEMAGALHAES AV, 1986, REV I MED TROP, V28, P253, DOI 10.1590/S0036-46651986000400008
   ELSTNER EF, 1976, ANAL BIOCHEM, V70, P616, DOI 10.1016/0003-2697(76)90488-7
   Fadok VA, 2001, J IMMUNOL, V166, P6847, DOI 10.4049/jimmunol.166.11.6847
   Faurschou M, 2003, MICROBES INFECT, V5, P1317, DOI 10.1016/j.micinf.2003.09.008
   Gantt KR, 2001, J IMMUNOL, V167, P893, DOI 10.4049/jimmunol.167.2.893
   GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115
   GRIMALDI G, 1984, PARASITE IMMUNOL, V6, P397, DOI 10.1111/j.1365-3024.1984.tb00811.x
   Guimaraes-Costa AB, 2009, P NATL ACAD SCI USA, V106, P6748, DOI 10.1073/pnas.0900226106
   HEIFETS L, 1980, J RETICULOENDOTH SOC, V28, P391
   Henson PM, 2001, CURR BIOL, V11, pR795, DOI 10.1016/S0960-9822(01)00474-2
   Khouri R, 2009, J IMMUNOL, V182, P2525, DOI 10.4049/jimmunol.0802860
   LIEW FY, 1990, J IMMUNOL, V144, P4794
   Lima GMAC, 1998, IMMUNOL LETT, V64, P145, DOI 10.1016/S0165-2478(98)00099-6
   Maioli TU, 2004, PARASITOL RES, V94, P207, DOI 10.1007/s00436-004-1193-6
   McFarlane E, 2008, INFECT IMMUN, V76, P532, DOI 10.1128/IAI.01388-07
   Miranda KM, 2001, NITRIC OXIDE-BIOL CH, V5, P62, DOI 10.1006/niox.2000.0319
   MURRAY HW, 1982, J IMMUNOL, V129, P351
   Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785
   Nauseef WM, 2007, IMMUNOL REV, V219, P88, DOI 10.1111/j.1600-065X.2007.00550.x
   Pedrosa J, 2000, INFECT IMMUN, V68, P577, DOI 10.1128/IAI.68.2.577-583.2000
   Peters NC, 2008, SCIENCE, V321, P970, DOI 10.1126/science.1159194
   POMPEU ML, 1991, ACTA TROP, V48, P185, DOI 10.1016/0001-706X(91)90046-M
   Ribeiro-Gomes FL, 2004, J IMMUNOL, V172, P4454, DOI 10.4049/jimmunol.172.7.4454
   Ribeiro-Gomes FL, 2007, J IMMUNOL, V179, P3988, DOI 10.4049/jimmunol.179.6.3988
   Rocha FJS, 2007, INFECT IMMUN, V75, P3823, DOI 10.1128/IAI.01335-06
   Rogers KA, 2002, FEMS MICROBIOL LETT, V209, P1, DOI 10.1111/j.1574-6968.2002.tb11101.x
   Rousseau D, 2001, BMC Microbiol, V1, P17, DOI 10.1186/1471-2180-1-17
   Sa-Nunes A, 2007, MICROBES INFECT, V9, P1393, DOI 10.1016/j.micinf.2006.10.007
   SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528
   Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957
   SAYLES PC, 1996, NAT IMMUN, V15, P249
   SILVA MT, 1989, MICROB PATHOGENESIS, V6, P369, DOI 10.1016/0882-4010(89)90079-X
   Smelt SC, 2000, J IMMUNOL, V164, P3681, DOI 10.4049/jimmunol.164.7.3681
   Smith DF, 2007, INT J PARASITOL, V37, P1173, DOI 10.1016/j.ijpara.2007.05.015
   Spath GF, 2001, EXP PARASITOL, V99, P97, DOI 10.1006/expr.2001.4656
   SPEER CP, 1984, J IMMUNOL, V133, P2151
   Tacchini-Cottier F, 2000, J IMMUNOL, V165, P2628, DOI 10.4049/jimmunol.165.5.2628
   Takeuchi D, 2008, INFECT IMMUN, V76, P3657, DOI 10.1128/IAI.00112-08
   Tan BH, 2006, J IMMUNOL, V177, P1864, DOI 10.4049/jimmunol.177.3.1864
   Tateda K, 2001, J IMMUNOL, V166, P3355, DOI 10.4049/jimmunol.166.5.3355
   TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x
   Venuprasad K, 2002, J IMMUNOL, V169, P920, DOI 10.4049/jimmunol.169.2.920
   Woo CH, 2003, J IMMUNOL, V170, P6273, DOI 10.4049/jimmunol.170.12.6273
NR 53
TC 83
Z9 83
U1 1
U2 7
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD DEC 15
PY 2009
VL 183
IS 12
BP 8088
EP 8098
DI 10.4049/jimmunol.0803720
PG 11
WC Immunology
SC Immunology
GA 533YE
UT WOS:000272861300054
PM 19923470
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU de Oliveira, CI
   Nascimento, IP
   Barral, A
   Soto, M
   Barral-Netto, M
AF de Oliveira, Camila I.
   Nascimento, Ivan P.
   Barral, Aldina
   Soto, Manuel
   Barral-Netto, Manoel
TI Challenges and perspectives in vaccination against leishmaniasis
SO PARASITOLOGY INTERNATIONAL
LA English
DT Review
DE Leishmania; Sand fly; Saliva; BCG
ID SAND FLY SALIVA; CONFERS PROTECTIVE IMMUNITY; REGULATORY T-CELLS; MAJOR
   PLUS BCG; CUTANEOUS LEISHMANIASIS; VISCERAL LEISHMANIASIS; BALB/C MICE;
   LUTZOMYIA-LONGIPALPIS; RECOMBINANT BCG; BRAZILIENSIS INFECTION
AB The leishmaniases are a group of diseases caused by protozoa of the genus Leishmania and affect millions of people worldwide. The leishmaniases are transmitted to vertebrate hosts by phlebotomine sand flies. in this review, we focus on several issues that have been poorly addressed in ongoing efforts to develop a vaccine against Leishmania, namely: vaccination with antigens present in sand fly saliva, vaccines based on intracellular Leishmania antigens, and use of recombinant BCG as a vehicle for vaccination. Additionally, we address the differences between L. major and L. braziliensis and the impact that these differences may have on strategies for immunoprophylaxis. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
C1 [Barral-Netto, Manoel] Fiocruz MS, CPqGM, LIMI, Salvador, BA, Brazil.
   [Barral, Aldina; Barral-Netto, Manoel] Inst Invest Imunol, Salvador, BA, Brazil.
   [Soto, Manuel] Univ Autonoma Madrid, Fac Ciencias, Dept Biol Mol, Ctr Biol Mol Severo Ochoa,CSIC, E-28049 Madrid, Spain.
RP Barral-Netto, M (corresponding author), Fiocruz MS, CPqGM, LIMI, Rua Waldemar Falcao 121, Salvador, BA, Brazil.
EM mbarral@bahia.fiocruz.br
RI Alvarez, Manuel Soto/Q-5234-2018; de Oliveira, Camila I/B-4358-2009;
   Nascimento, Ivan/G-9520-2012; Barral-Netto, Manoel/B-3904-2009;
   Nascimento, Ivan/G-9520-2012
OI Alvarez, Manuel Soto/0000-0001-6825-841X; de Oliveira, Camila
   I/0000-0002-7868-5164; Nascimento, Ivan/0000-0001-9843-1594;
   Barral-Netto, Manoel/0000-0002-5823-7903; Nascimento,
   Ivan/0000-0002-5293-3967
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FICCRUZ; FAPESB; CAPES from BrazilCAPES; Ministerio de Educacion
   y CienciaSpanish Government; AECI; FISInstituto de Salud Carlos III;
   Fundacion Ramon Areces from Spain; FAPESB fellowship
FX The work in the authors' laboratories is and has been supported by
   grants from CNPq, FICCRUZ, FAPESB and CAPES from Brazil, and from
   Ministerio de Educacion y Ciencia, AECI, FIS and Fundacion Ramon Areces
   from Spain. IPN was supported by a FAPESB fellowship. CIO, AB and MBN
   are senior investigators from CNPq.
CR ABDELHAK S, 1995, MICROBIOL-UK, V141, P1585, DOI 10.1099/13500872-141-7-1585
   ALDOVINI A, 1991, NATURE, V351, P479, DOI 10.1038/351479a0
   Andrade BB, 2007, SCAND J IMMUNOL, V66, P122, DOI 10.1111/j.1365-3083.2007.01964.x
   BARLETTA RG, 1990, RES MICROBIOL, V141, P931, DOI 10.1016/0923-2508(90)90132-A
   Barral A, 2000, AM J TROP MED HYG, V62, P740, DOI 10.4269/ajtmh.2000.62.740
   Belkaid Y, 2000, J IMMUNOL, V165, P969, DOI 10.4049/jimmunol.165.2.969
   Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152
   Belkaid Y, 2001, J EXP MED, V194, P1497, DOI 10.1084/jem.194.10.1497
   Bezerra HSD, 2001, MEM I OSWALDO CRUZ, V96, P349
   Bhardwaj S, 2009, EXP PARASITOL, V121, P29, DOI 10.1016/j.exppara.2008.09.019
   Bittencourt Achiléa, 2003, Braz J Infect Dis, V7, P229, DOI 10.1590/S1413-86702003000300009
   BITTENCOURT AL, 1995, TROPICAL PATHOLOGY, P597
   Borges MM, 2001, INFECT IMMUN, V69, P5270, DOI 10.1128/IAI.69.9.5270-5277.2001
   Bueno SM, 2008, P NATL ACAD SCI USA, V105, P20822, DOI 10.1073/pnas.0806244105
   Campos-Neto A, 2002, INFECT IMMUN, V70, P2828, DOI 10.1128/IAI.70.6.2828-2836.2002
   Carrion J, 2007, MICROBES INFECT, V9, P735, DOI 10.1016/j.micinf.2007.02.018
   Carvalho FAA, 2002, DIAGN MICR INFEC DIS, V43, P289, DOI 10.1016/S0732-8893(02)00410-8
   CASTES M, 1989, PARASITE IMMUNOL, V11, P211, DOI 10.1111/j.1365-3024.1989.tb00660.x
   Cayabyab MJ, 2009, J VIROL, V83, P5505, DOI 10.1128/JVI.02544-08
   Chang KP, 2003, ACTA TROP, V85, P375, DOI 10.1016/S0001-706X(02)00238-3
   CHAREST H, 1994, MOL CELL BIOL, V14, P2975, DOI 10.1128/MCB.14.5.2975
   Chege GK, 2009, VACCINE, V27, P4857, DOI 10.1016/j.vaccine.2009.05.064
   Collin N, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000441
   CONNELL ND, 1993, P NATL ACAD SCI USA, V90, P11473, DOI 10.1073/pnas.90.24.11473
   Convit J, 2004, MEM I OSWALDO CRUZ, V99, P57, DOI 10.1590/S0074-02762004000100010
   Costa DJ, 2004, INFECT IMMUN, V72, P1298, DOI 10.1128/IAI.72.3.1298-1305.2004
   COSTA JML, 1986, J TROP MED HYG, V89, P319
   de Carvalho LP, 2003, MICROBES INFECT, V5, P7, DOI 10.1016/S1286-4579(02)00051-5
   de Moura TR, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000084
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   DeKrey GK, 1998, INFECT IMMUN, V66, P827, DOI 10.1128/IAI.66.2.827-829.1998
   Dominguez M, 2003, MICROBES INFECT, V5, P507, DOI 10.1016/S1286-4579(03)00071-6
   Ghedin E, 1997, CLIN DIAGN LAB IMMUN, V4, P530, DOI 10.1128/CDLI.4.5.530-535.1997
   Ghosh A, 2001, VACCINE, V19, P3169, DOI 10.1016/S0264-410X(01)00023-8
   Ghosh A, 2001, VACCINE, V20, P59, DOI 10.1016/S0264-410X(01)00322-X
   GICQUEL B, 1995, BIOLOGICALS, V23, P113, DOI 10.1006/biol.1995.0021
   Gomes RB, 2002, J INFECT DIS, V186, P1530, DOI 10.1086/344733
   Gomes R, 2008, P NATL ACAD SCI USA, V105, P7845, DOI 10.1073/pnas.0712153105
   GOTO Y, 1997, VACCINE, V16, P7450
   Goto Y, 2009, VET PARASITOL, V160, P215, DOI 10.1016/j.vetpar.2008.10.097
   Grevelink SA, 1996, J AM ACAD DERMATOL, V34, P257, DOI 10.1016/S0190-9622(96)80121-6
   Guerfali FZ, 2009, INFECT GENET EVOL, V9, P344, DOI 10.1016/j.meegid.2008.02.011
   Guimaraes-Costa AB, 2009, P NATL ACAD SCI USA, V106, P6748, DOI 10.1073/pnas.0900226106
   Gurunathan S, 1997, J EXP MED, V186, P1137, DOI 10.1084/jem.186.7.1137
   HAESELEER F, 1993, MOL BIOCHEM PARASIT, V57, P117, DOI 10.1016/0166-6851(93)90249-W
   Handman E, 2001, CLIN MICROBIOL REV, V14, P229, DOI 10.1128/CMR.14.2.229-243.2001
   Herrera-Najera C, 2009, PROTEOMICS, V9, P1293, DOI 10.1002/pmic.200800533
   Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2
   Iborra S, 2007, CLIN EXP IMMUNOL, V150, P375, DOI 10.1111/j.1365-2249.2007.03501.x
   Iborra S, 2005, INFECT IMMUN, V73, P5842, DOI 10.1128/IAI.73.9.5842-5852.2005
   Iborra S, 2004, VACCINE, V22, P3865, DOI 10.1016/j.vaccine.2004.04.015
   Iborra S, 2003, INFECT IMMUN, V71, P6562, DOI 10.1128/IAI.71.11.6562-6572.2003
   Kamhawi S, 2000, SCIENCE, V290, P1351, DOI 10.1126/science.290.5495.1351
   Khalil EAG, 2000, LANCET, V356, P1565, DOI 10.1016/S0140-6736(00)03128-7
   Khalil EAG, 2006, ANN TROP PAEDIATR, V26, P357, DOI 10.1179/146532806X152890
   Khamesipour A, 2006, INDIAN J MED RES, V123, P423
   LAGRANDERIE M, 1993, VACCINE, V11, P1283, DOI 10.1016/0264-410X(93)90096-G
   Launois P, 1997, IMMUNITY, V6, P541, DOI 10.1016/S1074-7613(00)80342-8
   Levick MP, 1998, MOL BIOCHEM PARASIT, V96, P125, DOI 10.1016/S0166-6851(98)00122-4
   Liu WJ, 2009, CANCER IMMUNOL IMMUN, V58, P1647, DOI 10.1007/s00262-009-0673-z
   Maalej IA, 2003, AM J TROP MED HYG, V68, P312, DOI 10.4269/ajtmh.2003.68.312
   MARSDEN PD, 1986, T ROY SOC TROP MED H, V80, P859, DOI 10.1016/0035-9203(86)90243-9
   Martins DRA, 2006, INFECT IMMUN, V74, P6940, DOI 10.1128/IAI.02032-05
   MATSUO K, 1990, INFECT IMMUN, V58, P4049, DOI 10.1128/IAI.58.12.4049-4054.1990
   Melby PC, 2001, INFECT IMMUN, V69, P4719, DOI 10.1128/IAI.69.8.4719-4725.2001
   Mendez S, 2004, J EXP MED, V200, P201, DOI 10.1084/jem.20040298
   Menezes MJ, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-12
   Momeni AZ, 1999, VACCINE, V17, P466, DOI 10.1016/S0264-410X(98)00220-5
   Montoya Y, 1997, T ROY SOC TROP MED H, V91, P674, DOI 10.1016/S0035-9203(97)90520-4
   MOUGNEAU E, 1995, SCIENCE, V268, P563, DOI 10.1126/science.7725103
   Nascimento IP, 2000, INFECT IMMUN, V68, P4877, DOI 10.1128/IAI.68.9.4877-4883.2000
   Noazin S, 2008, VACCINE, V26, P6759, DOI 10.1016/j.vaccine.2008.09.085
   Norsworthy NB, 2004, INFECT IMMUN, V72, P1240, DOI 10.1128/IAI.72.3.1240-1247.2004
   NYLEN S, 2007, J EXP MED, V26, P204
   OKWOR I, 2009, HUMAN VACCINES, V12, P5
   Peters NC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000484
   Probst P, 2001, J IMMUNOL, V166, P498, DOI 10.4049/jimmunol.166.1.498
   Rafati S, 2007, VACCINE, V25, P4159, DOI 10.1016/j.vaccine.2007.03.006
   Reithinger R, 2007, LANCET INFECT DIS, V7, P581, DOI 10.1016/S1473-3099(07)70209-8
   Requena JM, 2000, PARASITOL TODAY, V16, P246, DOI 10.1016/S0169-4758(00)01651-3
   Requena JM, 2004, EXPERT OPIN BIOL TH, V4, P1505, DOI 10.1517/14712598.4.9.1505
   Rocha FJS, 2007, INFECT IMMUN, V75, P3823, DOI 10.1128/IAI.01335-06
   Rogers KA, 2003, PARASITE IMMUNOL, V25, P127, DOI 10.1046/j.1365-3024.2003.00623.x
   Salay G, 2007, CLIN VACCINE IMMUNOL, V14, P1173, DOI 10.1128/CVI.00060-07
   SAMUELSON J, 1991, J EXP MED, V173, P49, DOI 10.1084/jem.173.1.49
   Sharifi I, 1998, LANCET, V351, P1540, DOI 10.1016/S0140-6736(98)09552-X
   Smith DF, 2007, INT J PARASITOL, V37, P1173, DOI 10.1016/j.ijpara.2007.05.015
   Soto M, 1999, CLIN EXP IMMUNOL, V115, P342, DOI 10.1046/j.1365-2249.1999.00796.x
   Streit JA, 2000, EXP PARASITOL, V94, P33, DOI 10.1006/expr.1999.4459
   TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436
   Valenzuela JG, 2001, J EXP MED, V194, P331, DOI 10.1084/jem.194.3.331
   Vinhas V, 2007, EUR J IMMUNOL, V37, P3111, DOI 10.1002/eji.200737431
   Webb JR, 1998, INFECT IMMUN, V66, P3279, DOI 10.1128/IAI.66.7.3279-3289.1998
   Wilson ME, 2005, MICROB PATHOGENESIS, V38, P147, DOI 10.1016/j.micpath.2004.11.002
NR 94
TC 28
Z9 30
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1383-5769
J9 PARASITOL INT
JI Parasitol. Int.
PD DEC
PY 2009
VL 58
IS 4
BP 319
EP 324
DI 10.1016/j.parint.2009.07.013
PG 6
WC Parasitology
SC Parasitology
GA 515TR
UT WOS:000271496300001
PM 19698801
OA Green Published
DA 2020-12-08
ER

PT J
AU Boaventura, VS
   de Oliveira, JGS
   Costa, JML
   Novais, FO
   de Oliveira, CI
   Barral-Netto, M
   Barral, A
AF Boaventura, Viviane S.
   de Oliveira, Jene G. S.
   Costa, Jackson M. L.
   Novais, Fernanda O.
   de Oliveira, Camila I.
   Barral-Netto, Manoel
   Barral, Aldina
TI Short Report: The Value of the Otorhinolaryngologic Exam in Correct
   Mucocutaneous Leishmaniasis Diagnosis
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
AB An increase in mucocutaneous leishmaniasis (ML) cases in northern (Brazil) motivated this study. In 44 ML patients with clinical diagnosis, only 13 parasitologically confirmed cases exhibited mucosal lesion suggestive of ML. Other conditions involving nasal manifestations are frequently confounded with ML. Therefore, otorhinolaryngologic examination is important in the clinical management of ML.
C1 [Boaventura, Viviane S.; Costa, Jackson M. L.; Novais, Fernanda O.; de Oliveira, Camila I.; Barral-Netto, Manoel; Barral, Aldina] Fiocruz MS, Ctr Pesquisas Goncalo Moniz, BR-40296710 Salvador, BA, Brazil.
   [de Oliveira, Jene G. S.] Fundacao Hosp Acre, BR-69900000 Rio Brano, AC, Brazil.
RP Barral, A (corresponding author), Fiocruz MS, Ctr Pesquisas Goncalo Moniz, Rua Waldemar Falcao 121, BR-40296710 Salvador, BA, Brazil.
EM voliveira@aluno.bahia.fiocruz.br; junior.jene@uol.com.br;
   jcosta@bahia.fiocruz.br; novais@aluno.fiocruz.br;
   camila@bahia.fiocruz.br; mbarral@bahia.fiocruz.br;
   abarral@bahia.fiocruz.br
RI de Oliveira, Camila I/B-4358-2009; Boaventura, Viviane S/H-9165-2015;
   Barral-Netto, Manoel/B-3904-2009
OI de Oliveira, Camila I/0000-0002-7868-5164; Barral-Netto,
   Manoel/0000-0002-5823-7903
FU Brazilian Ministry of Health; CAPESCAPES; CNPqNational Council for
   Scientific and Technological Development (CNPq)
FX This study was funded by the Brazilian Ministry of Health. V Boaventura
   and F. O. Novais were supported by a CAPES fellowship. J. M. Costa, C.
   I. de Oliveira, M. Barral-Netto, and A. Barral are senior investigators
   from CNPq.
CR BARRAL A, 1991, AM J TROP MED HYG, V44, P536, DOI 10.4269/ajtmh.1991.44.536
   Costa J M, 1986, Rev Soc Bras Med Trop, V19, P109, DOI 10.1590/S0037-86821986000200012
   de Oliveira CI, 2003, CLIN INFECT DIS, V37, pE149, DOI 10.1086/379610
   GROGL M, 1992, AM J TROP MED HYG, V47, P117, DOI 10.4269/ajtmh.1992.47.117
   Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2
   LLANOSCUENTAS EA, 1984, LANCET, V2, P295, DOI 10.1016/S0140-6736(84)90346-5
   Manzur A, 2006, Dermatol Online J, V12, P2
   Marsden PD, 1998, AM J TROP MED HYG, V59, P543, DOI 10.4269/ajtmh.1998.59.543
   MARSDEN PD, 1986, T ROY SOC TROP MED H, V80, P859, DOI 10.1016/0035-9203(86)90243-9
   Oliveira JGS, 2005, ACTA TROP, V94, P55, DOI 10.1016/j.actatropica.2004.12.003
   Szeinbach SL, 2008, BMC FAM PRACT, V9, DOI 10.1186/1471-2296-9-47
   da Silva ACT, 2006, TROP MED INT HEALTH, V11, P1388, DOI 10.1111/j.1365-3156.2006.01695.x
   Younis RT, 2002, LARYNGOSCOPE, V112, P224, DOI 10.1097/00005537-200202000-00005
   ZAJTCHUK JT, 1989, LARYNGOSCOPE, V99, P925, DOI 10.1288/00005537-198909000-00006
NR 14
TC 6
Z9 6
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD SEP
PY 2009
VL 81
IS 3
BP 384
EP 386
DI 10.4269/ajtmh.2009.81.384
PG 3
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 487QW
UT WOS:000269290900004
PM 19706900
OA Bronze, Green Published
DA 2020-12-08
ER

PT J
AU de Toledo, JS
   dos Santos, AFJ
   de Moura, TR
   Antoniazi, SA
   Brodskyn, C
   de Oliveira, CI
   Barral, A
   Cruz, AK
AF de Toledo, Juliano Simoes
   Junqueira dos Santos, Andre F.
   de Moura, Tatiana Rodrigues
   Antoniazi, Simone Aparecida
   Brodskyn, Claudia
   de Oliveira, Camila Indiani
   Barral, Aldina
   Cruz, Angela Kaysel
TI Leishmania (Viannia) braziliensis transfectants overexpressing the
   miniexon gene lose virulence in vivo
SO PARASITOLOGY INTERNATIONAL
LA English
DT Article
DE Leishmania (V.) braziliensis; Virulence; Miniexon; Overexpression; SL
   RNA
ID TRYPANOSOMA; EVOLUTION; PARASITE; TRANSCRIPTION; SELECTION; LOCATION;
   GENOME; MICE
AB The miniexon gene has a central role in the processing of polycistronic pre-mRNA of kinetoplastids. It is added to the 5' extremity of each mRNA, supplying the 5'-capped structure to the molecule. Previous studies in Leishmania (Leishmania) major showed that the overexpression of the miniexon array attenuates the Virulence of the parasite in in vivo assays. The results presented here extend those findings to Vionnia subgenus. Leishmania (Vionnia) braziliensis was transfected with a cosmid harboring a tandem array of one hundred miniexon gene copies and then characterized by Northern blot analysis. The overexpression of the exogenous gene was confirmed and its effect on the virulence of L (V.) braziliensis was investigated in hamsters. In BALB/c mice we could not detect parasites during the course of 15 weeks of infection. In addition, hamsters infected with transfectants overexpressing the miniexon gene exhibited only a minor footpad swelling of late onset and failed to develop progressive lesion, these attenuated parasites could be recovered from the inoculation site 1 year after infection. The persistence of parasites in the host indicates that a stable line overexpressing the miniexon may be tested as live vaccine against leishmaniasis. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
C1 [de Toledo, Juliano Simoes; Junqueira dos Santos, Andre F.; Antoniazi, Simone Aparecida; Cruz, Angela Kaysel] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Biol Celular & Mol & Bioagentes Patogen, BR-14049900 Ribeirao Preto, SP, Brazil.
   [de Moura, Tatiana Rodrigues; Brodskyn, Claudia; de Oliveira, Camila Indiani; Barral, Aldina] Fiocruz MS, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [Brodskyn, Claudia; Barral, Aldina] Inst Invest Imunol, Salvador, BA, Brazil.
RP Cruz, AK (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Biol Celular & Mol & Bioagentes Patogen, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
EM akcruz@fmrp.usp.br
RI Barral, Aldina/B-4191-2009; Inbeqmedi, Inct/I-1929-2013; Toledo,
   Juliano/G-2666-2012; Brodskyn, Claudia/A-9970-2010; Cruz, Angela
   Kaysel/N-8445-2014; de Oliveira, Camila I/B-4358-2009; 4,
   INCT/H-4499-2013; Antoniazi Pereira, SImone/F-3537-2014
OI Barral, Aldina/0000-0002-7177-464X; Toledo, Juliano/0000-0001-5013-6246;
   Cruz, Angela Kaysel/0000-0002-4260-4713; de Oliveira, Camila
   I/0000-0002-7868-5164; Antoniazi Pereira, SImone/0000-0001-8814-5850; ,
   Tatiana/0000-0002-7442-4434
FU Fundacao de Amparo Pesquisa do Estado de SAO PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [FAPESP-99/12403-3, 01/092815,
   03/02366-0]; Conselho Nacional de Desenvolvimento Cientifico e
   TecnolegicoNational Council for Scientific and Technological Development
   (CNPq)
FX We thank Viviane A. Trombela and Fernanda O. Novais for technical
   assistance. This work was supported by Fundacao de Amparo Pesquisa do
   Estado de SAO Paulo (FAPESP-99/12403-3) and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnolegico. AFJS and JST were supported by
   fellowships from FAPESP (01/092815 and 03/02366-0).
CR Antoniazi S, 2000, MOL BIOCHEM PARASIT, V107, P57, DOI 10.1016/S0166-6851(99)00232-7
   Bastian H, 1998, INT J TECHNOL ASSESS, V14, P3, DOI 10.1017/S0266462300010485
   Beverley SM, 2003, NAT REV GENET, V4, P11, DOI 10.1038/nrg980
   CAMPBELL DA, 1984, NATURE, V311, P350, DOI 10.1038/311350a0
   Clayton C, 1998, MOL BIOCHEM PARASIT, V97, P221, DOI 10.1016/S0166-6851(98)00115-7
   Clayton CE, 2002, EMBO J, V21, P1881, DOI 10.1093/emboj/21.8.1881
   COOK GA, 1987, MOL BIOCHEM PARASIT, V25, P113, DOI 10.1016/0166-6851(87)90024-7
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   Desjeux P, 2004, NAT REV MICROBIOL, V2, P692, DOI 10.1038/nrmicro981
   Ebert D, 1998, SCIENCE, V282, P1432, DOI 10.1126/science.282.5393.1432
   FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9
   FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266
   FERNANDES O, 1994, MOL BIOCHEM PARASIT, V66, P261, DOI 10.1016/0166-6851(94)90153-8
   GREEN MS, 1983, T ROY SOC TROP MED H, V77, P152, DOI 10.1016/0035-9203(83)90054-8
   IOVANNISCI DM, 1989, MOL BIOCHEM PARASIT, V34, P177, DOI 10.1016/0166-6851(89)90009-1
   Ivens AC, 2005, SCIENCE, V309, P436, DOI 10.1126/science.1112680
   KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084
   LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996
   Pedrosa AL, 2002, MOL BIOCHEM PARASIT, V122, P141, DOI 10.1016/S0166-6851(02)00093-2
   SAMARAS N, 1987, MOL BIOCHEM PARASIT, V25, P279, DOI 10.1016/0166-6851(87)90092-2
   Sambrook J., 1989, MOL CLONING LAB MANU
   SPITHILL TW, 1987, MOL BIOCHEM PARASIT, V24, P23, DOI 10.1016/0166-6851(87)90112-5
   TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x
   ULLU E, 1993, MOL CELL BIOL, V13, P720, DOI 10.1128/MCB.13.1.720
   Wincker P, 1996, NUCLEIC ACIDS RES, V24, P1688, DOI 10.1093/nar/24.9.1688
   Zhang WW, 2004, MOL MICROBIOL, V54, P1051, DOI 10.1111/j.1365-2958.2004.04327.x
NR 26
TC 7
Z9 7
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1383-5769
J9 PARASITOL INT
JI Parasitol. Int.
PD MAR
PY 2009
VL 58
IS 1
BP 45
EP 50
DI 10.1016/j.parint.2008.09.006
PG 6
WC Parasitology
SC Parasitology
GA 413FA
UT WOS:000263777100008
PM 18992366
OA Green Published
DA 2020-12-08
ER

PT J
AU Clarencio, J
   de Oliveira, CI
   Favali, C
   Medina, O
   Caldas, A
   Costa, CH
   Costa, DL
   Brodskyn, C
   Barral, A
   Barral-Netto, M
AF Clarencio, Jorge
   de Oliveira, Camila I.
   Favali, Cec-lia
   Medina, Omar
   Caldas, Arlene
   Costa, Carlos Henrique
   Costa, Dorcas L.
   Brodskyn, Claudia
   Barral, Aldina
   Barral-Netto, Manoel
TI Could the lower frequency of CD8+CD18+CD45RO+lymphocytes be biomarkers
   of human VL?
SO INTERNATIONAL IMMUNOLOGY
LA English
DT Article
ID EXPERIMENTAL VISCERAL LEISHMANIASIS; REGULATORY T-CELLS; CYTOKINE
   PROFILES; GRANULOMA-FORMATION; INTERFERON-GAMMA; IN-VIVO; INFECTION;
   IMMUNITY; CD8(+); RESPONSES
AB Toward obtaining a more comprehensive understanding of factors governing activation and/or function during visceral leishmaniasis (VL), we have compared active disease (pre-treatment) versus post-chemotherapy immune response in VL patients by means of ex vivo staining with different cell markers. Our results show that during active disease, the frequency of T cells positive for CD25, CTLA-4 and CD45RO was significantly lower in VL patients compared with healthy controls, whereas cells staining positive for Annexin V and CD95 were significantly higher. In all cases, chemotherapy was able to restore these frequencies to normal levels. Interestingly, significant differences in the frequency of CD18 and in the frequency of CD45RO-positive cells were observed in the CD8+ T cell subset. These two frequencies were also significantly higher in bone marrow when compared with peripheral blood, suggesting a possible compartmentalization of certain CD8+ T cell populations during active disease. Given that CD8+ T cells have been shown to play an essential role in immunity to infection with Leishmania, our data indicate that the lower frequency of CD18+ and CD45RO+ lymphocytes in the bone marrow CD8+ T cell subset may be considered a biomarker of acute VL.
C1 [Clarencio, Jorge; de Oliveira, Camila I.; Favali, Cec-lia; Medina, Omar; Brodskyn, Claudia; Barral, Aldina; Barral-Netto, Manoel] Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [Caldas, Arlene] Univ Fed Maranhao, Sao Luis, Brazil.
   [Costa, Carlos Henrique; Costa, Dorcas L.] Univ Fed Piaui, Teresina, Brazil.
   [Brodskyn, Claudia; Barral, Aldina; Barral-Netto, Manoel] Univ Fed Bahia, Salvador, BA, Brazil.
   [Brodskyn, Claudia; Barral, Aldina; Barral-Netto, Manoel] Inst Invest Imunol, Salvador, BA, Brazil.
RP Barral-Netto, M (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
EM mbarral@bahia.fiocruz.br
RI Brodskyn, Claudia/A-9970-2010; de Oliveira, Camila I/B-4358-2009;
   Favali, Cecilia/C-1028-2009; Barral-Netto, Manoel/B-3904-2009;
   Clarencio, Jorge/H-3940-2012
OI de Oliveira, Camila I/0000-0002-7868-5164; Favali,
   Cecilia/0000-0003-0343-8393; Barral-Netto, Manoel/0000-0002-5823-7903;
   Clarencio, Jorge/0000-0002-4289-5450
FU Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational
   Council for Scientific and Technological Development (CNPq)
FX Conselho Nacional de Desenvolvimento Cientifico e Tecnologico fellowship
   to C. F.
CR Almeida RP, 1996, AM J TROP MED HYG, V54, P178, DOI 10.4269/ajtmh.1996.54.178
   Antonelli LRV, 2004, CLIN EXP IMMUNOL, V136, P341, DOI 10.1111/j.1365-2249.2004.02426.x
   BADARO R, 1986, AM J TROP MED HYG, V35, P72, DOI 10.4269/ajtmh.1986.35.72
   Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152
   Caldas A, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-113
   Caldas AJM, 2006, ACTA TROP, V97, P252, DOI 10.1016/j.actatropica.2005.09.010
   CENINI P, 1993, J INFECT DIS, V168, P986, DOI 10.1093/infdis/168.4.986
   CILLARI E, 1995, CYTOKINE, V7, P740, DOI 10.1006/cyto.1995.0088
   Gollob JA, 1998, J CLIN INVEST, V102, P561, DOI 10.1172/JCI3861
   Hailu A, 2005, CLIN IMMUNOL, V117, P182, DOI 10.1016/j.clim.2005.06.015
   Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645
   KARP CL, 1993, J CLIN INVEST, V91, P1644, DOI 10.1172/JCI116372
   Marski M, 2005, J IMMUNOL, V175, P7889, DOI 10.4049/jimmunol.175.12.7889
   Mary C, 1999, INFECT IMMUN, V67, P5559, DOI 10.1128/IAI.67.11.5559-5566.1999
   MCELRATH MJ, 1988, J EXP MED, V167, P1927, DOI 10.1084/jem.167.6.1927
   Milon G, 1988, Mem Inst Oswaldo Cruz, V83 Suppl 1, P414, DOI 10.1590/S0074-02761988000500036
   MULLER I, 1994, INFECT IMMUN, V62, P2575
   MURRAY HW, 1992, J IMMUNOL, V148, P1858
   Nylen S, 2007, J EXP MED, V204, P805, DOI 10.1084/jem.20061141
   Sanchez MA, 2004, AM J TROP MED HYG, V70, P618, DOI 10.4269/ajtmh.2004.70.618
   SCHOUTEN T, 2000, SETAC GLOBE, V1, P30
   Smelt SC, 1997, J IMMUNOL, V158, P3813
   STERN JJ, 1988, J IMMUNOL, V140, P3971
   Tsagozis P, 2003, PARASITE IMMUNOL, V25, P569, DOI 10.1111/j.0141-9838.2004.00672.x
   Wang HL, 2008, J CLIN INVEST, V118, P2629, DOI 10.1172/JCI34916
   Wilson ME, 2005, MICROB PATHOGENESIS, V38, P147, DOI 10.1016/j.micpath.2004.11.002
   Wilson ME, 1996, J IMMUNOL, V156, P2231
NR 27
TC 9
Z9 9
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0953-8178
EI 1460-2377
J9 INT IMMUNOL
JI Int. Immunol.
PD FEB
PY 2009
VL 21
IS 2
BP 137
EP 144
DI 10.1093/intimm/dxn131
PG 8
WC Immunology
SC Immunology
GA 401SP
UT WOS:000262962700004
PM 19088063
OA Bronze, Green Published
DA 2020-12-08
ER

PT J
AU Afonso, L
   Borges, VM
   Cruz, H
   Ribeiro-Gomes, FL
   DosReis, GA
   Dutra, AN
   Clarencio, J
   de Oliveira, CI
   Barral, A
   Barral-Netto, M
   Brodskyn, CI
AF Afonso, Lilian
   Borges, Valeria M.
   Cruz, Heloisa
   Ribeiro-Gomes, Flavia L.
   DosReis, George A.
   Dutra, Alberto Noronha
   Clarencio, Jorge
   de Oliveira, Camila I.
   Barral, Aldina
   Barral-Netto, Manoel
   Brodskyn, Claudia I.
TI Interactions with apoptotic but not with necrotic neutrophils increase
   parasite burden in human macrophages infected with Leishmania
   amazonensis
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Article
DE apoptosis; necrosis; phagocytosis; TGF-beta 1; NE
ID GROWTH-FACTOR-BETA; CUTANEOUS LEISHMANIASIS; MURINE MACROPHAGES;
   REACTIVE NITROGEN; CELLS; PHAGOCYTOSIS; ELASTASE; INFLAMMATION;
   GRANULOCYTES; INHIBITION
AB Neutrophils are involved in the initial steps of most responses to pathogens. In the present study, we evaluated the effects of the interaction of apoptotic vs. necrotic human neutrophils on macrophage infection by Leishmania amazonensis. Phagocytosis of apoptotic, but not viable, neutrophils by Leishmania-infected macrophages led to an increase in parasite burden via a mechanism dependent on TGF-beta 1 and PGE(2). Conversely, infected macrophages' uptake of necrotic neutrophils induced killing of L. amazonensis. Leishmanicidal activity was dependent on TNF-alpha and neutrophilic elastase. Nitric oxide was not involved in the killing of parasites, but the interaction of necrotic neutrophils with infected macrophages resulted in high superoxide production, a process reversed by catalase, an inhibitor of reactive oxygen intermediate production. Initial events after Leishmania infection involve interactions with neutrophils; we demonstrate that phagocytosis of these cells in an apoptotic or necrotic stage can influence the outcome of infection, driving either parasite survival or destruction.
C1 [Afonso, Lilian; Borges, Valeria M.; Cruz, Heloisa; Dutra, Alberto Noronha; Clarencio, Jorge; de Oliveira, Camila I.; Barral, Aldina; Barral-Netto, Manoel; Brodskyn, Claudia I.] Fiocruz MS, Ctr Pesquisas Goncalo Moniz CPqGM, Lab Imunoparasitol LIP, BR-40295001 Salvador, BA, Brazil.
   [Afonso, Lilian; Cruz, Heloisa; Barral, Aldina; Barral-Netto, Manoel; Brodskyn, Claudia I.] Univ Fed Bahia, Salvador, BA, Brazil.
   [Ribeiro-Gomes, Flavia L.; DosReis, George A.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas, Rio De Janeiro, Brazil.
   [Borges, Valeria M.; Ribeiro-Gomes, Flavia L.; DosReis, George A.; de Oliveira, Camila I.; Barral, Aldina; Barral-Netto, Manoel; Brodskyn, Claudia I.] Inst Invest Immunol 3, Salvador, BA, Brazil.
RP Brodskyn, CI (corresponding author), Fiocruz MS, Ctr Pesquisas Goncalo Moniz CPqGM, Lab Imunoparasitol LIP, Rua Waldemar Falcao 121, BR-40295001 Salvador, BA, Brazil.
EM brodskyn@bahia.fiocruz.br
RI de Oliveira, Camila I/B-4358-2009; Clarencio, Jorge/H-3940-2012; Borges,
   Val/N-6647-2019; Barral, Aldina/B-4191-2009; Brodskyn,
   Claudia/A-9970-2010; Barral-Netto, Manoel/B-3904-2009; Ribeiro-Gomes,
   Flavia/F-7609-2015; Borges, Valeria/G-2009-2014
OI de Oliveira, Camila I/0000-0002-7868-5164; Borges,
   Val/0000-0002-2775-5409; Barral, Aldina/0000-0002-7177-464X;
   Barral-Netto, Manoel/0000-0002-5823-7903; Ribeiro-Gomes,
   Flavia/0000-0003-0297-6341; DosReis, George/0000-0002-8924-4727;
   Clarencio, Jorge/0000-0002-4289-5450
CR Aga E, 2002, J IMMUNOL, V169, P898, DOI 10.4049/jimmunol.169.2.898
   Appelberg R, 2007, TRENDS MICROBIOL, V15, P87, DOI 10.1016/j.tim.2006.11.009
   Arruda MA, 2004, J IMMUNOL, V173, P2023, DOI 10.4049/jimmunol.173.3.2023
   BARRAL A, 1995, INT J DERMATOL, V34, P474, DOI 10.1111/j.1365-4362.1995.tb00613.x
   BARRAL A, 1995, AM J PATHOL, V147, P947
   BARRALNETTO M, 1992, SCIENCE, V257, P545, DOI 10.1126/science.1636092
   Borregaard N, 2007, TRENDS IMMUNOL, V28, P340, DOI 10.1016/j.it.2007.06.002
   BRAY RS, 1983, ACTA TROP, V40, P29
   Chung SB, 2000, NAT CELL BIOL, V2, P931
   Cocco RE, 2001, MOL BIOL CELL, V12, P919, DOI 10.1091/mbc.12.4.919
   Diaz NL, 2006, CLIN EXP DERMATOL, V31, P114, DOI 10.1111/j.1365-2230.2005.01991.x
   Erel O, 1999, MEM I OSWALDO CRUZ, V94, P179, DOI 10.1590/S0074-02761999000200009
   Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112
   Fadok VA, 2001, J IMMUNOL, V166, P6847, DOI 10.4049/jimmunol.166.11.6847
   Faurschou M, 2003, MICROBES INFECT, V5, P1317, DOI 10.1016/j.micinf.2003.09.008
   Freire-de-Lima CG, 2006, J BIOL CHEM, V281, P38376, DOI 10.1074/jbc.M605146200
   Freire-de-Lima CG, 2000, NATURE, V403, P199, DOI 10.1038/35003208
   Gantt KR, 2001, J IMMUNOL, V167, P893, DOI 10.4049/jimmunol.167.2.893
   Greene CM, 2005, J IMMUNOL, V174, P1638, DOI 10.4049/jimmunol.174.3.1638
   Gregory CD, 2004, IMMUNOLOGY, V113, P1, DOI 10.1111/j.1365-2567.2004.01959.x
   Ishihara K, 1999, RES COMMUN MOL PATH, V103, P139
   Kandil H, 2005, CLIN EXP IMMUNOL, V140, P54, DOI 10.1111/j.1365-2249.2005.02730.x
   Laskay T, 2003, TRENDS MICROBIOL, V11, P210, DOI 10.1016/S0966-842X(03)00075-1
   LEE A, 1993, J LEUKOCYTE BIOL, V54, P283
   Lee WL, 2001, AM J RESP CRIT CARE, V164, P896, DOI 10.1164/ajrccm.164.5.2103040
   Lima RG, 2002, J INFECT DIS, V185, P1561, DOI 10.1086/340412
   Meimaridou E, 2005, FREE RADICAL BIO MED, V38, P1553, DOI 10.1016/j.freeradbiomed.2005.02.020
   Murray HW, 1999, J EXP MED, V189, P741, DOI 10.1084/jem.189.4.741
   Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785
   Nauseef WM, 2007, IMMUNOL REV, V219, P88, DOI 10.1111/j.1600-065X.2007.00550.x
   OLIVIER M, 1987, INFECT IMMUN, V55, P467, DOI 10.1128/IAI.55.2.467-471.1987
   Rainger GE, 1998, BLOOD, V92, P4819, DOI 10.1182/blood.V92.12.4819.424k16_4819_4827
   Ribeiro-Gomes FL, 2004, J IMMUNOL, V172, P4454, DOI 10.4049/jimmunol.172.7.4454
   Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722
   SAVILL J, 1995, SEMIN CELL BIOL, V6, P385, DOI 10.1016/S1043-4682(05)80009-1
   Serarslan G, 2005, CLIN EXP DERMATOL, V30, P267, DOI 10.1111/j.1365-2230.2005.01758.x
   Tacchini-Cottier F, 2000, J IMMUNOL, V165, P2628, DOI 10.4049/jimmunol.165.5.2628
   Tsujimoto H, 2005, SHOCK, V23, P39, DOI 10.1097/01.shk.0000145936.31967.d7
   van Zandbergen G, 2004, J IMMUNOL, V173, P6521, DOI 10.4049/jimmunol.173.11.6521
   Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022
   Wanderley JLM, 2006, J IMMUNOL, V176, P1834, DOI 10.4049/jimmunol.176.3.1834
   Zamboni DS, 2004, INFECT IMMUN, V72, P2075, DOI 10.1128/IAI.72.4.2075-2080.2004
NR 42
TC 61
Z9 63
U1 1
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0741-5400
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD AUG 1
PY 2008
VL 84
IS 2
BP 389
EP 396
DI 10.1189/jlb.0108018
PG 8
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA 332OF
UT WOS:000258091600109
PM 18483206
OA Green Published
DA 2020-12-08
ER

PT J
AU Gomes, R
   Teixeira, C
   Teixeira, MJ
   Oliveira, F
   Menezes, MJ
   Silva, C
   de Oliveira, CI
   Miranda, JC
   Elnaiem, DE
   Kamhawi, S
   Valenzuela, JG
   Brodskyn, CI
AF Gomes, Regis
   Teixeira, Clarissa
   Jania Teixeira, Maria
   Oliveira, Fabiano
   Jose Menezes, Maria
   Silva, Claire
   de Oliveira, Calmila I.
   Miranda, Jose C.
   Elnaiem, Dia-Eldin
   Kamhawi, Shaden
   Valenzuela, Jesus G.
   Brodskyn, Claudia I.
TI Immunity to a salivary protein of a sand fly vector protects against the
   fatal outcome of visceral leishmaniasis in a hamster model
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE antisaliva immunity; Leishmania; sand fly saliva; vector-based vaccine
ID LUTZOMYIA-LONGIPALPIS; CUTANEOUS LEISHMANIASIS; NITRIC-OXIDE;
   BORRELIA-BURGDORFERI; CLINICAL EVOLUTION; GOLDEN-HAMSTER; INFECTION;
   DONOVANI; TRANSMISSION; RESISTANCE
AB Visceral leishmaniasis (VL) is a fatal disease for humans, and no vaccine is currently available. Sand fly salivary proteins have been associated with protection against cutaneous leishmaniasis. To test whether vector salivary proteins can protect against VL, a hamster model was developed involving intradermal inoculation in the ears of 100,000 Leishmania infantum chagasi parasites together with Lutzomyia longipalpis saliva to mimic natural transmission by sand flies. Hamsters developed classical signs of VL rapidly, culminating in a fatal outcome 5-6 months postinfection. Saliva had no effect on the course of infection in this model. Immunization with 16 DNA plasmids coding for salivary proteins of Lu. longipalpis resulted in the identification of LJM19, a novel 11-kDa protein, that protected hamsters against the fatal outcome of VL. LJM19-immunized hamsters maintained a low parasite load that correlated with an overall high IFN-gamma/TGF-beta ratio and inducible NOS expression in the spleen and liver up to 5 months postinfection. Importantly, a delayed-type hypersensitivity response with high expression of IFN-gamma was also noted in the skin of LJM19-immunized hamsters 48 h after exposure to uninfected sand fly bites. Induction of IFN-gamma at the site of bite could partly explain the protection observed in the viscera of LJM19-immunized hamsters through direct parasite killing and/or priming of anti-Leishmania immunity. We have shown that immunity to a defined salivary protein (LJM19) confers powerful protection against the fatal outcome of a parasitic disease, which reinforces the concept of using components of arthropod saliva in vaccine strategies against vector-borne diseases.
C1 [Gomes, Regis; Teixeira, Clarissa; Oliveira, Fabiano; Elnaiem, Dia-Eldin; Kamhawi, Shaden; Valenzuela, Jesus G.] NIAID, Vector Mol Biol Unit, Lab Malaria & Vector Res, Natl Inst Hlth, Rockville, MD 20852 USA.
   [Gomes, Regis; Teixeira, Clarissa; Jania Teixeira, Maria; Oliveira, Fabiano; Jose Menezes, Maria; Silva, Claire; de Oliveira, Calmila I.; Miranda, Jose C.; Brodskyn, Claudia I.] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, BR-40296710 Salvador, BA, Brazil.
   [Brodskyn, Claudia I.] Inst Invest Imunol, BR-40296710 Salvador, BA, Brazil.
RP Valenzuela, JG (corresponding author), NIAID, Vector Mol Biol Unit, Lab Malaria & Vector Res, Natl Inst Hlth, 12735 Twinbrook Pkwy, Rockville, MD 20852 USA.
EM jvalenzuela@niaid.nih.gov; brodskyn@cpqgm.fiocruz.br
RI Oliveira, Fabiano/AAG-5388-2019; de Oliveira, Camila I/B-4358-2009;
   Brodskyn, Claudia/A-9970-2010; Oliveira, Fabiano/B-4251-2009
OI Oliveira, Fabiano/0000-0002-7924-8038; de Oliveira, Camila
   I/0000-0002-7868-5164; Oliveira, Fabiano/0000-0002-7924-8038
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [ZIAAI000932, Z01AI000932, ZIAAI000932, Z01AI000932, ZIAAI000932,
   ZIAAI000932, ZIAAI000932, Z01AI000932, ZIAAI000932, ZIAAI000932,
   ZIAAI000932, ZIAAI000932, Z01AI000932, ZIAAI000932, Z01AI000932,
   Z01AI000932] Funding Source: NIH RePORTER; Intramural NIH HHSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA Funding Source: Medline
CR Anderson CF, 2007, J EXP MED, V204, P285, DOI 10.1084/jem.20061886
   Barral A, 2000, AM J TROP MED HYG, V62, P740, DOI 10.4269/ajtmh.2000.62.740
   Basu R, 2005, J IMMUNOL, V174, P7160, DOI 10.4049/jimmunol.174.11.7160
   Belkaid Y, 1998, J EXP MED, V188, P1941, DOI 10.1084/jem.188.10.1941
   BELL JF, 1979, AM J TROP MED HYG, V28, P876, DOI 10.4269/ajtmh.1979.28.876
   Bories C, 1998, ANN TROP MED PARASIT, V92, P685, DOI 10.1080/00034989859140
   CARVALHO EM, 1992, J INFECT DIS, V165, P535, DOI 10.1093/infdis/165.3.535
   Charlab R, 1999, P NATL ACAD SCI USA, V96, P15155, DOI 10.1073/pnas.96.26.15155
   Donovan MJ, 2007, INFECT IMMUN, V75, P2523, DOI 10.1128/IAI.01928-06
   GIANNINI MS, 1974, J PROTOZOOL, V21, P521, DOI 10.1111/j.1550-7408.1974.tb03692.x
   Gomes RB, 2002, J INFECT DIS, V186, P1530, DOI 10.1086/344733
   Jankovic D, 2007, J EXP MED, V204, P273, DOI 10.1084/jem.20062175
   Kamhawi S, 2000, SCIENCE, V290, P1351, DOI 10.1126/science.290.5495.1351
   Labuda M, 2006, PLOS PATHOG, V2, P251, DOI 10.1371/journal.ppat.0020027
   Lima HC, 1997, PARASITOL TODAY, V13, P80, DOI 10.1016/S0169-4758(96)40010-2
   Marsollier L, 2007, PLOS MED, V4, P288, DOI 10.1371/journal.pmed.0040064
   Melby PC, 1998, INFECT IMMUN, V66, P18, DOI 10.1128/IAI.66.1.18-27.1998
   Melby PC, 2001, J IMMUNOL, V166, P1912, DOI 10.4049/jimmunol.166.3.1912
   Miles SA, 2005, J EXP MED, V201, P747, DOI 10.1084/jem.20041470
   MODI GB, 1983, J MED ENTOMOL, V20, P568, DOI 10.1093/jmedent/20.5.568
   Monteiro MC, 2007, AM J TROP MED HYG, V76, P88, DOI 10.4269/ajtmh.2007.76.88
   Morris RV, 2001, J IMMUNOL, V167, P5226, DOI 10.4049/jimmunol.167.9.5226
   MURRAY HW, 1992, J IMMUNOL, V148, P1858
   Nazario S, 1998, AM J TROP MED HYG, V58, P780, DOI 10.4269/ajtmh.1998.58.780
   Nylen S, 2007, J EXP MED, V204, P805, DOI 10.1084/jem.20061141
   Oliveira F, 2006, VACCINE, V24, P374, DOI 10.1016/j.vaccine.2005.07.085
   Oliveira F, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000226
   PALATNIKDESOUSA CB, 1994, BRAZ J MED BIOL RES, V27, P547
   RIBEIRO JMC, 1989, SCIENCE, V243, P212, DOI 10.1126/science.2783496
   RIBEIRO JMC, 1986, COMP BIOCHEM PHYS A, V83, P683, DOI 10.1016/0300-9629(86)90709-7
   Rogers ME, 2004, NATURE, V430, P463, DOI 10.1038/nature02675
   Rohousova I, 2005, PARASITOLOGY, V130, P493, DOI 10.1017/S003118200400681X
   Rohousova I, 2006, FOLIA PARASIT, V53, P161, DOI 10.14411/fp.2006.022
   Silva F, 2005, AM J TROP MED HYG, V72, P94, DOI 10.4269/ajtmh.2005.72.94
   Singh N, 2007, PARASITOL RES, V101, P919, DOI 10.1007/s00436-007-0562-3
   Stanley AC, 2007, IMMUNOL CELL BIOL, V85, P138, DOI 10.1038/sj.icb7100011
   Thiakaki M, 2005, MICROBES INFECT, V7, P760, DOI 10.1016/j.micinf.2005.01.013
   TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436
   Travi BL, 2002, INFECT IMMUN, V70, P2288, DOI 10.1128/IAI.70.5.2288-2296.2002
   Valenzuela JG, 2004, J EXP BIOL, V207, P3717, DOI 10.1242/jeb.01185
   Valenzuela JG, 2001, J EXP MED, V194, P331, DOI 10.1084/jem.194.3.331
   Wikel SK, 1997, INFECT IMMUN, V65, P335, DOI 10.1128/IAI.65.1.335-338.1997
   WILSON ME, 1987, J PARASITOL, V73, P55, DOI 10.2307/3282344
NR 43
TC 157
Z9 159
U1 0
U2 12
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 3
PY 2008
VL 105
IS 22
BP 7845
EP 7850
DI 10.1073/pnas.0712153105
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 312DF
UT WOS:000256648600040
PM 18509051
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Menezes, MJ
   Costa, DJ
   Clarencio, J
   Miranda, JC
   Barral, A
   Barral, M
   Brodskyn, C
   de Oliveira, CI
AF Menezes, Maria Jose
   Costa, Dirceu J.
   Clarencio, Jorge
   Miranda, Jose Carlos
   Barral, Aldina
   Barral-Netto, Manoel
   Brodskyn, Claudia
   de Oliveira, Camila I.
TI Immunomodulation of human monocytes following exposure to Lutzomyia
   intermedia saliva
SO BMC IMMUNOLOGY
LA English
DT Article
ID SAND FLY SALIVA; AMERICAN CUTANEOUS LEISHMANIASIS; NITRIC-OXIDE
   PRODUCTION; IMMUNE-RESPONSE; IN-VITRO; CYTOKINE PRODUCTION; MOUSE
   MACROPHAGES; DENDRITIC CELLS; MAJOR INFECTION; VECTOR SALIVA
AB Background: Sand fly saliva contains potent and complex pharmacologic molecules that are able to modulate the host's hemostatic, inflammatory, and immune systems. In this study, we evaluated the effects of salivary gland sonicate (SGS) of Lutzomyia intermedia, the natural vector of Leishmania braziliensis, on monocytes obtained from the peripheral blood mononuclear cells (PBMC) of healthy volunteers. We investigated the effects of sand fly saliva on cytokine production and surface molecule expression of LPS-stimulated human monocytes uninfected or infected with L. braziliensis.
   Results: Pre-treatment of non-infected human monocytes with L. intermedia SGS followed by LPS-stimulation led to a significant decrease in IL-10 production accompanied by a significant increase in CD86, CD80, and HLA-DR expression. Pre-treatment with SGS followed by LPS stimulation and L. braziliensis infection led to a significant increase in TNF-alpha, IL-6, and IL-8 production without significant alterations in co-stimulatory molecule expression. However, pre-treatment with L. intermedia SGS did not result in significant changes in the infection rate of human monocytes.
   Conclusion: Our data indicate that L. intermedia saliva is able to modulate monocyte response, and, although this modulation is dissociated from enhanced infection with L. braziliensis, it may be associated with successful parasitism.
C1 [Menezes, Maria Jose; Costa, Dirceu J.; Clarencio, Jorge; Miranda, Jose Carlos; Barral, Aldina; Barral-Netto, Manoel; Brodskyn, Claudia; de Oliveira, Camila I.] Fiocruz MS, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [Barral, Aldina; Barral-Netto, Manoel; Brodskyn, Claudia] Univ Fed Bahia, Salvador, BA, Brazil.
   [Barral, Aldina; Barral-Netto, Manoel; Brodskyn, Claudia] Inst Invest Imunol, Salvador, BA, Brazil.
RP de Oliveira, CI (corresponding author), Fiocruz MS, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
EM mjmenezes@usp.br; dirceu@bahia.fiocruz.br; jorgec@bahia.fiocruz.br;
   jmiranda@bahia.fiocruz.br; abarral@bahia.fiocruz.br;
   mbarral@bahia.fiocruz.br; brodskyn@bahia.fiocruz.br;
   camila@bahia.fiocruz.br
RI Clarencio, Jorge/H-3940-2012; Barral, Aldina/B-4191-2009; Costa,
   Dirceu/D-7993-2013; Barral-Netto, Manoel/B-3904-2009; de Oliveira,
   Camila I/B-4358-2009; Brodskyn, Claudia/A-9970-2010
OI Barral, Aldina/0000-0002-7177-464X; Costa, Dirceu/0000-0002-0334-3899;
   Barral-Netto, Manoel/0000-0002-5823-7903; de Oliveira, Camila
   I/0000-0002-7868-5164; Clarencio, Jorge/0000-0002-4289-5450
CR AEBISCHER T, 1993, INFECT IMMUN, V61, P220, DOI 10.1128/IAI.61.1.220-226.1993
   Andrade BB, 2007, SCAND J IMMUNOL, V66, P122, DOI 10.1111/j.1365-3083.2007.01964.x
   Antonelli LRV, 2005, IMMUNOL LETT, V101, P226, DOI 10.1016/j.imlet.2005.06.004
   Belkaid Y, 1998, J EXP MED, V188, P1941, DOI 10.1084/jem.188.10.1941
   Belkaid Y, 2000, J IMMUNOL, V165, P969, DOI 10.4049/jimmunol.165.2.969
   BITTENCOURT AL, 1995, TROPICAL PATHOLOGY, V8, P597
   Brodie TM, 2007, INFECT IMMUN, V75, P2359, DOI 10.1128/IAI.01812-06
   BUELENS C, 1995, EUR J IMMUNOL, V25, P2668, DOI 10.1002/eji.1830250940
   Castilho TM, 2003, J CLIN MICROBIOL, V41, P540, DOI 10.1128/JCM.41.2.540-546.2003
   Costa DJ, 2004, INFECT IMMUN, V72, P1298, DOI 10.1128/IAI.72.3.1298-1305.2004
   de Moura TR, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000084
   Diehl S, 2002, MOL IMMUNOL, V39, P531, DOI 10.1016/S0161-5890(02)00210-9
   Elloso MM, 1999, J IMMUNOL, V162, P6708
   Favali C, 2005, MICROBES INFECT, V7, P86, DOI 10.1016/j.micinf.2004.09.015
   HALL LR, 1995, J IMMUNOL, V155, P3501
   Laskay T, 2003, TRENDS MICROBIOL, V11, P210, DOI 10.1016/S0966-842X(03)00075-1
   LOCKSLEY RM, 1993, SCIENCE, V261, P1448, DOI 10.1126/science.8367726
   Machado P, 2002, EUR J DERMATOL, V12, P449
   MCMAHONPRATT D, 1982, J IMMUNOL, V129, P926
   Mendonca MG, 2004, J INFECT DIS, V189, P1018, DOI 10.1086/382135
   MODI GB, 1983, J MED ENTOMOL, V20, P568, DOI 10.1093/jmedent/20.5.568
   Norsworthy NB, 2004, INFECT IMMUN, V72, P1240, DOI 10.1128/IAI.72.3.1240-1247.2004
   Pompeu MML, 2001, INFECT IMMUN, V69, P7453, DOI 10.1128/IAI.69.12.7453-7460.2001
   RIBEIRO JMC, 1995, INFECT AGENT DIS, V4, P143
   Rogers KA, 2003, PARASITE IMMUNOL, V25, P127, DOI 10.1046/j.1365-3024.2003.00623.x
   Rohousova I, 2005, PARASITE IMMUNOL, V27, P469, DOI 10.1111/j.1365-3024.2005.00787.x
   SAMUELSON J, 1991, J EXP MED, V173, P49, DOI 10.1084/jem.173.1.49
   Schubach A, 1998, AM J TROP MED HYG, V58, P824, DOI 10.4269/ajtmh.1998.58.824
   SCOTT P, 1989, EXP PARASITOL, V68, P369, DOI 10.1016/0014-4894(89)90120-3
   Soares MBP, 1998, J IMMUNOL, V160, P1811
   THEODOS CM, 1993, PARASITE IMMUNOL, V15, P481, DOI 10.1111/j.1365-3024.1993.tb00634.x
   TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436
   Titus RG, 2006, PARASITE IMMUNOL, V28, P131, DOI 10.1111/j.1365-3024.2006.00807.x
   Valenzuela JG, 2001, J EXP MED, V194, P331, DOI 10.1084/jem.194.3.331
   Waitumbi J, 1998, INFECT IMMUN, V66, P1534, DOI 10.1128/IAI.66.4.1534-1537.1998
NR 35
TC 12
Z9 12
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2172
J9 BMC IMMUNOL
JI BMC Immunol.
PD APR 10
PY 2008
VL 9
AR 12
DI 10.1186/1471-2172-9-12
PG 8
WC Immunology
SC Immunology
GA 297ZX
UT WOS:000255657000001
PM 18402685
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Giunchetti, RC
   Corriba-Oliveira, R
   Martins-Filho, OA
   Teixeira-Carvalho, A
   Roatt, BM
   Aguiar-Soares, RDDO
   Coura-Vital, W
   de Abreu, RT
   Malaquias, LCC
   Gontijo, NF
   Brodskyn, C
   de Oliveira, CI
   Costa, DJ
   de Lana, M
   Reis, AB
AF Giunchetti, Rodolfo Cordeiro
   Corriba-Oliveira, Rodrigo
   Martins-Filho, Olindo Assis
   Teixeira-Carvalho, Andrea
   Roatt, Bruno Mendes
   Aguiar-Soares, Rodrigo Dian de Oliveira
   Coura-Vital, Wendel
   de Abreu, Raquel Tropia
   Malaquias, Luiz Cosme Cotta
   Gontijo, Nelder Figueiredo
   Brodskyn, Claudia
   de Oliveira, Camila Indiani
   Costa, Dirceu Joaquim
   de Lana, Marta
   Reis, Alexandre Barbosa
TI A killed Leishmania vaccine with sand fly saliva extract and saponin
   adjuvant displays immunogenicity in dogs
SO VACCINE
LA English
DT Article
DE canine visceral leishmaniasis; cell and humoral immune response; flow
   cytometry
ID CANINE VISCERAL LEISHMANIASIS; MAJOR HISTOCOMPATIBILITY COMPLEX;
   EXCRETED-SECRETED ANTIGENS; LONG-LASTING PROTECTION;
   LUTZOMYIA-LONGIPALPIS; PARASITE DENSITY; IMMUNE-RESPONSE; FML-VACCINE;
   CUTANEOUS LEISHMANIASIS; INTERFERON-GAMMA
AB A vaccine against canine visceral. leishmaniasis (CVL), comprising Leishmania braziliensis promastigote protein, sand fly gland extract (SGE) and saponin adjuvant, was evaluated in dog model, in order to analyse the immunogenicity of the candidate vaccine. The vaccine candidate elicited strong antigenicity in dogs in respect of specific SGE and Leishmania humoral. immune response. The major saliva proteins recognized by serum from immunized dogs exhibited molecular weights of 35 and 45 kDa, and were related to the resistance pattern against Leishmania infection. Immunophenotypic analysis revealed increased circulating CD21(+) B-cells and CD5(+) T-cells, reflected by higher counts of CD4(+) and CD8(+) T-cells. The observed interaction between potential antigen - presenting cells (evaluated as CD14(+) monocytes) and lymphocyte activation status indicated a relationship between innate and adaptive immune responses. The higher frequency in L. chagasi antigen-specific CD8(+) T-lymphocytes, and their positive association with intense cell proliferation, in addition to the progressively higher production of serum nitric oxide levels, showed a profile compatible with anti-CVL vaccine potential. Further studies on immunological response after challenge with L. chagasi may provide important information that will lead to a better understanding on vaccine trial and efficacy. (c) 2007 Elsevier Ltd. All rights reserved.
C1 [Giunchetti, Rodolfo Cordeiro; Teixeira-Carvalho, Andrea; Roatt, Bruno Mendes; Aguiar-Soares, Rodrigo Dian de Oliveira; Coura-Vital, Wendel; de Abreu, Raquel Tropia; Reis, Alexandre Barbosa] Univ Fed Ouro Preto, Inst Cienacias Exatas & Biol, Lab Immunupatol Nucl Pesquisas & Ciencias Biol, BR-400000 Ouro Preto, Minas Gerias, Brazil.
   [Giunchetti, Rodolfo Cordeiro; Corriba-Oliveira, Rodrigo; Reis, Alexandre Barbosa] Fundacao Oswaldo Cruz, Lab Imunol Celular & Mol, Inst Rene Rachou, Belo Horizonte, MG, Brazil.
   [Martins-Filho, Olindo Assis; Teixeira-Carvalho, Andrea] Fundacao Oswaldo Cruz, Lab Biomaracadores Diagnost & Monitoracao, Inst Rene Rachou, Belo Horizonte, MG, Brazil.
   [Malaquias, Luiz Cosme Cotta] Univ Vale Rio Doce, Governador Valadares, MG, Brazil.
   [Gontijo, Nelder Figueiredo] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Parasitol, Lab Fisiol Insetos Hematofagos, Belo Horizonte, MG, Brazil.
   [Brodskyn, Claudia; de Oliveira, Camila Indiani; Costa, Dirceu Joaquim] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Lab Imunoparasitol, Salvador, BA, Brazil.
   [de Lana, Marta] Univ Fed Ouro Preto, Inst Ciencias Exatas & Biol, Lab Doenca Chagas Nucl Pesquisas & Ciencias Biol, Ouro Preto, MG, Brazil.
   [de Lana, Marta; Reis, Alexandre Barbosa] Univ Fed Ouro Preto, Escola Farma, Dept Anal Clin, Ouro Preto, MG, Brazil.
RP Giunchetti, RC (corresponding author), Univ Fed Ouro Preto, Inst Cienacias Exatas & Biol, Lab Immunupatol Nucl Pesquisas & Ciencias Biol, Morro Cruzeiro 35, BR-400000 Ouro Preto, Minas Gerias, Brazil.
EM giunchetti@nupeb.ufop.br; atexreis@nupeb.ufop.br
RI Roatt, Bruno M/R-5502-2016; Giunchetti, Rodolfo/O-9878-2014; de Oliveira
   Aguiar-Soares, Rodrigo Dian/ABB-7973-2020; de Oliveira, Camila
   I/B-4358-2009; Oliveira, Fabiano/AAG-5388-2019; Malaquias, Luiz
   Cosme/K-7210-2013; Gontijo, Nelder F/D-2539-2013; Brodskyn,
   Claudia/A-9970-2010; Costa, Dirceu/D-7993-2013
OI Roatt, Bruno M/0000-0001-5281-3263; de Oliveira Aguiar-Soares, Rodrigo
   Dian/0000-0001-8705-7357; de Oliveira, Camila I/0000-0002-7868-5164;
   Oliveira, Fabiano/0000-0002-7924-8038; Malaquias, Luiz
   Cosme/0000-0002-4920-072X; Gontijo, Nelder F/0000-0003-3357-2497; Costa,
   Dirceu/0000-0002-0334-3899; de Oliveira Aguiar Soares, Rodrigo
   Dian/0000-0002-3390-7990; Lana, Marta/0000-0002-1565-4707; Cordeiro
   Giunchetti, Rodolfo/0000-0003-4181-7546; Correa-Oliveira,
   Rodrigo/0000-0001-6419-9459; Martins-Filho, Olindo
   Assis/0000-0002-5494-4889; /0000-0002-1434-7676
CR ABRANCHES P, 1991, J PARASITOL, V77, P557, DOI 10.2307/3283159
   Alvar J, 2004, ADV PARASIT, V57, P1, DOI 10.1016/S0065-308X(04)57001-X
   Anderson JM, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-52
   Andrade BB, 2007, SCAND J IMMUNOL, V66, P122, DOI 10.1111/j.1365-3083.2007.01964.x
   Bahia D, 2007, PARASITOL RES, V100, P449, DOI 10.1007/s00436-006-0307-8
   Baneth G, 2002, VET PARASITOL, V106, P315, DOI 10.1016/S0304-4017(02)00115-2
   Barral A, 2000, AM J TROP MED HYG, V62, P740, DOI 10.4269/ajtmh.2000.62.740
   Belkaid Y, 1998, J EXP MED, V188, P1941, DOI 10.1084/jem.188.10.1941
   Borj-Cabrera GP, 2002, VACCINE, V20, P3277, DOI 10.1016/S0264-410X(02)00294-3
   Borja-Cabrera GP, 2004, VACCINE, V22, P2234, DOI 10.1016/j.vaccine.2003.11.039
   Bourdoiseau G, 1997, VET IMMUNOL IMMUNOP, V59, P21, DOI 10.1016/S0165-2427(97)00072-X
   Brodskyn Claudia, 2003, Expert Rev Vaccines, V2, P705, DOI 10.1586/14760584.2.5.705
   Campos-Neto A, 2001, INFECT IMMUN, V69, P4103, DOI 10.1128/IAI.69.6.4103-4108.2001
   CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209
   Cavalcante RR, 2003, PARASITOLOGY, V127, P87, DOI 10.1017/S0031182003003329
   Chamizo C, 2005, VET IMMUNOL IMMUNOP, V103, P67, DOI 10.1016/j.vetimm.2004.08.010
   Charlab R, 1999, P NATL ACAD SCI USA, V96, P15155, DOI 10.1073/pnas.96.26.15155
   COBBOLD S, 1994, TISSUE ANTIGENS, V43, P137, DOI 10.1111/j.1399-0039.1994.tb02315.x
   Courtenay O, 2002, J INFECT DIS, V186, P1314, DOI 10.1086/344312
   da Silva VO, 2000, VACCINE, V19, P1082, DOI 10.1016/S0264-410X(00)00339-X
   Day MJ, 2007, VET PARASITOL, V147, P2, DOI 10.1016/j.vetpar.2007.03.037
   DEANE L. M., 1961, REV ASSOC MED BRASIL, V7, P161
   Dole VS, 2000, VACCINE, V19, P423, DOI 10.1016/S0264-410X(00)00207-3
   Gillespie RD, 2000, PARASITE IMMUNOL, V22, P319, DOI 10.1046/j.1365-3024.2000.00309.x
   GIUNCHETTI RC, 2006, RES VET SCI, V135, P100
   Giunchetti RC, 2008, RES VET SCI, V85, P106, DOI 10.1016/j.rvsc.2007.09.008
   Giunchetti RC, 2008, VET IMMUNOL IMMUNOP, V121, P23, DOI 10.1016/j.vetimm.2007.07.009
   Giunchetti RC, 2007, VACCINE, V25, P7674, DOI 10.1016/j.vaccine.2007.08.009
   Gomes RB, 2002, J INFECT DIS, V186, P1530, DOI 10.1086/344733
   Gradoni L, 2001, VET PARASITOL, V100, P87, DOI 10.1016/S0304-4017(01)00486-1
   GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X
   GUTMAN SI, 1992, CLIN CHEM, V38, P2152
   Holzmuller P, 2005, VET IMMUNOL IMMUNOP, V106, P247, DOI 10.1016/j.vetimm.2005.03.001
   Hommel M, 1995, ANN TROP MED PARASIT, V89, P55, DOI 10.1080/00034983.1995.11813015
   Kamhawi S, 2000, SCIENCE, V290, P1351, DOI 10.1126/science.290.5495.1351
   Kamhawi S, 2000, MICROBES INFECT, V2, P1765, DOI 10.1016/S1286-4579(00)01331-9
   KEENAN CM, 1984, VET PATHOL, V21, P74, DOI 10.1177/030098588402100113
   Kensil CR, 1996, CRIT REV THER DRUG, V13, P1
   Khamesipour A, 2006, INDIAN J MED RES, V123, P423
   Lage RS, 2007, VET IMMUNOL IMMUNOP, V115, P135, DOI 10.1016/j.vetimm.2006.10.001
   LAINSON R, 1978, NATURE, V273, P595, DOI 10.1038/273595a0
   Lasri S, 1999, VET RES, V30, P441
   Lemesre JL, 2007, VACCINE, V25, P4223, DOI 10.1016/j.vaccine.2007.02.083
   Lemesre JL, 2005, VACCINE, V23, P2825, DOI 10.1016/j.vaccine.2004.11.061
   LERNER EA, 1991, J BIOL CHEM, V266, P11234
   Lima HC, 1996, INFECT IMMUN, V64, P5442, DOI 10.1128/IAI.64.12.5442-5445.1996
   Marciani DJ, 2003, DRUG DISCOV TODAY, V8, P934, DOI 10.1016/S1359-6446(03)02864-2
   Mauel J., 2002, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V2, P201, DOI 10.2174/1568008023340631
   Mayrink W, 1996, MEM I OSWALDO CRUZ, V91, P695, DOI 10.1590/S0074-02761996000600006
   Mejia JS, 2006, TRENDS PARASITOL, V22, P367, DOI 10.1016/j.pt.2006.06.001
   MODI GB, 1983, J MED ENTOMOL, V20, P568, DOI 10.1093/jmedent/20.5.568
   Mohebali M, 2004, VACCINE, V22, P4097, DOI 10.1016/j.vaccine.2004.03.058
   Moreno J, 2002, TRENDS PARASITOL, V18, P399, DOI 10.1016/S1471-4922(02)02347-4
   Morris RV, 2001, J IMMUNOL, V167, P5226, DOI 10.4049/jimmunol.167.9.5226
   Nogueira FS, 2005, VACCINE, V23, P4805, DOI 10.1016/j.vaccine.2005.05.011
   Noli C, 2005, VET DERMATOL, V16, P213, DOI 10.1111/j.1365-3164.2005.00460.x
   Oliveira F, 2006, VACCINE, V24, P374, DOI 10.1016/j.vaccine.2005.07.085
   Oliveira-Freitas E, 2006, VACCINE, V24, P3909, DOI 10.1016/j.vaccine.2006.02.034
   Panaro MA, 2001, COMP IMMUNOL MICROB, V24, P187, DOI 10.1016/S0147-9571(00)00026-6
   Parra LE, 2007, VACCINE, V25, P2180, DOI 10.1016/j.vaccine.2006.11.057
   Peruhype-Magalhaes V, 2006, CLIN EXP IMMUNOL, V146, P124, DOI 10.1111/j.1365-2249.2006.03171.x
   Pinelli E., 1997, P217
   Radosevich TJ, 2003, HUM GENE THER, V14, P1765, DOI 10.1089/104303403322611773
   Rafati S, 2005, VACCINE, V23, P3716, DOI 10.1016/j.vaccine.2005.02.009
   Rajput Zahid Iqbal, 2007, Journal of Zhejiang University-Science B, V8, P153, DOI 10.1631/jzus.2007.B0153
   Ramiro MJ, 2003, VACCINE, V21, P2474, DOI 10.1016/S0264-410X(03)00032-X
   Ravindran R, 2004, CURR MOL MED, V4, P697, DOI 10.2174/1566524043360212
   Reis AB, 2006, CLIN EXP IMMUNOL, V146, P303, DOI 10.1111/j.1365-2249.2006.03206.x
   Reis AB, 2005, VET IMMUNOL IMMUNOP, V103, P173, DOI 10.1016/j.vetimm.2004.08.014
   Reis AB, 2006, VET IMMUNOL IMMUNOP, V112, P102, DOI 10.1016/j.vetimm.2006.02.001
   Reis AB, 2006, RES VET SCI, V81, P68, DOI 10.1016/j.rvsc.2005.09.011
   Requena JM, 2004, EXPERT OPIN BIOL TH, V4, P1505, DOI 10.1517/14712598.4.9.1505
   SAMUELSON J, 1991, J EXP MED, V173, P49, DOI 10.1084/jem.173.1.49
   Santos FN, 2007, VACCINE, V25, P6176, DOI 10.1016/j.vaccine.2007.06.005
   Santos WR, 2003, VACCINE, V21, P4668, DOI 10.1016/S0264-410X(03)00527-9
   Santos WR, 2002, VACCINE, V21, P30, DOI 10.1016/S0264-410X(02)00444-9
   Saraiva EM, 2006, VACCINE, V24, P2423, DOI 10.1016/j.vaccine.2005.11.061
   THEODOS CM, 1991, INFECT IMMUN, V59, P1592, DOI 10.1128/IAI.59.5.1592-1598.1991
   TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436
   Titus RG, 2006, PARASITE IMMUNOL, V28, P131, DOI 10.1111/j.1365-3024.2006.00807.x
   Titus RG, 1998, EXP PARASITOL, V89, P133, DOI 10.1006/expr.1998.4272
   Valenzuela JG, 2004, J EXP BIOL, V207, P3717, DOI 10.1242/jeb.01185
   Valenzuela JG, 2001, J EXP MED, V194, P331, DOI 10.1084/jem.194.3.331
   WARBURG A, 1994, PHILOS T R SOC B, V345, P223, DOI 10.1098/rstb.1994.0097
   Webb JR, 1996, J IMMUNOL, V157, P5034
   Webb JR, 1998, INFECT IMMUN, V66, P3279, DOI 10.1128/IAI.66.7.3279-3289.1998
   WHITLEY EM, 1995, ANTICANCER RES, V15, P923
   WILSON ME, 1995, INFECT IMMUN, V63, P2062, DOI 10.1128/IAI.63.5.2062-2069.1995
   Yukinawa N, 2006, BMC GENOMICS, V7, P1, DOI 10.1186/1471-2164-7-190
NR 89
TC 34
Z9 35
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 30
PY 2008
VL 26
IS 5
BP 623
EP 638
DI 10.1016/j.vaccine.2007.11.057
PG 16
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 258YK
UT WOS:000252906100005
PM 18180079
OA Green Published
DA 2020-12-08
ER

PT J
AU de Moura, TR
   Oliveira, F
   Novais, FO
   Miranda, JC
   Clarencio, J
   Follador, I
   Carvalho, EM
   Valenzuela, JG
   Barral, M
   Barral, A
   Brodskyn, C
   de Oliveira, CI
AF de Moura, Tatiana R.
   Oliveira, Fabiano
   Novais, Fernanda O.
   Miranda, Jose Carlos
   Clarencio, Jorge
   Follador, Ivonise
   Carvalho, Edgar M.
   Valenzuela, Jesus G.
   Barral-Netto, Manoel
   Barral, Aldina
   Brodskyn, Claudia
   de Oliveira, Camila I.
TI Enhanced Leishmania braziliensis Infection Following Pre-Exposure to
   Sandfly Saliva
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID DELAYED-TYPE HYPERSENSITIVITY; LUTZOMYIA-LONGIPALPIS; CUTANEOUS
   LEISHMANIASIS; PHLEBOTOMINE SANDFLIES; MAJOR INFECTION; MOUSE MODEL; FLY
   SALIVA; VECTOR; MICE; ANTIGENS
AB Background: Sand fly saliva has an array of pharmacological and immunomodulatory components, and immunity to saliva protects against Leishmania infection. In the present study, we have studied the immune response against Lutzomyia intermedia saliva, the main vector of Leishmania braziliensis in Brazil, and the effects of saliva pre-exposure on L. braziliensis infection employing an intradermal experimental model.
   Methodology/principal findings: BALB/c mice immunized with L. intermedia salivary gland sonicate (SGS) developed a saliva-specific antibody response and a cellular immune response with presence of both IFN-gamma and IL-4. The inflammatory infiltrate observed in SGS-immunized mice was comprised of numerous polymorphonuclear and few mononuclear cells. Mice challenged with live L. braziliensis in the presence of saliva were not protected although lesion development was delayed. The inoculation site and draining lymph node showed continuous parasite replication and low IFN-gamma to IL-4 ratio, indicating that pre-exposure to L. intermedia saliva leads to modulation of the immune response. Furthermore, in an endemic area of cutaneous leishmaniasis, patients with active lesions displayed higher levels of anti-L. intermedia saliva antibodies when compared to individuals with a positive skin test result for Leishmania.
   Conclusion: These results show that pre-exposure to sand fly saliva plays an important role in the outcome of cutaneous leishmaniasis, in both mice and humans. They emphasize possible hurdles in the development of vaccines based on sand fly saliva and the need to identify and select the individual salivary candidates instead of using whole salivary mixture that may favor a non-protective response.
C1 [de Moura, Tatiana R.; Oliveira, Fabiano; Novais, Fernanda O.; Miranda, Jose Carlos; Clarencio, Jorge; Barral-Netto, Manoel; Barral, Aldina; Brodskyn, Claudia; de Oliveira, Camila I.] Fdn Oswaldo Cruz FIOCRUZ, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [Oliveira, Fabiano; Valenzuela, Jesus G.] NIAID, Vector Mol Biol Unit, NIH, Rockville, MD USA.
   [Follador, Ivonise; Carvalho, Edgar M.; Barral-Netto, Manoel; Barral, Aldina; Brodskyn, Claudia] Univ Fed Bahia, Salvador, BA, Brazil.
   [Barral-Netto, Manoel; Barral, Aldina; Brodskyn, Claudia] Inst Invest & Imunol, Salvador, BA, Brazil.
RP de Moura, TR (corresponding author), Fdn Oswaldo Cruz FIOCRUZ, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
EM camila@bahia.fiocruz.br
RI Oliveira, Fabiano/AAG-5388-2019; de Oliveira, Camila I/B-4358-2009;
   Brodskyn, Claudia/A-9970-2010; , Tatiana/AAN-1194-2020; Barral-Netto,
   Manoel/B-3904-2009; Clarencio, Jorge/H-3940-2012
OI Oliveira, Fabiano/0000-0002-7924-8038; de Oliveira, Camila
   I/0000-0002-7868-5164; , Tatiana/0000-0002-7442-4434; Barral-Netto,
   Manoel/0000-0002-5823-7903; Clarencio, Jorge/0000-0002-4289-5450
FU FAPESB; PAPES/FIOCRUZ; CNPqNational Council for Scientific and
   Technological Development (CNPq); EMC; MBN; AB; CB; CIO; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [Z01AI000932, Z01AI000932, ZIAAI000932, ZIAAI000932, ZIAAI000932,
   ZIAAI000932, Z01AI000932, Z01AI000932, ZIAAI000932, Z01AI000932,
   ZIAAI000932, ZIAAI000932, ZIAAI000932, ZIAAI000932, Z01AI000932,
   ZIAAI000932] Funding Source: NIH RePORTER
FX This work was supported by grants from FAPESB, PAPES/FIOCRUZ and CNPq.
   TRM was supported by a CNPq fellowship; FON was supported by FAPESB
   fellowship. EMC, MBN, AB, CB and CIO are senior investigators from CNPq.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Barral A, 2000, AM J TROP MED HYG, V62, P740, DOI 10.4269/ajtmh.2000.62.740
   BATES PA, 2007, INT J PARASITOL
   Belkaid Y, 2000, P NATL ACAD SCI USA, V97, P6704, DOI 10.1073/pnas.97.12.6704
   Belkaid Y, 1998, J EXP MED, V188, P1941, DOI 10.1084/jem.188.10.1941
   BITTENCOURT AL, 1995, TROPICAL PATHOLOGY, P597
   Cerna P, 2002, INSECT BIOCHEM MOLEC, V32, P1691, DOI 10.1016/S0965-1748(02)00109-1
   Costa DJ, 2004, INFECT IMMUN, V72, P1298, DOI 10.1128/IAI.72.3.1298-1305.2004
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   Donnelly KB, 1998, J PARASITOL, V84, P97, DOI 10.2307/3284537
   Follador I, 2002, CLIN INFECT DIS, V34, pE54, DOI 10.1086/340261
   Gomes RB, 2002, J INFECT DIS, V186, P1530, DOI 10.1086/344733
   Kamhawi S, 2000, SCIENCE, V290, P1351, DOI 10.1126/science.290.5495.1351
   Lanzaro GC, 1999, INSECT MOL BIOL, V8, P267, DOI 10.1046/j.1365-2583.1999.820267.x
   MARSDEN PD, 1986, T ROY SOC TROP MED H, V80, P859, DOI 10.1016/0035-9203(86)90243-9
   MODI GB, 1983, J MED ENTOMOL, V20, P568, DOI 10.1093/jmedent/20.5.568
   Morris RV, 2001, J IMMUNOL, V167, P5226, DOI 10.4049/jimmunol.167.9.5226
   Norsworthy NB, 2004, INFECT IMMUN, V72, P1240, DOI 10.1128/IAI.72.3.1240-1247.2004
   Oliveira F, 2006, VACCINE, V24, P374, DOI 10.1016/j.vaccine.2005.07.085
   RIBEIRO JMC, 1987, ANNU REV ENTOMOL, V32, P463, DOI 10.1146/annurev.en.32.010187.002335
   Ribeiro-Gomes FL, 2004, J IMMUNOL, V172, P4454, DOI 10.4049/jimmunol.172.7.4454
   Rohousova I, 2005, PARASITOLOGY, V130, P493, DOI 10.1017/S003118200400681X
   Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933
   Sacks D, 2001, ANNU REV MICROBIOL, V55, P453, DOI 10.1146/annurev.micro.55.1.453
   SAMUELSON J, 1991, J EXP MED, V173, P49, DOI 10.1084/jem.173.1.49
   Silva F, 2005, AM J TROP MED HYG, V72, P94, DOI 10.4269/ajtmh.2005.72.94
   Teixeira MJ, 2005, INFECT IMMUN, V73, P1191, DOI 10.1128/IAI.73.2.1191-1195.2005
   Thiakaki M, 2005, MICROBES INFECT, V7, P760, DOI 10.1016/j.micinf.2005.01.013
   TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436
   Titus RG, 2006, PARASITE IMMUNOL, V28, P131, DOI 10.1111/j.1365-3024.2006.00807.x
   TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x
   Valenzuela JG, 2001, J EXP MED, V194, P331, DOI 10.1084/jem.194.3.331
   van Zandbergen G, 2004, J IMMUNOL, V173, P6521, DOI 10.4049/jimmunol.173.11.6521
   Volf P, 2001, PARASITOLOGY, V122, P37, DOI 10.1017/S0031182000007046
   Volf P, 2000, MED VET ENTOMOL, V14, P251, DOI 10.1046/j.1365-2915.2000.00240.x
   WARBURG A, 1994, PHILOS T R SOC B, V345, P223, DOI 10.1098/rstb.1994.0097
NR 35
TC 64
Z9 64
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD NOV
PY 2007
VL 1
IS 2
AR e84
DI 10.1371/journal.pntd.0000084
PG 10
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 383XI
UT WOS:000261707300006
PM 18060088
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Salay, G
   Dorta, ML
   Santos, NM
   Mortara, RA
   Brodskyn, C
   Oliveira, CI
   Barbieri, CL
   Rodrigues, MM
AF Salay, G.
   Dorta, M. L.
   Santos, N. M.
   Mortara, R. A.
   Brodskyn, C.
   Oliveira, C. I.
   Barbieri, C. L.
   Rodrigues, M. M.
TI Testing of four Leishmania vaccine candidates in a mouse model of
   infection with Leishmania (Viannia) braziliensis, the main causative
   agent of cutaneous leishmaniasis in the new world
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID IMMUNE-RESPONSE; PROTECTIVE IMMUNITY; DNA VACCINE; PROTEIN; ANTIGEN;
   IMMUNIZATION; RESISTANCE; MURINE; CHEMOTHERAPY; AMASTIGOTES
AB We evaluated whether four recombinant antigens previously used for vaccination against experimental infection with Leishmania (Leishmania) major could also induce protective immunity against a challenge with Leishmania (Viannia) braziliensis, the species responsible for 90% of the 28,712 annual cases of cutaneous and mucocutaneous leishmaniasis recorded in Brazil during the year of 2004. Initially, we isolated the homolog genes encoding four L. (V.) braziliensis antigens: (i) homologue of receptor for activated C kinase, (ii) thiol-specific antioxidant, (iii) Leishmania elongation and initiation factor, and (iv) L. (L.) major stress-inducible protein 1. At the deduced amino acid level, all four open reading frames had a high degree of identity with the previously described genes of L. (L.) major being expressed on promastigotes and amastigotes of L. (V.) braziliensis. These genes were inserted into the vector pcDNA3 or expressed as bacterial recombinant proteins. After immunization with recombinant plasmids or proteins, BALB/c mice generated specific antibody or cell-mediated immune responses (gamma interferon production). After an intradermal challenge with L. (V.) braziliensis infective promastigotes, no significant reduction on the lesions was detected. We conclude that the protective immunity afforded by these four vaccine candidates against experimental cutaneous leishmaniasis caused by L. (L.) major could not be reproduced against a challenge with L. (V.) braziliensis. Although negative, we consider our results important since they suggest that studies aimed at the development of an effective vaccine against L. (V.) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World, should be redirected toward distinct antigens or different vaccination strategies.
C1 UNIFESP EPM, CINTERGEN Ctr Interdisciplinar Terapia Gen, BR-04044010 Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Escola Paulista Med, Dept Microbiol Imunol Parasitol, Disciplina Parasitol, BR-04023062 Sao Paulo, Brazil.
   Fdn Oswaldo Crus, Ctr Pesquisas Goncalo Moniz, BR-40295001 Salvador, BA, Brazil.
   Univ Fed Gouania, Dept Microbiol Imunono & Parasitol, Disciplina Imunol, Goiania, Go, Brazil.
   Univ Fed Bahia, Inst Ciencias Saude, Dept Biointeracao, BR-40110160 Salvador, BA, Brazil.
RP Rodrigues, MM (corresponding author), UNIFESP EPM, CINTERGEN Ctr Interdisciplinar Terapia Gen, Rua Mirassoi 207, BR-04044010 Sao Paulo, Brazil.
EM mrodrigues@ecb.epm.br
RI Rodrigues, Mauricio M./B-8512-2012; Oliveira, Fabiano/AAG-5388-2019;
   Mortara, Renato A./C-1864-2012; de Oliveira, Camila I/B-4358-2009;
   Moreira Santos, Nathalia/B-9133-2012; Brodskyn, Claudia/A-9970-2010;
   Barbieri, Clara L./E-1505-2012
OI Oliveira, Fabiano/0000-0002-7924-8038; Mortara, Renato
   A./0000-0002-2311-8349; de Oliveira, Camila I/0000-0002-7868-5164;
   Barbieri, Clara L./0000-0001-9426-2308
CR ALFIERI SC, 1987, PARASITOLOGY, V95, P31, DOI 10.1017/S0031182000057528
   BARBIERI CL, 1990, EXP PARASITOL, V71, P218, DOI 10.1016/0014-4894(90)90024-7
   BERMAN JD, 1988, REV INFECT DIS, V10, P560
   Boscardin SB, 2003, INFECT IMMUN, V71, P2744, DOI 10.1128/IAI.71.5.2744-2757.2003
   Campos-Neto A, 2002, INFECT IMMUN, V70, P2828, DOI 10.1128/IAI.70.6.2828-2836.2002
   Campos-Neto A, 2001, INFECT IMMUN, V69, P4103, DOI 10.1128/IAI.69.6.4103-4108.2001
   *CENEPI, 2007, MAN SURV AM INT LEIS
   CHAMPSI J, 1988, INFECT IMMUN, V56, P3272, DOI 10.1128/IAI.56.12.3272-3279.1988
   Coler RN, 2005, TRENDS PARASITOL, V21, P244, DOI 10.1016/j.pt.2005.03.006
   Coler RN, 2002, INFECT IMMUN, V70, P4215, DOI 10.1128/IAI.70.8.4215-4225.2002
   CONVIT J, 1993, T ROY SOC TROP MED H, V87, P444, DOI 10.1016/0035-9203(93)90030-T
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   FONG D, 1984, P NATL ACAD SCI USA, V78, P7624
   GROGL M, 1992, AM J TROP MED HYG, V47, P117, DOI 10.4269/ajtmh.1992.47.117
   Gurunathan S, 1998, NAT MED, V4, P1409, DOI 10.1038/4000
   Gurunathan S, 1997, J EXP MED, V186, P1137, DOI 10.1084/jem.186.7.1137
   Melby PC, 2001, INFECT IMMUN, V69, P4719, DOI 10.1128/IAI.69.8.4719-4725.2001
   Mendez A, 2002, VACCINE, V20, P3702, DOI 10.1016/S0264-410X(02)00376-6
   Mendez S, 2001, J IMMUNOL, V166, P5122, DOI 10.4049/jimmunol.166.8.5122
   MOUGNEAU E, 1995, SCIENCE, V268, P563, DOI 10.1126/science.7725103
   Reed Steven G, 2003, Expert Rev Vaccines, V2, P239, DOI 10.1586/14760584.2.2.239
   Rhee EG, 2002, J EXP MED, V195, P1565, DOI 10.1084/jem.20020147
   Rodrigues MM, 1999, INFECT IMMUN, V67, P3855, DOI 10.1128/IAI.67.8.3855-3863.1999
   Rojas R, 2006, J INFECT DIS, V193, P1375, DOI 10.1086/503371
   Sambrook J., 1989, MOL CLONING LAB MANU
   Shaw Jeffrey Jon, 1999, Memoirs on Entomology International, V14, P503
   Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003
   SKEIKY YAW, 1995, J EXP MED, V181, P1527, DOI 10.1084/jem.181.4.1527
   Skeiky YAW, 1998, J IMMUNOL, V161, P6171
   Skeiky YAW, 2002, VACCINE, V20, P3292, DOI 10.1016/S0264-410X(02)00302-X
   SOONG L, 1995, INFECT IMMUN, V63, P3559, DOI 10.1128/IAI.63.9.3559-3566.1995
   ULLMAN B, 1995, J BIOENERG BIOMEMBR, V27, P77, DOI 10.1007/BF02110334
   Vasconcelos JRC, 2003, IMMUNOL CELL BIOL, V81, P121, DOI 10.1046/j.0818-9641.2002.01136.x
   Webb JR, 1996, J IMMUNOL, V157, P5034
   Webb JR, 1998, INFECT IMMUN, V66, P3279, DOI 10.1128/IAI.66.7.3279-3289.1998
   Webb JR, 1997, MOL BIOCHEM PARASIT, V89, P179, DOI 10.1016/S0166-6851(97)00115-1
NR 36
TC 28
Z9 28
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
EI 1556-679X
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD SEP
PY 2007
VL 14
IS 9
BP 1173
EP 1181
DI 10.1128/CVI.00060-07
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 210XH
UT WOS:000249488400015
PM 17626159
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Andrade, BB
   de Oliveira, CI
   Brodskyn, CI
   Barral, A
   Barral-Netto, M
AF Andrade, B. B.
   de Oliveira, C. I.
   Brodskyn, C. I.
   Barral, A.
   Barral-Netto, M.
TI Role of sand fly saliva in human and experimental leishmaniasis: Current
   insights
SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY
LA English
DT Review
ID DELAYED-TYPE HYPERSENSITIVITY; LUTZOMYIA-LONGIPALPIS; CUTANEOUS
   LEISHMANIASIS; VISCERAL LEISHMANIASIS; IMMUNE-RESPONSE; VECTOR SALIVA;
   BALB/C MICE; INFECTION; BRAZILIENSIS; MODEL
AB Leishmaniases are wide spread diseases transmitted to their vertebrate host by infected sand fly. The saliva from these arthropods contains a vast repertoire of pharmacologically active molecules that hampers the host's haemostatic, inflammatory and immune responses. The early interactions between Leishmania and the host's immune response are closely linked to disease evolution or protection against the protozoan, and the ectoparasite saliva contributes directly to these interactions. Current studies have depicted these features, and these relations are being widely explored. There are concrete indications that the host response against sand fly saliva influences disease outcome in leishmaniasis. Additionally, there are demonstrations that immunization with whole sand fly saliva, or its components, leads to protection against leishmaniasis in different host species. The combination of these evidences opens up optimistic perspectives for improving vaccine development against Leishmania infection.
C1 Fiocruz MS, Ctr Pesquisas Goncalo Moniz, BR-40295001 Salvador, BA, Brazil.
   Univ Fed Bahia, Salvador, Brazil.
   Inst Invest Imunol, Inst Milenio, Salvador, BA, Brazil.
RP Barral-Netto, M (corresponding author), Fiocruz MS, Ctr Pesquisas Goncalo Moniz, Rua Waldemar Falcao 121, BR-40295001 Salvador, BA, Brazil.
EM mbarral@cpqgm.fiocruz.br
RI Barral-Netto, Manoel/B-3904-2009; Andrade, Bruno/AAI-2248-2020;
   Brodskyn, Claudia/A-9970-2010; de Oliveira, Camila I/B-4358-2009;
   Andrade, Bruno/J-9111-2012
OI Barral-Netto, Manoel/0000-0002-5823-7903; de Oliveira, Camila
   I/0000-0002-7868-5164; Andrade, Bruno/0000-0001-6833-3811
CR Anderson JM, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-52
   Andrade BB, 2005, AN ACAD BRAS CIENC, V77, P665, DOI 10.1590/S0001-37652005000400008
   ANJILI CO, 1995, ACTA TROP, V60, P97, DOI 10.1016/0001-706X(95)00112-R
   Barral A, 2000, AM J TROP MED HYG, V62, P740, DOI 10.4269/ajtmh.2000.62.740
   Belkaid Y, 2000, P NATL ACAD SCI USA, V97, P6704, DOI 10.1073/pnas.97.12.6704
   Belkaid Y, 1998, J EXP MED, V188, P1941, DOI 10.1084/jem.188.10.1941
   Charlab R, 1999, P NATL ACAD SCI USA, V96, P15155, DOI 10.1073/pnas.96.26.15155
   Costa DJ, 2004, INFECT IMMUN, V72, P1298, DOI 10.1128/IAI.72.3.1298-1305.2004
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   Ghosh KN, 1998, INT J PARASITOL, V28, P275, DOI 10.1016/S0020-7519(97)00152-5
   Gomes RB, 2002, J INFECT DIS, V186, P1530, DOI 10.1086/344733
   Kamhawi S, 2000, SCIENCE, V290, P1351, DOI 10.1126/science.290.5495.1351
   Kamhawi S, 2000, MICROBES INFECT, V2, P1765, DOI 10.1016/S1286-4579(00)01331-9
   LERNER EA, 1991, J BIOL CHEM, V266, P11234
   Lima HC, 1996, INFECT IMMUN, V64, P5442, DOI 10.1128/IAI.64.12.5442-5445.1996
   Mbow ML, 1998, J IMMUNOL, V161, P5571
   Monteiro MC, 2007, AM J TROP MED HYG, V76, P88, DOI 10.4269/ajtmh.2007.76.88
   Morris RV, 2001, J IMMUNOL, V167, P5226, DOI 10.4049/jimmunol.167.9.5226
   Oliveira F, 2006, VACCINE, V24, P374, DOI 10.1016/j.vaccine.2005.07.085
   RIBEIRO JMC, 1995, INFECT AGENT DIS, V4, P143
   Ribeiro-Mendes HN, 2002, TROP ZOOL, V15, P5, DOI 10.1080/03946975.2002.10531163
   Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933
   SAMUELSON J, 1991, J EXP MED, V173, P49, DOI 10.1084/jem.173.1.49
   Silva F, 2005, AM J TROP MED HYG, V72, P94, DOI 10.4269/ajtmh.2005.72.94
   Teixeira CR, 2005, J IMMUNOL, V175, P8346, DOI 10.4049/jimmunol.175.12.8346
   THEODOS CM, 1991, INFECT IMMUN, V59, P1592, DOI 10.1128/IAI.59.5.1592-1598.1991
   TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436
   Valenzuela JG, 2001, J EXP MED, V194, P331, DOI 10.1084/jem.194.3.331
   WARBURG A, 1994, PHILOS T R SOC B, V345, P223, DOI 10.1098/rstb.1994.0097
   Zerpa O, 2001, MEM I OSWALDO CRUZ, V96, P901, DOI 10.1590/S0074-02762001000700003
NR 30
TC 52
Z9 53
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0300-9475
EI 1365-3083
J9 SCAND J IMMUNOL
JI Scand. J. Immunol.
PD AUG-SEP
PY 2007
VL 66
IS 2-3
BP 122
EP 127
DI 10.1111/j.1365-3083.2007.01964.x
PG 6
WC Immunology
SC Immunology
GA 196TC
UT WOS:000248504100005
PM 17635789
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Clarencio, J
   de Oliveira, CI
   Bomfim, G
   Pompeu, MM
   Teixeira, MJ
   Barbosa, TC
   Souza-Neto, S
   Carvalho, EM
   Brodskyn, C
   Barral, A
   Barral-Netto, M
AF Clarencio, Jorge
   de Oliveira, Camila I.
   Bomfim, Gloria
   Pompeu, Margarida M.
   Teixeira, Maria Jania
   Barbosa, Theolis C.
   Souza-Neto, Sebastiao
   Carvalho, Edgar M.
   Brodskyn, Claudia
   Barral, Aldina
   Barral-Netto, Manoel
TI Characterization of the T-Cell receptor V beta repertoire in the human
   immune response against Leishmania parasites
SO INFECTION AND IMMUNITY
LA English
DT Article
ID AMERICAN CUTANEOUS LEISHMANIASIS; POLYMERASE CHAIN-REACTION;
   TOXIC-SHOCK-SYNDROME; IN-VITRO; BALB/C MICE; TEGUMENTARY LEISHMANIASIS;
   VISCERAL LEISHMANIASIS; RHEUMATOID-ARTHRITIS; ANTIGEN RECEPTORS;
   FLOW-CYTOMETRY
AB In order to explore a possible presence of hyperreactive T-cell clones in human cutaneous leishmaniasis (CL), we have investigated, by How cytometry, the expression of V beta chains of T-cell receptors (TCRs) in the following types of cells: (i) peripheral blood mononuclear cells (PBMCs) from CL patients, which were then compared to those from normal volunteers; (ii) unstimulated and soluble Leishmania antigen-stimulated draining lymph node cells from CL patients; (iii) PBMCs from volunteers before versus after Leishmania immunization; and (iv) PBMCs from healthy volunteers that were primed in vitro with live Leishmania parasites. Our results show a modulation in the TCR V beta repertoire during CL and after antigen stimulation of patients' cells. Vaccination, however, leads to a broad expansion of different V beta TCRs. We also observed an association between TCR V beta 12 expression, T-cell activation, and gamma interferon production upon in vitro priming with Leishmania. Collectively, these results both indicate that infection with live parasites or exposure to parasite antigen can modulate the TCR V beta repertoire and suggest that TCR V beta 12 may be implicated in the response to Leishmania.
C1 Fiocruz MS, Ctr Pesquisas Goncalo Moniz, BR-40296710 Salvador, BA, Brazil.
   UFBA, Fac Med, BR-40025010 Salvador, BA, Brazil.
   UFC, BR-60430160 Fortaleza, Ceara, Brazil.
   UFBA, ICS, Dept Biointeracao, BR-40110160 Salvador, BA, Brazil.
   Inst Invest Imunol, Sao Paulo, Brazil.
RP Clarencio, J (corresponding author), Fiocruz MS, Ctr Pesquisas Goncalo Moniz, Rua Waldemar Falcao,121, BR-40296710 Salvador, BA, Brazil.
EM jorgec@cpqgm.fiocruz.br
RI Brodskyn, Claudia/A-9970-2010; Barral, Aldina/B-4191-2009; de Oliveira,
   Camila I/B-4358-2009; Bessa, Theolis Costa Barbosa/A-1855-2010;
   Clarencio, Jorge/H-3940-2012; Martins de Souza Neto,
   Sebastiao/D-4506-2013; Barral-Netto, Manoel/B-3904-2009
OI Barral, Aldina/0000-0002-7177-464X; de Oliveira, Camila
   I/0000-0002-7868-5164; Bessa, Theolis Costa Barbosa/0000-0003-1928-0404;
   Barral-Netto, Manoel/0000-0002-5823-7903; Clarencio,
   Jorge/0000-0002-4289-5450
CR Almeida RP, 1996, AM J TROP MED HYG, V54, P178, DOI 10.4269/ajtmh.1996.54.178
   BARRAL A, 1995, AM J TROP MED HYG, V53, P256, DOI 10.4269/ajtmh.1995.53.256
   BARRAL A, 1992, AM J TROP MED HYG, V47, P587, DOI 10.4269/ajtmh.1992.47.587
   BARRAL A, 1991, AM J TROP MED HYG, V44, P536, DOI 10.4269/ajtmh.1991.44.536
   Beck RC, 2003, AM J CLIN PATHOL, V120, P785, DOI 10.1309/835B04QXGNNFNRJU
   BITTENCOURT AL, 1995, TROPICAL PATHOLOGY, V8, P597
   Brodskyn C, 2000, CLIN EXP IMMUNOL, V119, P299, DOI 10.1046/j.1365-2249.2000.01122.x
   Chini L, 2002, SCAND J IMMUNOL, V56, P512, DOI 10.1046/j.1365-3083.2002.01153.x
   CHOI YW, 1990, J EXP MED, V172, P981, DOI 10.1084/jem.172.3.981
   Da-Cruz AM, 2005, BRIT J DERMATOL, V153, P537, DOI 10.1111/j.1365-2133.2005.06647.x
   DACRUZ AM, 1994, INFECT IMMUN, V62, P2614, DOI 10.1128/IAI.62.6.2614-2618.1994
   DAVIES TF, 1991, NEW ENGL J MED, V325, P238, DOI 10.1056/NEJM199107253250404
   DEINOCENCIO J, 1995, J IMMUNOL, V154, P4836
   DUCHMANN R, 1993, DNA CELL BIOL, V12, P217, DOI 10.1089/dna.1993.12.217
   Faint JM, 1999, J IMMUNOL METHODS, V225, P53, DOI 10.1016/S0022-1759(99)00027-7
   FITZGERALD JE, 1995, J IMMUNOL, V154, P3538
   Freedman DO, 1999, J IMMUNOL, V162, P1756
   GOLLOB KJ, 1992, P NATL ACAD SCI USA, V89, P5138, DOI 10.1073/pnas.89.11.5138
   GRIMALDI G, 1989, AM J TROP MED HYG, V41, P687, DOI 10.4269/ajtmh.1989.41.687
   Harty JT, 2000, ANNU REV IMMUNOL, V18, P275, DOI 10.1146/annurev.immunol.18.1.275
   Jenson JS, 2002, EUR J IMMUNOL, V32, P858, DOI 10.1002/1521-4141(200203)32:3<858::AID-IMMU858>3.0.CO;2-E
   Kharbanda M, 2003, CLIN DIAGN LAB IMMUN, V10, P53, DOI 10.1128/CDLI.10.1.53-58.2003
   Kim BS, 2005, J NEUROSCI RES, V81, P846, DOI 10.1002/jnr.20611
   LASKAY T, 1995, EUR J IMMUNOL, V25, P2220, DOI 10.1002/eji.1830250816
   Launois P, 1997, IMMUNITY, V6, P541, DOI 10.1016/S1074-7613(00)80342-8
   Lin YT, 2003, J IMMUNOL, V171, P1102, DOI 10.4049/jimmunol.171.2.1102
   Mancia L, 1998, SCAND J IMMUNOL, V48, P443
   Matsuda JL, 2000, J EXP MED, V192, P741, DOI 10.1084/jem.192.5.741
   McCormick JK, 2001, ANNU REV MICROBIOL, V55, P77, DOI 10.1146/annurev.micro.55.1.77
   MENDONCA SCF, 1995, AM J TROP MED HYG, V53, P195, DOI 10.4269/ajtmh.1995.53.195
   Menezes CAS, 2004, CLIN EXP IMMUNOL, V137, P129, DOI 10.1111/j.1365-2249.2004.02479.x
   MILON G, 1986, J IMMUNOL, V136, P1467
   MODLIN RL, 1985, CLIN EXP IMMUNOL, V60, P241
   MODLIN RL, 1989, NATURE, V339, P544, DOI 10.1038/339544a0
   MOEBIUS U, 1990, EUR J IMMUNOL, V20, P889, DOI 10.1002/eji.1830200426
   Moro M, 2002, EUR J IMMUNOL, V32, P3566, DOI 10.1002/1521-4141(200212)32:12&lt;3566::AID-IMMU3566&gt;3.0.CO;2-O
   NITTA T, 1990, SCIENCE, V249, P672, DOI 10.1126/science.2382141
   OKSENBERG JR, 1991, NATURE, V353, P94, DOI 10.1038/353094a0
   Pied S, 1997, INT IMMUNOL, V9, P17, DOI 10.1093/intimm/9.1.17
   PIRMEZ C, 1990, J IMMUNOL, V145, P3100
   Pompeu MML, 2001, INFECT IMMUN, V69, P7453, DOI 10.1128/IAI.69.12.7453-7460.2001
   REED SG, 1986, AM J TROP MED HYG, V35, P79, DOI 10.4269/ajtmh.1986.35.79
   Reiner SL, 1998, J IMMUNOL, V160, P884
   REINER SL, 1993, SCIENCE, V259, P1457, DOI 10.1126/science.8451641
   Rocha PN, 1999, J INFECT DIS, V180, P1731, DOI 10.1086/315071
   ROSENBERG WMC, 1992, EUR J IMMUNOL, V22, P541, DOI 10.1002/eji.1830220237
   ROTH ME, 1989, BIOTECHNIQUES, V7, P746
   Russo DM, 1998, J INFECT DIS, V177, P1345, DOI 10.1086/515284
   SHANKAR AH, 1993, J EXP MED, V178, P101, DOI 10.1084/jem.178.1.101
   SOUSA AD, 1995, AM J TROP MED HYG, V53, P380
   UYEMURA K, 1993, J IMMUNOL, V151, P7095
   WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X
   Yamazaki K, 1996, CLIN EXP IMMUNOL, V106, P329, DOI 10.1046/j.1365-2249.1996.d01-834.x
   Zadeh HH, 2001, J DENT RES, V80, P356, DOI 10.1177/00220345010800011101
NR 54
TC 20
Z9 20
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD AUG
PY 2006
VL 74
IS 8
BP 4757
EP 4765
DI 10.1128/IAI.00265-06
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 068NO
UT WOS:000239381400041
PM 16861664
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU de Moura, TR
   Novais, FO
   Oliveira, F
   Clarencio, J
   Noronha, A
   Barral, A
   Brodskyn, C
   de Oliveira, CI
AF de Moura, TR
   Novais, FO
   Oliveira, F
   Clarencio, J
   Noronha, A
   Barral, A
   Brodskyn, C
   de Oliveira, CI
TI Toward a novel experimental model of infection to study American
   cutaneous leishmaniasis caused by Leishmania braziliensis
SO INFECTION AND IMMUNITY
LA English
DT Article
ID HUMAN-SKIN FIBROBLASTS; REGULATORY T-CELLS; SAND FLY SALIVA; BALB/C
   MICE; MAJOR INFECTION; VIANNIA BRAZILIENSIS; IMMUNE-RESPONSES; NATURAL
   MODEL; PROMASTIGOTES; SUSCEPTIBILITY
AB Leishmania spp. cause a broad spectrum of diseases collectively known as leishmaniasis. Leishmania braziliensis is the main etiological agent of American cutaneous leishmaniasis (ACL) and mucocutaneous leishmaniasis. In the present study, we have developed an experimental model of infection that closely resembles ACL caused by L. braziliensis. In order to do so, BALB/c mice were infected in the ear dermis with 10(5) parasites and distinct aspects of the infection were evaluated. Following inoculation, parasite expansion in the ear dermis was accompanied by the development of an ulcerated dermal lesion which healed spontaneously, as seen by the presence of a scar. Histological analysis of infected ears showed the presence of a mixed inflammatory infiltrate consisting of both mononuclear and polymorphonuclear cells. In draining lymph nodes, parasite replication was detected throughout the infection. In vitro restimulation of draining lymph node cells followed by intracellular staining showed an up-regulation in the production of gamma interferon (IFN-gamma) and in the frequency of IFN-gamma-secreting CD4(+) and CD8(+) T cells. Reverse transcription-PCR of ears and draining lymph node cells showed the expression of CC chemokines. The dermal model of infection with L. braziliensis herein is able to reproduce aspects of the natural infection, such as the presence of an ulcerated lesion, parasite dissemination to lymphoid areas, and the development of a Th1-type immune response. These results indicate that this model shall be useful to address questions related to the concomitant immunity to reinfection and parasite persistence leading to mucocutaneous leishmaniasis.
C1 Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, BR-40295001 Salvador, BA, Brazil.
   Univ Fed Bahia, Fac Med Bahia, BR-40025010 Salvador, BA, Brazil.
   Univ Fed Bahia, Inst Ciencias Saude, Dept Biointeracao, BR-40110160 Salvador, BA, Brazil.
RP de Oliveira, CI (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Rua Waldemar Falcao,121, BR-40295001 Salvador, BA, Brazil.
EM camila@cpqgm.fiocruz.br
RI Barral, Aldina/B-4191-2009; Brodskyn, Claudia/A-9970-2010; Clarencio,
   Jorge/H-3940-2012; Oliveira, Fabiano/AAG-5388-2019; ,
   Tatiana/AAN-1194-2020; de Oliveira, Camila I/B-4358-2009
OI Barral, Aldina/0000-0002-7177-464X; Oliveira,
   Fabiano/0000-0002-7924-8038; , Tatiana/0000-0002-7442-4434; de Oliveira,
   Camila I/0000-0002-7868-5164; Clarencio, Jorge/0000-0002-4289-5450
CR AEBISCHER T, 1993, INFECT IMMUN, V61, P220, DOI 10.1128/IAI.61.1.220-226.1993
   ANDRADE ZA, 1984, AM J PATHOL, V114, P137
   Baldwin TM, 2003, INFECT IMMUN, V71, P6830, DOI 10.1128/IAI.71.12.6830-6834.2003
   BARRAL A, 1992, AM J TROP MED HYG, V47, P587, DOI 10.4269/ajtmh.1992.47.587
   Belkaid Y, 1998, J EXP MED, V188, P1941, DOI 10.1084/jem.188.10.1941
   Belkaid Y, 2000, J IMMUNOL, V165, P969, DOI 10.4049/jimmunol.165.2.969
   Belkaid Y, 2002, J IMMUNOL, V168, P3992, DOI 10.4049/jimmunol.168.8.3992
   Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152
   Bhattacharyya S, 2002, J INFECT DIS, V185, P1704, DOI 10.1086/340820
   BITTENCOURT AL, 1991, MEM I OSWALDO CRUZ, V86, P51, DOI 10.1590/S0074-02761991000100009
   Brodskyn Claudia, 2003, Expert Rev Vaccines, V2, P705, DOI 10.1586/14760584.2.5.705
   Castilho TM, 2003, J CLIN MICROBIOL, V41, P540, DOI 10.1128/JCM.41.2.540-546.2003
   CHANG KP, 1978, AM J TROP MED HYG, V27, P1084, DOI 10.4269/ajtmh.1978.27.1084
   CHILDS GE, 1984, ANN TROP MED PARASIT, V78, P25, DOI 10.1080/00034983.1984.11811769
   COSTA JML, 1986, J TROP MED HYG, V89, P319
   Courret N, 2003, INT J PARASITOL, V33, P1373, DOI 10.1016/S0020-7519(03)00179-6
   CUENTAS EAL, 1984, T ROY SOC TROP MED H, V78, P845, DOI 10.1016/0035-9203(84)90043-9
   de Oliveira CI, 2004, MICROBES INFECT, V6, P977, DOI 10.1016/j.micinf.2004.05.009
   DEDET JP, 1983, ANN TROP MED PARASIT, V77, P35, DOI 10.1080/00034983.1983.11811670
   DeKrey GK, 1998, INFECT IMMUN, V66, P827, DOI 10.1128/IAI.66.2.827-829.1998
   Donnelly KB, 1998, J PARASITOL, V84, P97, DOI 10.2307/3284537
   FAHEY TJ, 1992, J IMMUNOL, V148, P2764
   Gumy A, 2004, INT J PARASITOL, V34, P433, DOI 10.1016/j.ijpara.2003.11.021
   JONES TC, 1987, J INFECT DIS, V156, P73, DOI 10.1093/infdis/156.1.73
   Kupper TS, 2004, NAT REV IMMUNOL, V4, P211, DOI 10.1038/nri1310
   LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8
   Lima GMAC, 1998, IMMUNOL LETT, V64, P145, DOI 10.1016/S0165-2478(98)00099-6
   Lima HC, 1999, MEM I OSWALDO CRUZ, V94, P71, DOI 10.1590/S0074-02761999000100015
   Louis J, 1998, CURR OPIN IMMUNOL, V10, P459, DOI 10.1016/S0952-7915(98)80121-0
   MARSDEN PD, 1986, T ROY SOC TROP MED H, V80, P859, DOI 10.1016/0035-9203(86)90243-9
   MCMAHONPRATT D, 1982, J IMMUNOL, V129, P926
   Mendez S, 2004, J EXP MED, V200, P201, DOI 10.1084/jem.20040298
   Mendonca MG, 2004, J INFECT DIS, V189, P1018, DOI 10.1086/382135
   MOORE KJ, 1994, J IMMUNOL, V152, P2930
   NEAL RA, 1983, PARASITOLOGY, V87, P7, DOI 10.1017/S0031182000052379
   Norsworthy NB, 2004, INFECT IMMUN, V72, P1240, DOI 10.1128/IAI.72.3.1240-1247.2004
   Pinto-da-Silva LH, 2002, INT J PARASITOL, V32, P1371, DOI 10.1016/S0020-7519(02)00137-6
   Porrozzi R, 2004, AM J TROP MED HYG, V71, P297, DOI 10.4269/ajtmh.2004.71.297
   Ramirez JL, 1997, MEM I OSWALDO CRUZ, V92, P333, DOI 10.1590/S0074-02761997000300006
   REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.immunol.13.1.151
   Ribeiro-Gomes FL, 2004, J IMMUNOL, V172, P4454, DOI 10.4049/jimmunol.172.7.4454
   Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933
   SAMUELSON J, 1991, J EXP MED, V173, P49, DOI 10.1084/jem.173.1.49
   Schubach A, 1998, J INFECT DIS, V178, P911, DOI 10.1086/515355
   SCHWARTZMAN JD, 1985, AM J TROP MED HYG, V34, P850, DOI 10.4269/ajtmh.1985.34.850
   Tacchini-Cottier F, 2000, J IMMUNOL, V165, P2628, DOI 10.4049/jimmunol.165.5.2628
   Teixeira MJ, 2005, INFECT IMMUN, V73, P1191, DOI 10.1128/IAI.73.2.1191-1195.2005
   TITUS RG, 1987, EUR J IMMUNOL, V17, P1429, DOI 10.1002/eji.1830171007
   TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x
   Venuprasad K, 2003, HUM IMMUNOL, V64, P38, DOI 10.1016/S0198-8859(02)00689-4
NR 50
TC 68
Z9 70
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
EI 1098-5522
J9 INFECT IMMUN
JI Infect. Immun.
PD SEP
PY 2005
VL 73
IS 9
BP 5827
EP 5834
DI 10.1128/IAI.73.9.5827-5834.2005
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 958PK
UT WOS:000231460000058
PM 16113301
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Oliveira, JGS
   Novais, FO
   de Oliveira, CI
   da Cruz, AC
   Campos, LF
   da Rocha, AV
   Boaventura, V
   Noronha, A
   Costa, JML
   Barral, A
AF Oliveira, JGS
   Novais, FO
   de Oliveira, CI
   da Cruz, AC
   Campos, LF
   da Rocha, AV
   Boaventura, V
   Noronha, A
   Costa, JML
   Barral, A
TI Polymerase chain reaction (PCR) is highly sensitive for diagnosis of
   mucosal leishmaniasis
SO ACTA TROPICA
LA English
DT Article
DE polymerase chain reactions; Leishmania braziliensis; mucosal
   leishmaniasis
ID CUTANEOUS LEISHMANIASIS; CLINICAL SPECIMENS; AMPLIFICATION
AB We evaluated the use of polymerase chain reaction (PCR) for diagnosis of mucosal leishmaniasis (ML) in an endemic area in Acre, Brazil, where Leishmania braziliensis is present. Leishmania DNA was detected 34 of 35 cases, yielding a positivity rate of 97.1%, which was higher than the positivity rates for all of the other diagnostic methods studied, namely Montenegro skin test (MST), anti-Leishmania serological testing and microscopic examination of lesion biopsy specimens. These findings have led us to propose guidelines for the diagnosis of ML that use PCR as the principal method of parasitological confirmation of cases. (c) 2005 Elsevier B.V. All rights reserved.
C1 Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Muniz, BR-40295001 Salvador, BA, Brazil.
   Fundacao Hosp Acre, BR-69914220 Rio Branco, AC, Brazil.
   Univ Fed Bahia, Fac Med Bahia, BR-40025010 Salvador, BA, Brazil.
RP Barral, A (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Muniz, Rua Waldemar Falcao,Av Waldemar Falcao,121 Brotas, BR-40295001 Salvador, BA, Brazil.
EM abarral@cpqgm.fiocruz.br
RI Barral, Aldina/B-4191-2009; Boaventura, Viviane S/H-9165-2015; de
   Oliveira, Camila I/B-4358-2009
OI Barral, Aldina/0000-0002-7177-464X; de Oliveira, Camila
   I/0000-0002-7868-5164
CR Aviles H, 1999, J PARASITOL, V85, P181, DOI 10.2307/3285616
   BARRAL A, 1991, AM J TROP MED HYG, V44, P536, DOI 10.4269/ajtmh.1991.44.536
   Belli A, 1998, AM J TROP MED HYG, V58, P102, DOI 10.4269/ajtmh.1998.58.102
   Cuba Cuba C A, 1980, Bol Oficina Sanit Panam, V89, P195
   de Oliveira CI, 2003, CLIN INFECT DIS, V37, pE149, DOI 10.1086/379610
   DEBRUIJN MHL, 1992, ACTA TROP, V52, P45, DOI 10.1016/0001-706X(92)90006-J
   *FUNASA, 2000, MAN CONTR LEISHM TEG, P62
   Isaza Diana Maria, 2002, Trans R Soc Trop Med Hyg, V96 Suppl 1, pS165, DOI 10.1016/S0035-9203(02)90070-2
   MARSDEN PD, 1994, BAHIA BRAZIL REV SOC, V27, P93
   Onuma H, 2001, INT J DERMATOL, V40, P765, DOI 10.1046/j.1365-4362.2001.01332.x
   PASSOS VMA, 2002, REV SOC BRAS MED TRO, V34, P5
   Pinero J, 1999, ACTA TROP, V73, P21, DOI 10.1016/S0001-706X(99)00015-7
   Pirmez C, 1999, J CLIN MICROBIOL, V37, P1819, DOI 10.1128/JCM.37.6.1819-1823.1999
   REED SG, 1986, AM J TROP MED HYG, V35, P79, DOI 10.4269/ajtmh.1986.35.79
   RIBEIRO FAQ, 1994, DOENCAS ULCERO GRANU, P71
   RODGERS MR, 1990, EXP PARASITOL, V71, P267, DOI 10.1016/0014-4894(90)90031-7
   Rodrigues EHG, 2002, J CLIN MICROBIOL, V40, P3572, DOI 10.1128/JCM.40.10.3572-3576.2002
   Romero GAS, 2001, ACTA TROP, V79, P225, DOI 10.1016/S0001-706X(01)00140-1
   Uezato Hiroshi, 1998, Journal of Dermatology (Tokyo), V25, P623
   Weigle KA, 2002, J CLIN MICROBIOL, V40, P601, DOI 10.1128/JCM.40.2.601-606.2002
NR 20
TC 62
Z9 62
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0001-706X
EI 1873-6254
J9 ACTA TROP
JI Acta Trop.
PD APR
PY 2005
VL 94
IS 1
BP 55
EP 59
DI 10.1016/j.actatropica.2004.12.003
PG 5
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 919DE
UT WOS:000228597700007
PM 15777720
OA Green Published
DA 2020-12-08
ER

PT J
AU de Oliveira, CI
   Teixeira, MJ
   Teixeira, CR
   de Jesus, JR
   Rosato, AB
   da Silva, JS
   Brodskyn, C
   Barral-Netto, M
   Barral, A
AF de Oliveira, CI
   Teixeira, MJ
   Teixeira, CR
   de Jesus, JR
   Rosato, AB
   da Silva, JS
   Brodskyn, C
   Barral-Netto, M
   Barral, A
TI Leishmania braziliensis isolates differing at the genome level display
   distinctive features in BALB/c mice
SO MICROBES AND INFECTION
LA English
DT Article
DE Leishmania braziliensis; random amplification of polymorphic DNA;
   interferon gamma; interleukin-12p70; interleukin-10
ID NATURAL-KILLER-CELLS; VIANNIA BRAZILIENSIS; CUTANEOUS LEISHMANIASIS;
   IMMUNE-RESPONSE; INFECTION; SUSCEPTIBILITY; RESISTANCE; LYMPHADENOPATHY;
   HETEROGENEITY; POLYMORPHISM
AB Leishmania braziliensis is the species responsible for the majority of cases of human cutaneous leishmaniasis in Brazil. In the present study, L. braziliensis isolates from two different geographic areas in Brazil were studied by RAPD, using arbitrary primers. We also evaluated other biological features of these two isolates. We compared (a) the clinical features they initiate or not once delivered subcutaneously as stationary-phase promastigotes in the footpad of BALB/c mice; (b) the parasite load in both the footpad and the draining lymph node; (c) the cytokines present in the supernatant of cultures of the cell suspensions from the draining lymph nodes; and (d) the cell types present at the site of parasite delivery. The results show that the L. braziliensis strain from Ceara (H3227) is genotypically different from the L. braziliensis strain from Bahia (BA788). H3227-parasitized mice developed detectable lesions, whereas BA788-parasitized mice did not. Fifteen days post parasite inoculation there was an increase in the numbers of macrophages and lymphocytes in the footpads, whatever the parasite inoculum. Parasite load at the inoculation site-namely the footpad-did not differ significantly; in draining lymph nodes, however, it increased over the period under study. Early after parasite inoculation, the cells recovered from the draining lymph nodes of BA788-parasitized mice produced higher levels of IFN-gamma, a feature coupled to a higher number of NK cells. Later, after the parasite inoculation, there was an increased content of IL-12p70 and IL-10 in the supernatant of cells recovered from the lymph nodes of H3227-parasitized mice. This comparative analysis points out that L. braziliensis isolates differing in their genomic profiles do establish different parasitic processes in BALB/c mice. (C) 2004 Elsevier SAS. All rights reserved.
C1 Fdn Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, BR-40295001 Salvador, BA, Brazil.
   Univ Sao Paulo, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil.
   Univ Fed Bahia, Inst Ciencias Saude, BR-40110160 Salvador, BA, Brazil.
   Univ Fed Bahia, Fac Med, BR-40110160 Salvador, BA, Brazil.
RP Barral, A (corresponding author), Fdn Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Rua Waldemar Falcao 121, BR-40295001 Salvador, BA, Brazil.
EM abarral@cpqgm.fiocruz.br
RI Barral-Netto, Manoel/B-3904-2009; Silva, Joao S/A-4484-2008; Brodskyn,
   Claudia/A-9970-2010; de Oliveira, Camila I/B-4358-2009; Barral,
   Aldina/B-4191-2009
OI Barral-Netto, Manoel/0000-0002-5823-7903; Silva, Joao
   S/0000-0002-3410-3927; de Oliveira, Camila I/0000-0002-7868-5164;
   Barral, Aldina/0000-0002-7177-464X
CR Almeida RP, 1996, AM J TROP MED HYG, V54, P178, DOI 10.4269/ajtmh.1996.54.178
   BARRAL A, 1995, AM J TROP MED HYG, V53, P256, DOI 10.4269/ajtmh.1995.53.256
   BARRAL A, 1992, AM J TROP MED HYG, V47, P587, DOI 10.4269/ajtmh.1992.47.587
   BARRAL A, 1991, AM J TROP MED HYG, V44, P536, DOI 10.4269/ajtmh.1991.44.536
   Berzunza-Cruz M, 2000, EXP PARASITOL, V95, P277, DOI 10.1006/expr.2000.4541
   Bezerra HSD, 2001, MEM I OSWALDO CRUZ, V96, P349
   Bogdan CT, 2000, IMMUNOL REV, V173, P17, DOI 10.1034/j.1600-065X.2000.917307.x
   Castilho TM, 2003, J CLIN MICROBIOL, V41, P540, DOI 10.1128/JCM.41.2.540-546.2003
   CHILDS GE, 1984, ANN TROP MED PARASIT, V78, P25, DOI 10.1080/00034983.1984.11811769
   COSTA JML, 1986, J TROP MED HYG, V89, P319
   Cupolillo E, 2003, J CLIN MICROBIOL, V41, P3126, DOI 10.1128/JCM.41.7.3126-3132.2003
   Cupolillo E, 1998, MEM I OSWALDO CRUZ, V93, P663, DOI 10.1590/S0074-02761998000500018
   DeKrey GK, 1998, INFECT IMMUN, V66, P827, DOI 10.1128/IAI.66.2.827-829.1998
   Donnelly KB, 1998, J PARASITOL, V84, P97, DOI 10.2307/3284537
   GOMES RF, 1995, EXP PARASITOL, V80, P681, DOI 10.1006/expr.1995.1084
   Kebaier C, 2001, INFECT IMMUN, V69, P4906, DOI 10.1128/IAI.69.8.4906-4915.2001
   Lima HC, 1996, INFECT IMMUN, V64, P5442, DOI 10.1128/IAI.64.12.5442-5445.1996
   MARSDEN PD, 1990, BRIT MED J, V301, P656, DOI 10.1136/bmj.301.6753.656
   Matlashewski G, 2001, MED MICROBIOL IMMUN, V190, P37, DOI 10.1007/s004300100076
   MCMAHONPRATT D, 1982, J IMMUNOL, V129, P926
   Muller K, 2001, MED MICROBIOL IMMUN, V190, P73
   NEAL RA, 1983, PARASITOLOGY, V87, P7, DOI 10.1017/S0031182000052379
   PIRMEZ C, 1993, J CLIN INVEST, V91, P1390, DOI 10.1172/JCI116341
   Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933
   SAMUELSON J, 1991, J EXP MED, V173, P49, DOI 10.1084/jem.173.1.49
   SCHARTON TM, 1993, J EXP MED, V178, P567, DOI 10.1084/jem.178.2.567
   SOUSA AD, 1995, AM J TROP MED HYG, V53, P380
   TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x
   Volpini AC, 2001, PARASITOL RES, V87, P1056
NR 29
TC 31
Z9 31
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1286-4579
EI 1769-714X
J9 MICROBES INFECT
JI Microbes Infect.
PD SEP
PY 2004
VL 6
IS 11
BP 977
EP 984
DI 10.1016/j.micinf.2004.05.009
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 854BK
UT WOS:000223874900003
PM 15345228
OA Green Published
DA 2020-12-08
ER

PT J
AU de Oliveira, CI
   Bafica, A
   Oliveira, F
   Favali, CBF
   Correa, T
   Freitas, LAR
   Nascimento, E
   Costa, JM
   Barral, A
AF de Oliveira, CI
   Bafica, A
   Oliveira, F
   Favali, CBF
   Correa, T
   Freitas, LAR
   Nascimento, E
   Costa, JM
   Barral, A
TI Clinical utility of polymerase chain reaction-based detection of
   Leishmania in the diagnosis of American cutaneous leishmaniasis
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID NEW-WORLD LEISHMANIA; KINETOPLAST DNA; PCR ASSAY; BRAZIL;
   IDENTIFICATION; AMPLIFICATION; SPECIMENS; VIANNIA
AB We evaluated the use of polymerase chain reaction (PCR) for diagnosis of American cutaneous leishmaniasis (ACL) in an area in Bahia, Brazil, where Leishmania braziliensis is endemic. Leishmania DNA was detected in 50 cases, yielding a positivity rate of 100%, which was higher than the rates for all of the other diagnostic methods studied-namely, the Montenegro skin test, anti-Leishmania serological testing, and microscopic examination of lesion biopsy specimens. These findings have led us to propose guidelines for the diagnosis of ACL that use PCR as the principal means of parasitological confirmation of cases.
C1 Fiocruz MS, Ctr Pesquisas Goncalo Muniz, BR-40295001 Salvador, BA, Brazil.
   Univ Fed Bahia, Fac Med, Salvador, BA, Brazil.
   Ctr Referencia Doencas Endem Piraja Silva, Jequie, Brazil.
RP de Oliveira, CI (corresponding author), Fiocruz MS, Ctr Pesquisas Goncalo Muniz, Av Waldemar Falcao 121, BR-40295001 Salvador, BA, Brazil.
RI Bafica, Andre/ABF-5986-2020; de Oliveira, Camila I/B-4358-2009; Barral,
   Aldina/B-4191-2009; Oliveira, Fabiano/AAG-5388-2019; Oliveira,
   Fabiano/B-4251-2009
OI Bafica, Andre/0000-0002-5148-600X; de Oliveira, Camila
   I/0000-0002-7868-5164; Barral, Aldina/0000-0002-7177-464X; Oliveira,
   Fabiano/0000-0002-7924-8038; Oliveira, Fabiano/0000-0002-7924-8038
CR Aviles H, 1999, J PARASITOL, V85, P181, DOI 10.2307/3285616
   BARRAL A, 1995, AM J TROP MED HYG, V53, P256, DOI 10.4269/ajtmh.1995.53.256
   BARRAL A, 1991, AM J TROP MED HYG, V44, P536, DOI 10.4269/ajtmh.1991.44.536
   Belli A, 1998, AM J TROP MED HYG, V58, P102, DOI 10.4269/ajtmh.1998.58.102
   Castilho TM, 2003, J CLIN MICROBIOL, V41, P540, DOI 10.1128/JCM.41.2.540-546.2003
   Cuba Cuba C A, 1980, Bol Oficina Sanit Panam, V89, P195
   DEBRUIJN MHL, 1992, ACTA TROP, V52, P45, DOI 10.1016/0001-706X(92)90006-J
   DEGRAVE W, 1994, MEM I OSWALDO CRUZ, V89, P463, DOI 10.1590/S0074-02761994000300032
   Gontijo CMF, 2002, ACTA TROP, V81, P143, DOI 10.1016/S0001-706X(01)00205-4
   Harris E, 1998, J CLIN MICROBIOL, V36, P1989, DOI 10.1128/JCM.36.7.1989-1995.1998
   Isaza Diana Maria, 2002, Trans R Soc Trop Med Hyg, V96 Suppl 1, pS165, DOI 10.1016/S0035-9203(02)90070-2
   MARSDEN PD, 1986, T ROY SOC TROP MED H, V80, P859, DOI 10.1016/0035-9203(86)90243-9
   Pirmez C, 1999, J CLIN MICROBIOL, V37, P1819, DOI 10.1128/JCM.37.6.1819-1823.1999
   REED SG, 1986, AM J TROP MED HYG, V35, P79, DOI 10.4269/ajtmh.1986.35.79
   RODGERS MR, 1990, EXP PARASITOL, V71, P267, DOI 10.1016/0014-4894(90)90031-7
   Rodrigues EHG, 2002, J CLIN MICROBIOL, V40, P3572, DOI 10.1128/JCM.40.10.3572-3576.2002
   Romero GAS, 2001, ACTA TROP, V79, P225, DOI 10.1016/S0001-706X(01)00140-1
   ULIANA SRB, 1994, J EUKARYOT MICROBIOL, V41, P324, DOI 10.1111/j.1550-7408.1994.tb06085.x
   Weigle KA, 2002, J CLIN MICROBIOL, V40, P601, DOI 10.1128/JCM.40.2.601-606.2002
   *WHO, 1990, WHO TECH REP SER, V753, P154
NR 20
TC 45
Z9 45
U1 0
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD DEC 1
PY 2003
VL 37
IS 11
BP E149
EP E153
DI 10.1086/379610
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 743LD
UT WOS:000186572500026
PM 14614687
OA Bronze, Green Published
DA 2020-12-08
ER

PT J
AU Gomes, RB
   Brodskyn, U
   de Oliveira, CI
   Costa, J
   Miranda, JC
   Caldas, A
   Valenzuela, JG
   Barral-Netto, M
   Barral, A
AF Gomes, RB
   Brodskyn, U
   de Oliveira, CI
   Costa, J
   Miranda, JC
   Caldas, A
   Valenzuela, JG
   Barral-Netto, M
   Barral, A
TI Seroconversion against Lutzomyia longipalpis saliva concurrent with the
   development of anti-Leishmania chagasi delayed-type hypersensitivity
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID SAND FLY SALIVA; CUTANEOUS LEISHMANIASIS; MAJOR INFECTION; VECTOR
   SALIVA; MAXADILAN; MICE
AB Antibody responses to salivary gland sonicate (SGS) from Lutzomyia longipalpis were investigated using serum samples from individuals living in an area where visceral leishmaniasis is endemic. Individuals were classified into 2 groups, according to the alteration of their responses to Leishmania chagasi antigen over the course of 6 months. Group 1 included children who experienced anti-L. chagasi seroconversion from negative to positive; group 2 included children who experienced delayed-type hypersensitivity (DTH) response to L. chagasi antigen conversion from negative to positive. Individuals who experienced seroconversion against L. chagasi antigens did not have increased anti-saliva antibody response, whereas those who developed a positive anti-L. chagasi DTH response had increased immunoglobulin (Ig) G, IgG1 and IgE anti-SGS antibody levels. Despite wide variation, serum samples from individuals in group 2 recognized more bands in SGS than did those from individuals in group 1. This simultaneous appearance of anti-saliva humoral response and anti-L. chagasi cell-mediated immunity supports the hypothesis that induction of immune response against SGS can facilitate induction of a protective response against leishmaniasis.
C1 Fdn Oswaldo Cruz, Ctr Pesquisa Goncalo Moniz, Lab Imunoparasitol, BR-40295001 Salvador, BA, Brazil.
   Univ Fed Bahia, Inst Ciencias Saude, Lab Imunol, Salvador, BA, Brazil.
   Univ Fed Maranhao, Dept Patol, Sao Luis, Maranhao, Brazil.
   Immunol Invest Inst, Sao Paulo, Brazil.
   NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA.
RP Barral, A (corresponding author), Fdn Oswaldo Cruz, Ctr Pesquisa Goncalo Moniz, Lab Imunoparasitol, Rua Valdemar Falcao 121, BR-40295001 Salvador, BA, Brazil.
RI de Oliveira, Camila I/B-4358-2009; Barral, Aldina/B-4191-2009;
   Barral-Netto, Manoel/B-3904-2009
OI de Oliveira, Camila I/0000-0002-7868-5164; Barral,
   Aldina/0000-0002-7177-464X; Barral-Netto, Manoel/0000-0002-5823-7903
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-30639] Funding Source: Medline; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, ZIAAI000932, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, Z01AI000932, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, ZIAAI000932, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   Z01AI000932, P50AI030639, ZIAAI000932, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, Z01AI000932, ZIAAI000932,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, ZIAAI000932,
   P50AI030639, P50AI030639, P50AI030639, Z01AI000932, P50AI030639,
   ZIAAI000932, ZIAAI000932, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, Z01AI000932, P50AI030639, ZIAAI000932, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, ZIAAI000932, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   Z01AI000932, P50AI030639, P50AI030639, ZIAAI000932, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639] Funding Source: NIH RePORTER
CR Arlian LG, 2002, ANNU REV ENTOMOL, V47, P395, DOI 10.1146/annurev.ento.47.091201.145224
   Barral A, 2000, AM J TROP MED HYG, V62, P740, DOI 10.4269/ajtmh.2000.62.740
   Belkaid Y, 1998, J EXP MED, V188, P1941, DOI 10.1084/jem.188.10.1941
   Charlab R, 1999, P NATL ACAD SCI USA, V96, P15155, DOI 10.1073/pnas.96.26.15155
   deVries JE, 1995, CURR OPIN IMMUNOL, V7, P771, DOI 10.1016/0952-7915(95)80046-8
   HUSSAIN R, 1992, J IMMUNOL, V148, P2731
   Kamhawi S, 2000, SCIENCE, V290, P1351, DOI 10.1126/science.290.5495.1351
   Mbow ML, 1998, J IMMUNOL, V161, P5571
   MELLANBY K, 1946, NATURE, V158, P554, DOI 10.1038/158554c0
   Morris RV, 2001, J IMMUNOL, V167, P5226, DOI 10.4049/jimmunol.167.9.5226
   Soares MBP, 1998, J IMMUNOL, V160, P1811
   STEBBINGS JH, 1974, PERSPECT BIOL MED, V17, P233
   THEODOS CM, 1991, INFECT IMMUN, V59, P1592, DOI 10.1128/IAI.59.5.1592-1598.1991
   TITUS RG, 1990, PARASITOL TODAY, V6, P157, DOI 10.1016/0169-4758(90)90338-5
   Valenzuela JG, 2001, J EXP MED, V194, P331, DOI 10.1084/jem.194.3.331
NR 15
TC 103
Z9 105
U1 0
U2 9
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 15
PY 2002
VL 186
IS 10
BP 1530
EP 1534
DI 10.1086/344733
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 609EQ
UT WOS:000178891000025
PM 12404176
OA Bronze, Green Published
DA 2020-12-08
ER

PT J
AU Gonzalez-Aseguinolaza, G
   de Oliveira, C
   Tomaska, M
   Hong, S
   Bruna-Romero, O
   Nakayama, T
   Taniguchi, M
   Bendelac, A
   Van Kaer, L
   Koezuka, Y
   Tsuji, M
AF Gonzalez-Aseguinolaza, G
   de Oliveira, C
   Tomaska, M
   Hong, S
   Bruna-Romero, O
   Nakayama, T
   Taniguchi, M
   Bendelac, A
   Van Kaer, L
   Koezuka, Y
   Tsuji, M
TI alpha-Galactosylceramide-activated V alpha 14 natural killer T cells
   mediate protection against murine malaria
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID IMMUNE-SYSTEM; NKT CELLS; ANTIGEN PRESENTATION; PLASMODIUM-VIVAX;
   CUTTING EDGE; MICE; MOUSE; LYMPHOCYTES; IL-4; CD1
AB Natural killer T (NKT) cells are a unique population of lymphocytes that coexpress a semiinvariant T cell and natural killer cell receptors, which are particularly abundant in the liver. To investigate the possible effect of these cells on the development of the liver stages of malaria parasites, a glycolipid. alpha-galactosylceramide (alpha-GalCer), known to selectively activate V alpha 14 NKT cells in the context of CD1d molecules, was administered to sporozoite-inoculated mice. The administration of alpha-GalCer resulted in rapid, strong antimalaria activity, inhibiting the development of the intrahepatocytic stages of the rodent malaria parasites Plasmodium yoelii and Plasmodium berghei. The antimalaria activity mediated by alpha-GalCer is stage-specific, since the course of blood-stage-induced infection was not inhibited by administration of this glycolipid. Furthermore, it was determined that IFN-gamma is essential for the antimalaria activity mediated by the glycolipid. Taken together, our results provide the clear evidence that NKT cells can mediate protection against an intracellular microbial infection.
C1 NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10010 USA.
   Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Howard Hughes Med Inst, Nashville, TN 37232 USA.
   Chiba Univ, Sch Med, Dept Mol Immunol, Chiba 260, Japan.
   Princeton Univ, Dept Biol Mol, Princeton, NJ 08544 USA.
   Kirin Brewery Co Ltd, Pharmaceut Res Lab, Gunma 370, Japan.
RP Tsuji, M (corresponding author), NYU, Sch Med, Dept Med & Mol Parasitol, 341 East 25th St, New York, NY 10010 USA.
RI Taniguchi, Masaru/N-7932-2015; Nakayama, Toshinori/E-1067-2017; Tsuji,
   Moriya/B-1471-2008; BRUNA-ROMERO, OSCAR/B-3918-2010; de Oliveira, Camila
   I/B-4358-2009; Van Kaer, Luc/H-1033-2015
OI Taniguchi, Masaru/0000-0001-7821-7179; Nakayama,
   Toshinori/0000-0002-1434-2007; BRUNA-ROMERO, OSCAR/0000-0002-8855-4969;
   de Oliveira, Camila I/0000-0002-7868-5164; Van Kaer,
   Luc/0000-0001-5275-2309; Tsuji, Moriya/0000-0001-8587-277X
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI36526, AI40656] Funding Source: Medline;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI036526, R01AI036526, R29AI040656, R01AI036526, R29AI040656,
   R01AI036526, R29AI040656, R01AI036526, R29AI040656, R01AI036526,
   R29AI040656, R01AI036526, R01AI036526] Funding Source: NIH RePORTER
CR Apostolou I, 1999, P NATL ACAD SCI USA, V96, P5141, DOI 10.1073/pnas.96.9.5141
   BENDELAC A, 1995, CURR OPIN IMMUNOL, V7, P367, DOI 10.1016/0952-7915(95)80112-X
   Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535
   BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697
   Briones MRS, 1996, MOL BIOCHEM PARASIT, V77, P7, DOI 10.1016/0166-6851(96)02574-1
   Burdin N, 1998, J IMMUNOL, V161, P3271
   Carnaud C, 1999, J IMMUNOL, V163, P4647
   Chen YH, 1997, IMMUNITY, V6, P459, DOI 10.1016/S1074-7613(00)80289-7
   Collins WE, 1996, AM J TROP MED HYG, V55, P243, DOI 10.4269/ajtmh.1996.55.243
   Cui JQ, 1997, SCIENCE, V278, P1623, DOI 10.1126/science.278.5343.1623
   Denkers EY, 1996, J EXP MED, V184, P131, DOI 10.1084/jem.184.1.131
   Doolan DL, 1999, J IMMUNOL, V163, P884
   Eberl G, 1998, IMMUNITY, V9, P345, DOI 10.1016/S1074-7613(00)80617-2
   Emoto M, 1999, EUR J IMMUNOL, V29, P650, DOI 10.1002/(SICI)1521-4141(199902)29:02<650::AID-IMMU650>3.0.CO;2-M
   FERREIRA A, 1986, SCIENCE, V232, P881, DOI 10.1126/science.3085218
   Flesch IEA, 1997, J IMMUNOL, V159, P7
   GOOSSENS PL, 1990, J IMMUNOL METHODS, V132, P137, DOI 10.1016/0022-1759(90)90407-M
   Hammond KJL, 1998, J EXP MED, V187, P1047, DOI 10.1084/jem.187.7.1047
   Hoffman SL, 1997, NAT MED, V3, P80, DOI 10.1038/nm0197-80
   Hong SM, 1999, IMMUNOL REV, V169, P31, DOI 10.1111/j.1600-065X.1999.tb01304.x
   INSHIHARA S, 1999, EUR J IMMUNOL, V29, P2406
   Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626
   Kobayashi E, 1995, ONCOL RES, V7, P529
   LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097
   Lehuen A, 1998, J EXP MED, V188, P1831, DOI 10.1084/jem.188.10.1831
   Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6
   Mendiratta SK, 1997, IMMUNITY, V6, P469, DOI 10.1016/S1074-7613(00)80290-3
   Mieza MA, 1996, J IMMUNOL, V156, P4035
   MIYAHIRA Y, 1995, J IMMUNOL METHODS, V181, P45, DOI 10.1016/0022-1759(94)00327-S
   Naidenko OV, 1999, J EXP MED, V190, P1069, DOI 10.1084/jem.190.8.1069
   Nakagawa R, 1998, CANCER RES, V58, P1202
   NARDIN EH, 1993, ANNU REV IMMUNOL, V11, P687, DOI 10.1146/annurev.iy.11.040193.003351
   Pied S, 2000, J IMMUNOL, V164, P1463, DOI 10.4049/jimmunol.164.3.1463
   Sakai T, 1999, J MED CHEM, V42, P1836, DOI 10.1021/jm990054n
   Spada FM, 1998, J EXP MED, V188, P1529, DOI 10.1084/jem.188.8.1529
   Szalay G, 1999, J IMMUNOL, V162, P6955
   TAKEDA K, 1994, J IMMUNOL, V152, P4407
   TSUJI M, 1990, J EXP MED, V172, P1353, DOI 10.1084/jem.172.5.1353
   TSUJI M, 1994, P NATL ACAD SCI USA, V91, P345, DOI 10.1073/pnas.91.1.345
   Vicari AP, 1996, IMMUNOL TODAY, V17, P71, DOI 10.1016/0167-5699(96)80582-2
   Whitby M, 1997, J ANTIMICROB CHEMOTH, V40, P749, DOI 10.1093/jac/40.6.749
NR 41
TC 226
Z9 230
U1 0
U2 8
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 18
PY 2000
VL 97
IS 15
BP 8461
EP 8466
DI 10.1073/pnas.97.15.8461
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 335YF
UT WOS:000088273900051
PM 10900007
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU de Oliveira, CI
   Wunderlich, G
   Levitus, G
   Soares, IS
   Rodrigues, MM
   Tsuji, M
   del Portillo, HA
AF de Oliveira, CI
   Wunderlich, G
   Levitus, G
   Soares, IS
   Rodrigues, MM
   Tsuji, M
   del Portillo, HA
TI Antigenic properties of the merozoite surface protein 1 gene of
   Plasmodium vivax
SO VACCINE
LA English
DT Article
DE Plasmodium vivax; merozoite surface protein 1; DNA vaccines
ID CIRCUMSPOROZOITE PROTEIN; AOTUS MONKEYS; PLASMID DNA; PROTECTIVE
   IMMUNITY; FALCIPARUM MALARIA; TERMINAL FRAGMENT; T-CELLS; IMMUNIZATION;
   VACCINE; MICE
AB Plasmodium vivax is responsible for an approximate 35 million yearly human cases of malaria. Unfortunately, due to the low mortality rate associated with it and the difficulties of continuously in vitro culturing of this parasite, vaccine development against this human malaria has been largely neglected. In here, the antigenic properties of the merozoite surface protein 1 gene of P. vivax (PvMSP-1), were studied. Thus, seven recombinant bacterial plasmids coding different regions of the PvMSP-1 protein were constructed and used to immunize BALB/c mice, The results demonstrated that a plasmid encoding the entire N-terminus comprising 682 amino acids and a plasmid encoding the C-terminus including the two juxtaposed epidermal growth factor (EGF)-like domains fused to the Hepatitis B surface antigen, were antigenic. Moreover, the elicited immune responses were similar to those reported for these same PvMSP-1 regions in natural human infections. (C) 1999 Published by Elsevier Science Ltd. All rights reserved.
C1 Univ Sao Paulo, Inst Ciencias Biomed 2, Dept Parasitol, BR-05508900 Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Escola Paulista Med, Dept Microbiol Imunol & Parasitol, Sao Paulo, Brazil.
   NYU, Med Ctr, Dept Med & Mol Pharmacol, New York, NY USA.
RP del Portillo, HA (corresponding author), Univ Sao Paulo, Inst Ciencias Biomed 2, Dept Parasitol, Ave Lineu Prestes 1374, BR-05508900 Sao Paulo, Brazil.
RI Wunderlich, Gerhard/G-8245-2012; de Oliveira, Camila I/B-4358-2009;
   Soares, Irene Silva/C-5974-2012; Rodrigues, Mauricio M./B-8512-2012; del
   Portillo, Hernando A/L-2131-2014; Tsuji, Moriya/B-1471-2008
OI Wunderlich, Gerhard/0000-0003-1724-0337; de Oliveira, Camila
   I/0000-0002-7868-5164; Soares, Irene Silva/0000-0002-3336-6856; del
   Portillo, Hernando A/0000-0002-5278-3452; Tsuji,
   Moriya/0000-0001-8587-277X
CR Angus CW, 1996, J EUKARYOT MICROBIOL, V43, pS117, DOI 10.1111/j.1550-7408.1996.tb05034.x
   Becker SI, 1998, INFECT IMMUN, V66, P3457, DOI 10.1128/IAI.66.7.3457-3461.1998
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Chang SP, 1996, INFECT IMMUN, V64, P253, DOI 10.1128/IAI.64.1.253-261.1996
   CHEUNG A, 1986, P NATL ACAD SCI USA, V83, P8328, DOI 10.1073/pnas.83.21.8328
   Costa F, 1998, VACCINE, V16, P768, DOI 10.1016/S0264-410X(97)00277-6
   DALY TM, 1995, J IMMUNOL, V155, P236
   DAVID PH, 1988, BIOL CELL, V64, P251, DOI 10.1016/0248-4900(88)90084-6
   DELPORTILLO HA, 1991, P NATL ACAD SCI USA, V88, P4030, DOI 10.1073/pnas.88.9.4030
   dOliveira C, 1997, VACCINE, V15, P1796, DOI 10.1016/S0264-410X(97)00197-7
   Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617
   Doolan DL, 1996, J EXP MED, V183, P1739, DOI 10.1084/jem.183.4.1739
   Egan A, 1997, INFECT IMMUN, V65, P3024, DOI 10.1128/IAI.65.8.3024-3031.1997
   Galinski MR, 1996, PARASITOL TODAY, V12, P20, DOI 10.1016/0169-4758(96)80641-7
   Good MF, 1998, ANNU REV IMMUNOL, V16, P57, DOI 10.1146/annurev.immunol.16.1.57
   Grifantini R, 1998, EUR J IMMUNOL, V28, P1225, DOI 10.1002/(SICI)1521-4141(199804)28:04<1225::AID-IMMU1225>3.0.CO;2-6
   HALL R, 1984, NATURE, V311, P379, DOI 10.1038/311379a0
   Hirunpetcharat C, 1997, J IMMUNOL, V159, P3400
   HOLDER AA, 1988, PROG ALLERGY, V41, P72
   Holder AA, 1981, NATURE, V294, P361, DOI 10.1038/294361a0
   KUMAR S, 1995, MOL MED, V1, P325, DOI 10.1007/BF03401557
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Leitner WW, 1997, J IMMUNOL, V159, P6112
   LEVITUS G, 1994, AM J TROP MED HYG, V51, P68, DOI 10.4269/ajtmh.1994.51.68
   LEVITUS G, 1997, BEHRING I MITT, V99, P107
   LING IT, 1994, PARASITE IMMUNOL, V16, P63, DOI 10.1111/j.1365-3024.1994.tb00324.x
   MANCILLA LI, 1994, EXP PARASITOL, V79, P148, DOI 10.1006/expr.1994.1074
   MIYAHIRA Y, 1995, J IMMUNOL METHODS, V181, P45, DOI 10.1016/0022-1759(94)00327-S
   Perera KLRL, 1998, INFECT IMMUN, V66, P1500, DOI 10.1128/IAI.66.4.1500-1506.1998
   Perrin L.H., 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene, V83, P53, DOI 10.1016/0035-9203(89)90604-4
   Phillips EJ, 1996, CLIN INFECT DIS, V23, P1171, DOI 10.1093/clinids/23.5.1171
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866
   SIDDIQUI WA, 1987, P NATL ACAD SCI USA, V84, P3014, DOI 10.1073/pnas.84.9.3014
   Soares IS, 1997, INFECT IMMUN, V65, P1606, DOI 10.1128/IAI.65.5.1606-1614.1997
   Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202
   Tian JH, 1998, PARASITE IMMUNOL, V20, P263, DOI 10.1046/j.1365-3024.1998.00138.x
   Tian JH, 1996, J IMMUNOL, V157, P1176
   Waine GJ, 1997, VACCINE, V15, P846, DOI 10.1016/S0264-410X(96)00258-7
   Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476
   XU D, 1995, IMMUNOLOGY, V84, P173
   ZAVALA F, 1985, J IMMUNOL, V135, P2790
NR 42
TC 21
Z9 24
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD AUG 6
PY 1999
VL 17
IS 23-24
BP 2959
EP 2968
DI 10.1016/S0264-410X(99)00176-0
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 225KD
UT WOS:000081957300004
PM 10462230
DA 2020-12-08
ER

EF